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Patients undergoing a percutaneous coronary intervention (PCI) and patients with an 
acute coronary syndrome (ACS) are generally treated with acetylsalicylic acid (ASA) and 
a P2Y12 receptor inhibitor as recommended by current guidelines.(1-3) This so-called 
dual antiplatelet therapy (DAPT) is used to reduce blood platelet aggregation, which 
plays an important role in the thrombotic occlusion of coronary vessels. ASA has an 
antithrombotic effect caused by the irreversible inhibition of platelet cyclooxygenase-1, 
which inhibits the generation of thromboxane A2 in platelets. Thromboxane A2 is part 
of the platelet activation cascade that ultimately leads to thrombus formation.
P2Y12 receptor inhibitors inhibit adenosine diphosphate (ADP)-induced platelet 
aggregation by preventing the binding of ADP to its P2Y12 receptor. Adding a P2Y12 
receptor inhibitor, for example clopidogrel, to ASA leads to a reduction in the incidence 
of atherothrombotic events such as stent thrombosis and acute myocardial infarction 
in both ACS and PCI patients.(4-9)
Clopidogrel and platelet reactivity
The inhibitory effect of clopidogrel on platelet reactivity can be measured with several 
ex vivo platelet function tests.(10,11) Clopidogrel is a prodrug that is converted to 
an active metabolite by cytochrome P450 isoenzymes. The CYP2C19 gene encodes 
the CYP2C19 enzyme involved in both steps of the two-step conversion. Different 
defective polymorphisms of the CYP2C19 gene have been identified, of which the loss-
of-function CYP2C19*2 and *3 allele are the most common. Patients with these alleles 
show higher levels of platelet reactivity on clopidogrel.(12,13) Besides CYP2C19 loss-
of-function genes there are several other known factors that influence the antiplatelet 
effect of clopidogrel such as age, a high body mass index, the presence of ACS, the 
presence of diabetes, and the administration of drugs and agents that use the same 
metabolic pathways as clopidogrel, such as certain proton pump inhibitors, some 
calcium channel blockers, and cigarette smoke.(14-19)
Approximately 25-35% of PCI patients treated with clopidogrel show high levels of 
platelet reactivity (HPR) and these patients are at increased risk of atherothrombotic 
events during follow-up.(10,11, 20, 21) Inadequate platelet inhibition is not the only 
problem that can be detected with platelet function tests. In contrast to patients 
with HPR, some patients have platelets that appear to be excessively inhibited with 
standard antiplatelet medication. This state of low platelet reactivity (LPR) could lead 
to bleeding events. Multiple studies have shown evidence for a therapeutic window 
for platelet inhibition with HPR at one end of the spectrum and LPR at the other end.
(10) This suggests that a “one-size-fits-all” strategy with clopidogrel is not the optimal 
treatment. 
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Prasugrel and ticagrelor
The antiplatelet drugs prasugrel, a pro-drug that leads to irreversible P2Y12 receptor 
inhibition, and ticagrelor, a direct-acting reversible P2Y12 receptor inhibitor, both yield 
lower levels of platelet reactivity than clopidogrel, with less inter-individual variability. 
These drugs have shown to reduce thrombotic risk compared to clopidogrel in ACS 
patients and are now recommended over clopidogrel in these patients.(2,3,22,23) 
However, these more potent drugs also increase the rate of bleeding events.(22-24)
Individualising antiplatelet therapy
Tailoring of antiplatelet therapy based on the patient’s thrombotic and bleeding risk 
might improve clinical outcomes as compared to the non-selective use of clopidogrel, 
prasugrel or ticagrelor. Platelet function testing could play a key role in this strategy, as 
it might help treating physicians to more accurately assess the thrombotic and bleeding 
risk of the individual patient. However, it is important to note that many factors can 
potentially influence platelet function test results, including patient characteristics 
and test conditions. Multiple studies have suggested that the performance of a PCI 
itself might increase platelet reactivity, which could make the interpretation of results, 
and thereby the assessment of an individual patient’s risk, more difficult. To optimize 
the use of platelet function testing in clinical practice, a full understanding of the 
factors that influence the test results is needed.
Concomitant use of oral anticoagulants
Not all PCI patients are only treated with DAPT. An increasing number of patients are 
treated with oral anticoagulants for indications such as atrial fibrillation or mechanical 
heart valves. These drugs inhibit thrombus formation by influencing the coagulation 
cascade instead of blood platelets. As the average life expectancy increases, the group 
of patients with an indication for both DAPT and oral anticoagulation also increases. 
As both treatments increase the risk of bleeding, it is difficult to assess when the use of 
triple therapy (ASA, a P2Y12 inhibitor and oral anticoagulation) is justified and when it 
leads to a disproportionally increased bleeding risk. Moreover, one study showed that 
the concomitant use of phenprocoumon, an oral anticoagulant, leads to an increase in 
platelet reactivity in PCI patients treated with clopidogrel.(25) Similar to clopidogrel, 
coumarin derivatives like phenprocoumon and acenocoumarol need several enzymes 
of the cytochrome P450 family, such as CYP3A4, CYP2C9, and CYP2C19, to catalyse 
their oxidative metabolism. CYP3A4 plays a major role as a catalyst of phenprocoumon 
hydroxylation reaction, whereas CYP2C9 activity is known as the principal determinant 
for acenocoumarol clearance.(26,27)
1.1
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The use of oral anticoagulants in the period around the PCI procedure is also an 
important issue regarding the ischemic and bleeding risk: the treating physician 
has to decide whether oral anticoagulation should be stopped before the procedure 
and whether bridging with heparins is required. Although this particular group of 
patients is increasing, data regarding the combination of antiplatelet treatment and 
anticoagulation is still lacking and many questions remain unanswered.
Patients undergoing coronary surgery
Difficult decisions regarding the use of antiplatelet treatment and ischemic and 
bleeding risk are not limited to the population of PCI patients. Many patients 
undergoing coronary artery bypass grafting surgery (CABG) are also treated with 
antiplatelet drugs. Some of them are treated with DAPT with ASA and clopidogrel, 
prasugrel or ticagrelor due to recent coronary stent implantation or ACS. It is clear 
that ASA should be used in all CABG patients to prevent the occlusion of bypass grafts, 
but it is unclear if patients benefit from the addition of a P2Y12 inhibitor after CABG. 
Current guidelines recommend the post-operative use of DAPT in these patients, but 
these guidelines are not based on trials on this specific subject and do not provide tools 
to weigh the risk of thrombotic and bleeding events in the individual patient.(1-3)
Aims and outline of this thesis
This thesis starts with an overview of the current literature regarding platelet function 
testing for both PCI and CABG patients, including descriptions to the most used 
platelet function tests (Chapter 1.1 and 1.2). Furthermore, the concept of a therapeutic 
window for platelet reactivity is tested in a meta-analysis (Chapter 1.3).
In chapter 2, the influences of different factors on platelet reactivity are studied. This 
is important because accounting for these factors may improve the predictive value of 
platelet function testing and improve discrimination between patients with high and 
low thrombotic risk. First, the influences of a PCI with stent implantation, the timing 
of blood sampling and the blood sample source on platelet reactivity are described 
(Chapter 2.1 and 2.2). Second, the effects of heparin and bivalirudin on platelet 
reactivity are shown (Chapter 2.2). Third, the influence of haematocrit on platelet 
reactivity is described and a formula for correcting results based on this influence is 
investigated (Chapter 2.3).
In chapter 3, the concomitant use of oral anticoagulants and antiplatelet drugs is 
described. The chapter starts with a review of current evidence (Chapter 3.1), followed 
by an analysis of the influence of the oral anticoagulant acenocoumarol on platelet 
reactivity in patients treated with clopidogrel (Chapter 3.4). Subsequently, the 
strategies of uninterrupted anticoagulation and bridging with heparin in PCI patients 
are compared (Chapter 3.5). 
17
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Chapter 4 describes two studies regarding the tailoring of antiplatelet treatment. 
First, a strategy of selective intensification of P2Y12 inhibitor treatment based on a 
risk score containing platelet function test, CYP2C19 metabolizer phenotype and 
clinical risk factors is compared to standard treatment with clopidogrel in non-urgent 
PCI patients (Chapter 4.1). Second, the rationale and design for a study of tailoring 
P2Y12 inhibitor treatment based on CYP2C9 genotype alone in ST-segment elevation 
myocardial infarction patients who underwent primary PCI is described (Chapter 4.2).
Chapter 5 describes the management of antiplatelet treatment in patients undergoing 
isolated CABG in Dutch cardiothoracic centres and discusses current evidence and 
knowledge gaps regarding this subject.
1.1
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A BST R AC T 
 
Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor inhibitor, has 
dramatically reduced the incidence of atherothrombotic events for patients with acute 
coronary syndrome and those undergoing a percutaneous coronary intervention (PCI). 
However, the platelet inhibitory effect of clopidogrel, the most commonly used P2Y12 
inhibitor, is variable between patients. Patients exhibiting high platelet reactivity 
(HPR) despite clopidogrel treatment are at higher risk of recurrent atherothrombotic 
events after PCI. In order to reduce the incidence of HPR, the more potent P2Y12 receptor 
inhibitors prasugrel and ticagrelor are used. However, these drugs increase the risk of 
bleeding. As there is evidence of a therapeutic window for platelet inhibition, platelet 
function tests could be helpful for tailoring antiplatelet therapy based on the patient’s 
thrombotic and bleeding risk. In the present article, we review the most commonly 
used platelet function tests and the current evidence for tailoring of antiplatelet 
therapy in PCI patients. 
1.2
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I N T RODUC T ION
Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor inhibitor, is 
considered the standard care for patients with acute coronary syndrome (ACS) and 
those undergoing a percutaneous coronary intervention (PCI) [1–5]. Blood platelets 
play an important role in the thrombotic occlusion of coronary vessels. P2Y12 
receptor inhibitors inhibit adenosine diphosphate (ADP)-induced platelet activation 
by preventing the binding of ADP to its P2Y12 receptor. The addition of the P2Y12 
receptor inhibitor clopidogrel to aspirin therapy has proven superior to aspirin alone 
in reducing the incidence of atherothrombotic events (e.g., stent thrombosis (ST), 
acute myocardial infarction (AMI), and death) in both ACS and PCI patients [6–11]. 
The lower response of platelets to ADP accounts for all of clopidogrel’s clinical effects, 
and the inhibitory effect of clopidogrel on platelet activation can be measured with 
several ex vivo platelet function tests [12]. 
In patients treated with clopidogrel, inhibition of platelet activation is suboptimal in 
approximately 25 %. This phenomenon is called high on-treatment platelet reactivity 
(HPR), and patients who exhibit HPR are at increased risk of atherothrombotic events 
[13–16]. HPR is considered a failure of antiplatelet treatment. Variability in platelet 
inhibition by aspirin has also been described, but its relationship to atherothrombotic 
events remains unclear [17]. Further discussion of this phenomenon is beyond the 
scope of this review. 
The prevalence of HPR in patients treated with clopidogrel suggests that a “one-size-
fits-all” strategy is not optimal for all patients. The antiplatelet drugs prasugrel and 
ticagrelor are more potent P2Y12 receptor inhibitors than clopidogrel, but the greater 
reduction in platelet reactivity is associated with a significant increase in bleeding 
events. In addition, these drugs are more expensive than clopidogrel as the latter has 
become generic. Instead of the nonselective use of prasugrel or ticagrelor, tailoring 
antiplatelet therapy based on the patient’s thrombotic and bleeding risk might 
therefore be preferred. Platelet function testing could play a key role in this strategy, 
as it might help cardiologists to more accurately assess these risks.
The present review discusses the rationale for platelet function testing in PCI patients 
treated with P2Y12 receptor inhibitors and how platelet function tests can be used 
in daily clinical practice. The current evidence for the tailoring of P2Y12 receptor 
inhibitor therapy as well as the future perspectives of this strategy are also discussed. 
VA R I A BILI T Y I N R E SPONSE TO CL OPIDOGR EL
In the Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated 
Patients Undergoing Elective PCI (POPULAR) study, platelet reactivity was assessed 
with several different tests in 1,069 consecutive patients who had a planned PCI. The 
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presence of HPR measured with light transmittance aggregometry (LTA) with 5 and 
20 μmol/L ADP, the VerifyNow® P2Y12 assay, Plateletworks®, and the Innovance® PFA 
P2Y assay all predicted the occurrence of the composite endpoint of allcause death, 
nonfatal AMI, ST, and ischemic stroke at 1-year follow-up [18].
The variability in P2Y12 inhibition by clopidogrel and the occurrence of HPR can be 
partly attributed to its metabolism. Clopidogrel is a prodrug that is converted to an 
active metabolite through a two-step enzymatic reaction that involves cytochrome 
P450 isoenzymes. The CYP2C19 gene encodes the CYP2C19 enzyme involved in 
both these steps. Different defective polymorphisms of the CYP2C19 gene have been 
demonstrated, of which the loss-of-function (LOF) CYP2C19*2 allele and CYP2C19*3 
allele are the most common. The presence of these LOF alleles is associated with higher 
levels of platelet reactivity on clopidogrel [19, 20].
In a study involving patients with stable coronary artery disease (CAD), a daily dose 
of 225 mg clopidogrel was necessary in CYP2C19*2 heterozygotes to achieve a degree 
of platelet inhibition similar to that observed in patients without a CYP2C19 LOF 
allele treated with a daily standard dose of 75 mg clopidogrel. In contrast, even a daily 
dose of 300 mg clopidogrel did not result in a similar degree of platelet inhibition in 
CYP2C19*2 homozygotes [21]. In a meta-analysis of seven prospective cohort studies 
that included 8,043 patients, the authors found a significant correlation between these 
LOF CYP2C19 polymorphisms and atherothrombotic events [22]. The variability in 
the inhibitory effect of clopidogrel associated with an impaired CYP2C19 metabolizer 
status has led to the “boxed warning” issued by the Food and Drug Administration 
advising health care professionals to consider using other antiplatelet drugs or 
alternative dosing strategies for clopidogrel in patients with a CYP2C19 LOF allele.
In contrast to the LOF alleles, a gain-of-function (GOF) CYP2C19*17 allele also exists. 
This allele is associated with an increased metabolism of clopidogrel and lower levels 
of platelet reactivity in response to clopidogrel [23, 24]. There are several other factors 
that influence the antiplatelet effect of clopidogrel such as age, a high body mass index, 
the presence of ACS, the presence of diabetes, and the administration of drugs and 
agents that use the same metabolic pathways as clopidogrel such as certain proton 
pump inhibitors, some calcium channel blockers, and cigarette smoke [13, 25–30]. 
T HE I N T RODUC T ION OF PR A SUGR EL A ND T IC AGR EL OR
As mentioned in the introduction, the P2Y12 receptor inhibitors prasugrel and 
ticagrelor are currently available and represent an alternative to clopidogrel. Platelet 
function testing has played an important role in the development of these P2Y12 
receptors inhibitors [31]. The characteristics of both drugs are briefly outlined in the 
following section. 
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Prasugrel 
Prasugrel, an irreversible P2Y12 receptor inhibitor, has a faster onset of action than 
clopidogrel and reaches more potent inhibition of platelet activation without the 
interindividual variability in response observed with clopidogrel [32, 33]. In the 
randomized Trial to Assess Improvement in Therapeutic Outcomes by Optimizing 
Platelet Inhibition with Prasugrel—Thrombolysis In Myocardial Infarction 38 
(TRITON-TIMI 38) study that included 13,608 patients with ACS who underwent 
a planned PCI, treatment with prasugrel reduced the occurrence of the composite 
endpoint of cardiovascular death, nonfatal AMI, and nonfatal stroke compared with 
clopidogrel [34]. However, the greater degree of platelet inhibition with prasugrel was 
associated with significantly more TIMI major bleeding events not related to coronary 
artery bypass grafting surgery (CABG) as well as more life threatening bleeding 
events. The benefits of treatment with prasugrel were nevertheless considered greater 
than the harm in the total study population. However, the subgroups of patients with 
previous stroke or low body weight, and the elderly did not benefit from prasugrel 
treatment. 
Prasugrel is a prodrug that requires biotransformation to an active metabolite via the 
CYP system in a manner similar to clopidogrel. Among patients receiving the drug, 
a secondary data analysis of the TRITON-TIMI 38 study did not reveal any effect of 
the CYP2C19 genotype on clinical cardiovascular event rates [35]. However, HPR can 
still occur in patients treated with prasugrel. Indeed, a recent study by Grosdidier et 
al. demonstrated that the CYP2C19 genotype had a significant effect on the incidence 
of HPR in these patients. In addition, Bonello et al. demonstrated that HPR despite 
prasugrel therapy was associated with adverse events [36].
Ticagrelor
Another newly developed drug is ticagrelor, a direct-acting reversible P2Y12 receptor 
inhibitor. Like prasugrel, this drug has a more rapid onset of action and establishes 
a greater degree of platelet inhibition during maintenance therapy than clopidogrel. 
In addition, normal levels of platelet reactivity are reached faster after ticagrelor 
cessation than after clopidogrel cessation [37, 38]. 
In the double-blind, randomized Platelet Inhibition and Patient Outcomes (PLATO) 
study that included 18,624 ACS patients, ticagrelor treatment was associated with a 
significant reduction in the occurrence of all-cause mortality, AMI, and ST compared 
with clopidogrel. As with prasugrel, the rate of major bleeding events not related to 
CABG was higher with ticagrelor and included more cases of fatal intracranial bleeding 
but fewer fatal bleeding of other types. Importantly, the rate of death from any 
cause was reduced with ticagrelor. In contrast to clopidogrel and prasugrel, platelet 
inhibition in patients treated with ticagrelor does not appear to be affected by the 
CYP2C19 genotype [39].
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Based on the results from TRITON and PLATO, both prasugrel and ticagrelor were 
included as treatment strategies in the latest iterations of the AHA/ACC and ESC 
guidelines (IA indication) [2–5].
 
OV ERV IEW OF PL AT ELET F U NC T ION T E ST S
Platelet function tests can be used to measure the response to antiplatelet therapy and 
identify patients with reactive platelets despite antiplatelet therapy. Many different 
tests are available as multiple pathways of thrombus formation can be measured. It 
is, however, important to acknowledge that the reproducibility and applicability vary 
between these tests. The underlying principles of the most commonly used platelet 
function tests are briefly discussed below.
Light Transmittance Aggregometry
Turbidimetric light transmittance aggregometry (LTA) is the classic platelet function 
test. The test is often referred to as the “gold standard” of platelet function testing. 
It is based on the optical detection (a light beam is directed through the sample) of 
aggregates in platelet-rich plasma. Platelet-rich plasma (PRP) and platelet-poor plasma 
(PPP) are obtained from citrated whole blood in two separate centrifugation steps. The 
PPP serves as a control sample as the amount of light transmitted through the PPP is 
defined as 100 % aggregation, while the light transmitted through the PRP is defined 
as 0 % aggregation. Maximal platelet aggregation (MPA) is subsequently triggered in 
the PRP samples by the addition of platelet agonists (arachidonic acid (AA) and ADP). 
The formation of platelet aggregates modifies the optical density of the samples which 
is measured and expressed as a percentage of aggregation. However, because LTA is 
not standardized, it is subject to many methodological variables leading to a poor 
reproducibility between laboratories. Furthermore, it is time consuming and labor 
intensive which limits its use in daily clinical practice.
VerifyNow®
TheVerifyNow®System (Accumetrics, SanDiego, CA, USA) is a turbidimetric-based, 
optical detection point-of-care device designed to measure platelet aggregation in 
citrated whole blood. The device can be used to determine the response of platelets to 
aspirin and P2Y12 receptor inhibitors. It uses cartridges that contain different agonists 
to activate the platelets. The platelets bind to fibrinogen-coated beads, the aggregates 
subsequently drop to the bottom of the cartridge, and an infrared light is directed 
through the mixing chamber to measure the difference in the optical density that 
occurs after the agglutination of the beads. The aspirin assay uses AA as the agonist and 
the P2Y12 assay contains two chambers with agonists. In the first chamber, the agonist 
is ADP with prostaglandin E1 as an antagonist while the second chamber contains 
the thrombin receptor-activated peptide as the agonist which is used to determine 
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the baseline of the maximal off-drug platelet reactivity. Results are then reported in 
P2Y12 reaction units (PRU), a BASE value, and a percentage of inhibition. A higher PRU 
result indicates that platelet aggregation is less inhibited. The test is easy to perform 
and results are reproducible and quickly available. These characteristics make it a 
promising test for use in daily clinical practice. The VerifyNow® assays correlate very 
well with LTA [40-43].
The Multiplate®
The Multiplate® (Dynabyte, Germany) uses a hirudin-anticoagulated whole blood 
multiple electrode aggregometry system and it detects the increase in the electrical 
impedance resulting from the adhesion and aggregation of platelets on two independent 
sensor units in the test cuvette [44]. The increase in impedance is then transformed and 
reported as arbitrary aggregation units (AU) that are plotted against time (AU•min). 
Different agonists are available to monitor the effects of antiplatelet therapy. The so-
called ASPItest is sensitive to aspirin and theADPtest is sensitive to P2Y12 receptor 
inhibitors. The test is semiautomatic and requires the manual preparation of agonists 
and pipetting. The results from the Multiplate® correlate well with LTA [44].
Vasodilator-Stimulated Phosphoprotein Assay
The vasodilator-stimulated phosphoprotein (VASP) is an intraplatelet actin regulatory 
protein. Activation of the P2Y12 receptor by ADP causes the dephosphorylation of VASP 
and the activation of the glycoprotein IIb/IIIa receptor, which is the main receptor 
for platelet adhesion and aggregation, on the surface of the platelet [45]. Conversely, 
the inhibition of the P2Y12 receptor induces the phosphorylation of VASP (VASP-P). 
VASP-P state reflects the extent of P2Y12 inhibition. Flow cytometric analysis of the 
VASP-P state is performed using a standardized diagnostic assay kit (PLT VASP/P2Y12-
assay from BioCytex, Marseille, France) [46]. The test result is expressed as a platelet 
reactivity index (PRI) and a high PRI represents poor platelet inhibition by the P2Y12 
receptor inhibitor. The PLT VASP/P2Y12 assay has shown a good correlation with LTA, 
but the test is time consuming and requires expertise [47]. 
Cutoff Values for HPR
The results from most platelet function tests are expressed as the level of platelet 
reactivity on a continuous scale. When the relationship between platelet reactivity 
and adverse thrombotic events after PCI was discovered, the cutoff values that 
best predicted these adverse events were established based on receiver–operator 
characteristic (ROC) curve analyses. These cutoff values separate patients in groups 
with and without HPR and, as shown in Table 1, different studies found different 
cutoff points for the same tests. A consensus document regarding the use of platelet 
function testing and cutoff values for HPR was published in 2010 [13]. The results 
from different studies that show a relationship between HPR (defined by a cutoff 
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Test Technique Bench/bedside Studies
Observed
cut-off value(s)
for HPR
Consensus cut-
off values* 
LTA
Turbidimetric 
based optical 
detection
Bench
Breet et al [18]
Gurbel et al.[48]
Cuisset et al. [49]
Frere et al [50]
Gurbel Platelets 2008 [48]
Breet et al JAMA 2010 [18]
ADP 5 mmol:
MPA > 42.9%
MPA > 46%
ADP 10 mmol:
MPA > 67% 
MPA > 70%
ADP 20 mmol:
MPA > 59%
MPA > 64.5%
ADP 5 mmol:
MPA > 46%
VerifyNow®
Turbidimetric
based optical
detection
Bedside
Campo et al [51]
Price et al [52] 
Breet et al [18]
Mangiacapra et al. [53]
Patti et al. [54], Marcucci et
al. [54]
Suh et al. [56]
PRU ≥ 208
PRU ≥ 235
PRU ≥ 236
PRU ≥ 239
PRU ≥ 240
PRU ≥ 252.5
PRU ≥ 235-240
Multiplate®
Multiple
electrode
aggregometry
Bedside Sibbing et al. [57] AU·min ≥ 468 AU·min ≥ 468
VASP
Flowcytometric
analysis of 
VASP-P
Bench
Blindt et al. [58]
Bonello et al. [59]
Frere et al. [50]
PRI > 48%
PRI > 50%
PRI > 53%
PRI > 50%
Table 1: This table provides an overview of the most used platelet function tests and their corresponding cutoff 
values obtained with receiver–operator characteristic (ROC) curve analyses in different studies ADP adenosine 
diphosphate, AU aggregation units, HPR high platelet reactivity, LTA light transmittance aggregometry, 
MPA maximal platelet aggregation, PRI platelet reactivity index, PRU platelet reactivity units, VASP 
vasodilator-stimulated phosphoprotein, VASP-P vasodilator-stimulated phosphoprotein phosphorylation 
a These values were published in a consensus document written by the Working Group on High On-treatment 
Platelet Reactivity in 2010
Table 1: Platelet function tests and their corresponding cutoff values
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Table 2: The association between HPR on clopidogrel and adverse clinical outcome
Study No. of patients Population Test(s)
HPR cut-off 
value(s)
Outcome with 
HPR
Gurbel et al. 
[48] 297 PCI for stable CAD
LTA 5 μmol ADP
LTA 20 μmol ADP
MPA > 46 %
MPA > 59 %
Increased rate of 
ischemic events 
at 2 years
Breet et al. 
[18] 1,069 PCI for stable CAD
LTA 5 μmol ADP
LTA 20 μmol ADP
VerifyNow®
MPA > 42.9 %
MPA > 64.5 %
PRU ≥ 236
Increased rate 
of death, AMI, 
ST and stroke at 
1 year
Cuisset et al. 
[49] 598 PCI for NSTE-ACS LTA 10 μmol ADP MPA > 67 %
Increased rate of 
ST at 30 days
Frere et al. 
[50] 195 PCI for NSTE-ACS
LTA 10 μmol ADP
VASP
MPA > 70 %
PRI > 53 %
Increased rate of 
MACE and stroke 
at 30 days
Parodi et al. 
[61] 1,789 PCI for ACS LTA 10μM ADP MPA ≥70%
Increased rate 
of cardiac 
death, AMI, any 
urgent coronary 
revascularization 
and stroke at 2 
years
Campo et al. 
[51]
1,277 PCI for stable CAD VerifyNow® PRU ≥208
Increased rate of 
death, AMI and 
stroke at 1 year
Mangiacapra 
et al. [53] 732 PCI for stable CAD VerifyNow® PRU ≥239
Increased rate 
of death, AMI, 
and target vessel 
revascularization 
at 30 days
Campo et al. 
[60] 300
PCI for stable CAD 
or NSTE-ACS VerifyNow® PRU ≥235
Increased rate of 
death, AMI and 
stroke between 
1–12 months 
after PCI
Patti et al. 
[54] 160
PCI for stable CAD 
or NSTE-ACS VerifyNow® PRU ≥240
Increased rate of 
cardiac death, MI 
and target vessel 
revascularization 
at 1 month
Price et al. 
[52] 380
PCI for stable CAD 
or NSTE-ACS VerifyNow® PRU ≥235
Increased rate of 
CV death,non-
fatal MI, and ST 
at 6 months
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Price et al. 
[62] 2,796
PCI for stable CAD 
or NSTE-ACS VerifyNow® PRU ≥208
Increased rate 
of CV death, 
nonfatal AMI and 
ST at 60 days
Suh et al. 
[56] 915
PCI for stable CAD 
or ACS VerifyNow® PRU ≥252.5
Increased rate 
of cardiac death, 
nonfatal AMI, 
clinically driven 
target lesion 
revascularization 
and ischemic 
stroke at 6 
months
Marcucci et 
al. [55] 683
PCI for ACS  
(including STE-
ACS)
VerifyNow® PRU ≥240
Increased rate 
of CV death and 
nonfatal AMI at 
1 year
Sibbing et al. 
[57] 1,608
PCI for stable CAD 
or ACS (including 
STE-ACS)
Multiplate® AU·min ≥468
Increased rate of 
death and ST at 1 
month
Sibbing et al. 
[63] 564 PCI for NSTEMI Multiplate® AU·min ≥468
Increased 
rate of death, 
AMI, urgent 
target vessel 
revascularization 
at 30 days
Blindt et al. 
[58] 99 PCI VASP PRI > 48%
Increased rate of 
ST at 6 months
Bonello et al. 
[59] 144
PCI for stable CAD 
or IAP VASP PRI > 50%
Increased rate 
of combined 
endpoint of 
CV death, 
ischemic stroke, 
recurrent ACS, 
and repeated 
evascularization 
at 6 months
Table 2: These studies all showed an association between HPR with clopidogrel (defined by a specific cutoff 
value) and adverse clinical outcome
ACS acute coronary syndrome, ADP adenosine diphosphate, AMI acute myocardial infarction, AU aggregation 
units, CAD coronary artery disease, CV cardiovascular, HPR high platelet reactivity, IAP instable angina 
pectoris, LTA light transmittance aggregometry, MACE major adverse cardiac events, MPA maximal platelet 
aggregation, NSTE-ACS non-ST elevation acute coronary syndrome, NSTEMI non-ST elevation myocardial 
infarction, PCI percutaneous coronary intervention, PRU platelet reactivity units, VASP-PRI vasodilator-
stimulated phosphoprotein platelet reactivity index.
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value) and clinical outcome are summarized in Table 2. As can be seen in the last 
column, the presence of HPR in patients treated with clopidogrel predicts the 
occurrence of a wide range of thrombotic events after PCI, including death, AMI, ST, 
and stroke. Therefore, HPR is an important risk factor for patients undergoing PCI. 
A T HER A PEU T IC W I NDOW FOR PL AT ELET I NHIBI T ION
Inadequate platelet inhibition is not the only problem that can be detected with platelet 
function tests. In contrast with patients with HPR, some patients have platelets that 
appear to be excessively inhibited with standard antiplatelet medication. This state 
of low platelet reactivity (LPR) could lead to bleeding events. There is evidence from 
multiple studies for a therapeutic window for platelet inhibition with HPR at one 
end of the spectrum and LPR at the other end [53, 64–66]. Sibbing et al. assessed 
platelet inhibition in the presence of clopidogrel with the Multiplate® in an all-comer 
PCI population (2,533 patients including ST elevation acute coronary syndrome (STE-
ACS) patients) [67]. An enhanced clopidogrel response, defined by a cutoff value of 188 
AU•min obtained through ROC analysis, was associated with in-hospital TIMI major 
bleeding events, but minor bleeding was not significantly different between groups. 
Campo et al. evaluated the relationship between platelet reactivity and outcome 
in PCI patients [60]. Patients presenting with STE-ACS and patients with adverse 
events during the first month after the PCI were excluded. In 300 patients, platelet 
reactivity was assessed with the VerifyNow® P2Y12 assay before PCI and at 1 and 6 
month follow-up. HPR (PRU≥235) at 1 month follow-up was a strong independent 
predictor for ischemic events. A total of 19 TIMI bleeding events were reported, four 
of which were major. After multivariable analysis, platelet reactivity at 1 month, age as 
a continuous variable, and CYP2C9*17 genotype independently predicted bleeding. On 
ROC analysis, a cutoff of PRU≤85 was found to best predict bleeding.
The Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty–
Platelet Reactivity for Outcome Validation Effort (ARMYDA-PROVE) study by 
Mangiacapra et al. assessed platelet reactivity in response to clopidogrel before 
patients underwent their elective PCI [53]. Platelet reactivity was measured with 
the VerifyNow® P2Y12 assay and the study population consisted of 732 patients who 
were stratified according to their PRU values (using optimal cutoff values based on 
ROC curve analysis) in order to assess the impact of pre-PCI platelet reactivity on 
the 30-day incidence of ischemic (death, AMI, or target vessel revascularization) and 
bleeding events. Patients with a PRU≤178 had significantly more bleeding events and 
were classified as having LPR while patients with a PRU≥239 had significantly more 
ischemic events and were classified as having HPR. Patients without LPR or HPR were 
classified as having normal platelet reactivity and they had a 50 % lower risk for the 
combined endpoint of ischemic and bleeding events. This indicates that there was a 
“sweet spot” for PRU between 179 and 238.
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Studies regarding LPR and bleeding in prasugrel-treated patients have also been 
conducted. Bonello et al. investigated the relationship between platelet reactivity 
and the 1-year atherothrombotic and bleeding risk in ACS patients that underwent 
a successful PCI [36]. Platelet reactivity was assessed with VASP after a loading dose 
of 60 mg prasugrel. A total of 301 patients were prospectively included and follow-up 
was available for 292 patients. Using a cutoff value of 53.5 % PRI for HPR, the patients 
exhibiting HPR had a significantly higher rate of thrombotic events. A cutoff value of 
16 % PRI was found to be the best predictor for bleeding events.
A recent study by Grosdidier et al. in 730 ACS patients who underwent a successful PCI 
compared the influence of cytochrome CYP2C19 *2 LOF and *17 GOF genetic variants 
on the platelet response to clopidogrel and prasugrel maintenance therapy and also 
assessed the relationship between platelet reactivity and bleeding complications 
[68]. Clopidogrel 150 mg daily was prescribed to 517 patients and 213 were treated 
with prasugrel 10 mg daily. Platelet reactivity was assessed with VASP 1 month after 
discharge. HPR was defined as a VASP-PRI>50 % and LPR as a VASP-PRI<20 %. Patients 
were considered ultra-rapid metabolizers when they did not have a *2 allele but had a 
*17 allele, poor metabolizers when they had a *2 allele but did not have a *17 allele, and 
intermediate metabolizers when they had both a *2 allele and a *17 allele or neither 
a *2 or a *17 allele. The rate of HPR was significantly higher in clopidogrel- (35 %) 
than in prasugrel-treated patients (7 %). In contrast, LPR was present in a significantly 
greater proportion of patients treated with prasugrel (31 %) than in those treated with 
clopidogrel (10 %). In all 730 patients, the patients who developed non-access site-
related bleeding events within 1 month of follow-up had a significantly lower VASP-
PRI (26±15 %) than those without complications (30±14 %) (p<0.0001). The rate of 
bleeding complications in patients with LPR was significantly higher (22 %, 26/120) 
than in those without LPR (6 %, 34/610).
The results from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting 
Stents (ADAPT-DES) study, which were presented at the 24th annual Transcatheter 
Cardiovascular Therapeutics scientific symposium in October 2012, support the 
existence of a therapeutic window as well [69]. The study was a large multicenter 
registry of patients undergoing PCI. Platelet reactivity in patients treated with aspirin, 
clopidogrel, and GPIIb/IIIa therapy was assessed with the VerifyNow Aspirin, P2Y12, 
and IIb/IIIa assays, respectively. HPR was shown to be significantly associated with the 
occurrence of ST and AMI but was also associated with a lower rate of major bleeding. 
The presence of HPR did not independently predict mortality on multivariable analysis.
All these studies suggest that excessive platelet inhibition leads to bleeding 
complications and that platelet function testing can help cardiologists assess a 
patient’s risk of bleeding. In contrast to the cutoff values for HPR, as of yet, there is no 
consensus as to the cutoff levels for LPR that are associated with bleeding.
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Tailoring of Antiplatelet Therapy Based on Platelet Reactivity
The discovery of the relationship between HPR and adverse events led to the concept of 
tailoring antiplatelet therapy based on platelet function test results. It was hypothesized 
that lowering platelet reactivity in HPR patients by adjusting antiplatelet therapy 
would lower the incidence of atherothrombotic events such as ST and AMI. Numerous 
studies have applied this strategy. Most studies have focused solely on the presence 
of HPR as the predictive value of LPR was demonstrated more recently. The strategy 
employed to lower platelet reactivity in HPR patients was often the administration of 
higher doses of clopidogrel, but studies using GP IIb/IIIa inhibitors and ticlopidine 
have also been performed [70–78]. Table 3 summarizes the largest studies that were 
conducted, which we review in this section. 
Bonello et al.
This multicenter, prospective, randomized study by Bonello et al. included patients 
undergoing PCI for stable CAD or non-ST elevation ACS (NSTE-ACS) [77]. Platelet 
reactivity was assessed with VASP between 6 and 24 hours after a loading dose of 
600 mg clopidogrel and HPR was defined as a VASP-PRI >50 %. A total of 429 HPR 
patients were randomized to a control group or a VASP-guided group. In the control 
group, the PCI was carried out without an additional loading dose of clopidogrel, while 
patients in the VASP-guided group received up to three additional loading doses of 
600 mg clopidogrel to achieve a VASP-PRI <50 %. A VASP-PRI <50 % could not be 
achieved in 17 patients (8 %). The maintenance dose of clopidogrel was not adjusted. 
The rates of ST and major adverse cardiac events (cardiovascular death, recurrent acute 
coronary syndrome, and urgent coronary revascularization) at 1-month follow-up 
were significantly lower in the VASP-guided group, while bleeding rates were similar 
in both groups. 
Valgimigli et al. (3T/2R) 
The Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin 
and/or Resistance to  Clopidogrel (3T/2R) trial was a double-blind, multicenter, 
randomized trial in patients undergoing elective PCI  [79]. Poor responders to aspirin 
and/or clopidogrel were identified with the VerifyNow® assay. A total of 1,277 patients 
were screened: 136 (14.8 %) were poor responders to aspirin, 174 (27 %) were poor 
responders to clopidogrel, and 26 (9.2 %) showed poor responsiveness to both drugs. 
These patients were randomized to receive tirofiban or a matching placebo on top of 
aspirin and clopidogrel. Periprocedural AMI occurred in 27 (20.4 %) patients in the 
tirofiban group and 46 (35.1 %) patients in the placebo group (relative risk, 0.58; 95 % 
CI, 0.39 to 0.88; p = 0.0089) [38, 51]. 
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Price et al. (GRAVITAS) 
The Gauging Responsiveness with A VerifyNow® assay—Impact on Thrombosis And 
Safety (GRAVITAS) was a randomized, double-blind, active-control trial in patients 
undergoing PCI for stable CAD or NSTE-ACS [80]. Similar to the 3T/2R trial, patients 
with HPR with clopidogrel were identified with the VerifyNow® P2Y12 assay. HPR 
with clopidogrel (PRU≥230) was present in 2,214 patients (41 %) and these patients 
were randomized to continued treatment with the standard 75 mg maintenance dose 
clopidogrel or the administration of an additional loading dose of 600 mg clopidogrel 
followed by a higher daily maintenance dose of 150 mg. At 6-month follow-up, the 
primary composite endpoint of death from cardiovascular causes, nonfatal AMI, and 
ST was identical in both groups (2.3 %) with no significant difference in bleeding 
events. There are several potential explanations for these null results including a 
low event rate in this low-risk patient population resulting in an inadequate power. 
Another explanation could be that a doubled dose of clopidogrel is not sufficient to 
overcome HPR as the prevalence of HPR was only reduced in 60 % of patients at 30-day 
follow-up. Due to the low rate of events in this study, only a highly effective treatment 
that would completely reduced HPR could have produced positive results. 
A post hoc analysis of the GRAVITAS trial suggested that the achievement of on-
clopidogrel reactivity <208 PRU at 12 to 24 h after PCI or during follow-up was an 
independent predictor of event-free survival at 60 days (hazard ratio 0.23; 95 % CI, 
0.05–0.98; p = 0.047) and strongly trended to be an independent predictor at 6 months 
(hazard ratio 0.54; 95 % CI, 0.28–1.04; p = 0.06) [62].
Parodi et al. (RECLOSE 2-ACS)
The Responsiveness to Clopidogrel and Stent-Related Events in Acute Coronary 
Syndrome (RECLOSE 2-ACS) was a prospective, open-label, observational study that 
only recruited ACS patients (including those with ST elevation) undergoing PCI [61]. 
Poor responders to a 600-mg loading dose clopidogrel were identified by LTA and HPR 
was identified in 248 of a total of 1,789 patients. In patients with HPR, the maintenance 
dose of clopidogrel was increased to 150–300 mg daily or clopidogrel was replaced by 
ticlopidine 500–1,000 mg daily. The choice of medication and its maintenance dose 
were guided by repeated LTA measurements. However, 94 patients (38 %) still exhibited 
HPR after this treatment adjustment. At 2 years, the rate of the primary endpoint (a 
composite of cardiac death, AMI, urgent revascularization, or stroke) was significantly 
higher in the HPR group (14.5 %) than in the normal-response group (8.7 %) with 
nearly doubled rates of cardiac mortality and ST in the HPR group. However, increases 
in the maintenance dose of clopidogrel or switching ticlopidine failed to mitigate the 
increased atherothrombotic risk in the HPR group. This could partly be due to the 
proportion of patients that still had HPR after the adjustment of antiplatelet therapy.
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Wang et al.
Wang et al. conducted a randomized, controlled trial in patients that underwent PCI 
for stable CAD or NSTE-ACS [81]. Platelet inhibition during treatment with clopidogrel 
was assessed with VASP at 1 month after PCI and HPR was defined as VASP-PRI>50 
%. HPR was present in 306 patients who were randomized to a VASP-guided group 
or a control group. VASP was repeated at 3, 6, and 9 months after randomization and 
every time VASP-PRI was >50 % in the VASP-guided group the maintenance dose of 
clopidogrel was increased by 75 mg. No dose adjustments were made in the control 
group. The rate of a combined endpoint of cardiovascular death, angiographically 
confirmed ST, recurrent ACS, and recurrent revascularization at 1 year after PCI 
was significantly higher in the control group. The rate of bleeding events was not 
significantly different between the VASP-guided and control group.
Trenk et al. (TRIGGER-PCI)
The Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on 
Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) study was 
conducted in patients undergoing elective PCI [82]. Platelet reactivity with clopidogrel 
was measured with the VerifyNow® P2Y12 assay and HPR was defined as a PRU >208 
which is a lower cutoff value than the one that was used in GRAVITAS and other studies. 
Of these patients, a total of 2,150 subjects with HPR were planned to be randomized to 
receive either a 60-mg loading dose followed by a daily 10-mg dose prasugrel or a 600-
mg loading dose followed by a daily 75-mg dose clopidogrel. The primary endpoint of 
the trial was AMI or cardiovascular death at 6 months of follow-up. 
The trial was prematurely halted after 18 months of enrollment because of futility as a 
blinded interim analysis in 432 patients (250 of whom had reached the 6-month follow-
up) yielded a primary endpoint event rate that was much lower than expected (2.3 % 
versus the expected 7 % rate). This low event rate has been attributed to the fact that 
low-risk patients were enrolled as high-risk ACS patients and patients with previous 
stroke or unsuccessful or complicated PCI procedures were excluded. In addition, the 
use of second-generation drug-eluting stents, which are associated with lower rates of 
post-PCI ischemic or thrombotic events, could have played a role. However, the lower 
cutoff for HPR might also have altered the predictive performance of VerifyNow®.
Collet et al. (ARCTIC)
The latest study evaluating antiplatelet tailoring on the basis of HPR is the Conventional 
Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent 
Implantation and of Treatment Interruption versus Continuation One Year after 
Stenting (ARCTIC) study [83]. This was a randomized, multicenter, open-label trial in 
patients with a planned PCI. Approximately one quarter of the 2,440 enrolled patients 
presented with NSTE-ACS. In the 1,213 patients randomized to the platelet function 
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testing (PFT)-guided treatment group, clopidogrel and aspirin responsiveness was 
assessed with the VerifyNow® assay. Platelet reactivity was measured prior to the PCI 
and 2 to 4weeks after PCI. In the PFT group, HPR was present in 419 (34.5 %) patients.
General recommendations for treatment adjustments based on the PFT results were 
provided in the PFT group. However, the choice of antiplatelet therapy was left to 
the operator’s discretion in both the PFT and conventional group. Most patients who 
exhibited HPR prior to the PCI were treated with a maintenance dose of clopidogrel 150 
mg daily after the intervention. Only a subset of patients was treated with prasugrel 
as the drug became available during the conduction of this trial. In contrast to earlier 
studies, this study also incorporated a strategy for patients with LPR. Patients on 
prasugrel 10 mg daily or clopidogrel 150 mg daily that exhibited LPR at 2 to 4 weeks 
after PCI were switched to clopidogrel at a maintenance dose of 75mg. The proportion 
of patients that exhibited LPR and subsequently received a medication adjustment 
was not reported in the paper. At 1-year follow-up, the rate of the primary endpoint, 
a composite of death, AMI, stroke or transient ischemic attack, urgent coronary 
revascularization, and ST, did not differ between treatment groups (34.6 vs. 31.1 %; 
HR 1.13 [95%CI, 0.98–1.29]). The composite endpoint was driven by troponin-defined 
periprocedural AMI which may not have been thrombosis-mediated as strong GPIIb/
IIIa inhibition had no protective effect. The rates of the more important hard endpoints 
such as death and ST were low (<2 % during 1 year of follow-up). Furthermore, a 
substantial number of patients were not treated according to protocol as not all HPR 
patients received a GPIIb/IIIa inhibitor or stronger platelet inhibitor during follow-up. 
Similar to many of the preceding trials, the adjustments in antiplatelet therapy did not 
result in the abolishment of HPR in all patients. Of the 34.5 % of patients with HPR 
prior to PCI, 15.6 % still had HPR at 2 to 4 weeks after PCI.
 
CONCLUSION
On the basis of the available evidence, we conclude that there is no place in daily 
clinical practice for the routine measurement of platelet reactivity in stable CAD 
patients undergoingPCI. The presence of HPR, despite treatment with P2Y12 receptor 
inhibitors, is associated with an increased risk of atherothrombotic events but no 
benefit has been shown with respect to the adjustment of antiplatelet therapy in this 
patient group. Most trials investigating this strategy used higher doses of clopidogrel 
or temporary measures like GPIIb/IIIa inhibitors to alleviate HPR, although it was not 
abolished in a substantial proportion of patients. These HPR rates might be further 
reduced with the administration of prasugrel or ticagrelor. However, the rate of 
atherothrombotic events is already low in stable CAD or PCI patients and, therefore, 
it would be difficult to improve this rate by tailoring antiplatelet therapy. Even if a 
reduction in adverse events could be achieved, a very large study population would be 
needed to demonstrate this difference in a clinical trial. Moreover, the administration 
of prasugrel or ticagrelor in HPR patients increases the risk of bleedingwhich, in fact, 
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could counteract the reduction in atherothrombotic events. In contrast to the tailoring 
of antiplatelet therapy in low-risk, stable patients, the adjustment of treatment based 
on platelet function testing in ACS patients has not been extensively studied.
 
F U T UR E PER SPEC T I V E S
Future research regarding tailoring of antiplatelet therapy on the basis of HPR should 
focus on testing patients with a high risk for atherothrombotic events such as patients 
with ST elevation myocardial infarction (STEMI) or patients with a history of ST [84]. 
In addition, more focus on the downside of platelet inhibition, namely the relationship 
between LPR and bleeding complications, is needed. The definite determination of a 
“therapeutic window” of platelet inhibition could be helpful to guide the choice for 
antiplatelet therapy to prevent both ischemic and bleeding complications. 
Besides platelet function testing to guide antiplatelet therapy, the use of genetic 
testing could also be useful in tailoring antiplatelet therapy. At our institution, we are 
currently recruiting STEMI patients for the POPULAR GENETICS study, (ClinicalTrials.
gov Identifier, NCT01761786) in which antiplatelet therapy is tailored to CYP2C19 
metabolizer status. In the genotyping group of this randomized controlled trial, the 
patients that present with a CYP2C19 LOF allele are treated with ticagrelor or prasugrel 
and non-carriers of these LOF alleles are treated with clopidogrel. The control group is 
treated with ticagrelor or prasugrel as recommended by the ESC STEMI guidelines [4].
The Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI) trial (ClinicalTrials.gov 
Identifier: NCT01742117) also investigates the tailoring of antiplatelet therapy on the 
basis of CYP2C19 genotype. This study will recruit patients presenting with ACS or 
stable coronary artery disease. In the genotyping group, CYP2C19 LOF allele carriers 
are treated with ticagrelor and non-carriers are treated with clopidogrel, which is 
similar to the strategy employed in the POPULAR GENETICS study. The control group, 
however, is treated with clopidogrel as there currently is no indication for the more 
potent P2Y12 receptor inhibitors in stable CAD patients. In addition, the ACCF/AHA 
STEMI guidelines do not recommend the use of ticagrelor or prasugrel instead of 
clopidogrel as the ESC guideline does [2]. 
The results from both these studies will hopefully determine if tailoring of antiplatelet 
therapy based on CYP2C19 genotype is a feasible and effective strategy.
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A BST R AC T
Antiplatelet drugs are widely used in the treatment of patients with coronary artery 
disease. Dual antiplatelet therapy with acetylsalicylic acid (ASA) and a P2Y12 inhibitor 
(clopidogrel, prasugrel or ticagrelor) is the recommended strategy for patients 
undergoing a percutaneous coronary intervention (PCI), while patients that undergo 
coronary artery bypass grafting (CABG) are treated with ASA monotherapy. However, 
the response to these drugs as assessed with platelet function tests varies between 
patients. Despite these drugs, many patients still exhibit high on-treatment platelet 
reactivity (HPR), while platelet reactivity seems to be excessively inhibited in other 
patients. This review will discuss the use of platelet function testing in the prediction 
of atherothrombotic and bleeding events in patients undergoing PCI or CABG. 
Furthermore, options for tailoring based on platelet function testing in these patients 
are described. 
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1.  I N T RODUC T ION
Millions of people worldwide are treated with antiplatelet agents for the prevention 
of atherothrombotic cardiovascular events. The introduction of these drugs has 
immensely improved the clinical outcome of patients suffering from coronary artery 
disease (CAD). Acetylsalicylic acid (ASA) monotherapy is the recommended strategy 
for patients with stable CAD.1 Dual antiplatelet therapy (DAPT) consisting of a 
combination of ASA and a P2Y12 inhibitor is the recommended strategy for patients 
presenting with an acute coronary syndrome (ACS) and patients who undergo 
percutaneous coronary intervention (PCI) with stent placement.1-3 The most used 
P2Y12 inhibitor worldwide is clopidogrel.
Despite these treatment strategies, the rate of atherothrombotic events in these 
patient populations remains quite high. For ACS patients treated with ASA and 
clopidogrel, the rate of all-cause death, MI and stroke at 1 year are 5.9%, 6.9% and 
1.3%, respectively, in the Study of Platelet Inhibition and Patient Outcomes (PLATO)4. 
In PCI patients treated with ASA and clopidogrel, all-cause death occurs in 1.9% of 
patients, 3.1% experience MI and 0.84% experience stent thrombosis (ST) during 1 
year follow-up.5 These numbers leave room for improvement, but the way to improve 
clinical outcome is different for each patient population and also depends on the 
currently employed treatment regimen.
For patients who are treated for an ACS and/or undergo PCI the focus for reducing 
atherothrombotic events has been on clopidogrel. Clopidogrel is associated with great 
interindividual variability in its platelet inhibiting effect, as assessed with platelet 
function tests, with around 30% of patients exhibiting high on-treatment platelet 
reactivity (HPR).6 New P2Y12 inhibitors, such as prasugrel and ticagrelor, have been 
developed with the help of platelet function tests, to try to further reduce platelet 
reactivity. Both prasugrel and ticagrelor inhibit platelet reactivity more potently than 
clopidogrel and with less interindividual variability. In accordance with these results, 
the newer drugs have shown to improve clinical outcome compared to clopidogrel in 
ACS patients and are now recommended instead of clopidogrel in ACS patients. 2-4, 7 
However, the more potent drugs also increase the rate of bleeding events.4, 7 This could 
lead to problems, as was shown in the recently published Comparison of Prasugrel at 
the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of 
Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial.8 
Pretreatment with prasugrel did not reduce the rate of atherothrombotic events among 
patients with non ST-segment elevation myocardial infarction (NSTEMI) undergoing 
PCI included in this trial, but did increase the rate of TIMI major bleeding. It might 
therefore be preferable to use antiplatelet treatment regimens that are tailored to the 
individual patient. One way to do this could be to use the aforementioned platelet 
function tests.
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The recommended antiplatelet treatment for patients that undergo coronary artery 
bypass surgery (CABG) is ASA monotherapy.9-12 Many of these patients receive 
saphenous vein grafts (SVGs). Multiple studies performed in CABG patients show that 
the frequency of SVG occlusion is up to five times higher in patients who are not treated 
with ASA, compared to those who received different doses of ASA after surgery.13 
However, SVG occlusion still occurs in 6.8-26% of all grafts at 1 year of follow-up after 
CABG.14-17 Furthermore, the rate of all-cause death is still 3.5-5.0%, the rate of MI 
is 3.3-7.5% and the rate of stroke is 1.7-2.2% at 1 year follow-up.18, 19  Comparable to 
treatment in ACS and PCI patients, treatment in CABG patients needs to be improved.
Since variability in the effect of ASA on platelets has been found in CABG patients on 
ASA monotherapy20, other treatment options, such as the addition of or substitution 
by dipyridamole, warfarin or clopidogrel, have been explored.16, 21-24 As of yet, no other 
treatment regimen has been proven to be superior, but multiple studies, including trials 
using the newer agents prasugrel and ticagrelor, are still underway (NCT01560780, 
NCT01755520).
Bleeding, which is the downside of ASA and P2Y12 inhibitors, has been an important 
subject in research regarding CABG patients for much longer than in ACS or PCI 
patients. Assessment of platelet reactivity in CABG patients treated with antiplatelet 
drugs could be useful to determine if an operation has to be postponed to allow platelet 
reactivity to recover after antiplatelet therapy discontinuation.25 These tests could also 
be helpful in guiding interventions in patients who bleed during or after surgery.26 
This review will highlight the current evidence regarding platelet function testing in 
PCI and CABG patients. The ability to predict atherothrombotic and bleeding events 
with these tests and the possibilities for tailoring treatment based on their results will 
be discussed. First, we will further describe the response variability in clopidogrel and 
ASA treated patients.
 
2 .  VA R I A BLE R E SPONSE TO A N T IPL AT ELET DRUG S
2 .1 P2Y 1 2 I NHIBI T OR S
The variability in inhibition of platelet reactivity by clopidogrel is well-established. 
Part of this variability can be attributed to the fact that the pro-drug needs to be 
converted to an active metabolite before it can prevent adenosine diphosphate 
(ADP) from activating platelets through their P2Y12 receptors. The cytochrome P450 
2C19 (CYP2C19) enzyme, which is encoded in the CYP2C19 gene, is involved in this 
conversion and different defective polymorphisms of the CYP2C19 gene have been 
demonstrated. The most common loss-of-function (LOF) alleles are the CYP2C19*2 
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and CYP2C19*3 allele. Carriers of these LOF alleles show higher levels of platelet 
reactivity on clopidogrel.27, 28 In CYP2C19*2 heterozygotes, daily doses of 225 mg of 
clopidogrel are necessary to achieve a degree of platelet inhibition which is comparable 
to that observed in patients without a CYP2C19 LOF allele who are treated with 
standard daily doses of 75 mg of clopidogrel. Moreover, the level of platelet inhibition 
in non-carriers cannot be achieved with clopidogel in CYP2C19*2 homozygotes, 
even when daily doses of 300 mg are used.29 In addition to a relation with platelet 
reactivity, the LOF CYP2C19 polymorphisms are also associated with the occurrence 
of atherothrombotic events.30-32 Besides LOF alleles, there is also a gain-of-function 
(GOF) allele, called CYP2C19*17. CYP2C19*17 carriers have an increased metabolism 
of clopidogrel and show lower levels of platelet reactivity on clopidogrel.33, 34 This GOF 
allele has been associated with an increased risk of bleeding after PCI.35 In addition 
to these polymorphisms that affect the antiplatelet effect of clopidogrel, factors such 
as age, body mass index, diabetes, and drugs and agents that use the same metabolic 
pathways as clopidogrel (certain proton pump inhibitors, some calcium channel 
blockers, phenprocoumon and cigarette smoke) all influence platelet reactivity as 
well.36-46 Moreover, part of the response variability is still unexplained.47
2 . 2 A S A
In contrast to the response variability observed with the use of clopidogrel, the 
variability on ASA treatment is less well-established. The inhibitory effect of ASA on 
blood platelets can be assessed with various laboratory tests. The antiplatelet effect of 
ASA is primarily attributed to the irreversible acetylation of cyclooxygenase enzyme-1 
(COX-1) in platelets. This prevents arachidonic acid (AA) from binding to the catalytic 
site and thereby inhibits prostaglandin H2 (PGH2) synthesis. As a result the generation 
of thromboxane A2 (TxA2), and thereby TxA2-induced platelet aggregation, are 
inhibited.
Platelet function tests measure platelet reactivity in vitro and thereby quantify 
the inhibiting effect of ASA on platelets. Other tests determine the effect of 
ASA by measuring the serum levels of thromboxane B2 (TxB2) or urine levels of 
11-dehydro-thromboxane B2 (UTxB2), because TxA2 is rapidly hydrolyzed to the 
stable physiologically inactive metabolite TxB2. If these levels are too high, patients 
are deemed “aspirin resistant”. However, there is no uniformly accepted reliable and 
specific laboratory method to test the effect of ASA on platelets as of yet.48 If platelet 
function tests are used, the term HPR on ASA might be a more apt description of 
the observed effect. As different tests use various methods of platelet activation, it 
is important to note that shear and stimulation by ADP, collagen, and epinephrine 
can activate platelets even in the presence of COX-1 blockade. Methods that use these 
agonists can therefore not be used as surrogates for the assessment of COX-1 blockade 
by ASA. However, these tests have been used to detect the inhibition of platelet 
reactivity in the past, which is why the reported rates of “aspirin resistance” vary 
greatly. The prevalence of “aspirin resistance” after CABG for example, ranges from 
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10% to up to >90% in different studies, and seems to depend on both the assay used 
and the timing of measurements.13, 49
Gluckman et al., for instance, studied ASA resistance in 229 CABG patients treated 
with ASA.50 Three days after surgery 73% of all patients had an elevated UTxB2 level, 
but after 6 months this percentage declined to 31%. HPR was present in 16% of all 
patients as assessed with the VerifyNow Aspirin Assay and in 64% as assessed with the 
PFA-100 COL/EPI test at 3 days after surgery. In contrast, these rates were 10% and 
12% respectively at 6 months. 
The optimal definition of “aspirin resistance” is residual activity of COX-1. Therefore, 
measurements of serum TxB2 or agonist induced TxB2 in platelet-rich plasma 
and AA-induced platelet aggregation are the most specific assays to determine if 
“aspirin resistance” is present.51, 52 The problem with these tests is that serum TxB2 
measurement may be affected by non-platelet sources, such as leukocytes, and 
leukocyte cyclooxygenase enzyme-2 (COX-2) activity may play a role in the response of 
platelets to AA, which is used in all the platelet function tests. Moreover, UTxB2 may 
be influenced by non-platelet sources as it represents whole body TxB2 production, 
especially in pathological conditions of inflammation and high-risk CVD.53 All in all, 
there are many pitfalls in determining the presence of “aspirin resistance”.
The underlying mechanisms of “aspirin resistance” or HPR on ASA are still unclear. 
Specifically for CABG patients, possible factors contributing to its occurrence are 
increased platelet turnover, enhanced platelet reactivity, systemic inflammation, 
and drug-drug interactions some of which are related to the cardiopulmonary bypass 
(CPB) that is often used during surgery.13 An association between HPR on ASA and a 
genetic polymorphism and obesity has also been suggested.54
3.  PAT IE N T S U NDERGOI NG PERCU TA NEOUS  
CORONA RY I N T ERV E N T IONS
3.1 PL AT EL E T F U NC T ION A S A PR EDIC T OR FOR 
AT HERO T HROMBO T IC E V E N T S A F T ER PC I
3.1 .1 P2Y 1 2 I NHIBI T OR S
A great variability is observed with the use of clopidogrel in PCI patients. The clinical 
implication of higher levels of platelet reactivity in clopidogrel treated patients 
undergoing PCI was elucidated by studies that assessed the correlation between 
platelet reactivity and clinical outcomes in these patients. These studies showed that 
there was a clear correlation between platelet reactivity on clopidogrel treatment 
and atherothrombotic events during follow-up and cut-off values that predict for 
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atherothrombotic events were established for many different platelet function tests 
in a consensus document published in 2010.36 A platelet reactivity level above these 
cut-off points is called HPR. The relationship between HPR and an increased incidence 
of atherothrombotic events such as ST and MI in patients undergoing PCI who were 
treated with clopidogrel is shown in Table 1. Moreover, recent observational studies 
suggest that HPR is also relevant in patients treated with the new P2Y12 inhibitors.
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3.1. 2 .  A S A
 “Aspirin resistance” was associated with higher risk of ischaemic events in a few 
studies77, 78, but most of these results were derived from patients treated with ASA 
monotherapy, and not with dual anti-platelet therapy (DAPT). Many of these studies 
were performed with the non-specific tests that not only measure the inhibition of 
COX-1, but total platelet reactivity. This makes it hard to recognize the value of “aspirin 
resistance” in PCI patients.79, 80
Platelet reactivity on ASA was measured in 422 patients undergoing elective PCI with 
stent implantation in the Do Platelet Function Assays Predict Clinical Outcomes 
in Clopidogrel-Pretreated Patients Undergoing Elective PCI (POPular) study.81 The 
tests that were used were AA-induced light transmittance aggregometry (LTA), the 
VerifyNow (Accumetrics, San Diego, CA, USA) Aspirin Assay, AA prestimulated 
IMPACT-R (Matis Medical, Beersel, Belgium) and the Platelet Function Analyzer (PFA-
100, Dade International Inc. Miami, FL, USA) collagen/epinephrine cartridge (PFA-
100 COL/EPI). Optimal cut-off values for HPR on ASA for each test were established 
by ROC curve analysis. At 1 year follow-up, the composite of all-cause death, non-fatal 
acute myocardial infarction (AMI), ST and ischemic stroke occurred more frequently 
in patients with HPR on ASA when assessed by LTA [10.1% vs. 6.0%, P = 0.020 (n = 
925)] and VerifyNow [13.3%vs. 5.9%,P = 0.015 (n = 422)], while the IMPACT-R (n = 
791) and the PFA-100 COL/EPI (n = 719) were unable to discriminate between patients 
with and without primary endpoint at 1 year follow-up. 
Table 1: These studies all showed an association between HPR, defined by a specific cut-off value, in 
PCI patients treated with clopidogrel and atherothrombotic events during follow-up. Abbreviations: 
ACS = acute coronary syndrome, ADP = adenosine diphosphate, AU = arbitrary units, CAD = coronary 
artery disease, CV = cardiovascular, d = day(s), HPR = high on-treatment platelet reactivity, LTA = light 
transmittance aggregometry, MA = maximum amplitude, MACE = major adverse cardiac events, MI = 
myocardial infarction, mo = month(s), MPA = maximal platelet aggregation, N = number of patients, 
NSTE-ACS = non-ST-segment elevation acute coronary syndrome, NSTEMI = non-ST-segment 
elevation myocardial infarction, PCI = percutaneous coronary intervention, PRI = platelet reactivity 
index, PRU = P2Y12 Reaction Units, ST = stent thrombosis, TEG = thromboelastography, TVR = target 
vessel revascularization, UA = unstable angina, VASP = vasodilator-stimulated phosphoprotein-
phosphorylation, y = year(s).
57
The use of platelet function testing in PCI and CABG patients
Pl
at
el
et
 fu
nc
ti
on
 t
es
t
H
PR
 d
efi
ni
ti
on
PC
I i
nd
ic
at
io
n
N
O
ut
co
m
e 
as
so
ci
at
ed
 w
it
h 
H
PR
Ca
m
po
 e
t a
l. 
20
10
59
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
20
8
St
ab
le
 C
A
D
46
8
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
an
d 
st
ro
ke
 a
t 1
y
M
an
gi
ac
ap
ra
 e
t a
l. 
20
12
60
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
23
9
St
ab
le
 C
A
D
73
2
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
an
d 
T
V
R
 a
t 3
0d
Br
ee
t e
t a
l. 
20
10
6
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
23
6
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
1,
05
2
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
ST
, a
nd
 s
tr
ok
e 
at
 1
y
Ca
m
po
 e
t a
l.6
1
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
23
5
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
30
0
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
an
d 
st
ro
ke
 b
et
w
ee
n 
1-
12
m
o
Pa
tt
i e
t a
l 2
00
86
2
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
24
0
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
16
0
In
cr
ea
se
d 
ra
te
 o
f M
A
CE
 (m
ai
nl
y 
du
e 
to
 p
er
ip
ro
ce
du
ra
l M
I)
 a
t 3
0d
Pr
ic
e 
et
 a
l. 
20
08
63
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
23
5
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
38
0
In
cr
ea
se
d 
ra
te
 o
f C
V
 d
ea
th
, n
on
fa
ta
l M
I a
nd
 S
T 
at
 6
m
o
Pr
ic
e 
et
 a
l. 
20
11
64
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
20
8
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
2,
79
6
In
cr
ea
se
d 
ra
te
 o
f c
ar
di
ov
as
cu
la
r 
de
at
h,
 n
on
fa
ta
l M
I a
nd
 S
T 
at
 6
0d
Su
h 
et
 a
l. 
20
11
65
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
25
2.
5
St
ab
le
 C
A
D
 o
r 
A
CS
71
6
In
cr
ea
se
d 
ra
te
 o
f c
ar
di
ac
 d
ea
th
, n
on
fa
ta
l M
I, 
cl
in
ic
al
ly
 d
ri
ve
n
ta
rg
et
 le
si
on
 re
va
sc
ul
ar
iz
at
io
n,
 a
nd
 is
ch
em
ic
 s
tr
ok
e 
at
 6
m
o
St
on
e 
et
 a
l. 
20
13
5
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 >
20
8
St
ab
le
 C
A
D
 o
r 
A
CS
8,
44
9
In
cr
ea
se
d 
ra
te
 o
f S
T 
an
d 
M
I a
t 1
y
M
ar
cu
cc
i e
t a
l. 
20
09
66
Ve
ri
fy
N
ow
 P
2Y
12
PR
U
 ≥
24
0
A
CS
68
3
In
cr
ea
se
d 
ra
te
 o
f C
V
 d
ea
th
 a
nd
 n
on
fa
ta
l M
I a
t 1
y
G
ur
be
l e
t a
l. 
20
10
67
TE
G
M
A
A
D
P
A
 >
47
m
m
St
ab
le
 C
A
D
22
5
In
cr
ea
se
d 
ra
te
 o
f a
 c
om
po
si
te
 e
nd
po
in
t c
on
si
st
in
g 
of
 c
ar
di
ac
 
de
at
h,
 S
T,
 M
I, 
is
ch
em
ic
 s
tr
ok
e,
 a
nd
 u
np
la
nn
ed
 re
va
sc
ul
ar
iz
at
io
n
at
 3
y
Bl
in
dt
 e
t a
l. 
20
07
68
VA
SP
PR
I >
48
%
St
ab
le
 C
A
D
 o
r 
A
CS
99
In
cr
ea
se
d 
ra
te
 o
f S
T 
at
 6
m
o
Bo
ne
llo
 e
t a
l. 
20
07
69
VA
SP
PR
I >
50
%
St
ab
le
 C
A
D
 o
r 
U
A
14
4
In
cr
ea
se
d 
ra
te
 o
f M
A
CE
 a
t 6
m
o
Fr
er
e 
et
 a
l. 
20
07
70
VA
SP
PR
I >
53
%
N
ST
E-
A
CS
 
19
5
In
cr
ea
se
d 
ra
te
 o
f M
A
CE
 a
nd
 s
tr
ok
e 
at
 3
0d
Cu
is
se
t e
t a
l. 
20
13
71
VA
SP
PR
I >
50
%
A
CS
1,
54
2
In
cr
ea
se
d 
ra
te
 o
f S
T 
at
 6
m
o
Si
bb
in
g 
et
 a
l. 
20
09
72
M
ul
ti
pl
at
e 
AU
·m
in
 ≥
46
8
St
ab
le
 C
A
D
 o
r 
A
CS
1,
60
8
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
 a
nd
 S
T 
at
 3
0d
Si
bb
in
g 
et
 a
l. 
20
12
73
M
ul
ti
pl
at
e 
AU
·m
in
 ≥
46
8
N
ST
EM
I
56
4
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
ur
ge
nt
 T
V
R
 a
t 3
0d
G
ur
be
l e
t a
l. 
20
08
74
LT
A
 5
 μ
m
ol
 A
D
P 
LT
A
 2
0 
μm
ol
 A
D
P
M
PA
 >
46
%
M
PA
 >
59
%
St
ab
le
 C
A
D
29
7
In
cr
ea
se
d 
ra
te
 o
f i
sc
he
m
ic
 e
ve
nt
s 
at
 2
y
Br
ee
t e
t a
l. 
20
10
6
LT
A
 5
 μ
m
ol
 A
D
P 
LT
A
 2
0 
μm
ol
 A
D
P
M
PA
 >
42
.9
%
M
PA
 >
64
.5
%
St
ab
le
 C
A
D
 o
r 
N
ST
E-
A
CS
1,
04
9
1,
05
1
In
cr
ea
se
d 
ra
te
 o
f d
ea
th
, M
I, 
ST
, a
nd
 s
tr
ok
e 
at
 1
y
Cu
is
se
t e
t a
l. 
20
09
75
LT
A
 1
0 
μm
ol
 A
D
P
M
PA
 >
67
%
N
ST
E-
A
CS
59
7
In
cr
ea
se
d 
ra
te
 o
f S
T 
at
 3
0d
Fr
er
e 
et
 a
l. 
20
07
70
LT
A
 1
0 
μm
ol
 A
D
P
M
PA
 ≥
70
%
N
ST
E-
A
CS
 
19
5
In
cr
ea
se
d 
ra
te
 o
f M
A
CE
 a
nd
 s
tr
ok
e 
at
 3
0d
Pa
ro
di
 e
t a
l. 
20
11
76
LT
A
 1
0 
μm
ol
 A
D
P
M
PA
 ≥
70
%
A
CS
1,
78
9
In
cr
ea
se
d 
ra
te
 o
f c
ar
di
ac
 d
ea
th
, M
I, 
an
y 
ur
ge
nt
 c
or
on
ar
y 
re
va
sc
ul
ar
iz
at
io
n,
 a
nd
 s
tr
ok
e 
at
 2
y
Ta
bl
e 
1:
 H
PR
 in
 P
C
I p
at
ie
nt
s 
tr
ea
te
d 
w
it
h 
cl
op
id
og
re
l a
nd
 t
he
 o
cc
ur
re
nc
e 
of
 t
hr
om
bo
ti
c 
ev
en
ts
58
Chapter 1.3
In contrast to this study, the large Assessment of Dual Antiplatelet Therapy With 
Drug-Eluting Stents (ADAPT-DES) registry, which contains 8,583 patients, found 
no correlation between HPR on ASA, defined as VerifyNow Aspirin >550 ARU, and 
ST.5 Therefore, current evidence does not support the screening for ASA response in 
patients after PCI to predict atherothrombotic risk. Moreover, there currently is no 
viable alternative for ASA in patients treated with DAPT.
3. 2 PL AT ELET F U NC T ION A S A PR EDIC TOR FOR BLEEDI NG 
E V E N T S A F T ER PCI
3. 2 .1 .  P2Y 1 2 I NHIBI T OR S
The variability of platelet reactivity levels on clopidogrel treatment does not only lead 
to inadequate platelet inhibition and HPR. On the other side of the spectrum, some 
patients’ platelets appear to be excessively inhibited by standard doses of antiplatelet 
medication.
Multiple large studies using a wide array of platelet function tests in patients 
undergoing PCI have shown no relationship between platelet function test results and 
bleeding events in clopidogrel and prasugrel treated patients.6, 82-85
However, other studies did find a correlation between the presence of LPR on 
treatment and bleeding (see Table 2). Cuisset et al., for example, showed that the rate 
of TlMl major and minor bleeding was significantly higher in PCI patients with platelet 
reactivity on clopidogrel below 40% as assessed with the LTA (10 μmol/L ADP), as 
compared to patients with higher levels of platelet reactivity: 6.6% vs 1.4% (p=0.001).75 
In another study, conducted by Parodi et al., LTA was used to assess the relationship 
between platelet reactivity and bleeding in 298 PCI patients treated with prasugrel. 
LPR, defined as <40% aggregation as assessed with LTA on stimulation with 10 μmol/l 
ADP at 7-30 days after PCI, independently predicted TIMI (minimal, minor or major) 
bleeding at multivariable analysis (Odds Ratio 0.91, 0.88 to 0.95, p=0.001).90
But not only studies using LTA showed this correlation between LPR and bleeding. 
The VerifyNow P2Y12 assay has also been associated with bleeding events in a study 
by Patti et al. In 310 PCI patients a strong correlation was found between PRU ≤189 
and TIMI major bleeding or entry-site complications (hematoma >10 cm in diameter, 
pseudoaneurysm, or arteriovenous fistula) at 30 days follow-up in a multivariable 
analysis.86
Mohktar et al. included 346 PCI patients treated with clopidogrel and showed that 
LPR on treatment as assessed with the vasodilator-stimulated phosphoprotein-
phosphorylation (VASP-P) assay (Diagnostica Stago, Biocytex, Asnières, France) 
before PCI is an independent predictor of non-CABG related TIMI major bleeding.87 
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Grosdidier et al. also assessed platelet reactivity with VASP.88 In 730 ACS patients who 
underwent PCI and were treated with clopidogrel or prasugrel maintenance therapy 
the VASP was performed 1 month after discharge. A total of 517 patients were treated 
with clopidogrel 150 mg daily and 213 patients were treated with prasugrel 10 mg 
daily. HPR (VASP platelet reactivity index (PRI) >50%) was present significantly more 
often in clopidogrel- (35%) than in prasugrel-treated patients (7%). In contrast, LPR 
(VASP-PRI<20%) was exhibited by a significantly greater proportion of patients treated 
with prasugrel (31%) than patients treated with clopidogrel (10%). Patients with LPR 
had a signiﬁcantly greater rate of bleeding complications than patients without LPR in 
multivariable analysis (OR 3.5, 95% CI 2.2 to 9.6; p <0.01). 
Sibbing et al. used a different platelet function test, which is called multiple electrode 
platelet aggregometery (Multiplate Analyzer, F. Hoffmann-La Roche Ltd., Basel, 
Switzerland). This test can be performed with addition of agonists ADP (ADPtest, 6.4 
mM), collagen (COLtest, 3.2 mg/ml), AA (ASPItest, 0.5 mM) or thrombin receptor 
agonist peptide-6 agonist (TRAPtest, 32 mM). Sibbing et al. used the ADPtest in an 
all-comer population of 2,533 PCI patients treated with clopidogrel which included 
ST-segment elevation acute coronary syndrome (STE-ACS) patients. LPR, which was 
defined as <188 AU·min, was significantly associated with post-procedural TIMI 
major bleeding in-hospital (OR 2.6, 95% CI 1.3–5.2; P = 0.005). However, LPR was not 
associated with TIMI minor bleeding events in this study (OR 1.1, 95% CI 0.8–1.5; P 
= 0.68).89, 91
Although not all studies showed a relation between platelet reactivity and bleeding 
events, there is sufficient evidence to conclude that platelet function tests can 
determine bleeding risk in patients treated with P2Y12 inhibitors undergoing PCI. 
Cut-off values to predict bleeding after PCI were proposed in a consensus document 
published in 2013 and are shown in Table 3.48
3. 2 . 2 .  A S A
In the POPular study, platelet reactivity on ASA was measured with AA-induced 
LTA, VerifyNow Aspirin Assay, IMPACT-R AA and PFA-100 COL/EPI in 422 patients 
undergoing elective PCI with stent implantation and none of these platelet function 
tests was able to predict the occurrence of TIMI major or minor bleeding.81
In contrast to these results, the ADAPT-DES study showed that an ARU >550 was 
inversely associated with clinically relevant bleeding (p=0.04). Since an ARU of 550 
was used as the cut-off value for HPR on ASA, it is possible that there is a more optimal 
cut-off value to predict clinically relevant bleeding in PCI patients treated with ASA.5 
Not many other studies have tried to correlate platelet reactivity on ASA with bleeding 
events, so there is insufficient evidence to determine if platelet reactivity on ASA can 
truly predict bleeding events in PCI patients in a reliable fashion.
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Test Value Therapeutic Window
VerifyNow  
·P2Y12 Assay PRU 85
61-2085, 61
Multiplate Analyzer 
·ADPtest AU·min 19-4691
TEG Platelet Mapping Assay 
·ADP-induced platelet-fibrin clot strength mm 32-4767
VASP PRI 16-4956
Table 3. These cut-off values were proposed in a consensus document from Tantry et al. published 
in 2013.48 Abbreviations: AU = arbitrary units, TEG = thromboelastography, VASP vasodilator-
stimulated phosphoprotein-phosphorylation, PRI = platelet reactivity index, PRU = P2Y12 Reaction 
Units.
Table 3. Proposed cut-off values for a Therapeutic Window  
Figure 1: A visualisation of the therapeutic window of platelet reactivity
Platelet reactivity in patients treated with P2Y12 inhibitors is associated with the risk of both ischemic 
and bleeding events. A therapeutic window of platelet reactivity has therefore been proposed, which 
means on-treatment platelet reactivity is neither too low nor too high. Keeping patients in this range 
might reduce the incidence of both ischemic and bleeding events. The values that were proposed for this 
window for different platelet function tests in a consensus document are represented in this figure. 
Abbreviations: AU = arbitrary units, TEG ADP = thromboelastography stimulated with adenosine 
diphosphate, VASP PRI = vasodilator-stimulated phosphoprotein-phosphorylation platelet reactivity 
index, VN PRU = VerifyNow P2Y12 Reaction Units. Adapted with permission from Tantry et al. J Am 
Coll Cardiol. 2013;62:2261-73.48 Figure made by R.G.W. Janssen.
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3. 3 A T HER A PEU T IC W I N DOW
As multiple studies have shown that LPR on clopidogrel can predict bleeding and 
HPR on clopidogrel can predict atherothrombotic events, the concept of a therapeutic 
window for platelet inhibition with a sweet spot flanked by HPR on the one side and 
LPR at the other was developed (Figure 1).60, 75, 84, 91
A study in which a therapeutic window was found for platelet reactivity as measured 
with the VerifyNow P2Y12 assay was performed by Campo et al.
61 Platelet reactivity 
on clopidogrel was assessed in 300 patients both before PCI and at 1 and 6 month 
follow-up. HPR, which was defined as a P2Y12 Reaction Units (PRU) ≥235, at 1 month 
follow-up was a strong independent predictor for ischemic events. Bleeding was 
also independently predicted by platelet reactivity at 1 month, as well as by age as 
a continuous variable, and CYP2C9*17 genotype after multivariable analysis. ROC 
curve analysis revealed that a cutoff of PRU ≤85 best predicted bleeding. Mangiacapra 
et al. also assessed platelet reactivity on clopidogrel with the VerifyNow P2Y12 assay in 
732 patients before they underwent their elective PCI.60 Patients with a PRU ≥239 had 
significantly more ischemic events (death, AMI, or target vessel revascularization) at 
30-day follow-up and were classified as having HPR, while patients with a PRU ≤178 
had significantly more bleeding events at 30-day follow-up and were classified as 
having LPR. Patients without HPR or LPR were classified as having normal platelet 
reactivity and they had a 50% lower risk for the combined endpoint of ischemic and 
bleeding events. This indicates that there was window of optimal treatment between 
179 and 238 PRU. 
A different test that can be used to predict the occurrence of both ischemic and 
bleeding events in PCI patients is thromboelastography (TEG Analyzer, Haemoscope 
Corporation, Niles, IL, USA). This point-of-care whole blood coagulation monitor 
provides information on specific aspects of coagulation, which distinguishes the tests 
from the platelet function tests that are most frequently used in PCI patients. The 
TEG reports the time to production of initial fibrin strands (R-time), time to develop 
a bloodclot (R-time, K-time), rate of fibrin build-up and cross linking (alpha-angle), 
maximum clot strength (maximum amplitude [MA]) and also measures fibrinolysis 
(decreasing amplitude post-MA). An abnormal clot formation, principally an increased 
R-time, implies reduced levels of clotting factors, while a reduced MA implies a reduced 
platelet function, reduced amount of platelets or reduced fibrinogen levels. Multiple 
adaptations have been made in the different studies, mainly by using different reagents. 
Gurbel et al. showed that an MA on stimulation with ADP (MAADP) ≤31 determined 
18-24 hours post-PCI was associated with TIMI major or minor bleeding, while MAADP 
>47mm was independently and significantly associated with adverse ischemic events 
in 225 PCI patients treated with clopidogrel.67
A therapeutic window of platelet reactivity has also been suggested for prasugrel-
treated patients. Bonello et al. assessed platelet reactivity with VASP in 301 patients 
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who were loaded with 60mg prasugrel and who underwent a successful PCI.56 Clinical 
follow-up was available for 292 patients. Patients with HPR, defined as >53.5% PRI, 
had a significantly higher rate of thrombotic events, while a cutoff value of 16% PRI 
was found to be the best predictor for bleeding events. A different study by Cuisset et 
al. used the VASP in 1,542 ACS patients undergoing PCI (19% on clopidogrel 75mg, 
56% on clopidogrel 150mg, 25% on prasugrel 10mg).71 VASP PRI ≤10% independently 
predicted any BARC bleeding not related to the access site and PRI >50% independently 
predicted ST at 6 months after PCI. When ST and BARC bleeding ≥2 were pooled, 
patients with PRI >10% and <50% experienced the least events.
The results from the recently published large multicenter ADAPT-DES study also 
support the existence of a therapeutic window.5 In this registry including 8,583 
patients undergoing PCI, platelet reactivity in patients treated with ASA, clopidogrel, 
and glycoprotein (GP) IIb/IIIa inhibitors was assessed with the VerifyNow Aspirin, 
P2Y12, and IIb/IIIa assays, respectively. HPR was significantly associated with the 
occurrence of ST and AMI, but was also inversely correlated with major bleeding. The 
presence of HPR did not independently predict mortality on multivariable analysis. 
All these studies suggest that there is therapeutic window for platelet reactivity. Both 
cutoff levels for HPR and LPR have been established and are described in consensus 
documents (Table 3).36, 48
 
3.4 PL AT EL E T F U NC T ION GU I DED T R E AT ME N T A F T ER PC I
The relationship between HPR and adverse events led to the concept of platelet 
function based tailoring of antiplatelet therapy. The hypothesis was that lowering 
platelet reactivity in HPR patients would reduce the incidence of atherothrombotic 
events such as ST and MI. Multiple studies have been conducted, of which most were 
focused solely on the presence of HPR as the predictive value of LPR was demonstrated 
more recently. The strategy that was chosen to lower platelet reactivity in HPR patients 
was often the administration of higher doses of clopidogrel, but studies using GP IIb/
IIIa inhibitors and ticlopidine have also been performed. A lot of these trials were 
relatively small, and we will not discuss these small studies in this review. 
The large studies that were conducted regarding this topic are summarized in Table 
4. While some of these trials showed a reduction in atherothrombotic events in the 
platelet function guided group, the largest trials within this selection did not show 
this benefit. The Conventional Antiplatelet Strategy versus a Monitoring-guided 
Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption versus 
Continuation One Year after Stenting (ARCTIC) study was the latest study evaluating 
antiplatelet tailoring on the basis of HPR.82 This randomized, multicenter, open-label 
trial included 2,440 patients (approximately 25% of whom presented with NSTE-ACS) 
who underwent a planned PCI, of whom 1,213 were randomized to a platelet function 
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The use of platelet function testing in PCI and CABG patients
testing guided group. Platelet reactivity on clopidogrel and ASA was assessed with the 
VerifyNow prior to PCI and treatment was adjusted according to these measurements 
in the intervention group. The rate of the primary endpoint, which was a composite of 
death, MI, stroke or transient ischemic attack, urgent coronary revascularization, and 
ST, did not differ between treatment groups at 1 year of follow-up (34.6 vs. 31.1 %; HR 
1.13 [95 % CI, 0.98–1.29]). This composite endpoint was driven by troponin-defined 
periprocedural MI, while the rates of the more important hard endpoints such as death 
and ST were low (<2 % during 1 year of follow-up).
Multiple explanations can be given for the lack of effect of tailoring antiplatelet 
treatment based on platelet function testing in these trials. Some claim that HPR is 
a non-modifiable risk factor, but this is contested by others based on the fact that 
drugs that were designed to achieve a lower level of platelet reactivity also improve 
clinical outcome.4, 7 One important point is that the chosen strategy to reduce HPR 
has generally not been effective, with double doses of clopidogrel or the temporary 
platelet inhibition with GP IIb/IIIa inhibitors. Although the rate of HPR was reduced 
in these trials, it was not abolished in the platelet function guided group. Another 
obstacle is the low event rate in the selected populations. With ST rates as low as 0.7% 
in the control group of the ARCTIC, for instance, it is indeed very difficult to make a 
difference by changing treatment in approximately 30% of the platelet function guided 
group (the patients with HPR), even if the selected intervention was able to reduce 
HPR in all patients. Future trials should therefore aim to include high-risk populations 
and use more potent means of reducing the occurrence of HPR, such as prasugrel or 
ticagrelor, in all patients with HPR. Additionally, they should focus on the safety 
of this intervention by using a therapeutic window of platelet reactivity, to prevent 
overtreatment and an associated increased risk of bleeding as much as possible.
Preliminary data from 300 ACS patients treated with prasugrel who were tested for 
LPR and accordingly switched to clopidogrel if on-treatment reactivity was indeed 
too low, demonstrated a lower rate of minor bleeding following the down-titration 
of antiplatelet therapy. This indicates that adjustment of treatment based on LPR 
might indeed be a viable option.92 Some trials in which the tailoring of antiplatelet 
treatment based on platelet function testing in PCI patients is investigated are still 
ongoing (ANTARCTIC [NCT01538446], PLATFORM [NCT01943903]93), which 
could give us more insight into what patient population to select for this strategy. 
Table 4: These are the largest studies that investigated a strategy of tailoring antiplatelet therapy 
based on platelet function testing in PCI patients treated with clopidogrel. Abbreviations: ACS = 
acute coronary syndrome, ADP = adenosine diphosphate, AU = arbitrary units, CAD = coronary 
artery disease, d = day(s), HPR = high on-treatment platelet reactivity, LTA = light transmittance 
aggregometry, MACE = major adverse cardiac events, mo = month(s), MPA = maximal platelet 
aggregation, NSTE-ACS = non-ST-segment elevation acute coronary syndrome, PCI = percutaneous 
coronary intervention, PRI = platelet reactivity index, PRU = P2Y12 Reaction Units, ST = stent 
thrombosis, TEG = thromboelastography, TVR = target vessel revascularization, UA = unstable angina, 
VASP = vasodilator-stimulated phosphoprotein-phosphorylation, y = year(s).
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4 .  PAT IE N T S U NDERGOI NG CORONA RY A RT ERY BY PA S S 
GR A F T I NG 
4 .1 PL AT EL E T F U NC T ION A S A PR EDIC T OR FOR BL EEDI NG 
E V E N T S A F T ER C A BG
In contrast to the use of platelet function tests in PCI patients, the primary focus of 
platelet function testing in patients undergoing surgery has been on bleeding events. 
This is why this section starts by describing the evidence for platelet function tests as 
a predictor for bleeding after CABG.
Post-operative bleeding can be divided into surgical or microvascular bleeding. When 
a surgical bleed occurs, the surgeon generally has to intervene. When microvascular 
bleeding occurs, however, a surgical intervention will not be effective. In this case, 
adequate coagulation has to be achieved by returning clotting factor levels, platelet 
numbers and platelet function to normal. Different products can be used to recover 
coagulation, such as erythrocyte transfusions, platelets, and clotting factor products 
(fresh frozen plasma, prothrombin complex concentrate). These products are used 
quite often in patients undergoing cardiac surgery99, but there are downsides to this 
treatment, which include increased costs, transfusion reactions, and blood-borne 
infections.100, 101 
Cardiothoracic surgeons and anaesthesiologists are especially weary of bleeding 
complications when patients are treated with oral anticoagulants or antiplatelet agents 
before surgery. Recent exposure to clopidogrel, for instance, is related to periprocedure 
blood loss and the need for transfusion and hemostatic re-exploration after CABG.102-
105 Moreover, increased drain production is associated with higher 30-day mortality 
and other postoperative complications such as stroke.106
We will now discuss the studies that have been published with regard to the prediction 
of postoperative bleeding in patients undergoing cardiac surgery, including CABG. 
These studies used different tests and are displayed in Web table 1.
4 .1 .1 .  T HROM BOEL A S T OGR A PH Y A N D R E AGE N T- S U PPOR T E D 
T HROMBOEL A S T OME T RY 
The tests that have been used most often for the prediction of postoperative bleeding 
are TEG and Reagent-supported thromboelastometry (ROTEM, TEM International, 
Munich, Germany), a mechanically modified TEG with standardized reagents.129 Like 
with TEG, multiple adaptations have been made and different assays can be performed 
with ROTEM.
In the 1980s a correlation between TEG results and postoperative bleeding and 
reoperation after CABG with use of CPB was revealed. The TEG was a better predictor 
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than the routine coagulation tests activated clotting time (ACT), prothrombin time 
(PT), partial thromboplastin time (PTT), platelet count, and fibrinogen level that were 
used in routine practice.108, 109 The initial studies were quite small107, but Ereth et al. 
included a larger cohort of 200 patients undergoing cardiac surgery with CPB.117 TEG 
MA, with a cut-off value of 44 mm, was associated with increased blood loss during 
the first 4 hours after surgery in this study. Kwak et al. studied a total of 100 patients 
undergoing CABG without CPB use who were treated with ASA 100 mg and clopidogrel 
75 mg for at least 1 week.114 In a multivariable analysis, the highest tertile of platelet 
inhibition on clopidogrel was the only independent risk factor for transfusion 
requirement.
ROTEM analyses can be performed with different activators including tissue factor 
activation (EXTEM), tissue factor activation and platelet inhibition (FIBTEM) and 
contact activation (INTEM). Reinhöfer et al. used the ROTEM in a study that included 
150 patients undergoing elective CABG with CPB, of whom around 50% was pre-
treated with antiplatelet drugs.118 Patients with EXTEM and FIBTEM values outside 
the reference ranges had signiﬁcantly more postoperative blood loss when compared 
with those with values within the reference ranges. ROTEM was also performed in a 
study by Cammerer et al., who included 255 patients undergoing cardiac surgery (53% 
of whom underwent isolated CABG).119 In addition, they used the PFA-100 stimulated 
with ADP and epinephrine. Both ROTEM and the PFA tests after cessation of CPB were 
significantly different in patients who showed abnormal blood loss in the postoperative 
period. However, the relationship between bleeding and the TEG variables, although 
statistically significant, had little positive predictive value and were mainly significant 
as a result of the large number of patients in each group.
In contrast to the previously mentioned studies, other studies did not show any 
correlation between ROTEM or TEG variables and postoperative blood loss, including 
a study by Wang et al. in 101 patients undergoing CABG and/or valve surgery.110-113 The 
inconsistency in results that were obtained in the various studies could in part be due 
to differences in the ROTEM and TEG tests that were applied and the timing of testing. 
4 .1 . 2 .  PL AT EL E T WOR K S
Dálen et al. studied 49 patients who underwent primary isolated CABG with CPB 
using the Plateletworks ® (Helena Laboratories, Beaumont, TX, USA).122 Tubes 
primed with thylenediaminetetraacetic acid (EDTA; 1.8 mg), and 10 μg/ml collagen, 
were used in all patients. Stimulation with ADP (20 μ mol/l) was only used in the 33 
patients treated with clopidogrel. The tertile of patients with the lowest ADP-induced 
platelet aggregation had larger chest drainage volumes and received significantly 
more transfusions of any blood product (packed red cells, platelet concentrates and 
plasma) during the ﬁrst 24 hours postoperatively than remaining patients. Moreover, 
this tertile contained all four patients that underwent re-exploration. The correlation 
between ADP-induced platelet reactivity and chest drain output remained signiﬁcant 
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after logistic regression analysis. However, anaesthesiologists were not blinded to 
preoperative antiplatelet therapy in this trial, leaving a possible bias for patients with 
recent intake of clopidogrel (and therefore lower levels of platelet aggregation on ADP 
stimulation) to be more likely to receive postoperative administration of platelet 
concentrates, plasma, coagulation factor concentrates and tranexamic acid.
Ostrowsky et al. also showed a signiﬁcant correlation between preoperative platelet 
function assessed with Plateletworks stimulated with collagen and postoperative chest 
drainage volume in patients undergoing CABG, as did Orlov et al.115, 123 In contrast, 
Lennon et al. found no such correlation.121 Orlov et al., Chen et al. and a very recent 
study by Dalén et al. did not find a correlation between ADP stimulated Plateletworks 
results and postoperative bleeding.120, 123, 130
4 .1 . 3.  M U LT I PL AT E
The Multiplate is another test that has been used to asses platelet reactivity in patients 
undergoing surgery. Reece et al. measured platelet reactivity with Multiplate and LTA 
in 44 patients undergoing routine coronary artery surgery.124 Platelet aggregation 
measured with ADPtest (18 U vs 29 U, p=0.01) and TRAPtest (65 U vs 88 U, p=0.01) 
was reduced in patients who received blood transfusions compared to patients 
who did not. Petricevic et al. performed the Multiplate in 211 patients undergoing 
isolated CABG in a prospective observational study.126 Although this study showed a 
statistically signiﬁcant correlation between the ASPItest and the ADPtest and chest 
tube (CT) output after surgery, these correlations were not strong. This might in part 
be explained by the fact that Multiplate tests were performed prior to surgery and 
therefore did not asses the effect of CPB on platelet function and the consequent risk 
of bleeding. Patients who received packed red blood cells (PRBC) transfusion had 
signiﬁcantly lower ASPI test values compared to the patients not exposed to PRBC (p 
= 0.002).
Solomon et al. assessed platelet reactivity with both the Multiplate test (ADPtest, 
ASPItest, and COLtest) and another whole-blood platelet analyzer: the cone and 
plate(let) analyzer Impact-R.128 This test investigates platelet function in citrate-
anticoagulated whole blood by measuring adhesion and aggregation of platelets 
subjected to shear stress on a thrombogenic surface and expressing it as percentage 
of surface coverage (SC) and average size of platelet aggregates (AS). The ASPItest, 
ADPtest and COLtest all significantly correlated with the number of units of platelet 
concentrates transfused intraoperatively. No correlations between preoperative 
aggregometry tests and intraoperative transfusion of other types of allogeneic blood 
products (RBC, FFP) were observed. Impact-R SC was correlated with intraoperative 
platelet concentrates transfusion.
In contrast to these results, Keyl et al. found no significant correlation between platelet 
reactivity assessed with the Multiplate ASPItest and TRAPtest and postoperative 
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mediastinal drain production at any time point in a total of 86 consecutive patients 
undergoing elective CABG with CPB.127
4 .1 .4 .  V ER I F Y NOW
Alström et al. performed an array of tests including VASP, TEG Platelet Mapping 
and the VerifyNow Aspirin and P2Y12 assays in 60 patients undergoing CABG who 
were treated with clopidogrel and ASA.116 The VerifyNow P2Y12 assay was the only 
measurement of platelet inhibition that correlated significantly with total blood loss 
(intra- and postoperative blood loss) and the total number of red blood cell transfusions. 
When patients were analyzed based on aprotinin treatment (yes or no), there was no 
significant correlation between VerifyNow P2Y12 and total blood loss. However, there 
was a weak, non-significant correlation in patients who did not receive aprotinin.
4 .1 . 5.  H E MOS TAT U S
While one study showed a high degree of correlation between clot ratio values as 
measured with the HemoSTATUS point-of-care test (Medtronic, Minneapolis, MN, 
USA) and cumulative CT drainage in the first 4 postoperative hours after CABG131, 
these results could not be reproduced in multiple other studies.117, 132, 133
Based on this evidence, we conclude that platelet function tests can indeed predict the 
occurrence of excessive bleeding. However, the optimal tests, cut-of values and timing 
of these tests all still have to be established as there are contrasting results in different 
studies. The use of different test methods and bleeding definitions in combination 
with variations in bleeding management in different centers make it hard to compare 
these studies and apply them to clinical practice. 
4 . 2 PL AT EL E T F U NC T ION A S A PR EDIC T OR FOR 
AT HERO T HROMBO T IC E V E N T S A F T ER C A BG
The evidence for the prediction of atherothrombotic events after CABG with platelet 
function testing is not as prevalent as it is for postoperative bleeding. However, 
some studies did show an association between high platelet reactivity on ASA or ASA 
resistance and atherothrombotic events. In a study by Poston et al., a TEG analysis 
specifically altered to test the effect of ASA in 76 patients who were maintained on 
perioperative ASA and underwent off-pump CABG, was significantly different in the 
8 patients that developed SVG thrombosis as compared to the other patients that did 
not.134
Furthermore, Bevilacqua et al. studied platelet function as measured with the PFA-100 
COL/EPI test at 1 month after CABG (with or without CPB) in 202 patients.135 A total 
of 68 (33.7%) patients underwent an urgent surgical procedure and usually stopped 
antiplatelet therapy a few days before surgery, while stable patients discontinued 
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antiplatelet medication 7 days before surgery. CPB was used in 185 patients and did not 
influence the distribution of platelet reactivity. The mean follow-up for clinical events 
in this study was 32 ± 10 months, which included annual stress tests. HPR, defined as 
a PFA-100 COL/EPI CT <190 seconds, was strongly and independently associated with 
the recurrence of angina, and with the occurrence of a composite endpoint consisting 
of cardiovascular death, recurrent angina or ischemia, and graft failure.
In a study by Gluckman et al., platelet reactivity was also assessed with the PFA-100. In 
addition to the COL/EPI test, the PFA-100 COL/ADP tests and the VerifyNow Aspirin 
Assay were performed in 229 CABG patients treated with ASA.50 Furthermore, TxA2 
generation was assessed by measuring UTxB2 levels and SVG patency was assessed at 6 
months after CABG by multidetector computed tomography. PFA-100 COL/ADP CT and 
UTxB2 measured at 6 months correlated with SVG occlusion at 6 months by univariate 
analysis when expressed both as continuous variables and as binary variables based 
on respective median (CT 88 seconds) and upper quartile values (UTxB2 450 pg/mg 
creatinine). This remained the case in multivariable analysis. 
A prospective trial with the aim to evaluate the prevalence of TEG-hypercoagulability 
in CABG patients and its association with clinical outcome at 30 days was conducted by 
Rafiq et al.136 In all 200 patients ASA and clopidogrel were discontinued 5 days before 
surgery. Patients withTEG-hypercoagulability, defined as an MA of ≥69 mm, were 
significantly more often on postoperative DAPT (ASA + clopidogrel). A multivariate 
logistic regression model demonstrated that higher age, platelet count and fibrinogen 
were independently associated with the occurrence of TEG-hypercoagulability. 
Hypercoagulable patients had a significantly higher 30-day combined event rate of 
MI, stroke and mortality as compared to normocoagulable patients (17.2 vs. 6.6%, 
p = 0.019). However, multivariate regression analysis revealed that only female 
gender was significantly associated with the 30-day combined event rate, while TEG-
hypercoagulability only demonstrated a trend (P = 0.065). 
Kim et al. performed a prospective cohort trial on 220 patients undergoing elective 
off-pump CABG who received ASA treatment.137 Pre-operative VerifyNow Aspirin 
Assays were used to identify ASA resistant patients. A total of 181 ASA responders 
(82.3%) and 39 ASA non-responders (17.7%) were identified. There were no significant 
differences in troponin I levels (ng/mL) between ASA responders and ASA non-
responders. Furthermore, no significant differences were observed with regard to 
in-hospital outcomes. However, postoperative dual antiplatelet therapy might have 
protected “aspirin resistant” patients as ticlopidine was used by all patients after 
surgery.
Even though most of these studies show the potential of platelet function testing to predict 
atherothrombotic events after CABG, the evidence is insufficient to recommend routine 
testing in CABG patients for this purpose. Larger trials are needed to confirm these results. 
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4 . 3 PL AT EL E T F U NC T ION GU I DED T R E AT ME N T A F T ER C A BG
While studies investigating platelet function guided treatment after PCI focus mainly 
on the long-term atherothrombotic outcome of patients, the studies employing 
tailoring strategies based on platelet function tests in CABG patients focus on short-
term bleeding complications. Several of these studies have investigated the effect of an 
algorithm containing platelet function tests to guide treatment with blood products 
after surgery.
4 . 3.1 .  GU I DA NC E OF T R A N SF U SION M A N AGE ME N T
The studies that investigated a strategy of platelet function testing to guide transfusion 
management/bleeding management are shown in Table 5. We will discuss the largest 
of these studies in this review. One of the first studies describing this treatment 
strategy is a retrospective study performed by Spiess et al. which sought to determine 
the impact of a coagulation and transfusion management program on blood utilization 
in 1,079 sequential patients that underwent myocardial revascularization and open 
heart surgery or combined procedures.139 The author compared 488 patients before and 
591 patients after institution of a TEG-guided coagulation protocol. Patients treated 
with the TEG-guided protocol had a significantly lower incidence of overall transfusion 
(78.5% v 86.3%) during hospitalization and a lower incidence in total transfusion in 
the operating room (57.9% v 66.4%). Mediastinal re-exploration for hemorrhage was 
also much higher before (5.7%) vs. after (1.5%) institution of the protocol. 
Chen et al. prospectively studied 90 patients undergoing primary elective CABG with 
use of CPB.130 A strict protocol based on platelet count, PT/PTT ratio, and platelet 
function testing with LTA (2 mmol/L ADP) and PFA-100 was used to guide transfusion 
management. The effect of this protocol was compared to a retrospective cohort of 481 
patients treated in the same center. The mean units of all blood components (FFP, RBC, 
platelets) transfused per patient was about one third lower in the protocol guided group 
as compared to the historical group, both in patients with and without clopidogrel. As 
surgeons were not blinded for pre-operative medication, their decisions might have 
been influenced by knowledge of pre-operative clopidogrel administration, although 
the investigators tried to mitigate this limitation by strict adherence to the protocol. 
Shore-Lesserson et al. compared management of postoperative bleeding based on a 
TEG guided protocol and a conventional protocol.140 There was no significant difference 
in CT drainage after surgery between both groups, but the administration of blood and 
blood components occurred significantly less often in the TEG guided group than in 
the conventional group. However, the TEG protocol did have more options than the 
conventional protocol. In addition, the protocol allowed for earlier intervention in the 
TEG guided group, which could have influenced results.
1.3
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In another study by Ak et al., 224 patients undergoing elective CABG with CPB were 
prospectively randomized to one of two groups according to transfusion strategies: 
110 patients were randomized to a clinician-directed group, where the need for blood 
transfusion was based on clinician’s discretion and standard coagulation tests, and 
114 to a TEG guided transfusion group, where a kaolin-activated (k) TEG-based 
algorithm guided perioperative transfusion management.143 There were no differences 
in consumption of packed cell units, blood loss, re-exploration for bleeding, and 
early clinical outcome between the two groups, but patients in the TEG group had 
signiﬁcantly lower median units of fresh frozen plasma and platelets compared 
to the clinician-directed group (p = 0.001). The median number of total allogeneic 
units transfused (packed cells and blood products) was signiﬁcantly reduced in the 
TEG group compared with the other group and the need for tranexamic acid was 
signiﬁcantly diminished in the TEG group as well. 
In a retrospective cohort study performed by Görlinger et al., the use of a transfusion 
protocol which included EXTEM-, INTEM-, FIBTEM- and the HEPTEM-test 
[heparinase-modified intrinsic activation]) and Multiplate (TRAPtest, ASPItest and 
ADPtest) in a total of 2,147 patients undergoing cardiac surgery led to a reduction 
in overall amount of transfusion requirements, median number of transfused PRBC 
and FFP, and a decrease in the reexploration rate as compared to a historic cohort 
of 1,718 patients.138 However, the tests were only performed in patients at high 
risk for bleeding or in those with signs of clinically relevant diffuse bleeding after 
heparin reversal with protamine. To further investigate the potential of these tests, 
Weber et al. recently conducted a prospective, randomized clinical trial in cardiac 
surgery patients that investigated the efficacy of point-of-care (POC) testing, 
including platelet function testing with ROTEM and Multiplate versus conventional 
Table 5: These studies investigated different treatment algorithms using platelet function tests 
to guide transfusion and/or bleeding management. All patients underwent surgery with CPB. 
Abbreviations: ACT = activated clotting time, ADP = adenosine diphosphate, aPTT = activated partial 
thromboplastin time, ASA = acetylsalicylic acid, BT = bleeding time, CABG = coronary artery bypass 
grafting, COL = collagen, CT = chest tube, EPI = epinephrine, FIB = fibrinogen level, FFP = fresh frozen 
plasma, FSP = fibrin split products, Hb = haemoglobin, Hct = haematocrit, LTA = light transmittance 
aggregometry, mo = month(s), MPV = mean platelet volume, MT = mediastinal tube, N = number of 
patients, PFA-100 = Platelet Function Analyzer 100, PLT = platelet count, PRBC = packed red blood 
cells, PT = prothrombin time, PTT = partial thromboplastin time, ROTEM = reagent-supported 
thromboelastometry, TEG = thromboelastography, TF = tissue factor, TT = thrombin time, VS=valve 
surgery.
*ROTEM and Multiplate tests were only performed in patients at high risk for bleeding or in those 
with signs of clinically relevant diffuse bleeding after heparin reversal with protamine. This resulted in 
ROTEM tests in 17.5% of patients and MEA tests in 10.6% of patient.
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coagulation analyses (ACT, aPTT, INR, fibrinogen levels, and platelet count).26 
A significant difference in erythrocyte transfusion rate was demonstrated in the 
conventional compared with the POC group (p < 0.001). In multivariate analysis group 
allocation was an independent significant predictor for 6-month mortality.
In contrast to these studies, Avidan et al. showed no difference in PRBC transfusion 
in 102 patients undergoing elective CABG, with CPB who were randomized into two 
groups in which bleeding was managed and transfusion triggers were set either by an 
algorithm based on near-patient haemostatic testing (Hepcon, TEG and the PFA-100) 
or by an algorithm using routine laboratory haemostatic tests.144
Many of these studies have shown that platelet function tests are capable of reducing the 
amount of transfused blood and blood components without increasing perioperative 
blood loss or deteriorating outcome after surgery. This can save both costs and adverse 
events related to the use of these blood products. However, all these studies employed 
different algorithms and no platelet function test or strategy has been universally accepted. 
4 . 3. 2 .  GU I DI NG T HE T I MI NG OF SU RGERY
Besides guiding of transfusions intra- and postoperatively, another possible use 
for platelet function testing in CABG patients is to determine when patients using 
antiplatelet drugs can best be operated. As clopidogrel’s effect is variable between 
patients, uniform guidelines for discontinuation before surgery are likely not effective 
in all patients. While some patients may still display lower levels of platelet reactivity 
after 4 days of discontinuation of clopidogrel, other patients might have normal levels 
of platelet reactivity. To determine the optimal time to operate the patient, without 
delaying surgery unnecessarily, platelet reactivity can be assessed to see if it has 
returned to acceptable levels after discontinuation of these drugs before surgery.
Mahla et al. included patients with and without clopidogrel undergoing elective first 
time isolated CABG with CPB in a prospective single-center, non-randomized study. In 
clopidogrel treated patients, timing of surgery was based on clopidogrel responsiveness 
which was determined by thrombelastography (MAADP). CABG was done within 1 day, 
3–5 days, and 5 days in patients with an MAADP  >50 mm, 35–50 mm, and <35 mm, 
respectively. In clopidogrel-treated patients, mean 24 hour CT drainage was 93% (95% 
confidence interval, 81–107%) of the amount observed in clopidogrel-naive patients, 
and the total amount of red blood cells transfused did not differ between groups 
(1.80 U vs. 2.08 U, respectively, P = 0.540). The mean waiting period in clopidogrel-
treated patients was 2.7 days per patient, which is 50% shorter waiting time than 
recommended in the current guidelines.
Although the preoperative waiting period corresponded with the predefined waiting 
time, protocol deviations occurred in 18–35% due to scheduling problems and 
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occurrence of ischemic symptoms while waiting for surgery. However, as the majority 
of these protocol deviations reduced the time between clopidogrel withdrawal and 
surgery, a negative impact on bleeding would be expected, but this was not the case. 
Further studies regarding this subject are needed.
4 . 3. 3.  PL AT EL E T F U NC T ION T E S T I NG I N T HE GU I DEL I N E S FOR 
C A BG
The 2012 Update to the Society of Thoracic Surgeons (STS) Guideline on Use of 
Antiplatelet Drugs in Patients High on-treatment platelet reactivity Having Cardiac 
and Noncardiac Operations reflects an increased emphasis on platelet function testing 
as a tool to manage perioperative antiplatelet treatment.10 This update includes a Class 
IIa (Level of evidence B) recommendation for patients who require urgent surgery and 
are on DAPT. In these patients, it is considered reasonable to make decisions about 
surgical delay based on tests of platelet function rather than arbitrary use of a specified 
period of surgical delay. The update also includes a Class IIb (B) recommendation for 
platelet function testing to assess bleeding risk and potentially identify patients who 
have HPR after usual doses of antiplatelet drugs and can undergo operation without 
elevated bleeding risk. Similarly, a Class IIb (B) recommendation support the use of 
perioperative platelet function testing that may limit blood transfusion, as discussed 
above.
1.3
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5.  CONCLUSION
Platelet function testing can currently not be used to routinely guide the antiplatelet 
treatment in PCI patients, while it can predict atherothrombotic and bleeding events 
in this population. Further studies that make full use of the newer antiplatelet agents, 
such as prasugrel and ticagrelor, are needed, and these studies should define a cut-off 
value for both HPR and LPR. The focus should be on keeping patients in a therapeutic 
window of platelet reactivity to try to optimize efficacy and safety of antiplatelet 
treatment. Furthermore, these studies should focus on high risk populations, as event 
rates in elective PCI patients are generally low.
In CABG patients, platelet function tests can predict perioperative blood loss and 
can be used to guide the administration of blood products and reduce post-operative 
bleeding. Multiple transfusion algorithms containing platelet function tests have 
been proposed, however, none of these have been universally accepted or are 
endorsed in guidelines. It is still unclear if these tests can also predict postoperative 
atherothrombotic events or long-term outcome after surgery.
6.  PR AC T ICE POI N T S
· Platelet function tests can predict atherothrombotic and bleeding events in PCI 
patients
· Today, there is no sufficient evidence for platelet function tests to be routinely 
used to guide treatment of PCI patients
· Platelet function tests can be used to predict bleeding in CABG patients
· Platelet function tests can be used to guide transfusion and substitution 
treatment in CABG patients
7.  R E SE A RCH AGE NDA
· Determine if platelet function test guided treatment can be used to guide 
treatment in selected groups of PCI patients
· Determine if platelet function tests can be used to predict atherothrombotic 
events after CABG
· Externally validate platelet function guided transfusion algorithms for CABG 
patients
· Determine what the optimal test is for each patient population
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The use of platelet function testing in PCI and CABG patients
1.3

Bleeding and stent thrombosis on P2Y12-inhibitors: 
collaborative analysis on the role of platelet reactivity 
for risk stratification after percutaneous coronary 
intervention.
1 . 4
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Collaborative analysis on the role of platelet reactivity for risk stratification
A BST R AC T
Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent 
thrombosis (ST) and bleeding, standardized and clinically validated thresholds for 
accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. 
We sought to determine the prognostic value of low platelet reactivity (LPR), optimal 
platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off 
values for standardized devices. 
Methods and results: Authors of studies published before January 2015, reporting 
associations between platelet reactivity, ST, and major bleed- ing were contacted for 
a collaborative analysis using consensus-defined, uniform cut-offs for standardized 
platelet func- tion assays. Based on best available evidence for each device (exploratory 
studies), LPR–OPR–HPR categories were defined as <95, 95–208, and >208 PRU for 
VerifyNow, <19, 19–46, and >46 U for the Multiplate analyser and <16, 16–50, and 
>50% for VASP assay. Seventeen studies including 20,839 patients were used for the 
analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with 
HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03 – 
3.69), P<0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71 – 0.99), P=0.04] 
com- pared with those with OPR. In contrast, patients with LPR had a higher risk for 
bleeding [RR: 1.74 (1.47–2.06), P<0.00001], without any further benefit in ST [RR: 
1.06 (0.68 – 1.65), P =0.78] in contrast to OPR. Mortality was sig- nificantly higher in 
patients with HPR compared with other categories (P< 0.05). Validation cohorts (n=14) 
confirmed all results of exploratory studies (n=3). 
Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-
inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or 
at an elevated risk for bleeding (LPR). 
1.4
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I N T RODUC T ION
Dual antiplatelet treatment (DAPT) consisting of aspirin and a P2Y12-inhibitor is 
recommended in patients undergoing percutaneous coronary interventions (PCIs) 
to prevent thrombotic complications.(1) However, adjunctive administration of all 
currently available P2Y12-inhibitors has been associated with an increased risk for 
bleeding.(2-4) Since both ischaemic and bleeding events are important correlates 
of overall patient survival, attempts minimizing both complications in PCI-treated 
patients are highly warranted.(5) Monitoring platelet reactivity during P2Y12-
inhibitors was hoped to help prevent bleeding and/or stent thrombosis (ST) as 
numerous prior studies have linked high platelet reactivity (HPR) to a greater risk 
for ischaemic complications, while low platelet reactivity (LPR) has been associated 
with greater bleeding events.(6,7) However, the pub- lished cut-offs for HPR and LPR 
are highly heterogeneous, usually non-validated outside of the exploratory studies, 
leading to controversies on the prognostic relevance of platelet function testing in 
patients undergoing PCI. Such methodical uncertainties might be— in part—the 
reasons for failures of two randomized studies (8,9) evaluating the impact of platelet 
function testing guidance of antiplatelet therapy. 
In the setting of a collaborative analysis, we sought to analyse the data from a large 
number of published studies to determine the prognostic impact of platelet reactivity, 
classified as low (LPR), optimal (OPR), or high (HPR) by applying standard cut-off 
criteria in patients treated with P2Y12-inhibitors. 
MET HODS
Study selection and literature search
For this collaborative analysis, we identified published studies reporting the rates of 
major (or clinically relevant) bleeding, mortality, and ST according to different levels 
of platelet reactivity in PCI-treated patients. In line with the recommendations of two 
prior consensus papers, only studies using standardized platelet function assays, such 
as the VerifyNow P2Y12 assay, the Multiplate analyser with ADP test, or the VASP assay, 
were included.(6,7) We conducted a PubMed database search for published articles until 
January 2015 using the following pre-defined search terms alone or in combination: 
platelet reactivity, clopidogrel, ticagrelor, prasugrel, VerifyNow, Multiplate, VASP, ST, 
and bleeding. Abstracts from major scientific meetings and reference lists of published 
reviews were also checked to identify relevant studies. Authors of selected studies were 
contacted for collaboration, and after a positive response, original data were provided 
by responsible authors for all analyses (Figure 1).
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Eligibility criteria and data extraction
We restricted our analysis to studies that met all of the following inclusion criteria: 
(i) patients with stable or acute coronary artery disease undergoing PCI with an 
assessment of platelet reactivity during or in close proximity (≤30 days) to the 
performed intervention; (ii) patients receiving aspirin and a P2Y12-receptor inhibitor 
for PCI; (iii) assessment of platelet function with the VerifyNow, Multiplate analyser, 
or VASP assay; and (iv) reporting clinical outcomes in relation to platelet reactivity 
findings including ST, major or clinically relevant bleeding, and mortality.
Exclusion criteria included application of less widely available or non-standardized 
assays for platelet function testing (e.g. light trasmission aggregometry), studies 
using other types of antiplatelet agents (e.g. cilostazol, vorapaxar). In addition, 
studies primarily conducted in non-Western patients were also excluded due to the 
hypothesized differences in the pharmacodynamics response to P2Y12-inhibitors 
across races, also referred to as the “East-Asian paradox”.(10)
The authors agreed that the cut-offs identified by exploratory studies (defined below) 
might not be applicable to the non-Western population given the low number of such 
ancestry in these cohorts. In studies where parallel results with different platelet 
function assays were presented in the same cohort, the assay with the largest numbers 
of tested individuals was used for the analysis to prevent over-representation of the 
studies in the analysis.
Platelet reactivity assessment and cut-off values
To test the prognostic relevance of platelet reactivity classified as low (LPR), optimal 
(OPR), or high (HPR), we used the best available evidence to identify cut-off values 
for the included platelet function assays. The chosen cut-off values were in line with 
recent recommendations of two expert opinion papers,(6,7) except for the LPR cut-off 
of the VerifyNow assay which was based on results of the large ADAPT-DES registry 
that was not available at the time of the consensus papers.(11) Therefore, the selected 
cut-off values for LPR, OPR, and HPR categories were <95, 95–208, and >208 PRU for 
VerifyNow,(11,12) <19, 19–46, and >46 U for the Multiplate analyser,(13,14) and <16, 
16–50, and >50% for VASP(15) assays, respectively.
Clinical endpoint definitions and subgroups
Definite or probable ST was defined according to the Academic Research Consortium 
(ARC) criteria. Clinically relevant major bleeding complications were recorded with 
the definition used in each study. Accepted bleeding scales included TIMI major, 
BARC type ≥ 2, and ADAPT- defined clinically relevant bleeding. When rates of major 
bleeding were not available, the combined rate of major and minor events was used 
in the analysis. All-cause mortality was used if available; otherwise cardiovascular 
1.4
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mortality was substituted. Outcomes were analysed for the longest follow-up period 
available within each study. Pre-specified sub-group analyses were planned for 
different platelet function assays, ACS vs. non-ACS patients, prasugrel/ticagrelor vs. 
clopidogrel treatment, and exploratory vs. validation trials.
Statistical analysis
For this collaborative analysis, responsible authors were contacted individually to 
provide the rate of ST, bleeding, and mortality according to the standardized cut-off 
values for LPR, OPR, and HPR groups in their specific cohorts. Using the obtained 
dataset, we performed a weighted fixed-effect meta-analysis using the Mantel – 
Haenszel method to compare the relative risk (risk ratio, RR) of outcome events in the 
HPR and LPR groups in contrast to patients with OPR, used as reference. Sensitivity 
analyses were performed in all outcomes with random-effect modelling. When risks 
of bleeding and ST were compared according to platelet reactivity categories in the 
same plot, absolute risk estimates were preferred rather than RR to demonstrate the 
clinical relevance of the trade-off between ST and bleeding. Therefore, fixed-effect 
Mantel–Haenszel weighted risk differences (RDs) were calculated with the OPR group 
as reference. To further corroborate our statistical findings, unweighted analyses were 
performed to obtain RR from pooled crude event rates. Consistency of the obtained 
results was analysed in pre-defined subgroups by interaction testing. A two-sided 
P-value of <0.05 was considered statistically significant in all comparisons. Statistical 
analyses were performed with Review Manager (RevMan) computer program version 
5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.) and 
the Comprehensive Meta-analysis software version 2 (Biostat, Englewood, NJ, USA).
R E SULT S
Study cohorts
Overall, 17 studies (9,12,13,15–28) with 20,839 patients were identified and included 
in the analysis (Figure 1). Median follow-up time was 8.5 months (minimum – 
maximum: 1 – 17). Baseline characteristics and clinical results of the included studies 
are summarized in Table 1. All studies reported definite/probable ST according to the 
ARC criteria. Thirteen of the 17 studies reported bleeding events according to the TIMI 
scale, two studies (22,28) used the BARC definition, one study reported moderate/
several events on the GUSTO scale(9), and one study used an own bleeding definition 
(ADAPT- DES)(12) for clinically relevant bleeding (Table 1). In total, data were 
available for 13,377 patients with the VerifyNow device, for 3,908 patients with the 
Multiplate analyser, and for 3,554 patients with the VASP assay. The vast majority of 
patients (97%) was treated with clopidogrel and only 3% received prasugrel. No eligible 
study was identified in patients on ticagrelor.
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Figure 1: Flowchart of study selection. 
LTA, light transmission aggregometry. 
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Outcome data
By applying standard cut-off values, 41% (n=8,554) of the patients had HPR, 
20% (n=4,073) LPR, and 39% (n=8,212) OPR. Patients with HPR demonstrated a 
significantly higher risk for ST compared with those with OPR (2.73, 95% CI: 2.03–
3.69, P<0.00001, Figure 2, Supplementary material online, Figure S1), while the risk 
of ST did not further differ between patients with LPR and OPR (RR: 1.06, 95% CI: 
0.68–1.65, P=0.78, Figure 2, Supplementary material online, Figure S2) Unweighted 
analyses were consistent with these findings (Figure 2). Regarding bleeding, patients 
with HPR showed a slight decrease compared with those with OPR (RR: 0.84, 95% CI: 
0.71 – 0.99, P=0.04), but patients with LPR had a significant, 1.7-fold higher risk in 
comparison to those with OPR (RR: 1.74, 95% CI: 1.47 – 2.06, P<0.00001, Figure 3, 
Supplementary material online, Figures S3 and S4) Unweighted analyses confirmed 
the higher risk of bleeding in the LPR group; however, the risk of bleeding did not 
differ between patients with HPR and OPR (Figure 3). In case of mortality, patients 
with HPR had a significantly higher risk compared with patients with OPR (HR: 
1.54, 95% CI: 1.22 – 1.94, P=0.0002) or LPR (HR: 1.45, 95% CI: 1.04 – 2.02, P=0.03, 
Figure 4, Supplementary material online, Figures S5 and S6).
Figure 3: Relative risk of bleeding events according to platelet reactivity levels. 
Figure 2: Relative risk of stent thrombosis to platelet reactivity levels. 
Figure 2: RR, risk ratio
Figure 3: RR, risk ratio
1.4
102
Chapter 1.4
Outcome data: rationale for the ‘optimal’ range of platelet reactivity
Since bleeding events were 3.4-fold more frequent than ST (total: 797 vs. 236 events) 
during the mean follow-up of 8.5 months, absolute RDs were used to better capture 
the trade-offs in bleeding and ST between various platelet reactivity groups (Figure 5). 
When platelet reactivity levels were grouped only as low or high, the results suggested 
that a significant reduction in ST in the non-HPR group may only be achieved at the 
price of a large increase in bleeding, and vice versa, lower risk for bleeding in the non-
LPR group was associated with an excess risk of ST (Figure 5A). However, when an 
Figure 4: Relative risk of mortality according to platelet reactivity levels.
Figure 5: Absolute risk of tent thrombosis and bleeding according to platelet reactivity levels. 
Figure 5: (A) Risk estimates when platelet reactivity is categorized into groups of low platelet 
reactivity or high platelet reactivity. (B) A comparison of platelet reactivity categorized as low, optimal, 
or high. ST, stent thrombosis.
Figure 4: RR, risk ratio.
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‘optimal’ range of platelet reactivity (OPR) was introduced and used as a reference, 
a large reduction in bleeding was observed in this group without any excess in ST 
compared with LPR (Figure 5B). Similarly, the OPR group had a significantly lower 
risk for ST, with only a slight absolute increase in bleeding compared with patients 
with HPR (Figure 5B).
Subgroup and sensitivity analyses
Based on interaction analyses, the impact of HPR on ST was consistent in all 
subgroups (Figure 6). The predicted risk of bleeding was also directionally similar 
for LPR in the tested subgroups; however, significant interactions for even stronger 
associations were observed in some subgroups (Figure 6). Random-effects modelling 
demonstrated similar results to fixed-effect analyses for all outcomes (Supplementary 
material online, Table S1).
Figure 6: Interaction analysis according to pre-defined subgroups.
Figure 6: ACS, acute cororanry syndrome;HPR, high platelet reactivity; LPR, low platelet reactivity.
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DISCUS SION
This collaborative analysis represents the first attempt towards clinical validation of 
standardized cut-off points for platelet function testing in a large sample of patients 
undergoing PCI. Main results can be summarized as follows:
(i) Thienopyridine-treated patients with HPR have a 2.7-fold higher risk for ST and a 
1.5-fold higher risk for mortality compared with those with OPR following PCI.
(ii) Patients with LPR show a 1.7-fold higher risk for major bleeding complications 
without any further reduction in the risk of ST compared to patients with OPR.
(iii) These results suggest the existence of an optimal range of P2Y12-inhibition (OPR) 
that can be considered as a therapeutic window, within which the predicted risk of ST 
and major bleeding is the lowest after PCI.
Finding the balance between efficacy and safety for patients treated with P2Y12-
inhibitors is a key aspect to improve prognosis in patients after PCI. Despite 
demonstrated reductions in ischaemic complications (including ST) with currently 
available P2Y12-inhibitors among patients undergoing PCI, the price to pay has always 
been a higher risk for bleeding.(2-4) Prior analyses have confirmed that the higher 
the level of P2Y12-inhibition, the lower the rate of thrombotic events(29); however, 
an inverse association exists for bleeding.(3,4) Moreover, active metabolite generation 
and platelet reactivity inhibition of available thienopyridine-type P2Y12-inhibitors are 
highly variable between patients, affected by common genetic variants and clinical 
factors that further complicate accurate risk assessment and selection of the optimal 
P2Y12-inhibitor for the individual.(7) Risk stratification by clinical scores is often 
flawed by the fact that most of the used risk markers for thrombotic complications 
are also predictors of bleeding events (such as age, hypertension, or renal failure). 
Therefore, clinical scores might help to predict bleeding and thrombosis, but have 
limited usefulness in balancing such complications in clinical practice because they 
do not well discriminate between the two unwanted outcomes. With this respect, 
measuring residual platelet reactivity during P2Y12-inhibitor treatment was suggested 
as a valuable option to help stratifying patients according to bleeding and thrombosis, 
as several observational studies have linked HPR to higher risk for ST and LPR to 
increased risk for bleeding.(12,14,15)
Despite these promising observations, major drawbacks towards recommending 
platelet function testing for risk assessment after PCI were the large methodical 
heterogeneity in assessing on-treatment platelet reactivity and lack of generally 
applicable cut-off values to define patients with HPR and LPR. In addition, it was 
also unclear how the two extreme platelet reactivity categories are related to an 
intermediate range of platelet inhibition, hypothesized as ‘optimal’ (OPR).(14) In spite 
of these limitations, two recent expert consensus papers (6,7) proposed specific cut-
off values to define HPR and LPR, acknowledging; however, the preliminary nature of 
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these values and lack of proper validation in sufficient studies. Therefore, the present 
collaborative analysis represents an im- portant step forward in defining standard 
cut-off points for selected platelet function assays and validating them in a large 
population of patients undergoing PCI. Based on our results, the proposed and herein 
tested cut-off values were highly significantly (P<0.00001) associated with ST (46 U 
for Multiplate, 208 PRU for VerifyNow, and 50% PRI for VASP) and bleeding (19 U 
for Multiplate, 95 PRU for VerifyNow, and 16% for VASP). According to the observed 
pattern of risk for bleeding and ST, patients in the OPR range had the lowest net rates of 
adverse events, enabling a unique and sharp discrimination of bleeding and ischaemia 
by a single biomarker assessment (Figure 5B). Interestingly, the more traditional view 
of platelet reactivity, categorizing it as only low (LPR) or high (HPR), suggested that 
the risk of bleeding and ST is complementary; i.e. a decreased risk in one side is always 
accompanied by a significant increase on the other (Figure 5A). This paradigm may be 
challenged by introducing the group of OPR, where a significant reduction in bleeding 
was observed without an excess risk in ST compared with LPR, and also, a significant 
reduction in ST was observed with only a minor, even doubtful (see Figure 3) increase 
in bleeding in contrast to HPR.
Importantly, interaction testing confirmed that our findings might be relevant in 
several subgroups: most importantly, validation cohorts corroborated the selection of 
cut-off points for HPR and LPR based on exploratory trials (Figure 6). Based on the 
interaction analyses for bleeding, some subgroups showed even stronger associations 
between LPR and bleeding; however, we believe these differences should be viewed 
and interpreted carefully given the heterogeneity of patients included in various 
subgroups.
It is important to highlight that despite the potential value of platelet reactivity to 
stratify patients into categories of risk for bleeding and ST, the clinical benefits of 
adjusting platelet reactivity based on monitoring treatment, by targeting the optimal 
range considered as a therapeutic window is still unknown, and cannot be answered on 
the basis of our analysis. In this regard, prior randomized clinical trials (GRAVITAS, 
TRIGGER-PCI, and ARCTIC)(8,9,30) using the VerifyNow assay were disappointing 
due to lack of clinical improvements after treatment adjustments based on platelet 
function testing. However, none of these studies targeted an optimal range of platelet 
reactivity, were characterized by no (9) or only minimal utilization (8) of potent 
antiplatelet agents, focused mainly on stable coronary artery disease patients (30) 
and were underpowered.(31) Additionally, the two large, completed randomized trials 
used cut-off values different from those proposed and validated in our analysis.(8,9) 
Thus, the concept of tailored antiplatelet treatment and its possible benefits remains 
unproven but cannot be deemed disproved based on these trials.(8,9,30) Future studies 
(NCT01959451, NCT01538446) are therefore required, using the validated cut-off 
values, focusing on high-risk cohorts of patients and implementing the therapeutic 
window concept of platelet inhibition to assess the clinical relevance of tailored P2Y12-
inhibition therapy.
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Although our analysis provides new evidence in a large sample of patients by validating 
cut-off points for risk stratification, we are aware of limitations. First, we were unable 
to perform adjusted Cox-proportional hazard analyses based on individual time-
dependent data. This limitation does not influence our conclusions regarding the 
prognostic importance of platelet reactivity for risk assessment. Although adjusted 
analyses are useful to understand whether the associations between platelet reactivity 
values and outcomes are independent from confounding factors, platelet function 
results are never adjusted according to these at the bedside. Conversely, adjusted 
analyses would be useful to project whether treatment adjustments based on platelet 
reactivity could reduce bleeding or ST; however, such adjustments are never perfect 
and cannot account for all known confounders. Secondly, although there were no 
meaningful interaction for outcomes between prasugrel and clopidogrel-treated 
patients, the low number of prasugrel-treated subjects may suggest that the associations 
between validated cut-offs and outcomes might be relevant for clopidogrel but need 
further confirmation for prasugrel. Moreover, any platelet function assessment in 
ticagrelor-treated patients would not be capable to measure possible pleiotropic effects 
of the drug, which might in fact be the underlying cause of the observed reduction in 
mortality risk in the PLATO trial.(4) Finally, we admit that the pooled studies were 
heterogeneous regarding the length of follow-up that may introduce bias towards the 
exact determination of early-, and long-term risk of ST and bleeding in relation to 
platelet reactivity levels after PCI.
In conclusion, the present analysis shows in a large sample of thienopyridine-treated 
patients that HPR, defined by validated cut-offs using standardized platelet assays, 
is associated with a significantly higher risk for ST and mortality, while LPR predicts 
a higher risk for bleeding. The lowest rates of net adverse events in patients within 
an intermediate range of platelet reactivity (OPR) suggest that platelet reactivity may 
be a valuable marker to discriminate between ST and bleeding in patients after PCI. 
Further randomized trials are warranted to test the potential benefit of tailoring 
treatment into the optimal range of platelet reactivity.
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SUPPLEME N TA L M AT ER I A L S
Supplement figure 1. Risk of definite or probable stent thrombosis in low (LPR) versus 
optimal platelet reactivity (OPR).
Supplement figure 1: *: only patients from control study groups.
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Supplement figure 2. Risk of definite or probable stent thrombosis in high (HPR) versus 
optimal platelet reactivity (OPR)
Supplement figure 2: *: only patients from control study groups.
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Supplement figure 3. Risk of major or clinically relevant bleeding in low (LPR) versus optimal 
platelet reactivity (OPR)
Supplement figure 3: *: only patients from control study groups.
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Supplement figure 4. Risk of major or clinically relevant bleeding in high (HPR) versus 
optimal platelet reactivity (OPR) 
Supplement figure 4: *: only patients from control study groups.
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Supplement figure 5. Risk of mortality in low (LPR) versus optimal platelet reactivity (OPR).
Supplement figure 5: *: only patients from control study groups.
117
Collaborative analysis on the role of platelet reactivity for risk stratification
Supplement Table 1. Comparison in results according to fixed-effect or random effect 
modeling
HPR vs. OPR LPR vs. OPR
Fixed-effect Random effect Fixed-effect Random effect
Definite/ 
probable ST
RR: 2.73(2.03-3.69)
p<0.00001
RR: 2.65(1.95-3.60)
p<0.00001
RR: 1.06(0.68-1.65)
p=0.78
1.10(0.69-1.76)
p=0.69
Major 
bleeding
RR: 0.84(0.71-0.99)
p=0.04
RR: 0.70(0.49-1.01)
p=0.06
RR: 1.74(1.47-2.06)
p<0.00001
RR: 2.32(1.51-3.56)
p=0.0001
Mortality
RR: 1.54(1.22-1.94)
p=0.0002
RR: 1.52(1.20-1.92)
p=0.0005
RR: 1.03(0.76-1.40)
p=0.85
RR: 1.10(0.77-1.56)
p=0.61
Abbreviations: HPR: high platelet reactivity; LPR: low platelet reactivity; OPR: optimal platelet reactivity; ST: 
stent thrombosis. 
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C H A P T E R  2
Factors that influence platelet reactivity 

Does percutaneous coronary stent implantation
increase platelet reactivity?
2 . 1
P.W.A. Janssen1,2,  E.A. Mol1,2,3, S.M.C. Geene1,2, E. Barbato4,5,
J.M. ten Berg1,2.
Accepted for publication in Blood Reviews
122
Chapter 2.1
 
Affiliations:
1 Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands 
2 St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands
3 Department of Cardiology, Laboratory of Experimental Cardiology, University Medical Center Utrecht, the 
Netherlands
4 Cardiovascular Research Center Aalst OLV Hospital, Aalst, Belgium 
5 Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
123
Coronary stent implantation and platelet reactivity
A BST R AC T
High platelet reactivity (PR) values on treatment with clopidogrel are associated with 
an increased rate of thrombotic events after a percutaneous coronary intervention 
(PCI). However, we do not know the optimal timing of the performance of the PR 
measurements. Platelets might be activated during a PCI, which means that the timing 
of PR measurements, before or after PCI, could influence the outcome. In turn, this 
could lead to misinterpretation of the patient’s response to antiplatelet therapy and 
a less accurate prediction of the patient’s risk of thrombotic events during follow-
up. We aimed to evaluate the effect of stent implantation on PR in patients with and 
without acute coronary syndromes who undergo PCI to assess the optimal timing of 
PR measurements. A systematic literature search was performed and the results are 
summarized in this review.
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1.  I N T RODUC T ION  
Angioplasty with stent implantation is routinely used to treat stenoses of coronary 
arteries. Patients undergoing such a percutaneous coronary intervention (PCI) receive 
dual anti-platelet therapy (DAPT), consisting of a combination of aspirin and a P2Y12 
inhibitor, to prevent aggregation of platelets and thereby reduce the incidence of 
thrombotic events, particularly stent thrombosis. Clopidogrel is the most used P2Y12 
inhibitor in patients undergoing PCI. However, a large inter-individual variability in 
the response to clopidogrel is observed1,2. A multitude of studies have demonstrated 
that a subset of patients undergoing PCI show higher levels of platelet reactivity (PR) 
despite antiplatelet treatment with clopidogrel, which is called high on-treatment 
platelet reactivity (HPR).These patients are at an increased risk of atherothrombotic 
events after PCI 1,3,4. There are several platelet function tests that can be used to 
measure PR5. However, the optimal timing for the performance of these platelet 
function tests is unknown. In some studies regarding PR, platelet function tests are 
performed before PCI6-8, while PR is assessed after PCI in other studies9-11.
There is a growing body of evidence that suggests that platelets are activated after 
PCI12,13. Additionally, the catheters that are used during the procedure can activate 
platelets within minutes after first contact14. The activation of platelets may be further 
stimulated  by adenosine diphosphate (ADP), which is  released from red blood cells 
and platelets that are damaged by contact with materials such as the stent or balloons, 
or by generated thrombin15.
If PR levels which are measured early after PCI are higher than the levels measured 
before PCI, the actual level of platelet inhibition achieved by treatment with 
clopidogrel or other antiplatelet agents might be better than suggested by the PR 
measurement directly after PCI. Therefore, measuring PR directly after PCI might lead 
to misinterpretation of the patient’s response to antiplatelet therapy and the patient’s 
risk of atherothrombotic events during follow-up PCI.
The aim of this systematic review is to provide an overview of all available information 
regarding the influence of PCI on platelet reactivity. Furthermore, we evaluate the 
level of platelet reactivity over time, up to six months after PCI.
 
2 .  MET HODS
2 .1 CR I T ER I A FOR CON SI DER I NG S T U DIE S I N T HIS R E V IE W 
2 .1 .1 .  T Y PE S OF S T U DI E S
This systematic search included studies in which platelet function measurements were 
performed on multiple time points. 
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2 .1 . 2 .  T Y PE S OF PA R T IC IPA N T S
Studies  with patients treated with aspirin and clopidogrel undergoing PCI with 
stenting were included. Adequate pre-treatment with clopidogrel at the time of blood 
sampling was a prerequisite for inclusion. Adequate pre-treatment was defined as a 
loading dose of 600 mg clopidogrel >6 h before blood sampling, 300 mg >12 h pre-
sampling, or a maintenance dose of 75 mg for >5 days for this review.
2 .1 . 3 T Y PE S OF I N T ERV E N T ION
In the studies that were included, patients underwent PCI. Platelet function assays 
had to be performed on multiple time points. The search included the most regularly 
used platelet function tests used to asses PR on clopidogrel: the VerifyNow assay, 
light transmission aggregometer, platelet function analyzer, Multiplate analyzer, 
flowcytometry (vasodilator-stimulated phosphoprotein [VASP] assay, P-selectin assay) 
and the thromboelastograph. By adding the search term ‘platelet aggregation’, we also 
tried to find studies using more obscure platelet function tests.
Articles were excluded based on the following criteria: 1) animal study; 2) review; 3) 
no platelet function measurements; 4) patients undergoing another intervention than 
PCI e.g. coronary artery bypass graft (CABG), stenting of cerebral or other arteries; 
5) effect of other agents (no clopidogrel or other drugs in addition to clopidogrel) on 
platelet function; 6) studies focusing on the association of platelet function with other 
factors such as cigarette smoke, cannabis or different gene variants; 7) measurements 
around loading dose administration or with different loading concentrations; 8) the 
discontinuation of clopidogrel was studied; 9) platelet function assay was performed 
at only a single time point.
2 . 2 SE A RCH ME T HOD
A systematic literature search of the electronic databases PubMed, EMBASE, and the 
Cochrane Library was performed. This search was limited to articles written in either 
English or Dutch. The terms ‘percutaneous coronary intervention’, ‘PCI’, and other 
procedures indicated with ‘stent*’ were used in the search as well as ‘platelet function’ 
or any of the platelet function tests described, and terms describing different forms 
of time indication. Detailed search strategies for PubMed, EMBASE, and the Cochrane 
Library are shown in Appendix 1.
2 . 3 DATA A N A LY SIS
The screening and selection of articles was performed by two independent authors (EM 
and SG) based on title and abstract. When there was uncertainty about the inclusion 
of an article, the full text of the article was screened. The references of the relevant 
articles were searched for useful articles that were not in the original search. Data 
from conference abstracts were also screened for relevance. Any disagreements about 
inclusion of articles were resolved by discussion, or by asking a third reviewer (PJ) to 
independently screen the article.
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3.  R E SULT S
The search in the PubMed database, EMBASE, and the Cochrane Library was performed 
on 11 March 2015. The results of this literature search are depicted in Figure 1. 
Most articles were excluded because platelet function measurements were performed 
to show the effect of other agents (e.g. tirofiban, abciximab) on PR.
Figure 1: Flow chart of literature search.
Figure 1: Abbreviations: CABG = coronary artery bypass graft.
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Table 1: Studies in elective PCI patients that measure platelet reactivity at multiple time points.
Study
Stent 
indication
N
Platelet 
function 
tests
Time of PR 
measurements
Outcome
Gurbel et al. [16] Stable CAD 50
LTA 5 μmol 
ADP
Before clopidogrel 
administration 
before PCI, and at 2 
h, 5 h, 12 h, 2 d, and 
5 d after PCI
Increased PR at  2 h after PCI 
(22±26 %inhibition) compared to 
before PCI (29±30 %inhibition). 
Stabilization of PR at 5 h after PCI 
(36±20 %inhibition). P-value was 
not reported.
Kaikita et al. [17] Stable CAD 104
VN, LTA 20 
μmol ADP
Before PCI, 
immediately after 
PCI, 1 d, 2 d, and 28 
d after PCI
PR is increased immediately after 
PCI as compared to baseline. 
Stabilization of PR at 1 d after PCI. 
Absolute values were not reported.
Mangiacapra et 
al. [18]
Stable CAD 65 MEA
Immediately 
before procedure, 
immediately after 
procedure, 24 h after 
procedure
PR is increased proportionally to 
procedural complexity. (ΔPR before 
and immediately after procedure: 
coronary angiography:-2.7±7.4 AU, 
PCI: 6.0±12.4 AU, RA:18.6±7.7, 
p<0.0001). 
Siller-Matula et 
al. [19]
Stable CAD 30 PFA, VASP
Immediately after 
PCI, 24 h after PCI
PR was higher after PCI (VASP PRI 
55%, PFA closure time 152 s) than 
1 d thereafter (VASP PRI 45%, 
p=0.009, PFA closure time 118 s, 
p=0.047). 
Campo et al. [20] Stable CAD 300 VN
Before PCI, 1 m, 6 m 
after PCI
Higher PRU before PCI (190±97 
PRU) than at 1 m (147±85, p<0.01). 
PR at 6 m was not significantly 
different from PR at 1 m (146±85, 
p=0.9).
Freynhofer et al. 
[21]
Stable CAD 29 VASP
6-12 h after PCI, 1 
m, 3 m, 6 m after 
PCI
PR higher after PCI than after 1 m 
(57.9±15.6 PRI vs 48.4±17.9 PRI, 
p<0.05). A small increase of PR 
again at 6 m after PCI (56.2±20.2).
Table 1: Abbreviations:  ADP = adenosine diphosphate, CAD = coronary artery disease, d = days, h = 
hours, LTA = light transmission aggregometer, m = months, MEA = multiple electrode aggregometry PCI = 
percutaneous coronary intervention, PFA = platelet function analyzer, PR = platelet reactivity, PRU = P2Y12 
reactivity units, RA = rotational atherectomy, s = seconds VASP = vasodilator-stimulator phosphoprotein 
phosphorylation assay, VN = VerifyNow.
2.1
128
Chapter 2.1
St
ud
y
St
en
t 
in
di
ca
ti
on
N
Pl
at
el
et
 fu
nc
ti
on
 t
es
ts
T
im
e 
of
 P
R
 m
ea
su
re
m
en
ts
O
ut
co
m
e
Pa
tt
i e
t a
l. 
[2
2]
N
ST
EM
I
31
0
V
N
Be
fo
re
 P
CI
, 8
 h
 a
ft
er
, 2
4 
h 
af
te
r 
PC
I
A
n 
in
cr
ea
se
 in
 P
R
 8
 h
 a
ft
er
 P
CI
, a
nd
 a
 d
ec
re
as
e 
of
 P
R
 a
t 2
4 
h 
af
te
r 
PC
I i
n 
pa
ti
en
ts
 w
it
h 
bl
ee
di
ng
 a
nd
 w
it
ho
ut
 b
le
ed
in
g 
(1
71
±4
9 
be
fo
re
 P
CI
, 2
10
±5
5 
8 
h 
af
te
r 
PC
I, 
17
9±
56
 2
4 
h 
af
te
r 
PC
I i
n 
bl
ee
di
ng
 p
at
ie
nt
s,
 a
nd
 2
27
±6
8 
vs
 2
37
±6
2 
vs
 1
97
±6
1,
 re
sp
ec
ti
ve
ly
, f
or
 p
at
ie
nt
s 
w
it
ho
ut
 b
le
ed
in
g)
. 
P-
va
lu
es
 w
er
e 
no
t r
ep
or
te
d.
Zh
an
g 
et
 a
l. 
[2
3]
N
ST
EM
I
22
8
V
N
, L
TA
 (1
0 
μm
ol
 A
D
P)
, M
EA
Be
fo
re
 P
CI
, 1
8-
24
 h
 a
ft
er
 P
CI
A
 m
in
or
 d
ec
re
as
e 
of
 P
R
 o
ve
r 
ti
m
e.
 L
TA
 p
re
-P
CI
 
49
.3
%
±1
9.
8%
, v
s 
af
te
r 
PC
I 4
4%
±1
8%
, V
N
 p
re
-P
CI
 
31
8.
4±
76
.8
 v
s 
27
2.
8±
83
.5
 P
RU
 a
ft
er
 P
CI
, a
nd
 M
EA
 b
ef
or
e 
PC
I 4
4.
8±
19
.9
 A
U
 v
s 
af
te
r 
PC
I 3
1.
3±
15
.7
 A
U
. P
-v
al
ue
s 
w
er
e 
no
t r
ep
or
te
d.
M
ar
cu
cc
i e
t a
l. 
[2
4]
A
CS
18
7
V
N
W
it
hi
n 
24
 h
 a
ft
er
 P
CI
, 1
 m
, 3
 m
 
af
te
r 
PC
I
In
 4
9%
 o
f t
he
 p
at
ie
nt
s 
PR
 s
lig
ht
ly
 d
ec
re
as
ed
 o
ve
r 
ti
m
e,
 in
 
51
%
 P
R
 w
as
 s
ta
bl
e 
ov
er
 ti
m
e.
 P
-v
al
ue
s 
w
er
e 
no
t r
ep
or
te
d.
Fe
do
r 
et
 a
l. 
[2
5]
ST
EM
I
26
LT
A
 (1
0 
μm
ol
 A
D
P)
, V
A
SP
Be
fo
re
 P
CI
, 1
 d
, 3
0 
d
PR
 a
t a
cu
te
 p
ha
se
 h
ig
he
r 
(7
3%
) t
ha
n 
1 
d 
af
te
r 
PC
I (
44
%
). 
PR
 w
as
 re
la
ti
ve
ly
 s
ta
bl
e 
at
 3
0 
d 
fo
llo
w
-u
p 
(4
5%
). 
P-
va
lu
es
 
w
er
e 
no
t r
ep
or
te
d.
Co
dn
er
 e
t a
l. 
[2
6]
 
N
ST
EM
I/
ST
EM
I
57
V
N
, M
EA
 
18
-2
4 
h,
 3
0 
d,
 6
 m
 a
ft
er
 A
M
I
PR
 w
as
 s
ta
bl
e 
ov
er
 ti
m
e.
 V
N
 2
07
.2
±1
0.
6 
af
te
r 
PC
I v
s 
20
5±
9.
9 
at
 3
0 
d 
vs
 2
01
.1
±1
0.
7 
at
 6
 m
. M
EA
 3
1.
6±
2.
2 
af
te
r 
PC
I v
s 
32
.8
±2
.7
 a
t 3
0 
d 
vs
 2
7.
5±
2.
3 
at
 6
 m
. P
-v
al
ue
s 
w
er
e 
no
t r
ep
or
te
d.
M
ee
n 
et
 a
l. 
[2
7]
N
ST
EM
I
31
M
EA
, L
TA
 (2
 μ
m
ol
 A
D
P,
 6
.5
 
μm
ol
 A
D
P,
 1
0 
μm
ol
 A
D
P)
Be
fo
re
 P
CI
, 9
 w
, 1
2 
w
 a
ft
er
 P
CI
PR
 w
as
 s
ta
bl
e 
ov
er
 ti
m
e.
 L
TA
 1
0 
μM
 3
6.
8±
16
.8
%
 b
ef
or
e 
PC
I v
s 
31
.5
±1
6.
9%
 a
t 9
 w
 v
s 
33
.9
±1
6.
5%
 a
t 1
2 
w
 a
ft
er
 
PC
I (
p<
0.
05
). 
M
EA
 1
0 
μM
: 4
5.
3±
27
.4
%
 A
U
 b
ef
or
e 
PC
I v
s 
41
.9
±2
3.
7%
 A
U
 a
t 9
 w
 v
s 
44
.8
±2
4.
6%
 A
U
 a
t 1
2 
w
. P
-v
al
ue
s 
w
er
e 
no
t r
ep
or
te
d.
Ta
bl
e 
2:
 A
bb
re
vi
at
io
ns
: A
CS
 =
 a
cu
te
 c
or
on
ar
y 
sy
nd
ro
m
e,
 A
D
P 
= 
ad
en
os
in
e 
di
ph
os
ph
at
e,
 A
M
I =
 a
cu
te
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 A
U
= 
ag
gr
eg
at
io
n 
un
it
s,
 d
 =
 d
ay
(s
), 
h 
= 
ho
ur
(s
), 
LT
A 
= 
lig
ht
 t
ra
ns
m
is
si
on
 a
gg
re
go
m
et
er
, m
 =
 m
on
th
(s
), 
m
ul
ti
pl
e 
el
ec
tr
od
e 
ag
gr
eg
om
et
ry
, N
ST
EM
I 
= 
no
n-
ST
 e
le
va
te
d 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 P
C
I 
= 
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
ti
on
, P
R 
= 
pl
at
el
et
 re
ac
ti
vi
ty
, S
TE
M
I =
 S
T 
el
ev
at
ed
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 V
A
SP
 =
 v
as
od
ila
to
r-
st
im
ul
at
ed
 p
ho
sp
ho
pr
ot
ei
n 
ph
os
ph
or
yl
at
io
n 
as
sa
y,
 V
N
 =
 V
er
if
yN
ow
, w
 
= 
w
ee
k(
s)
.
Ta
bl
e 
2:
 S
tu
di
es
 in
 A
C
S 
pa
ti
en
ts
 s
ho
w
in
g 
PR
 o
ve
r 
ti
m
e.
129
Coronary stent implantation and platelet reactivity
3.1 PL AT EL E T R E AC T I V I T Y I N S TA BL E PAT IE N T S U N DERG OI NG 
PCI
Several studies reported a change in PR directly after stent implantation in stable 
patients undergoing elective PCI, as shown in Table 1. Gurbel et al. studied different 
dosing regimens of clopidogrel in 50 patients undergoing elective PCI and found an 
increase in PR 2 h after PCI measured with the light transmission aggregometer (LTA) 
and the VerifyNow P2Y12 assay (VN)
16. After the increase in PR directly after PCI, PR 
returned  to baseline levels at 5 h post-PCI. Kaikita et al. studied 104 elective PCI 
patients and showed an increase in PR as measured with the VN and LTA immediately 
after PCI17.
The increase in PR seems to be associated with procedural complexity. A study by 
Mangiacapra et al. measured PR with multiple electrode aggregometry (MEA) using 
the Multiplate analyzer in 65 patients with stable coronary artery disease (CAD) and 
observed that the increase in PR was smaller in patients undergoing angiography 
alone as compared to patients undergoing PCI combined with more invasive rotational 
atherectomy18. This increase in PR was also associated with total inflation time and 
total stent length.
PR seems to return to baseline levels after some time. A study by Siller-Matula et al. 
included 30 stable CAD patients undergoing PCI in which PR was assessed with the 
VASP-assay, platelet function analyzer (PFA) and Multiplate analyzer just after PCI 
and 1 day thereafter19. PR on clopidogrel was higher after PCI as compared to one day 
thereafter, indicating that there is an activation of platelets immediately after PCI and 
a stabilization of PR at one day after PCI. In a substudy which included 5 additional 
patients, PR was measured at four different time points: immediately before PCI and 
before heparin administration, immediately after PCI, and at 1 day and 2 days after 
PCI. In these additional patients, PR immediately after PCI was higher compared to all 
other time points, but stabilized after 1-2 days. Furthermore, Kaikita et al. also showed 
that after the initial increase in PR after PCI, PR stabilized to levels comparable to 
before PCI at 1 day, 2 days, and 28 days after PCI17.
However, not all studies have reported stable levels of PR over a longer period of time. 
Campo et al. measured PR with the VerifyNow before PCI, and at 1 and 6 months after 
PCI in 300 patients undergoing PCI20. These patients showed higher PRU levels before 
PCI compared to 1 and 6 months after PCI. PR slightly decreased over time in this 
study.   
Furthermore, Freynhofer et al. observed that PR as assessed with the VASP assay was 
higher at 6-12 h after PCI than after 1 month in 29 stable angina patients undergoing 
PCI21. This decrease in PR after 1 month could be explained by possible activation of 
platelets after PCI. However, PR at 6 months was found to be higher than PR at 1 
month. The authors speculated that patients may not have adhered to the prescribed 
dual-antiplatelet therapy at 6 months.
2.1
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3. 2 PL AT EL E T R E AC T I V I T Y I N AC S PAT IE N T S U N DERG OI NG PC I
In addition to studies describing increased PR after PCI in stable coronary disease 
patients, an increase in PR is also described in studies which included patients with 
ACS (see Table 2). For instance, PR was assessed in 310 non-ST-elevation myocardial 
infarction (NSTEMI) patients with the VN P2Y12 assay before PCI, 8 h after PCI, and 
24 h after PCI22. An increase in PR was observed 8 h after PCI compared to before PCI, 
which indicates that platelets are activated during PCI. The level of PR decreased again 
at 24 h after PCI. 
Several studies have described the level of PR from PCI up until 6 months after PCI in ACS 
patients. However, these studies showed contrasting results. Some studies reported a 
decrease of PR over time, while other studies found stable levels of PR. A study by Zhang 
et al. in 228 NSTEMI patients compared PR measured with the VN, LTA, and MEA before 
PCI and 18-24 h after PCI23. A minor decrease of PR over time was found. Furthermore, 
Marcucci et al. studied the stability of HPR over time in 187 ACS patients24. HPR was de-
fined as PRU>240. PR was assessed with the VN in acute phase (within 24 h after PCI), at 
1 to 3 months, and at 6 to 12 months. In 49% of the patients, PR slightly decreased over 
time resulting in a decrease of the rate of patients with HPR, whereas stable levels of 
PR were observed in the other 51% of patients. Furthermore, Fedor et al. measured the 
response to clopidogrel in 26 STEMI patients and found that PR was higher before PCI 
as compared to 1 and 30 days after PCI25. In contrast to these studies, a study by Cod-
ner et al. showed that PR in ACS patients treated with PCI is stable over time26. In this 
study, PR was measured with MEA and VN in 57 acute myocardial infarction (AMI) 
patients at 18-24 h, 30 days, and 6 months after AMI. The level of PR was comparable 
at all time points. Furthermore, Meen et al. showed the same stability of PR over time 
in 31 NSTEMI patients undergoing PCI27. In this study, PR was measured with MEA 
and LTA before PCI and at 6 and 12 weeks after PCI and it was stable in most patients. 
Several other studies also showed a relatively stable PR up to 6 months after PCI22,28. 
4 .  DISC U S SION
This review provides an overview of the influence of PCI on PR and changes of PR over 
time, until 6 months after PCI. In elective patients undergoing PCI, it has been shown 
that PR is enhanced immediately following a stenting procedure. In stable patients 
undergoing elective PCI, PR seems to return to baseline levels around 24 h after PCI, 
although one study reports stabilization of PR already at 5 h after PCI. PR seems to 
remain stable up to 6 months after PCI, although one study reported a minor decrease 
of PR over time. Unfortunately, studies were too heterogenous to perform a meta-
analysis. 
One study showed that, platelets were also activated in the first hours following PCI 
in patients with ACS22. However, more research is necessary to demonstrate the effect 
of PCI on PR in ACS patients as there are multiple confounding factors in this group. 
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First, platelets of patients with ACS might not be fully inhibited by clopidogrel at the 
time of measurement due to the time between loading and testing. Most patients with 
ACS receive a loading dose of 600 mg clopidogrel at the time of the PCI procedure. 
Heestermans et al. studied the pharmacokinetic response to a 600 mg loading dose 
of clopidogrel in ACS patients and showed a diminished bioavailability of clopidogrel, 
resulting in a delayed onset of platelet inhibition29. The level of PR measured in the 
first hours after the procedure could therefore be higher than expected and therefore 
biased. The current ESC guidelines now recommend to treat patients with ACS with 
the stronger P2Y12inhibitors prasugrel and ticagrelor, which are more potent and 
have an earlier onset of platelet inhibition than clopidogrel30,31. Second, patients with 
ACS already are in a pro-thrombotic state, which means that platelet reactivity could 
increase both independently and in association to PCI. 
At 24 h after PCI, the amount of PR observed early after PCI seems to decrease to a 
baseline levels in ACS patients. Studies providing information about the stability of 
PR over a longer period of time showed contrary results. While some studies showed a 
minor decrease of PR at 1 and 6 months after PCI compared to baseline, other studies 
reported a stable level of PR up to 6 months after PCI.
A less likely explanation for the increase of PR during PCI in both elective patients 
and ACS patients is the effect of administration of heparin. Heparin, an anticoagulant 
which is routinely used during PCI procedures, is known to be a weak platelet 
activator32-34. Mangiacapra et al., however, found no significant effect of heparin 
on PR in 10 patients in which an additional blood sampling was performed 5 min. 
after heparin administration18. To show the effect of heparin on the results of PFA 
and VASP, Siller-Matula et al. performed an in-vitro experiment in which different 
concentrations of heparin were added to blood samples19. This study showed that 
heparin did not influence results from PFA and VASP. In contrast, minor differences in 
PR were observed with MEA performed with the Multiplate Analyzer, but there was no 
dose-dependent effect of heparin. 
Another explanation for the increase in PR after PCI could be activation of platelets 
by the large catheter that is placed in the blood vessels during the procedure. A 
study by Chan et al. showed that catheters activate platelets within minutes after 
first contact with blood14. However, catheters are also used in coronary angiography 
without subsequent coronary angioplasty or stenting. A study by Mangiacapra et al. 
found only a small change of PR before and after the procedure in patients undergoing 
coronary angiography, compared to patients undergoing PCI18. Thus, probably damage 
inflicted on the  vessel wall by balloon angioplasty and stenting during PCI increases 
shear stress and leads to an increased level of PR35.
More research focused on the effect of PCI on PR is required to find out why PR seems to 
be higher immediately after PCI. Furthermore, studying the procedural characteristics 
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of angioplasty and stenting can provide insight into which specific features of PCI can 
possibly cause activation of platelets during the procedure. 
Several studies in this review showed that the increase in PR after PCI seems to be 
stabilized after 24 h in both patients with stable CAD and patients with ACS. Therefore, 
PR should probably be assessed before, or at 1-2 days after PCI in studies where HPR 
is correlated to outcome or when treatment is adjusted based on PR. In the GRAVITAS 
study, for example, PR was measured at 12-24 h after PCI, which could have led to a 
poorer discrimination between high risk and low risk patients36.
5.  CONCLUSION
Most studies found in this systematic search showed an increase in PR immediately 
after PCI as compared to before PCI. Therefore, the PR of patients based on a blood 
sample taken shortly after a PCI procedure could lead to misinterpretation of the 
patient’s response to antiplatelet therapy and an overestimation of the patient’s risk 
of atherothrombotic events during follow-up after PCI. It could thereby hamper the 
predictive value of platelet function testing. This possible influence of PCI on PR should 
be taken into account when HPR is linked to clinical outcome and when antiplatelet 
therapy is adjusted based on PR measurements.
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6.  PR AC T ICE POI N T S
· Platelet reactivity on clopidogrel treatment is temporarily increased after  
 elective PCI
· The effect of PCI on platelet reactivity in ACS patients is still unclear
· A patient’s response to clopidogrel might be misinterpreted when platelet  
 reactivity is tested shortly after PCI
7.  R E SE A RCH AGE NDA
· Determine the effect of PCI on platelet reactivity in ACS patients
· Determine which particular components of a PCI procedure cause an increase  
 in   platelet reactivity
· Determine whether platelet function testing guided treatment can improve  
 clinical outcome after PCI
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A PPE N DI X 1:  SE A RCH S T R AT EGIE S
PubMed
(“Percutaneous Coronary Intervention”[Mesh] OR percutaneous coronary 
intervention*[tiab] OR pci[tiab] OR “Stents”[Mesh] OR stent*[tiab]) AND (“Platelet 
Function Tests”[Mesh] OR “platelet activation”[mesh] OR platelet function*[tiab] 
OR platelet reactivit*[tiab] OR platelet activat*[tiab] OR VerifyNow[tiab] OR 
Multiplate[tiab] OR P2Y12 assay*[tiab] OR VASP[tiab] OR P-selectin*[tiab] OR 
PFA[tiab] OR LTA[tiab] OR light transmission aggregometry[tiab] OR TEG[tiab] 
OR thromboelasto*[tiab] OR p2y12 reaction units[tiab] OR PRI[tiab]) AND 
(periprocedur*[tiab] OR peri[tiab] OR time points[tiab] OR over time[tiab] OR 
((pre[tiab] OR prior[tiab]) AND (after[tiab] OR post[tiab])))
EMBASE 
‘percutaneous coronary intervention’/exp OR (‘percutaneous coronary’ NEXT/1 
intervention*):ab,ti OR pci:ab,ti OR ‘stent’/exp OR stent*:ab,ti AND (‘thrombocyte 
function’/exp OR ‘thrombocyte function analyzer’/exp OR (platelet NEXT/1 
function*):ab,ti OR (platelet NEXT/1 reactivit*):ab,ti OR (platelet NEXT/1 
activat*):ab,ti OR verifynow:ab,ti OR multiplate:ab,ti OR (p2y12 NEXT/1 
assay*):ab,ti OR vasp:ab,ti OR ‘p-selectin’:ab,ti OR (p NEXT/1 selectin*):ab,ti 
OR pfa:ab,ti OR lta:ab,ti OR ‘light transmission aggregometry’:ab,ti OR teg:ab,ti 
OR thromboelasto*:ab,ti OR ‘p2y12 reaction units’:ab,ti OR pri:ab,ti) AND 
(periprocedur*:ab,ti OR peri:ab,ti OR ‘time points’:ab,ti OR ‘over time’:ab,ti OR 
(pre:ab,ti OR prior:ab,ti AND (after:ab,ti OR post:ab,ti))) NOT [medline]/lim
The Cochrane Library (Wiley Online Library)
(percutaneous coronary intervention* or pci or stent*) and (platelet function* or 
platelet reactivit* or platelet activat* or VerifyNow or Multiplate or P2Y12 assay* 
or VASP or P-selectin* or PFA or LTA or light transmission aggregometry or TEG or 
thromboelasto* or p2y12 reaction units or PRI) and (periprocedur* or peri or time 
points or over time or ((pre or prior) and (after or post))):ti,ab,kw
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A BST R AC T
Purpose: Studies have shown a correlation between platelet reactivity (PR) on 
clopidogrel and the occurrence of cardiovascular events after percutaneous coronary 
intervention (PCI). In these studies, PR was measured before or after PCI in arterial or 
venous blood samples. However, the blood sampling site and the performance of a PCI 
might influence PR and thereby the assessment of a patient’s response to clopidogrel.
Materials and methods: Patients undergoing non-urgent PCI who were adequately 
pre-treated with aspirin and clopidogrel were included in a prospective study. Arterial 
and venous blood samples were drawn before and after PCI. PR was measured with 
the VerifyNow P2Y12 assay and expressed in P2Y12 Reaction Units (PRU). Additional 
samples were drawn to explore the effects of heparin (n=25), bivalirudin (n=9), and 
delayed blood sampling (n=7).
Results: The primary analysis included 82 patients. PR increased during PCI in both 
arterial (236 ± 78 versus 291 ± 67 PRU; p<0.0001) and venous blood samples (187 ± 82 
versus 229 ± 77 PRU; p<0.0001). PR returned to baseline values after 24 hours. PR was 
significantly increased after the administration of heparin (222 ± 71 versus 259 ± 68 
PRU; p<0.0001), but not bivalirudin (275 ± 75 versus 279 ± 82 PRU; p=0.749). PR was 
higher in arterial blood samples than in venous blood samples.
Conclusion: The timing and blood sample source influence PR on clopidogrel. 
Therefore, previously established cutoff values might not provide optimal detection of 
patients with a high thrombotic risk when the timing or blood sample source differs.
2.2
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I N T RODUC T ION
Many patients with ischemic heart disease undergo percutaneous coronary 
interventions (PCI) to treat symptoms of ischemia and prevent atherothrombotic 
events. The standard treatment for patients undergoing PCI with stent implantation is 
dual antiplatelet therapy: aspirin in combination with a P2Y12 inhibitor.(1) Clopidogrel 
is the most widely used P2Y12-receptor inhibitor, but also shows more inter-individual 
variability in the inhibition of platelet reactivity (PR) as compared to other P2Y12 
inhibitors such as prasugrel and ticagrelor.
Several platelet function tests can be used to asses PR and high platelet reactivity 
(HPR) cut-off values have been determined for these tests by correlating PR to the 
occurrence of atherothrombotic events, such as stent thrombosis, myocardial 
infarction and death, during follow-up after PCI.(2) To optimize platelet inhibition, it 
should be considered to treat patients exhibiting HPR on clopidogrel with prasugrel or 
ticagrelor, as these drugs provide more potent platelet inhibition than clopidogrel and 
show less inter-individual variability in PR. Switching from clopidogrel to these drugs 
in patients with stable coronary artery disease and HPR might prevent the occurrence 
of atherothrombotic events, but this has yet to be proven.(3)
As of yet, there is no consensus on the timing and the site of blood sampling for PR 
testing. Some studies regarding PR testing have taken blood samples before PCI (4-6), 
while others have taken samples during or after PCI (7-9). Furthermore, some studies 
used venous blood samples and other studies used arterial blood samples (by using 
the access site of the PCI). In earlier reports it has been suggested that these variables 
might influence PR. Performance of a PCI has been suggested to temporarily increase 
PR values, but its impact on the classification of HPR is not clear.(10-14)
It is also unclear which specific aspects of a PCI are responsible for this increase in 
PR, such as manipulation with catheters in the blood stream, balloon dilatation in the 
coronary artery or the use of heparin. Heparin has been traditionally used to prevent 
coagulation during a PCI procedure, but is also known to be associated with platelet 
activation and could thereby contribute to an increase in PR after PCI (15-16). If there 
is indeed an increase in PR after PCI, the PR of patients during follow-up might be lower 
than suggested by a PR measurement shortly after a PCI procedure. Higher PR values 
can also be present in arterial blood samples as compared to venous blood samples, for 
instance due to the differences in shear stress. These factors might alter the predictive 
value of the PR test, especially if a cut-off value is used that was determined using 
different type of blood samples or different timing. 
143
The POPular Process study
Subsequently, this could lead to misinterpretation of the patient’s response to 
antiplatelet therapy and his or her risk of atherothrombotic events during follow-up 
after PCI.
We aimed to assess if performance of a PCI procedure leads to higher levels of PR. 
Furthermore, we aimed to determine if there are specific features of a PCI that can 
cause activation of platelets during the procedure and whether PR is different in arterial 
and venous blood samples. To answer these questions we performed the prospective 
cohort study “Is Platelet Reactivity Measured with the VerifyNow P2Y12 Platelet 
Function Assay Influenced by the Performance of a PCI Procedure and Procedural 
Characteristics” – The POPular Process study.
M AT ER I A L S A ND MET HODS
Patients
Patients scheduled for PCI in the St. Antonius Hospital (Nieuwegein, the Netherlands) 
were included in this prospective single centre study between January 2014 and 
December 2014. Inclusion criteria were: planned non-urgent PCI and adequate 
clopidogrel pre-treatment (600mg clopidogrel loading dose at least 6 hours before 
PCI, 300mg loading dose at least 12 hours before PCI or 75mg maintenance dose for 
at least 5 days before PCI). Exclusion criteria were: presentation with ST-segment 
elevation myocardial infarction, the use of GpIIb/IIIa-inhibitors within the last 
14 days or thrombolytic therapy within 24 hours before the procedure, or a platelet 
count <100 x109/L, hematocrit <0.33 L/L and/or haemoglobin <6.5 mmol/L. The 
study was conducted according to the principles of the Declaration of Helsinki and 
received approval from the human research ethics committee Verenigde Commissies 
Mensgebonden Onderzoek. Informed consent was obtained from all patients. All 
technicalities of the procedure, including the arterial access site, the type of catheter 
and sheath that were used, and the type of anticoagulation and stents that were used, 
were left to the operator’s discretion. The arterial puncture was performed using the 
Seldinger technique.
Blood sampling
Blood samples were obtained before and after the PCI procedure. For each sample, 
blood was obtained in two 2 mL 3.2% citrate blood tubes (Greiner). The first 5 mL of 
blood was discarded to prevent measuring spontaneous platelet activation related to 
the blood collection procedure itself. Two blood samples were drawn from the arterial 
sheath. One sample was taken at the beginning of the procedure, before heparin was 
administered, and the other sample was taken at the end of the procedure, just before 
the sheath was removed. Two venous blood samples were obtained, one before PCI 
through venipuncture and one as soon as possible after PCI from a venous line  (through 
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which no fluid was infused for at least 15 minutes) or by venipuncture. These samples 
were taken from the anticubital vein or another suitable vein in the arm. The venous 
sample before PCI was performed before the artery was punctured for introduction 
of the arterial sheath and the venous sample after PCI was obtained after the arterial 
sheath was removed. Some patients were included in a substudy for which a fifth blood 
sample was obtained in these patients. The timing of these blood samples is described 
in detail under the header for each substudy.
Point-of-care testing
The VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA), a point-of-care platelet 
function test, was performed on all blood samples to assess PR on clopidogrel. The 
intra-assay coefficient of variation with the use of cartridges from different production 
batches reported in the instruction manual ranged from 3.9%-7.4%. Two tests were 
performed on each sample and the mean values were registered. The VerifyNow is a 
whole blood turbidity agonist-induced aggregation assay. The test is performed by 
inserting a tube of citrated whole blood on to a P2Y12 cartridge, which is inserted into 
the instrument.(17) The results of this ADP-induced aggregation assay are expressed 
as P2Y12 reaction units (PRU). HPR was defined according to two regularly used cut-off 
values: PRU>208 and PRU ≥236.(18)
Main study and substudies
The main study was performed to compare samples drawn before and after PCI and 
to compare arterial and venous blood samples. In addition, we also conducted 3 
substudies, described below.
24-hours substudy
To evaluate whether a potential increase in PR after PCI diminishes shortly after 
PCI, we performed the 24 hours substudy. In this substudy, 7 patients were included 
and a fifth blood sample was collected 24 hours (± 3 hours) after PCI. The sample was 
drawn from a venous line or a venipuncture was performed. The maintenance dose of 
clopidogrel was given at approximately 10 p.m. on the day of PCI.
Heparin substudy
The aim of the heparin substudy was to assess the effects of heparin on PR. In this 
substudy, a fifth blood sample was collected from the arterial sheath directly after 
administration of heparin during the PCI procedure in 25 patients.
Bivalirudin substudy
The aim of this this substudy was to measure PR in patients who were not treated 
with heparin. Therefore, we included patients treated with bivalirudin, an alternative 
for heparin. A fifth blood sample was obtained from the arterial sheath directly after 
administration of bivalirudin in these patients.
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Statistical analysis
A paired t-test was performed to determine if there were statistically significant 
differences in PRU between samples before and after PCI, and between arterial and 
venous blood samples. Patients without stent implantation were excluded from the 
analysis. Patients included in the bivalirudin substudy were also excluded from the 
main analysis, but additional analyses were performed including these patients. The 
paired t-test was also performed in the substudies to detect significant differences 
in PR. In the 24-hours substudy, PRU values in venous blood samples before and 
after PCI were compared to PRU at 24 hours after PCI. In the heparin and bivalirudin 
substudy, PRU after administration of the specific drug was compared to PRU before 
administration of the drug and also to PRU at the end of the procedure.
The main outcome measures of this study were of a descriptive nature, therefore the 
sample size considerations were a matter of precision. We considered a sample size of at 
least 100 patients optimal in this study to provide answers to the two main questions. 
This estimation was based on the information from previously performed studies 
that showed significant differences with smaller populations and taking into account 
that we wanted to test multiple variables and perform multiple substudies.(11-13) 
Ultimately, more patients were included as substudies were added to the main study 
during the inclusion period. Baseline and procedural characteristics are expressed as 
mean ± standard deviation (SD) for continuous variables and categorical variables are 
expressed as counts and percentages. Paired t-tests were used to assess the differences 
in PRU. Generalized linear models (GLMs) were used to determine whether procedural 
characteristics were associated with the difference in PRU between measurements 
before and after PCI with stent implantation (ΔPRU). First, baseline and procedural 
characteristics were entered one by one in conjunction with the PRU value measured 
before PCI as a covariate and ΔPRU as the dependent variable. All variables with a 
p-value <0.10 and factors associated with this increase in other publications were then 
entered into one model in conjunction with the PRU value measured before PCI. This 
was done for both arterial and venous blood samples. Only factors with a significant 
p-value were entered in the final GLM.
A p-value of <0.05 was considered statistically significant. Statistical analyses were 
conducted using IBM SPSS Statistics version 22.0 (IBM corp., Armonk, United States 
of America).
R E SU LT S
A total of 111 patients scheduled for PCI were included. In 13 of the 111 patients no stent 
was implanted. Reasons were: coronary anatomy unsuitable for stent implantation (2 
patients), a contra-indication for dual antiplatelet therapy due to a scheduled biopsy 
procedure and possible surgery in the near future (1 patient), referral for coronary 
artery bypass grafting surgery (CABG) based on the new coronary angiogram (1 
patient), a non-significant coronary lesion on angiogram or with fractional flow 
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Characteristics
Demographics
Age, years 66.1 ± 10.3
Male gender 66 (80.5%)
Body mass index  (kg/m^2) 27.6 ± 4.1
CYP2C19 genotype
- EM (*1/*1) 54 (65.9%)
- IM (*1/*2, *1/*3) 27 (32.9%)
- PM (*2/*2, *2/*3, *3/*3) 0 (0)
Medical history
Hypertension 64 (78.0%)
Hypercholesterolemia 74 (90.2%)
Diabetes mellitus 19 (23.2%)
Active smoking (< 6weeks) 13 (15.9%)
Positive family history 42 (51.2%)
Medication pre-intervention
Clopidogrel loading
- Loading dose 35 (42.7%)
- Maintenance dose 47 (57.3%)
Beta-blocker use 66 (80.5%)
Lipid-lowering drug use 76 (92.7%)
ACE-inhibitor use 31 (37.8%)
Angiotensin-II-receptor antagonist use 15 (18.3%)
Nitrate use 43 (52.4%)
Diuretic use 28 (34.1%)
Proton-pump inhibitor use 49 (59.8%)
Calcium antagonist use 31 (37.8%)
Table 1: Characteristics of patients with stent implantation
reserve (3 patients), or because stent implantation was unsuccessful (6 patients). 
Study procedures were discontinued in a total of 6 patients. Of these 6 patients, 3 had 
haemoglobin levels <6.5 mmol/L and/or a hematocrit below 0.33 L/L and 1 patient 
had a platelet count <100 x109/L (exclusion criteria discovered after inclusion). In the 
remaining 2 patients study participation was discontinued by mistake (see Figure 1). 
The baseline characteristics of patients with stent implantation who did not receive 
bivalirudin are presented in Table 1.
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Cardiovascular history
ACS as indication for the procedure 5 (6.1%)
History of CVA/TIA 7 (8.5%)
History of PCI 28 (34.1%)
History of CABG 14 (17.1%)
History of MI 28 (34.1%)
LVEF 
- <30% 1 (1.2%)
- 30-49% 9 (11.0%)
- ≥50% 69 (84.1%)
Laboratory measurements
Hemoglobin (mmol/L) 8.8 ± 0.7
Platelet count (x109/L) 226 ± 55
Creatinine (mmol/L) 88 ± 24
Procedural characteristics
Arterial access site
- Femoral 40 (48.8%)
- Radial 42 (51.2%)
Catheter size
- 6F 80 (97.6%)
- 7F 1 (1.2%)
- 8F 1 (1.2%)
Total heparin dose, units 9158 ± 1846
Number of vessels with CAD
- 1 57 (69.5%)
- 2 25 (30.5%)
Number of vessels treated
- 1 71 (86.6%)
- 2 11 (13.4%)
Vessel(s) treated:
- Left main 3 (3.7%)
- LAD 35 (42.7%)
- Cx 31 (37.8%)
- RCA 19 (23.2%)
- Arterial graft 1 (1.2%)
- Vein graft 1 (1.2%)
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Predilatation 73 (89.0%) 
Total number of stents implanted 1.4 ± 0.6
Total length of stent(s), mm 24.8 ± 12.4
Maximal stent diameter, mm 3.1 ± 0.5
Maximal pressure on the stent(s), atm 14.8 ± 3.0
Postdilatation 22 (26.8%)
Radiation time, min 3.7 ± 2.7
Total procedure time, min 32.4 ± 17.2
Table 1: Characteristics of the 82 patients who underwent stent implantation and were not treated 
with bivalirudin. Continuous data are presented as mean ± SD and categorical data as n (%).
Abbreviations: ACE = angiotensin converting enzyme, ACS as indication for the procedure = acute 
coronary syndrome, which was defined as a diagnosis of unstable angina or non-ST-segment elevation
myocardial infarction, in the 14 days before the procedure, atm = atmosphere, CABG = coronary artery
bypass surgery, CAD = coronary artery disease, CVA = cerebrovascular accident, Cx = circumflex artery, 
EM = extensive metabolizer, F = French, IM = intermediate metabolizer, LAD = left anterior descending 
artery, LVEF =  left ventricular ejection fraction, MI = myocardial infarction, mm = millimeters, PCI 
= percutaneous coronary intervention, PM = poor metabolizer, RCA = right coronary artery. TIA = 
transient ischemic attack.
Results from the comparison of PRU values before and after PCI are shown in Figure 
2. The mean PRU in arterial samples was 55 units higher after the PCI procedure 
(before PCI: 236 ± 78 versus after PCI: 291 ± 67; p<0.0001). In venous samples, mean 
PRU showed an increase of 42 units after PCI (before PCI: 187 ± 82 versus after PCI: 
229 ± 77; p<0.0001). Figure 3 shows a comparison of PRU values measured in arterial 
and venous blood samples both before and after PCI. PR was significantly higher in 
arterial blood samples as compared to venous blood samples both before PCI (arterial: 
235 ± 79 versus venous: 190 ± 82; p<0.0001) as well as after PCI (arterial: 287 ± 66 
versus venous: 228 ± 76; p<0.0001).
Appendix 2 shows the results from the generalized linear models to predict ΔPRU 
between measurements after PCI as compared to before PCI in the arterial blood 
samples with a single baseline or procedural characteristic in conjunction with PRU 
before PCI. Pre-dilatation of the coronary artery, arterial access site, history of CABG, 
history of myocardial infarction, acute coronary syndrome (ACS) as indication for 
the procedure, CYP2C19 genotype and beta-blocker use all showed an association 
with ΔPRU (p-values <0.10). Factors associated with ΔPRU in literature, but not in 
this analysis, were total stent length and total procedure time.(10) We generated a 
GLM including all aforementioned characteristics in conjunction with PRU before the 
procedure to predict ΔPRU. 
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Figure 1: Study design.
Figure 1: Abbreviations: CAD= coronary artery disease, UAP= unstable angina pectoris, NSTEMI= 
non-ST elevation myocardial infarction, PR= platelet reactivity, PCI= percutaneous coronary
intervention.
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Figure 2: PRU before and after PCI. 
Figure 3: PRU in arterial and venous samples.
Figure 2: This figure shows a comparison of PRU values in arterial blood samples (left, n=81) and 
venous blood samples (right, n=77) obtained both before (hatched) and after (filled) PCI with stent 
implantation. P-values are displayed for the differences in mean values. PRU=P2Y12 reaction units, SD 
= standard deviation.
Figure 3: This figure shows a comparison of PRU values in venous and arterial blood samples both 
before (left, n= 79) and after PCI (right, n=78). Measurements from venous blood samples are shown
on the left side of each graph (hatched) and blood samples drawn from artery are shown on the right 
(filled). P-values are displayed for the differences in mean values. N=number of patients, PRU=P2Y12
reaction units, SD = standard deviation.
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Total stent length (p=0.151), total procedure time (p=0.422), ACS as indication for the 
procedure (p=0.068) and treatment of the right coronary artery (p=0.259) were all not 
significantly associated and therefore not included in the final GLM. The final GLM 
is presented in Table 2. The only procedural characteristics significantly associated 
with ΔPRU were predilatation and arterial access site. Predilatation was associated 
with a ΔPRU that was 17 units lower, independent of the other factors in the GLM. 
Other factors that influenced ΔPRU after PCI were patient characteristics (CYP2C19 
genotype, history of CABG, history of myocardial infarction, beta-blocker use) and 
the use of the radial artery as compared to the femoral artery, which did not change 
between measurements. Appendix 3 shows the results from the GLMs with single 
factors in the venous blood samples (n=77) and Table 3 shows the final GLM with 
multiple factors. 
Characteristics B P-value
Mean PRU before PCI -0.20 <0.001
CYP2C19 genotype 0.002
- EM (*1/*1) ref
- IM (*1/*2, *1/*3) 15.44
History of CABG 25.52 <0.001
History of MI -15.32 0.005
Beta-blocker use 14.11 0.019
Arterial access site 0.015
- Femoral +11.73
- Radial ref
Pre-dilatation -17.01 0.030
Table 2: GLM model to predict ΔPRU in arterial blood samples
Table 2: This table shows the association between characteristics and ΔPRU in arterial blood 
samples in the 82 patients who underwent stent implantation and were not treated with bivalirudin.
Continuous variables are presented as mean ± SD and categorical data as n (%).
Abbreviations: ACE = angiotensin converting enzyme, ACS as indication for the procedure = acute
coronary syndrome, which was defined as a diagnosis of unstable angina or non-ST-segment 
elevation myocardial infarction, in the 14 days before the procedure, atm = atmosphere, B =
regression coefficient, CABG = coronary artery bypass surgery, CAD = coronary artery disease, CVA
= cerebrovascular accident, Cx = circumflex artery, EM = extensive metabolizer, F = French, IM = 
intermediate metabolizer, LAD = left anterior descending artery, LVEF = left ventricular ejection 
fraction, MI = myocardial infarction, mm = millimeters, n = number of patients, PCI = percutaneous
coronary intervention, PM = poor metabolizer, RCA = right coronary artery, ref = reference group, TIA 
= transient ischemic attack.
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Characteristics B P-value
Mean PRU before PCI -0.15 <0.001
Male gender -18.40 0.017
Body mass index -2.33 0.001
Beta-blocker use 23.40 0.002
Radiation time, min -3.56 0.002
Total procedure time, min -0.40 0.030
Table 3: GLM model to predict ΔPRU in venous blood samples
Table 3. Generalized linear model for the factors that are significantly associated with the ΔPRU 
in venous blood samples in patients who underwent stent implantation and were not treated with
bivalirudin. B = regression coefficient, PRU=P2Y12 reaction units, PCI=percutaneous coronary
intervention.
Figure 4: HPR on different time points. 
Figure 4: This figure shows the number of patients exhibiting HPR at every time point defined 
according to two regularly used cut-off points (≥236 and >208 PRU). HPR: high on-treatment platelet 
reactivity.
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The only procedural characteristics associated with ΔPRU were total procedure time 
and radiation time, the rest were patient characteristics (male gender, body mass 
index and beta-blocker use).  
Each minute of total procedure time was associated with a decrease of 0.4 unit in ΔPRU, 
independent of all other factors in the GLM. Each minute of radiation was associated 
with a decrease of approximately 4 units in ΔPRU.
The number of patients with HPR at every time point are shown in Figure 4. The total 
number of patients exhibiting HPR, defined according to different cut-off values, was 
higher in arterial blood samples as compared to venous blood samples, and in samples 
taken after PCI as compared to before PCI. 
24-hours substudy
A total of 7 patients were included in the 24-hours substudy. However, this analysis 
contains data from 6 patients as blood was not obtained at 24h after PCI in one patient 
due to logistic reasons. Figure 5 shows that the mean PRU of venous blood samples 
significantly increased after PCI compared to before PCI in line with the results from 
the main study (before PCI: 176 ± 68 versus after PCI: 221 ± 73; p=0.003). After 
this increase, a significant drop in PRU was observed 24 hours after PCI (171 ± 79; 
p=0.015). The values measured before PCI and 24 hours after PCI did not significantly 
differ (before PCI: 176 ± 68 versus 24-h after PCI: 171 ± 79, p=0.732). 
Figure 5: 24 hours substudy. 
Figure 5: This figure shows a comparison of PRU values before, after and 24-hours after PCI in venous 
blood samples (n=6). The darker line shows the mean values. P-values are displayed for the differences
in mean values between each time point. N=number of patients, PRU=P2Y12 reaction units, SD =
standard deviation.
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Heparin substudy
A total of 25 patients were included in this substudy. Data from 19 patients were used 
for this analysis, as 3 patients did not receive a stent and PR data was incomplete for 
another 3 patients due to logistical errors (heparin was given before the sample pre-
heparinization could be obtained by study personnel). Figure 6 shows PRU values from 
arterial samples taken at 3 time points: 1) before heparin administration, 2) directly 
after heparin administration and 3) directly after PCI. PRU increased significantly 
after heparin administration (before heparin: 222 ± 71 versus after heparin: 259 ± 
68; p<0.0001). PRU further increased after PCI as compared to directly after heparin 
administration (281 ± 60; p=0.013). To conclude, the overall rise in mean PRU was 
59 from before to after PCI, of which a rise of 37 PRU was already seen directly after 
heparin administration and before performance of the PCI.
Bivalirudin substudy
A total of 9 patients were included in the bivalirudin substudy. Data from 8 patients 
were used for this analysis, as 1 patient in this substudy did not undergo stent 
implantation. Figure 7 shows PRU values from arterial samples taken at 3 time points: 
1) before bivalirudin administration, 2) directly after bivalirudin administration and 
3) after PCI. PR did not significantly increase after bivalirudin administration (before 
Figure 6: This figure shows a comparison of PRU values before and after administration of heparin 
and at the end of the procedure (n=19). The darker line shows the mean values. P-values are displayed 
for the differences in mean values between each time point. N=number of patients, PRU=P2Y12 reaction 
units, SD = standard deviation.
Figure 6: Heparin substudy. 
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bivalirudin: 275 ± 75 versus after bivalirudin: 279 ± 82; p=0.749). However, PRU 
was significantly higher at the end of the procedure as compared to after bivalirudin 
administration (after bivalirudin: 279 ± 82 versus after PCI: 300 ± 86, p=0.014). To 
conclude, the overall rise in mean PRU was 25 from before to after PCI, but a non-
significant rise of only 4 PRU was found after the administration of bivalirudin.
 
DISCUSSION
This study shows that PR on clopidogrel is significantly and substantially higher 
after a PCI procedure as compared to before the procedure (Figure 2). This increase 
led to a much higher percentage of patients with HPR, according to different cut-
off values. We attempted to identify factors that influence the size of this increase 
in PR by recording many procedural characteristics and creating GLMs. The only 
procedural characteristics that were associated with ΔPRU were arterial access site and 
predilatation in arterial samples and total procedure time and radiation time in venous 
blood samples. However, predilatation, which was performed in 88.9% of patients in 
the arterial sample group, was associated with a lower ΔPRU, and thus did not explain 
the increase in PRU observed after PCI. Performance of the PCI through the femoral 
artery was associated with a higher ΔPRU as compared to treatment through the radial 
Figure 7: This figure shows a comparison of PRU values before and after administration of bivalirudin 
and at the end of the procedure (n=8). The darker line shows the mean values. P-values are displayed for 
the differences in mean values between each time point. N=number of patients, PRU=P2Y12 reaction 
units, SD = standard deviation.
Figure 7: Bivalirudin substudy. 
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artery. The sampling site of the blood might have contributed to this difference, as 
blood was sampled through the sheath and a previous study has shown differences in 
PR measured from blood from the femoral and coronary artery.(19) Total radiation 
time and total procedure time both had a negative correlation with ΔPRU. This could 
be due to a longer duration between the administration of heparin and the sample at 
the end of PCI, which allows for more clearance of heparin in this period. However, the 
magnitude of the effect was not very large. We therefore conclude that performing a 
PCI procedure with stent implantation causes an increase in PR, and that variations in 
the procedure might only make a small difference. 
Other studies have also shown an increase in PR after PCI. The only study that found 
specific characteristics of the procedure associated with this increase was a study by 
Mangiacapra et al.(10) In this study, which included 65 patients, PR as measured with 
the Multiplate was increased after PCI and significantly correlated with total inflation 
time and total stent length. The increase in PR was also moderately correlated with 
total procedure time. Moreover, patients undergoing rotational atherectomy during 
PCI showed a larger increase in PR and patients undergoing coronary angiography 
without PCI showed a non-significant decrease in PR. Furthermore, the authors 
performed experiments by testing PR in blood flowing through porcine carotid arteries 
and plastic tubes in which they performed stenting procedures. They observed that PR 
increased significantly in the model with porcine carotid arties, but did not increase 
in the model with the plastic tubes. Based on these results they concluded that flow 
turbulence and shear stress induced by the procedures or the catheters (that are also 
used during coronary angiography without PCI) were not sufficient to induce platelet 
activation and that the interaction between the damaged vessel and circulating 
platelets after PCI is the key to the increase in PR.(10)
In the 24-hours substudy of the current study, PRU values directly after PCI were 
significantly higher than PRU values before PCI (p= 0.002) and 24 hours after PCI 
(p=0.015). The increase in PR observed after PCI therefore seems to last less than 24 
hours. These findings are in line with previously published data.(10,11,14) If PR testing 
is performed, it is therefore recommended to test before PCI or at least 24 hours after 
PCI to avoid the influence of the PCI procedure on PR.
Heparin and bivalirudin
We have further explored the administration of heparin as a possible factor for the 
increase in PR, since several studies have concluded that heparin causes platelet 
activation(15,16), although other studies did not find an increase in PR after heparin 
administration.(10,11) In the heparin substudy we observed that PRU was significantly 
higher after its administration, with a mean increase of 37 units. In contrast, the 
bivalirudin substudy showed no significant increase in PRU in after administration 
of bivalirudin. Although heparinization increases PR, it is not solely responsible for 
the total increase in PR observed after PCI, as PRU values increased further from 
measurements after the administration of both heparin and bivalirudin to after PCI.
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There are several mechanisms that could explain the differences between the effect of 
heparin and bivalirudin on PR. Multiple studies concluded that heparin initiates the 
activation of the amplification PI3K-pathway by binding at or near the ligand-binding 
site of glycoprotein IIb/IIIa (GP IIb/IIIa) on blood platelets.(20,21) This results in 
phosphorylation, and thereby activation, of the second messengers Akt and GsK 3-ȕ. 
For soluble heparin, this activation seems insufficient for platelet activation, but in the 
presence of weak stimuli, like ADP or thrombin, platelet responsiveness is enhanced by 
the second messengers.(20)The messenger focal adhesion kinase (FAK) that also plays 
a role in platelet signaling, is another factor that becomes phosphorylated by heparin 
inducing GP IIb/IIIa ligation. GP IIb/IIIa inhibitors inhibit the FAK-pathway and as a 
result heparin cannot activate this pathway. Patients treated with GP IIb/IIIa inhibitors 
were excluded from this study and therefore heparin was able to activate platelets in 
this population. Moreover, heparin is able to form multimolecular complexes with 
platelet factor 4 (PF4), after which an immune response can generate antibodies. 
These antibodies are able to bind to Fc’RIIa  receptors on the surface of platelets, which 
results in platelet activation and can lead to heparin-induced thrombocytopenia.(20) 
In contrast, bivalirudin has no direct effects on platelets but effectively inhibits clot-
bound and free thrombin, which prevents platelet activation because thrombin cannot 
bind to protease-activated receptor 1 (PAR-1) and PAR-4.(22,23)
Arterial versus venous blood samples
PR as measured with the VerifyNow was higher in arterial blood samples than in 
venous blood samples in this study. The increase in PR was substantial and resulted in 
a much higher percentage of patients with HPR.
Few studies have found a significant difference in PR between venous and arterial 
blood samples. Hu et al. studied the differences between venous blood samples from 
the femoral vein and arterial blood samples from the femoral artery and the coronary 
artery in 21 patients undergoing PCI.(19) PR was assessed with the VerifyNow in 
samples from these three sources before the procedure and showed PRU values of 
233.52 ± 17.29, 238.10 ± 18.31 and 255.19 ± 18.28 for the femoral vein, femoral artery 
and coronary artery, respectively (p =0.001). No p-value was reported for the small 
difference between samples from the femoral vein and artery. The PRU values of the 
femoral vein and artery did significantly differ from the PRU values in the coronary 
artery. The percentage of monocytes was the only variable associated with the 
differences in HPR in samples from the femoral vein and the coronary artery. Platelets 
and monocytes interact with each other and form aggregates as an inflammatory 
response. These platelet-monocyte complexes are associated with higher PR and are 
formed at the site of inflamed endothelial cells.(24) This could explain the difference 
between venous and arterial samples, since venous samples contain low levels of 
monocytes and exhibit low inflammatory response. However, one would then also 
expect to find a larger difference between the samples from the femoral vein and artery 
in this study by Hu et al., like the significant difference found in the present study.(19)
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Implications of this study for platelet function testing
The differences in PR found in this study are associated with a substantial shift in 
the proportion of patients deemed to have HPR on clopidogrel treatment. Therefore, 
the inhibitory effect of clopidogrel will be underestimated in a proportion of these 
patients, which could lead to a less accurate assessment of their thrombotic risk 
following PCI. To optimize the predictive value of PR testing, it could therefore be 
important to account for these differences and use cut-off values for HPR that have 
been determined under the same conditions regarding the timing (before versus after 
PCI) and blood collection site (arterial versus venous).
Limitations
This study has several limitations. First, our power calculations were based on a general 
estimation of the effect of PCI on PR based on previous studies. Second, we have only 
considered the main effects of each variable alone and an interaction between several 
variables was not assessed in our GLM to find specific procedural characteristics 
correlated with the increase in PR. Additionally, for many variables only a small 
number of patients deviated from the mean value in the population. For example, 
direct stenting without predilatation was performed in only 11% of patients, the dose 
of heparin was 10.000IE in 71% of patients and a catheter size other than 6 French 
was used in only two patients. We further determined the effect of heparin on PR by 
performing pre-specified substudies, but we could not do this for other factors that 
might influence PR during the procedure. Third, we tested the influence of heparin and 
bivalirudin on PR, but this treatment was not randomized, and therefore there is a risk 
of counding by indication. Fourth, we only tested patients treated with clopidogrel, 
and we therefore do not know if the same increase in PR is also present in patients 
treated with the more potent P2Y12 inhibitors prasugrel or ticagrelor.
CONCLUSION
The results from this study lead to the following conclusions:
1) PR on clopidogrel is increased directly after PCI as compared to before or 24 hours 
after PCI
2) No individual component of the PCI procedure was identified to be solely responsible 
for this increase in PR
3) PR is higher in arterial samples than in venous samples
4) The administration of heparin increases PR and the administration of bivalirudin 
does not
5) Accounting for the aforementioned effects on PR on clopidogrel, by using 
standardized testing methods and corresponding cut-off values, could lead to improved 
identification of patients at higher thrombotic risk after PCI.
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Table 2: Association between characteristics and ΔPRU in arterial blood
Characteristics B P-value
Mean PRU before PCI 236 ± 78 -0.21 <0.001
Age 66.0 + 10.3 -1.48 0.604
Male gender 65 (80.2%) -8.03 0.273
BMI 27.6 + 4.1 -1.04 0.139
CYP2C19 genotype 0.007
- EM (*1/*1) 53 (66.3%) ref
- IM (*1/*2, *1/*3) 27 (33.8%) 16.10
- PM (*2/*2, *2/*3, *3/*3) 0 (0%) -
Hypertension 63 (78.8%) 6.78 0.344
Hypercholesterolemia 73 (91.3%) 0.41 0.968
Diabetes mellitus 18 (22.2%) 3.65 0.601
Active smoking (< 6weeks) 13 (16.0%) 6.67 0.396
Positive family history 41 (55.4%) -8.77 0.137
Clopidogrel loading 0.705
- Loading dose 34 (42.0%) ref
- Maintenance dose 47 (58.0%) 2.23
Beta-blocker use 65 (80.2%) 12.66 0.081
Lipid-lowering drug use 75 (92.6%) -10.15 0.358
ACE-inhibitor use 31 (38.3%) -8.11 0.168
Angiotensin-II-receptor antagonist use 14 (17.3%) 3.02 0.692
Nitrate use 42 (51.9%) 3.19 0.581
Diuretic use 28 (34.6%) -3.15 0.604
Proton-pump inhibitor use 48 (59.3%) -0.07 0.990
Calcium antagonist use 31 (38.3%) -0.88 0.883
History of CVA/TIA 7 (8.6%) -6.17 0.551
History of PCI 28 (34.6%) -8.37 0.166
History of CABG 13 (16.0%) 19.31 0.012
ACS as indication for the procedure 5 (6.2%) -29.96 0.010
History of MI 28 (34.6%) -10.26 0.095
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LVEF 0.852
- <30% 1 (1.3%) ref
- 30-49% 9 (11.5%) -9.04
- ≥50% 68 (87.2%) -12.16
Hemoglobin (mmol/L) 8.8 ± 0.7 4.17 0.342
Hematocrit (%) 40.8 ± 3.2 0.81 0.404
Platelet count (x109/L) 226 ± 55 0.04 0.440
Creatinine (mmol/L) 87.8 ± 24.1 -0.20 0.116
Arterial access site
- Femoral 40 (49.4%) ref
- Radial 41 (50.6%) -9.70 0.093
Catheter size 0.811
- 6F 79 (97.5%) ref
- 7F 1 (1.2%) -4.51
- 8F 1 (1.2%) 16.30
Total heparin dose, units 9148 ± 1855 -0.001 0.499
Number of vessels with CAD 0.435
- 1 56 (69.1%) ref
- 2 25 (30.9%) -4.88
Number of vessels treated 0.603
- 1 70 (86.4%) ref
- 2 11 (13.6%) -4.40
Vessel(s) treated:
- Left main 3 (3.7%) 0.71 0.964
- LAD 35 (42.7%) 2.77 0.638
- Cx 31 (37.8%) 1.83 0.760
- RCA 19 (23.2%) -11.72 0.087
- Arterial graft 1 (1.2%) -4.6 0.861
- Vein graft 1 (1.2%) 15.6 0.551
Predilatation 72 (88.9%) -19.18 0.035
Total number of stents implanted 1.4 ± 0.7 -2.33 0.609
Total length of stent(s), mm 24.6 ± 12.3 -0.10 0.687
Maximal stent diameter, mm 3.1 ± 0.5 2.06 0.748
Maximal pressure on the stent(s), atm 14.8 ± 3.0 -0.06 0.949
Postdilatation 22 (27.2%) 4.05 0.535
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Radiation time, min 3.7 ± 2.7 0.88 0.409
Total procedure time, min 32.5 ± 17.2 1.10 0.294
Table 2: This table shows the association between characteristics and ΔPRU in arterial blood samples 
in the 82 patients who underwent stent implantation and were not treated with bivalirudin. Continuous 
variables are presented as mean ± SD and categorical data as n (%).
Abbreviations: ACE = angiotensin converting enzyme, ACS as indication for the procedure = acute 
coronary syndrome, which was defined as a diagnosis of unstable angina or non-ST-segment elevation 
myocardial infarction, in the 14 days before the procedure, atm = atmosphere, B = regression coefficient, 
CABG = coronary artery bypass surgery, CAD = coronary artery disease, CVA = cerebrovascular accident, 
Cx = circumflex artery, EM = extensive metabolizer, F = French, IM = intermediate metabolizer, LAD = 
left anterior descending artery, LVEF = left ventricular ejection fraction, MI = myocardial infarction, mm 
= millimeters, n = number of patients, PCI = percutaneous coronary intervention, PM = poor metabolizer, 
RCA = right coronary artery, ref = reference group, TIA = transient ischemic attack.
Characteristics B P-value
Mean PRU before PCI 187 ± 82 -0.14 0.001
Age 66.0 + 10.3 1.32 0.691
Male gender 62 (80.5%) -14.65 0.087
BMI 27.7 + 4.1 -2.1 0.010
CYP2C19 genotype 0.713
- EM (*1/*1) 51 (67.1%) ref
- IM (*1/*2, *1/*3) 25 (32.9%) -2.72
- PM (*2/*2, *2/*3, *3/*3) 0 (0%) -
Hypertension 62 (81.6%) 10.05 0.251
Hypercholesterolemia 69 (90.8%) -1.85 0.877
Diabetes mellitus 17 (22.1%) -1.13 0.891
Active smoking (< 6weeks) 13 (16.7%) 13.58 0.130
Positive family history 40 (56.3%) -1.95 0.785
Clopidogrel loading 0.513
- Loading dose 33 (42.9%) ref
- Maintenance dose 44 (57.1%) 4.50
Beta-blocker use 62 (80.5%) 21.96 0.009
Lipid-lowering drug use 71 (92.2%) -12.25 0.336
ACE-inhibitor use 29 (37.7%) -9.18 0.187
Angiotensin-II-receptor antagonist use 14 (18.2%) -3.71 0.674
Table 3: Association between characteristics and ΔPRU in venous blood
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Nitrate use 41 (53.2%) -0.29 0.967
Diuretic use 27 (35.1%) -7.81 0.271
Proton-pump inhibitor use 47 (61.0%) -6.96 0.317
Calcium antagonist use 30 (39.0%) -9.99 0.148
History of CVA/TIA 5 (6.5%) -13.28 0.334
History of CABG 12 (15.6%) 0.515 0.957
History of PCI 27 (35.1%) -14.91 0.032
ACS as indication for the procedure 4 (5.2%) -23.91 0.119
History of MI 27 (35.1%) -19.06 0.007
LVEF 0.107
- <30% 1 (1.4%) ref
- 30-49% 9 (12.2%) -56.33
- ≥50% 64 (86.5%) -38.63
Hemoglobin (mmol/L) 8.9 ± 0.7 -2.37 0.633
Hematocrit (%) 40.9 ± 3.3 -0.82 0.449
Platelet count (x109/L) 228 ± 55 0.01 0.877
Creatinine (mmol/L) 86.6 ± 22.8 -0.12 0.449
Arterial access site
- Femoral 38 (49.4%) +2.54
- Radial 39 (50.6%) ref 0.714
Catheter size 0.972
- 6F 75 (97.4%) ref
- 7F 1 (1.3%) -6.59
- 8F 1 (1.3%) 3.35
Total heparin dose, units 9169 ± 1835 -0.001 0.752
Number of vessels with CAD 0.932
- 1 53 (68.8%) ref
- 2 24 (31.2%) -0.63
Number of vessels treated 0.339
- 1 67 (87.0%) ref
- 2 10 (13.0%) 9.65
165
The POPular Process study
Vessel(s) treated:
- Left main 2 (2.6%) 0.02 0.999
- LAD 33 (43.4%) 4.40 0.526
- Cx 30 (39.0%) 2.05 0.771
- RCA 17 (22.1%) -1.74 0.832
- Arterial graft 1 (1.3%) -41.03 0.168
- Vein graft 1 (1.3%) 13.46 0.654
Predilatation 70 (90.9%) -23.51 0.048
Total number of stents implanted 1.4 ± 0.7 4.30 0.416
Total length of stent(s), mm 25.0 ± 12.7 0.21 0.450
Maximal stent diameter, mm 3.1 ± 0.5 -1.20 0.875
Maximal pressure on the stent(s), atm 14.8 ± 3.0 0.46 0.696
Postdilatation 21 (27.3%) 9.53 0.210
Radiation time, min 3.5 ± 2.6 -2.19 0.098
Total procedure time, min 32.4 ± 17.3 -0.37 0.054
Table 3: This table shows the association between characteristics and ΔPRU in venous blood samples in 
the 77 patients who underwent stent implantation and were not treated with bivalirudin. Continuous 
variables are presented as mean ± SD and categorical data as n (%). Abbreviations: ACE = angiotensin 
converting enzyme, ACS as indication for the procedure = acute coronary syndrome, which was defined as 
a diagnosis of unstable angina or non-ST-segment elevation myocardial infarction, in the 14 days before 
the procedure, atm = atmosphere, B = regression coefficient, CABG = coronary artery bypass surgery, 
CAD = coronary artery disease, CVA = cerebrovascular accident, Cx = circumflex artery, EM = extensive 
metabolizer, F = French, IM = intermediate metabolizer, LAD = left anterior descending artery, LVEF = 
left ventricular ejection fraction, MI = myocardial infarction, mm = millimeters, n = number of patients, 
PCI = percutaneous coronary intervention, PM = poor metabolizer, RCA = right coronary artery, ref = 
reference group, TIA = transient ischemic attack.
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A BST R AC T
Background
High on-treatment platelet reactivity is predictive for the occurrence of 
atherothrombotic events following percutaneous coronary interventions (PCI). A low 
hematocrit (HCT) value is associated with higher platelet reactivity values expressed 
in P2Y12 reaction units (PRU) as measured with the VerifyNow P2Y12 assay. However, 
it is suggested that this is only an in vitro phenomenon.
Objective
To determine whether adjusting PRU for HCT improves the predictive value for 
thrombotic events following PCI.
Material and methods
The VerifyNow P2Y12 assay was performed in clopidogrel-treated patients undergoing 
non-urgent PCI included in a prospective cohort study. PRU values were corrected for 
HCT with a formula proposed in recent literature. Receiver operating characteristic 
(ROC) curves were made to determine the optimal cut-off values to predict the 
occurence of the primary endpoint, a composite of all-cause death and nonfatal 
myocardial infarction, stent thrombosis and ischemic stroke, during one year of follow-
up and differences between ROC curves were assessed using bootstrapping analysis.
Results
A total of 978 patients were analyzed. A negative correlation between PRU and HCT 
was observed (R2 = 0.104). The optimal cut-off value for the corrected PRU was 215. 
ROC-analyses showed that prediction of the primary endpoint did not differ for the 
corrected PRU (area under the curve: 0.61, sensitivity: 0.57, specificity: 0.64) and the 
uncorrected PRU (area under the curve: 0.61, sensitivity: 0.69, specificity: 0.53). The 
ROC curves did not differ.
Conclusion
Correcting PRU for HCT does not improve the prediction of thrombotic events 
following PCI. 
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I N T RODUC T ION
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is used to reduce 
the incidence of atherothrombotic events, such as stent thrombosis, in patients 
undergoing percutaneous coronary intervention (PCI) with stent implantation.[1-
3]  Inadequate inhibition of blood platelets by treatment with a P2Y12 inhibitor, such 
as clopidogrel, results in high on-treatment platelet reactivity (HPR) which can be 
assessed with platelet function tests (e.g. the VerifyNow P2Y12 assay)[4,5] and is a 
predictor of thrombotic events after a PCI.[6-9]
The results of the VerifyNow P2Y12 assay are expressed in P2Y12 Reaction Units (PRU). 
Kakouros et al.[10] and Voisin et al.[11] showed that the PRU value is negatively 
correlated with hematocrit (HCT), which might be a relevant factor to account for 
when interpreting the test results. Because this correlation does not appear with 
light transmittance aggregometry (LTA), which is a different platelet function test, it 
is suggested that this is only an in vitro phenomenon associated with the VerifyNow 
P2Y12 assay.[10]
In contrast to the VerifyNow P2Y12 assay, which requires citrated whole blood, blood 
used for the LTA has to be centrifuged before platelet reactivity is assessed. Sodium 
citrate could influence whole blood assays, because it acts as an anticoagulant by binding 
calcium. Sodium citrate does not enter red blood cells and therefore its concentration 
in plasma is dependent on HCT levels. A low HCT renders a relative excess of calcium 
if a constant amount of citrate is used. With more calcium present, more coagulation 
could take place and HCT could thereby influence platelet aggregation measured by 
the VerifyNow P2Y12 test. In a publication by Kakouros et al.[10], the authors proposed 
to correct platelet reactivity measured with the VerifyNow P2Y12 assay for deviations 
in HCTAfter correcting for HCT, the prevalence of HPR as determined with several 
different cut-off values was reduced by 13-39%. The authors suggested that correcting 
PRU for HCT might increase the predictive value of HPR of thrombotic events during 
follow-up.In this analysis, we aimed to determine if PRU corrected for HCT is a better 
predictor of thrombotic events after PCI than uncorrected PRU. 
M A T E R I A L  A N D  M E T H O D S
Data from the Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-
Pretreated Patients Undergoing Elective PCI (POPular) study was used to asses the 
impact of correction for HCT on the prediction of atherothrombotic events after PCI. 
The study procedures of this prospective cohort study are summarized below and can 
be found in a previous publication.[12]
Study population
Patients undergoing non-urgent PCI at the St. Antonius Hospital in Nieuwegein 
were included in this study between December 2005 and December 2007. Adequate 
clopidogrel pre-treatment, which was defined as a maintenance dose of 75 mg a day 
171
Correcting VerifyNow P2Y12 assay results for hematocrit
for ≥5 days or a loading dose of 300 mg ≥24 hours or 600 mg ≥4 hours before PCI, was 
required for inclusion. Exclusion criteria were concomitant use of medication known 
to affect platelet function other than aspirin and clopidogrel (i.e. nonsteriodal anti-
inflammatory agents, dipyridamole, glycoprotein IIb/IIIa inhibitors used before blood 
sampling), a known platelet function disorder or a whole blood platelet count of less 
than 150x109/L. This study was approved by the local institutional medical ethical 
committee and was performed according to the guidelines of the revised version of the 
Helsinki Declaration. Written informed consent was obtained from all patients.
Blood sampling and platelet function testing
Before PCI and before the administration of heparin, blood was drawn from the 
femoral or radial artery through a 6 or 7 French sheath. The first 5 mL of blood was 
discarded in order to prevent dilution of the blood with infused fluids. HCT values 
were determined in the blood sample that was used for platelet function testing. For 
the VerifyNow P2Y12 assay, 3 mL of whole blood was collected in a 3.2% citrate tube. A 
higher PRU value means higher platelet reactivity.
Follow-up and primary endpoint
Follow-up was performed up to 1 year after PCI. The primary endpoint was a composite 
of all-cause death, nonfatal acute myocardial infarction, nonfatal stent thrombosis 
and nonfatal ischemic stroke. Definitions can be found in the original publication.[12]
Statistical analysis
Continuous data were reported as mean ± the standard deviation, whereas categorical 
data were reported as frequencies with the corresponding percentage. Missing data 
were not imputed. Linear regression was conducted to determine if there was a 
correlation between the PRU and HCT. PRU values were corrected for HCT with the 
formula composed by Kakouros et al.(corrected PRU = uncorrected PRU + ((HCT(%) 
-  42) * 7.5)) and a new correction coefficient calculated with data from our study 
cohort.[10] In order to determine this new correction coefficient, linear regression was 
performed with VerifyNow BASE and HCT values. BASE is not influenced by the use 
of clopidogrel as it represents maximum platelet reactivity. The correction coefficient 
was defined as the slope of the regression line. To evaluate the predictive value of 
the uncorrected (PRUuncorr) and corrected PRU (PRUcorr) for the primary endpoint at 
1 year follow-up, a receiver operating characteristic (ROC) curve was calculated for 
uncorrected and corrected PRU. ROC curves were used to determine a new optimal 
cut-off value to predict the primary endpoint, defined as the point with the highest 
combined sensitivity and specificity. Bootstrapping was used to compare the ROC 
curves. In further analyses, a PRU value less higher than or equal to the optimal 
cut-off value was deemed HPR.. The McNemar test was used for paired dichotomous 
data to compare the amount of misclassifications with the PRUcorr value with the new 
cut-off value and the PRUuncorr with the old cut-off value. All statistical analyses were 
performed using SPSS 22.0, except for the generation and comparison of the ROC 
curves, for which R version 3.0.2 was used. All analyses were two-sided with a p-value 
<0.05 considered as significant.
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R E SULT S
The POPular study included a total of 1069 PCI patients. One year follow-up was 
available for all patients. A total of 978 patients were selected for this analysis based 
on availability of PRU and HCT values. The baseline characteristics of these patients 
are presented in Table 1. 
Characteristic Mean ± SD / Number of patients (%)
General characteristics
Male gender 728 (74.4)
Age (years) 63.9 ± 10.6
Body mass index (kg/m2) 27.3 ± 4.1
Left ventricular ejection fraction <45% 152 (15.5)
Renal insufficiency* 77 (7.9)
Previous PCI 318 (32.5)
Previous coronary artery bypass surgery 103 (10.5)
Previous myocardial infarction 538 (55.0)
Cardiovascular risk factors
Current smoking 104 (10.6)
Hypertension 759 (77.6)
Hypercholesterolemia 781 (79.9)
Diabetes mellitus 181 (18.5)
Positive family history for CAD 585 (59.8)
Medication
Aspirin 875 (89.5)
Clopidogrel loading dose 500 (51.1)
Proton pump inhibitor 277 (28.3)
Glycoprotein IIb/IIIa blocker 69 (7.1)
Vitamin K antagonist 95 (9.7)
Laboratory measurements
Hematocrit 0.41 ± 0.04
PRU (uncorrected) 209 ± 76
Table 1: Baseline characteristics
Table 1: This table shows the baseline characteristics of the 978 patients included in this analysis. 
Abbreviations: CAD = coronary artery disease, PRU = P2Y12 reaction units, SD = standard deviation. * 
Defined as a creatinine level greater than 1.36 mg/dL.
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Endpoints
Primary endpoint 87 (8.9)
- All-cause death 17 (1.7)
- Non-fatal myocardial infarction 60 (6.1)
- Stent thrombosis 13 (1.3)
- Ischemic stroke  12 (1.2)
Table 2: Thrombotic endpoints during follow-up
Table 2. This table shows the incidence of the thrombotic endpoints during 1 year of follow-up after 
PCI in the cohort of 978 patients.
Figure 1: The correlation between hematocrit and PRU. A negative correlation is observed 
(R2=0.104, p <0.001). The black line depicts the linear correlation. The red striped line depicts the 
95% confidence interval of this linear correlation and the green dotted line depicts the prediction 
interval of the black linear regression line.
Table 2 shows the incidence of thrombotic events during 1 year of follow-up. PRU was 
negatively correlated to HCT (R2=0.104; p<0.0001) (see Figure 1) suggesting that a 
lower HCT would result in a higher PRU and vice versa.
The mean and standard deviation of PRUuncorr and PRUcorr (formula of Kakouros et 
al.[10]) values were 210 ± 76 and 204 ± 72, respectively.
Figure 1: The correlation between hematocrit and PRU.
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The primary endpoint and correction of PRU 
Figure 2 depicts the ROC curve of the occurrence of the primary endpoint in relation 
to the PRUuncorr (dotted line) and corrected PRUcorr (straigth line). The optimal cut-off 
value for PRUuncorr was 236 with an area under the curve (AUC) of 0.61, sensitivity 
of 0.57 and specificity of 0.64. The optimal cut-off value for PRUcorr was 215 (AUC 
0.61, sensitivity 0.69, specificity 0.53).The two ROC-curves did not significantly differ 
(p=0.444).
Patients were reclassified into a HPR and no HPR group using the PRUcorr. This increased 
the rate of HPR from 38.1% to 49.4%. The distribution of patients with and without 
events is shown in Table 3. 
We defined a misclassification as a patient who was assigned to the no HPR group 
while he or she experienced the primary endpoint or a patient who was assigned to 
the HPR group while he or she did not experience the primary endpoint. Correcting 
the PRU for HCT led to the misclassification of 450 patients (46.0%) instead of 358 
patients (36.6%, p<0.001) using PRUuncorr.
A significant difference was found between the occurrence of the primary endpoint 
in the no HPR and HPR group determined with PRUuncorr (odds ratio [OR] 2.51, 95% 
confidence interval [CI] 1.60 - 3.94; p<0.001). This difference was also found with the 
PRUcorr and corresponding cut-off value (OR 2.46; 95% CI: 1.55 - 4.00, p<0.001).
Determination of a new correction coefficient
Based on BASE and HCT data a new correction coefficient was determined: 6.7. This led 
to the following formula: corrected PRU = uncorrected PRU + (HCT(%)  -  42) * 6.7. The 
optimal cut-off value determined for PRUcorr was 216 PRU. The analysis yielded similar 
results to those described earlier for the comparison of the PRUuncorr and corresponding 
cut-off value and the PRUcorr according to the formula from Kakouros et al. (results 
shown in the appendices).
DISCUSSION
The most important findings in this study were: 1) a negative correlation between PRU 
and HCT was found; 2) when PRU was corrected for HCT according to the formula 
proposed by Kakouros et al.[10], the optimal cut-off value for the VerifyNow P2Y12 
assay to predict atherothrombotic events after PCI was 215 PRU; 3) the predictive 
value of PRU for thrombotic events during 1 year follow-up after PCI did not improve 
with correction for HCT, neither based on the formula proposed by Kakouros et al. nor 
by a correction coefficiënt determined in this study.
Multiple studies have shown a negative correlation between the VerifyNow P2Y12 
assay’s PRU and HCT.[10, 11, 17] Other assays like Multiplate and thromboelastography 
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Figure 2. Receiver operating curves of the occurence of the primary endpoint and corrected and 
uncorrected PRU. The red line represents the ROC-curve of the occurence of the primary endpoint and 
the uncorrected PRU (AUC: 0.608) and the black line represents the occurence of the primary end-
point and the corrected PRU (AUC: 0.607). The cut-off value with maximum sensitivity and specificity 
was 236 for the red line (sensitivity: 0.57, specificity: 0.64) and 215 for the black line (sensitivity: 
0.69, specificity: 0.53). These two lines do not significantly differ (p=0.444)
Figure 2. Receiver operating curves of the occurence of the primary endpoint and corrected 
and uncorrected PRU. 
Table 3: HPR according to uncorrected and corrected PRU and the primary endpoint
Uncorrected PRU Corrected PRU Primary endpoint
No Yes
NPR (<236)
NPR (<215) 441 23
HPR (≥215) 128 13
HPR (≥236)
NPR (<215) 27 4
HPR (≥215) 295 47
Table 3. This table shows the classification of patients in a HPR and a NPR group based on their P2Y12
reaction unit (PRU) value when it is uncorrected and when it is corrected according to the formula
proposed by Kakouros et al. Furthermore, the incidence of the primary endpoint during 1 year of follow-
up after PCI is shown for each group. Abbreviations: HPR = high on-treatment platelet reactivity, NPR
= normal on-treatment platelet reactivity.
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(TEG) are also influenced by HCT levels.[18] While HCT was not correlated with platelet 
reactivity measured with LTA in studies by Kakouros et al. or Pendyala et al.[10,17], 
Toma et al. did find a negative correlation between HCT and platelet reactivity 
measured by LTA.[19]
Correcting platelet reactivity test results for HCT only makes sense if the negative 
correlation is an artificial effect related to the assays instead of a true biological 
phenomenon. On the one hand, multiple arguments can be made that this correlation 
is only an in vitro phenomenon. Kakouros et al. observed that HCT had no effect on the 
magnitude of change in ADP-induced platelet aggregation after clopidogrel loading as 
compared to before clopidogrel loading as measured with the VerifyNow P2Y12 assay, 
whole blood aggregometry or LTA. Furthermore, HCT was an independent predictor 
of PRU after clopidogrel loading in multivariate modeling, which included LTA results 
to account for the clopidogrel-induced changes in intrinsic platelet reactivity. Prior 
studies have also shown that changes in HCT can affect calcium concentration in 
citrated blood used for the assays, such as the VerifyNow P2Y12 assay, and thereby 
influence the ADP-induced aggregation.[20,21] A lower HCT would lead to relatively 
less citrate and therefore higher calcium concentrations in the tested sample. When 
the citrate concentrations were adjusted for HCT, the difference in platelet reactivity 
was no longer evident.[22] 
On the other hand, multiple arguments support the concept of an in vivo correlation 
between HCT and HPR. The anemic milieu is often characterized by the presence of 
inflammatory biomarkers such as fibrinogen, von Willebrand factor, and inflammatory 
cytokines, which are associated with increased platelet reactivity.[23] Moreover, 
potential bone marrow hyperactivity as a result of the anemic condition could lead 
to a release of immature platelets, which are associated with lower responsiveness 
to clopidogrel and greater thrombogenic potential.[24] So, a lower HCT could lead 
to higher platelet reactivity. However, a lower concentration of red blood cells (and 
therefore HCT) should also lead to a diminished concentration of platelets at the 
vessel wall and could thereby decrease platelet reactivity [14,15]. We conclude that the 
current study does not support a relationship between HCT and thrombotic events.
Study limitations
Kakouros et al. calculated a formula to correct PRU for HCT by using pre- and post-
clopidogrel BASE and HCT values. Only post-clopidogrel BASE and HCT values were 
available in our study and we were therefore unable to replicate the calculation of the 
formula in our study cohort. Instead we both used the formula that was proposed by 
Kakouros et al. and calculated our own correction coefficient to correct PRUs for HCT. 
Another limitation is that we do not know the reason for the lower HCT values in 
some of the patients in this cohort. Anemia could be the manifestation of underlying 
chronic disease state or an acute process related to bleeding.
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CONCLUSION
A negative correlation between platelet reactivity measured with the VerifyNow P2Y12 
assay and HCT was found. However, correcting PRU for HCT does not improve the 
prediction of thrombotic events following non-urgent PCI.
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S U P P O R T I N G  M A T E R I A L
Results from the cut-off value based on BASE and HCT:
For the corrected PRU based on our own formula using the correction coefficient of 
6.7 the ROC-analysis revealed that the cut-off of 216 PRU best predicted the primary 
endpoint with an AUC of 0.598, a sensitivity of 0.67 and a specificity of 0.53. A 
significant difference was found between the occurrence of the primary endpoint in 
the NPR and HPR group (5.8% versus 12.1%, OR 2.24, 95% CI 1.42 - 3.61, p<0.001).
Appendix figure 1: Linear regression of P2Y12 reaction units (PRU), BASE units and 
hematocrit. The red line is the regression line for the black dots of BASE values and 
HCT. The green line is the regression line of the blue dots of PRU values and HCT. 
The slope of the red line is 6.7. This is the correction coefficient we used for our own 
formula to correct PRU for hematocrit.
Appendix table 1:  HPR according to uncorrected PRU and PRU corrected according 
to our own correction coefficient and the primary endpoint.
Uncorrected PRU Corrected PRU Primary endpoint
No Yes
NPR (<236)
NPR (<216) 447 25
HPR (≥216) 122 11
HPR (≥236)
NPR (<216) 24 4
HPR (≥216) 298 47
Appendix table 1. HPR according to uncorrected PRU and PRU corrected according to 
our own correction coefficient and the primary endpoint. This table shows the classification 
of patients in a HPR and a NPR group based on their corrected and uncorrected P2Y12 
reaction unit (PRU) value and the incidence of the primary endpoint in each of these groups. 
Abbreviations: HPR = high on-treatment platelet reactivity, NPR = normal on-treatment 
platelet reactivity.
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A BST R AC T
Chronic oral anticoagulant therapy (OAC) is recommended (class I) in patients with 
mechanical heart valves and in patients with atrial fibrillation (AF) with CHA2DS2-
VASc score ≥1. When these patients undergo percutaneous coronary intervention (PCI) 
with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes 
indicated.  To this date, guidelines recommend the use of triple therapy (vitamin 
K antagonists (VKA), aspirin and clopidogrel) for these patients. However, major 
bleeding is increasingly recognised as the Achilles’ heel of the triple therapy regimen. 
Current guideline recommendations are solely based on expert opinions and not on 
randomised trials.  Lately, various studies have investigated this topic, including a 
prospective randomised trial, and the evidence for adding aspirin to the regimen of 
VKA and clopidogrel seems to be weakened.  In this group of patients, the challenge 
is finding the optimal equilibrium to prevent thromboembolic events, such as stent 
thrombosis and thromboembolic stroke, without increasing bleeding risk.    
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I N T RODUC T ION
Chronic oral anticoagulation (OAC) is necessary in patients with mechanical heart 
valves and in patients with atrial fibrillation (AF) and CHA2DS2VASc score ≥1 (1,2). 
About 30% of these patients have concomitant coronary artery disease (CAD). When 
these patients have to undergo percutaneous coronary intervention (PCI), additional 
dual antiplatelet treatment (DAPT) with aspirin and clopidogrel becomes indicated to 
prevent stent thrombosis (3-5). In a rapidly aging population, the number of patients 
suffering both atrial fibrillation (AF) and CAD is steadily increasing. However, triple 
therapy is associated with a high annual bleeding risk of up to 45% and there is an 
association between major bleeding events, blood transfusion and an increased mortality 
risk (6-11).  Up to now, triple therapy including vitamin K antagonists (VKA), aspirin 
and clopidogrel (for as short a time as possible) is still recommended by the guidelines 
in these patients, but these recommendations are based on expert opinion and not 
on randomised trials (4,12). Recently, new evidence has emerged suggesting that the 
increased bleeding risk outweighs the efficacy (preventing stent thrombosis, myocardial 
infarction (MI), stroke and thromboembolism) benefit of triple therapy in these patients 
and possibly a new strategy of VKA and a P2Y12 inhibitor alone could be preferred (6,13-
15). This review will summarize guidelines, focus on some key evidence from the last 
years and address unanswered questions. 
 
GU IDELI NE S
Both European and North-American guidelines recommend triple antithrombotic 
therapy in a patient with AF undergoing PCI (4,12). This triple therapy consists of 
VKA with a revised target for international normalisation rate (INR) 2.0 – 2.5, aspirin 
and clopidogrel. Aspirin has always been the cornerstone in treating patients with 
acute coronary syndromes (ACS) and/or PCI. VKAs are needed for stroke prevention, 
whereas a second P2Y12 inhibitor is essential for the prevention of stent thrombosis in 
these patients (16-19).  However, this triple therapy strategy has never been studied 
prospectively until the recent  ‘What is the Optimal antiplatElet and anticoagulant 
therapy in patients with oral anticoagulation and coronary StenTing’ (WOEST) trial 
(6).
Guidelines recommend continuing VKAs and giving triple therapy for as short a period 
as possible after PCI, in general until endothelialisation of stent struts is expected to 
be complete.  The duration of prescribed triple therapy mostly depends on bleeding 
risk and stent type. Various recommendations are made to limit bleeding risk and 
these will be discussed in the `prevention of bleeding’ section. 
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NEW EV IDE NCE
The WOEST trial is a recently published randomised controlled trial (6,20). In the 
WOEST trial 573 patients using VKA undergoing PCI in an open-label, intention-to-
treat design were randomised to either double therapy (VKA and clopidogrel) or triple 
therapy (VKA, clopidogrel and aspirin).  The primary endpoint was the occurrence 
of any bleeding event. At 1 year, the cumulative incidence of all Thrombolysis in 
myocardial infarction (TIMI) bleeding events was 19.4% in the double therapy 
group compared to 44.4% in patients treated with triple therapy (HR 0.36; 95% CI 
0.26–0.50; P<0.0001) (6,21). The one-year incidence of serious bleeding according to 
Bleeding Academic Research Consortium criteria (BARC 3) was significantly lower in 
the double therapy group compared to the triple therapy group (6.5% vs. 12.7%; HR 
0.49; 95% CI 0.28-0.86; P=0.011) (6,22). Furthermore, the rate of blood transfusions 
was significantly lower in the double therapy group (3.9% vs. 9.5%, OR 0.39; 95% CI 
0.17-0.84; P=0.011). Secondary endpoints included MACCE (the composite of death, 
MI, stroke, systemic embolism, target vessel revascularization (TVR), and stent 
thrombosis), which occurred in 11.1% of patients receiving double therapy compared to 
17.6 % of patients receiving triple therapy (HR 0.56; 95% CI 0.35–0.91; P = 0.025). The 
WOEST trial clearly shows that double therapy (VKA and clopidogrel without aspirin) 
significantly reduces bleeding complications as compared to triple therapy after PCI in 
patients with an indication for OAC. By dropping aspirin in this high risk group there 
is a reduction of more than 50% in the occurrence of bleeding complications. 
After the results of the WOEST-trial were published, expert opinion was that it was 
too early to change the guidelines, even though current guidelines are not based on 
randomized trials (23).  The reasons for this statement were the limitations of the 
WOEST trial: First, the number of patients randomised was relatively low (n=573) 
and not every patient had AF (approximately 70%).  Second, there was no significant 
difference in TIMI major bleeding and the absolute number of major bleeds also was 
rather low (16 vs. 9). It was also emphasized that the difference in bleeding was mainly 
driven by TIMI minor bleeding. However, it should be mentioned that when bleeding 
events were classified according to the new standardized BARC bleeding criteria, 
there was a significant difference in BARC 3 bleeding, which corresponds with major 
bleeding, in favor of the combination of clopidogrel and VKA (6,22). Additionally, the 
importance of minor bleeding was already emphasized, since these events can lead 
to cessation of medication (e.g. clopidogrel) and major adverse events such as stent 
thrombosis (6). Third, compared to current recommendations, the rate of proton 
pump inhibitor (PPI) use at baseline was low (37%), the radial approach was used 
infrequently (26%), bare metal stents (BMS) were only used in 31%, target INR for the 
peri-procedural period was 2 and long term target INR post-procedurally (target INR 
2-3 for atrial fibrillation) was not lowered.  Current guidelines recommend standard 
PPI use, radial approach, BMS use and a lower long term target INR of 2-2,5 in this 
patient population. However, in 2008 when the WOEST study was designed, these 
recommendations were not available yet (4,12).  Fourth, the number of deaths was 
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significantly higher in triple therapy group, but this was driven by a higher number 
of non-cardiac deaths, which might be due to a play of chance. Fifth, there was no 
information on the time of INR in the therapeutic range (TTR). However we know 
from the RELY trial that the quality of oral anticoagulation is good in the Netherlands 
and Belgium, with a TTR of 65% in Belgium and TTR up to 70% in the Netherlands 
(23). Finally, the study was not powered to show non-inferiority of the secondary 
outcomes and the number of patients at high risk of stent thrombosis, such as those 
with recent ACS, was limited to a quarter of this WOEST trial population. However, the 
study population was a heterogeneous one, because the goal of the WOEST trial was to 
conduct a trial with a real life population representing daily practice (6).  Moreover, the 
WOEST trial was the first study to break the taboo of omitting treatment with aspirin 
after PCI, hypothesizing that inhibition of thrombin (a strong platelet activator) with 
VKA and inhibition of the P2Y12 receptor with clopidogrel would make inhibition of 
cyclo-oxygenase-1 (COX-1) less important in the protection against thrombotic and 
thromboembolic events, particularly since P2Y12 plays a major role in amplifying the 
effects of thromboxane A2. 
Recently, a Danish group published results of a real-life nationwide retrospective 
registry of 12,165 patients that supported the findings in the WOEST trial (13). 
The authors investigated the risk for thrombosis and bleeding according to multiple 
antithrombotic regimens after myocardial infarction or PCI in AF patients. After one 
year, there was no increased risk of recurrent coronary events for VKA plus clopidogrel 
(HR: 0.69, 95%CI: 0.48 to 1.00) relative to triple therapy and bleeding risk was also 
non-significantly lower for VKA plus clopidogrel (HR: 0.78, 95% CI: 0.55 to 1.12). 
Moreover, there was a similar risk for all-cause mortality in patients treated with an 
VKA plus clopidogrel and those treated with triple therapy, while the combinations 
of VKA plus aspirin and aspirin plus clopidogrel were associated with a significant 
increase of all-cause mortality compared to triple therapy (13).
The most important aspect of the Danish registry is that it suggests that the 
combination of OAC plus clopidogrel is sufficient to reduce the risk of thrombotic 
events. This was the missing part of the puzzle, since the WOEST trial was not powered 
to show non-inferiority on the secondary composite MACCE endpoint. Also, this is the 
second study in which no beneficial effect of adding aspirin to VKA and clopidogrel 
is found in this high-risk patient group. The authors explain that the bleeding rate 
was lower in the VKA plus clopidogrel patient group, but this difference likely failed 
to reach statistical significance because this registry only included bleeding events 
serious enough to warrant hospitalization, whereas all bleeding events were collected 
in the WOEST trial. 
Two other registries confirming the efficacy and safety of the combination of VKA 
and clopidogrel in patients with AF who underwent PCI were recently published. In 
the Atrial fibrillation undergoing coronary stenting (AFCAS) trial, a prospective non-
randomized study including 975 patients, the one year efficacy and safety of triple 
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therapy, DAPT and VKA + clopidogrel was comparable (15).  A total of 221 patients who 
received a drug-eluting stent (DES) were included in another German registry with a 
mean follow up of 19 months. Nonetheless, even with a shorter time of clopidogrel 
therapy (6-12 months) followed by VKA monotherapy, the combination of OAC plus 
clopidogrel again appeared both safe and effective at longer-term follow-up (14). 
CLI NIC A L IMPORTA NCE A ND PR E V E N T ION OF BLEEDI NG 
A F T ER PCI
Bleeding events are important as major bleeding events and blood transfusions have 
been associated with increased risk of death in several studies (7,8,25-28). This has 
led to an increased awareness of this problem and predictors of bleeding events in 
PCI patients have been identified. Strong predictors we can influence are the choice of 
vascular access (radial vs. femoral) and the choice of antithrombotic regimen (28-31). 
The importance of bleeding as an adverse event has been emphasized by the fact that 
bleeding has now become a primary endpoint in many PCI trials (7,17,28,32,33). In 
an effort to standardize the definition and detection of bleeding events in different 
studies, the academic research consortium published and validated new bleeding 
criteria (BARC) (22,34). Before the BARC criteria were established, different trials 
used different bleeding definitions and this was an important hindrance when trying 
to compare the bleeding rates of different trials (21,35). A second obstacle one has to 
overcome when comparing bleeding rates is the possible underreporting of bleeding 
events in studies (36).  Therefore, the impact of bleeding could be even larger in real life 
than reported. This could also explain why the bleeding rate reported in the WOEST 
trial was very high compared to other trials, as this study was specifically designed 
to detect bleeding events and data was collected for all types of bleeding rather than 
focusing on major bleeding events solely (6). 
Another issue that needs to be addressed is that the population with AF needing a 
PCI is a population that mainly consists of older patients with high co-morbidity. 
Many of them are octogenarians, a patient group that is frequently excluded from 
or underrepresented in randomized trials. It is questionable whether our current 
guidelines can be applied to this group. Additionally, we know that older patients 
with AF have a higher CHA2DS2VASc score, but also have a higher risk of bleeding 
when treated with VKA (37). Also, the role of non-major bleeding should not be 
underestimated. Even superficial or “nuisance” bleeding can lead to discontinuation of 
antiplatelet therapy and this can lead to subsequent thrombotic complications, such 
as stent thrombosis. This emphasizes that this high-risk population with much co-
morbidity is more prone to suffer adverse events (4,38).
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Over the last years, numerous risk factors have been identified to be associated with 
higher bleeding risk: age >55 years, female sex, glomerular filtration rate < 60ml/min, 
pre-existing anemia, use of low molecular weight heparin (LMWH) < 48 hours before 
PCI, use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the use of an intra-aortic 
balloon pump (27,39,40). To estimate bleeding risk, many bleeding risk-prediction 
scores have been proposed. The best known is the HAS-BLED score (40).  The HAS-
BLED score has been shown to be useful in the assessment of bleeding risk, and also 
shows some predictive value for cardiovascular events and mortality in anticoagulated 
patients with AF. Furthermore, this confirms that the number of bleeding and 
thrombotic events is higher in patients with high co-morbidity at baseline (41). The 
higher the patient’s bleeding risk, the more measures should be taken to avoid and 
to prevent bleeding, such as the standardized use of a risk score assessment, radial 
approach, smaller sheath size and early removal, BMS use, routine use of PPI, the use 
of a target INR range of 2.0-2.5, the choice and the dose of antithrombotics and P2Y12 
inhibitors, avoidance of crossing over from one antithrombotic to another, avoidance 
of an intra-aortic balloon pump, avoidance of the use of GPIIb/IIIa inhibitors and 
avoidance of peri-procedural bridging with LMWH if not strictly indicated. (4,12,28) 
 
PER I-PROCEDUR A L M A NAGEME N T
Besides the choice between dual or triple therapy, there is another decision that has 
to be made in patients on OAC that are planned for PCI. What to do with the VKA 
in the peri-procedural period? In patients scheduled for PCI treatment with VKA 
is often discontinued some days before the intervention exposing the patient to a 
higher risk of thromboembolic complications. Occasionally, the periods before and 
after the intervention are bridged (until a therapeutic INR is reached) with additional 
unfractionated heparin (UFH) or LMWH, exposing the patient to excess bleeding 
risk. When patients are treated with quadruple therapy (OAC, clopidogrel, aspirin and 
heparin) for a short period after the intervention until a therapeutic INR is reached, 
this bleeding risk is particularly high. Additionally, re-initiation of VKA may cause a 
transient prothrombotic state due to protein C and S suppression (4).  Bridging also 
prolongs hospitalization, which is unnecessary and wasteful from an economical 
point of view. Recent European guidelines recommended uninterrupted VKA as the 
preferred strategy in patients with AF undergoing PCI (4). In the AFCAS-trial and 
in a recent sub-analysis of the WOEST trial (43), it was shown that uninterrupted 
OAC was not associated with an increased risk of bleeding or thromboembolic events 
when compared to bridging therapy (44).  Furthermore, bleeding and other adverse 
events were not associated with INR levels in these studies (44). Also, in the BAAS 
(Prospective Balloon Angioplasty and Anticoagulation) study, the combination 
of aspirin plus VKA compared to aspirin alone was safe and effective during PCI 
performed with a target INR of 2.1-4.8 (45). So uninterrupted VKA not only leads 
to cost savings, but this strategy is also as safe as bridging and therefore should be 
the preferred strategy. Moreover, the radial approach is the best strategy in these 
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patients, because of proven lower rates of bleeding and possibly mortality, especially in 
STEMI patients (30). But one question regarding the peri-procedural strategy remains 
unanswered. Just as during a coronary angiography, it might be an option to perform 
PCI without administration of additional heparin in patients who receive therapeutic 
anticoagulation with a VKA. However, physicians did not avoid an additional heparin 
bolus during PCI in most patients included in the WOEST trial. This strategy was 
probably chosen out of fear for peri-procedural thromboembolic complications such 
as stent thrombosis (43). On the one hand, this additional heparin bolus could be 
an explanation for the higher than expected bleeding rates in the original WOEST 
trial (6). In the AFCAS study, 48% of patients also received pre-procedural a bolus of 
heparin or LMWH on top of therapeutic anticoagulation in the uninterrupted VKA 
group (44). On the other hand, a recently published study showed that the incidence 
of radial artery occlusion in patients receiving VKA who undergo transradial coronary 
angiography is higher in patients who do not receive an additional standard intravenous 
UFH bolus (46). As of yet, there is insufficient evidence to determine if a heparin 
bolus has to be given in patients with therapeutic INR requiring PCI. Furthermore, 
it is unclear what the optimal dosage would be if a heparin bolus is indeed necessary. 
POS SIBLE PI T FA LL S A ND O T HER U NA NSW ER ED QUE ST IONS
As bleeding occurs predominantly in the gastrointestinal tract in patients treated 
with triple therapy, protection of the gastric mucosa seems advisable.  In recent years, 
some articles suggested a potential danger in combining omeprazole and clopidogrel 
due to impairment of clopidogrel active metabolite formation by omeprazole leading 
to diminished antiplatelet effect (47,48). However, no clinical consequences of this 
interaction have been demonstrated so far.  The single randomized controlled trial on 
this topic (COGENT) showed that in patients after ACS the combination of omeprazole 
20mg and clopidogrel 75mg was superior to the combination of clopidogrel and placebo 
in reducing the rate of gastro-intestinal bleeding while the rate of cardiovascular 
adverse events was not significantly different (49). Many other reports that have been 
published since then have suggested that the use of PPI in these patients with multiple 
antiplatelet medications should not be avoided, but encouraged (48,50). 
A second possible pitfall for clopidogrel is the wide variability in the individual 
response to the drug, even in the absence of any drug interactions, with 12-15% of the 
variability accounted for by polymorphic variations in the gene for cytochrome P450 
2C19 (CYP2C19) (51-53). Patients who have a poor inhibitory effect of clopidogrel and/
or carry one or more loss-of-function alleles for CYP2C19 are at higher risk of stent 
thrombosis whereas those with a large inhibitory effect of clopidogrel appear to be at 
higher risk of bleeding. This potentially creates challenges for interpreting data on the 
combination of clopidogrel with VKA since the levels of platelet reactivity may vary 
widely between patients. For example, patients with a poor response to clopidogrel 
who develop a low INR may be at higher risk of stent thrombosis and other thrombotic 
3.1
194
Chapter 3.1
events, whereas patients with a large inhibitory effect of clopidogrel who develop a 
high INR may be at much higher risk of bleeding (51-53). 
A third possible pitfall is the possibility of VKA itself in modifying the clopidogrel 
drug responsiveness and efficacy. Both clopidogrel and VKA are metabolized by the 
hepatic cytochrome P 450 system. Concomitant phenprocoumon use has been shown 
to significantly attenuate the antiplatelet effects of clopidogrel and was associated 
with a significantly higher level of high on-platelet reactivity (HPR) (54).  HPR has 
been associated with a poor outcome, but there currently is no evidence for tailoring 
antiplatelet therapy based on the presence of HPR (52).  The clinical impact of this 
interaction between phenprocoumon and clopidogrel is still unknown. While it could 
be recommended to switch from clopidogrel to the stronger antiplatelet drugs 
prasugrel or ticagrelor in HPR patients without VKA, it is even more unclear what the 
optimal treatment strategy could be for HPR patients with VKA (52).  Theoretically, 
ticagrelor and prasugrel could be good alternatives for clopidogrel as they provide 
more potent platelet inhibition with less inter-individual variability (55,56). However, 
bleeding risk is also increased with treatment with ticagrelor and prasugrel as 
compared to clopidogrel (55,56). Furthermore, patients in both arms of the WOEST 
trial were treated with both a VKA and clopidogrel and it is debatable whether this 
possible phenprocoumon-clopidogrel interaction is clinically meaningful since there 
was no excess of stent thrombosis in either patient group (6). It is possible that the 
negative impact of the interaction between phenprocoumon and clopidogrel was 
counterbalanced by the anticoagulant effect of phenprocoumon and its subsequent 
effect on thrombotic events. The fourth and very important question is why we would 
want replace the combination of DAPT + VKA by the combination of VKA + clopidogrel? 
Since 2001, DAPT has become the standard therapy after PCI.  The CURE study 
included 12,562 patients who had presented within 24 hours after ACS without ST-
segment elevation and were randomized to receive either clopidogrel or placebo in 
addition to aspirin. Clopidogrel had beneficial effects because of a significant reduction 
in MACCE (9.3% vs 11.4%, P<0.001) (57). Then why would we try to replace aspirin by 
VKA? In these patients who also need VKA for stroke prevention there are many 
possible combinations, but it has already been shown that the combination VKA plus 
aspirin (leaving out clopidogrel) led to an increased rate of MI and stent thrombosis 
(13,58). In the Active-W study, withholding VKA (thus treating patients only with ASA 
and clopidogrel) in patients with AF led to an increased rate of cardiovascular events 
and mortality (16).  This leaves triple therapy and the combination of VKA and 
clopidogrel as the only alternatives.  But then why drop aspirin?  The hypothesis of the 
WOEST trial was that inhibition of thrombin with VKA and inhibition of P2Y12 with 
clopidogrel would lessen the importance of cyclo-oxygenase-1 inhibition by aspirin for 
protection against thrombotic and thromboembolic events, while triple therapy has 
been associated with an increased risk of both fatal and non-fatal bleeding (6,7,58-60). 
This hypothesis was based on the results of two large randomised trials that compared 
VKA with aspirin in the prevention of re-infarction and stroke in patients who had 
experienced a MI. VKA treatment was associated with lower recurrence rates but 
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higher risks of bleeding in these studies (61,62). Therefore, VKA seems at least as good 
as aspirin in protecting patients from thrombotic events. The hypothesis that aspirin 
is not needed in VKA treated patients who undergo PCI with stent implantation is 
supported by the results of the WOEST trial. Nevertheless, the WOEST trial was not 
powered to detect differences in the occurrence of thrombotic events, such as stent 
thrombosis, when aspirin was omitted, and this feature would need to be studied in a 
larger trial.  In the meanwhile, these results were confirmed by the results of a large 
Danish nation-wide registry, the AFCAS trial and a smaller German trial all showing 
favorable results for the combination of VKA and clopidogrel (6,13-15). The fifth 
dilemma is how to overcome the possibility of unopposed thromboxane-dependent 
platelet activation after stopping aspirin with subsequent cardiovascular events (63)? 
In two patient series in which aspirin monotherapy was stopped without a substitute, 
there were higher rates of thrombotic events (64,65). Of course, a patient group on 
aspirin monotherapy totally differs from the present patients on long term VKA and 
clopidogrel. Nevertheless, in the WOEST trial, the AFCAS trial, and the Danish and 
German registries, there was no excess of stent thrombosis in the aspirin free group 
(6,13-15). Therefore, it is debatable whether this unopposed thromboxane-dependent 
platelet activation after stopping aspirin is clinically meaningful in the present patient 
population. The negative impact of unopposed thromboxane-dependent platelet 
activation is possibly overruled by the anticoagulant effect of VKA and the antiplatelet 
effect of clopidogrel. The sixth unanswered question in patients on long-term VKA 
who received a coronary stent is how to treat patients after clopidogrel is discontinued 
(after 3, 6 or 12 months of treatment)? Do you treat patients with a combination of 
VKA and aspirin because of CAD or is VKA monotherapy enough to protect patients 
against thrombotic events? In the absence of randomised trials, there are two large 
registries: a recently published Danish registry containing 8,700 patients and the 
ORBIT-AF registry in which 4,804 patients on VKA were compared to 2,543 patients 
on OAC plus aspirin.  In both registries, the combination of VKA and aspirin was 
associated with significantly increased risk for bleeding without clear reduction of 
MACCE (66,67). The seventh possible pitfall is that the guidelines recommend the use 
of BMS in both elective and acute settings in AF patients with an indication for long-
term treatment with VKA (4,12). However, these guidelines were based upon expert 
opinion in the absence of randomised data. A recent sub-analysis of the WOEST trial 
shows no advantage for patients who received a BMS as compared to a DES. Moreover, 
the rate of TVR was significantly lower in patients treated with DES, despite the fact 
that baseline characteristics for this group were less favorable (such as a higher 
incidence of diabetes at baseline and more ACC/AHA type C lesions) (unpublished 
data). We also know that the rates of TVR and stent thrombosis are markedly lower 
after implantation of newer generation DES, such as everolimus-eluting stents (68), 
and the difference in the rate of stent thrombosis after DES as compared to BMS seems 
to have disappeared. Finally, recent data suggest the routine use of 3 months of DAPT 
instead of 12 months in some cases. In the recent OPTIMIZE trial, it was shown in 
3,199 patients with stable CAD or low-risk ACS treated with zotarolimus-eluting 
stents, that 3 months of DAPT was non-inferior to 12 months, without significantly 
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increasing the risk of stent thrombosis (69). Moreover, the EXCELLENT, PRODIGY 
and RESET trials are other randomized trials that tested different durations of DAPT 
(3 or 6 months vs. 12 or 24 months) with multiple DES, and results did not show 
benefits favouring prolonged DAPT (69-72). One can question if patients on long term 
OAC might benefit from a shorter treatment with clopidogrel that for sure would 
decrease bleeding risk in this patient group. But before adopting a regimen containing 
3 months of clopidogrel, some caution is needed. First, a 125,195 patient cohort study 
showed that the bleeding risk is the highest during the first 30 days of VKA therapy, 
with almost 1% of all new users admitted to hospital for haemorrhage during this 
period (37).  Second, it is not sure whether this applies for all DES, because zotarolimus-
eluting stents were especially chosen in the OPTIMIZE and RESET trials because of 
their early vessel healing characteristics (69,73).  Third, in the OPTIMIZE trial mostly 
patients with stable angina and low risk ACS were included while STEMI patients were 
excluded (69).  Therefore it might be too early to change the duration of routine 
clopidogrel administration to 3 months. 
 
NEW MEDIC AT ION, ONGOI NG T R I A L S A ND F U T UR E 
PER SPEC T I V E S 
Although double therapy with VKA and clopidogrel is probably a better option than 
triple therapy, there is still much room for improvement with regard to the incidence 
of both ischemic and bleeding events. Therefore, the search for newer and better 
antithrombotic medication and combinations of these drugs continues.  Over the last 
years, numerous new medications have challenged the classics.  In the PLATO trial in 
18,624 patients with ACS the combination of ticagrelor (a reversible P2Y12 inhibitor) 
and aspirin was found to be superior to clopidogrel and aspirin with also a decrease in 
mortality (55). The TRITON TIMI-38 trial showed that in 13,608 patients with ACS 
undergoing PCI the combination of prasugrel (a more potent thienopyridine than 
clopidogrel but similarly an irreversible P2Y12 inhibitor) and aspirin was more effective 
than clopidogrel and aspirin, but with an increased number of bleeding events (56). 
Both prasugrel and ticagrelor seem to be good alternatives to clopidogrel in patients 
with AF undergoing PCI, because they inhibit platelets more potently and have less 
inter-individual variability in effect than clopidogrel.  But both PLATO and TRITON 
TIMI-38 patient excluded patients with VKA. In a prospective registry of 377 patients 
the combination of prasugrel, aspirin and VKA was used by 21 patients and showed 
a fourfold increase in the risk of TIMI minor and major bleeding compared to the 
combination of clopidogrel, aspirin and VKA, without any significant difference in 
efficacy (76). We do not have any data about the combinations of VKA plus prasugrel, 
VKA plus ticagrelor, or triple therapy with VKA plus ticagrelor plus aspirin in AF 
patients undergoing PCI, but one could reasonably fear that combining these more 
potent platelet inhibitors with VKA could lead to more bleeding events. Over the 
last decade, new oral anticoagulants (NOACs) such as dabigatran, rivaroxaban and 
apixaban have been shown to offer advantages over VKA for stroke prevention in AF 
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(75-78). Their potential as anti-thrombotic therapy after ACS has subsequently been 
investigated. Moreover, the ATLAS ACS 2-TIMI 51 trial showed that by adding low-
dose rivaroxaban in 15,526 patients with a recent ACS, the composite end point of 
cardiac death, MI and stroke was reduced, while the risk of major and intracranial 
bleeding was simultaneously increased (32). The APPRAISE 2 trial, in which full 
dose apixaban was added to the double antiplatelet therapy in patients with ACS, 
was halted prematurely because of an excess in major bleeding events without a 
significant reduction in ischemic events (33). In the REDEEM trial dabigatran on top 
of DAPT also resulted in a dose-related increase of bleeding risk without reduction 
of ischemic clinical events (78). In AF patients who need PCI, none of these NOACs 
have been tested yet. As demonstrated by all these trials, finding the balance between 
reducing the risk of thromboembolic events without excessively increasing bleeding 
risk is difficult.  The challenge of using NOACs in AF patients who need PCI is just as 
difficult. First of all, there is the problem of finding the optimal NOAC dose for this 
indication, and the second question is which P2Y12 inhibitor to prescribe and whether 
or not to combine them with aspirin. The PIONEER-AF PCI trial (An Open-label, 
Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of 
Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in 
Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention) 
is the first trial to address this issue, although the number of different possibilities to 
investigate seems almost unlimited (79).  The PIONEER-AF-PCI trial is an innovative 
Phase IIb clinical study investigating safety and efficacy of rivaroxaban in AF patients 
undergoing PCI.  This study aims to include 2,100 patients and compares the safety of 
two rivaroxaban treatment strategies versus a dose-adjusted VKA treatment strategy. 
Patients will be treated for 12 months and the primary endpoint is the composite of 
TIMI major bleeding, minor bleeding and bleeding requiring medical attention (79). 
The Re-Dual PCI trial was also started recently. In this trial, the safety and efficacy 
of two dabigatran treatment strategies will be tested versus a dose-adjusted VKA 
treatment (80).  Unfortunately, the superior arm of the WOEST trial (VKA and 
clopidogrel) was left out of both trials (79,80).  Another trial which is still recruiting 
patients is the ISAR TRIPLE trial (Intracoronary Stenting and Antithrombotic 
Regimen: Testing of a Six-Week Versus a Six-Month Clopidogrel Treatment Regimen in 
Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-
Eluting Stenting) in which 600 patients are randomised to a six-week versus a six-
month triple therapy regimen after DES implantation. The primary endpoint of this 
trial is a net clinical benefit endpoint consisting of MACCE and major bleeding. (81) 
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CONCLUSION
The efficacy of triple therapy (VKA, aspirin and clopidogrel) in AF patients who need to 
undergo PCI with stent placement has never been proven, but this strategy increases 
bleeding risk significantly. New evidence, including a randomised controlled trial 
and a real-life nationwide registry of more than 12,000 patients, showed the great 
potential of the combination of VKA and clopidogrel without aspirin to improve 
clinical outcomes in comparison to triple therapy. Therefore, it might be a reasonable 
option to treat patients on long term OAC who undergo PCI with the only combination 
that has shown favourable results as compared to the recommended triple therapy in 
AF patients undergoing PCI.
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We read with interest the review article from Dewilde et al.(1) who nicely summarize the 
available evidence on triple antithrombotic therapy in patients with atrial fibrillation 
(AF) undergoing coronary stenting. The authors conclude that the combination of 
vitamin K antagonists (VKA) and clopidogrel may serve as a valuable alternative to a 
triple antithrombotic regimen also including aspirin, based on the results of 1 small 
randomized controlled trial and a large nationwide registry(2,3).
In a recent joint consensus document from multiple European Associations, endorsed 
by the Heart Rhythm Society and Asia-Pacific Heart Rhythm Society, dual therapy 
consisting of VKA and clopidogrel “may” (i.e., Class IIb) or even “should” (i.e., Class IIa) 
be considered in patients with stable coronary artery disease undergoing stenting with 
variable lengths and strengths of recommendation depending on individual stroke 
(i.e., CHA2DS2-VASc score=1 or ≥2) and bleeding (i.e., HAS-BLED=0 to 2 or ≥3) risks(4). 
We underscore that aspirin should not be dropped in patients at low bleeding risk on 
long-term VKA therapy in the context of an acute coronary syndrome (ACS)—with or 
without stenting, and for at least the first 6 months—because: 1) the benefit of dual 
antiplatelet therapy in ACS patients is established(5); and 2) the WOEST (What is the 
Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation 
and coronary StenTing) trial included only a minority (~25%) of patients with an 
ACS(2). Other limitations of the WOEST trial are also evident, including the prolonged 
period (12 months) of triple therapy and the endpoint driven by minor bleeds (with 
major bleeds not different between triple and dual therapy)(4). 
In the Danish registry, where only ACS patients where included by study design, 
the adjusted risk of all-cause mortality compared with aspirin mono-therapy was 
numerically, albeit not significantly, lower with triple antithrombotic therapy (i.e., 
hazard ratio: 1.04) than with a dual therapy regimen of VKA and clopidogrel (i.e., 
hazard ratio 1.22), whereas the risk of fatal and nonfatal bleeding was significantly 
increased with both regimens (3).As far as the duration of triple antithrombotic 
therapy is concerned, the joint European document points out that the period where 
maximum antithrombotic protection should be given (in patients at low or moderate 
bleeding risk) corresponds to the first 6 months after the onset of an ACS and/or a 
second-generation drug-eluting stent implantation (4). This has been recently found to 
be consistent with the 2014 European guidelines for myocardial revascularization (5) 
and the newly presented ISAR-TRIPLE (Intracoronary Stenting and Antithrombotic 
Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen 
In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-
Eluting stenting) study (presented at Transcatheter Cardiovascular Therapeutics, 
September 2014, Washington, DC).
Please note: Drs. Capodanno and Lip are coauthors of a recent joint consensus document 
from multiple European Associations, endorsed by the Heart Rhythm Society and Asia-
Pacific Heart Rhythm Society. Dr. Capodanno receives speaker’s honoraria from Bayer, 
AstraZeneca, Eli Lilly and Company/Daiichi-Sankyo, Abbott Vascular, and Stentys.
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We thank Drs. Capodanno and Lip for their interest in and valuable comments on 
our recent review (1) on triple therapy for atrial fibrillation (AF) and percutaneous 
coronary intervention (PCI). The conclusion of our review was that it might be a 
reasonable option to treat with a combination of vitamin K antagonists (VKA) and 
clopidogrel, which is the only combination having shown favorable results compared 
with triple therapy (TT), based on the results of a randomized trial and a nationwide 
registry (1). 
Drs. Capodanno and Lip highlight the recent guideline and consensus documents from 
multiple European associations (2,3) and state that aspirin should not be dropped in 
patients with low bleeding risk and acute coronary syndrome (ACS). We acknowledge 
the great work done by the authors of both guidelines and this consensus document 
(2,3). Of course, we recognize the limitations of the WOEST (What is the Optimal 
antiplatElet and anticoagulant therapy in patients with oral anti-coagulation and 
coronary StenTing) trial (only one-quarter of patients with ACS) and the Danish 
registry, and these limitations were extensively described in our recently published 
review (1,4,5). On the other hand, the Class IIA recommendation in the European 
consensus and guidelines to use TT in patients with AF and PCI is made on a Level 
of Evidence: C, which is “consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.” Unfortunately, there is not one randomised trial 
favoring TT.
Furthermore, Drs. Capodanno and Lip state that the number of major bleeding events 
in the WOEST trial did not differ. Again, we recognize the limitations of the WOEST 
trial in that most bleedings prevented were minor and minimal. However, Capodanno 
and Lip’s statement is not completely true. Although there was no significant difference 
in Thrombolysis In Myocardial Infarction major bleeding events, there was, however, 
a significant difference in the newer, but widely accepted, Bleeding Academic Research 
Consortium 3 bleeding classification, which corresponds with major bleeding (1,4)
Moreover, the Danish registry containing 12,000 patients provides sufficient power to 
state that the combination of VKA and clopidogrel is safe with regard to thrombotic 
and thromboembolic complications such as myocardial infarction and ischemic 
stroke, which was a major concern because of the lack of power regarding the ischemic 
endpoints in the WOEST trial (1,5).
In patients with AF and ACS, our conclusion was backed up by the recently presented 
AVIATOR registry containing 859 patients, which also showed fewer bleeding events 
in patients without aspirin, whereas no difference in the ischemic endpoints was 
observed in patients treated with dual therapy as compared with TT (presented at 
Transcatheter Cardiovascular Therapeutics, September 2014, Washington, DC). 
Finally, the authors attract attention to the results of the ISAR-TRIPLE (Intracoronary 
Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month 
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clopidogrel treatment Regimen In Patients with concomitant aspirin and oral 
anticoagulant therapy following drug-Eluting stenting) trial (presented at 
Transcatheter Cardiovascular Therapeutics, September 2014, Washington, DC). 
However, the design of this trial was vitally different from the WOEST trial because 
aspirin was continued in ISAR-TRIPLE, whereas aspirin was stopped in WOEST with 
the aim to reduce bleeding events. Additionally, clopidogrel was stopped early after 
stenting in ISAR-TRIPLE to reduce bleeding, whereas previous publications show 
clopidogrel to be essential in preventing stent thrombosis. The hypothesis of the 
WOEST trial was that clopidogrel needed to be continued to adequately prevent stent 
thrombosis (1,5).
In conclusion, we agree with Drs. Capodanno and Lip that the burden of evidence 
favoring the combination VKA + clopidogrel is still limited; on the other hand, we 
also have to acknowledge the fact that there is not one randomized trial favoring 
TT. Therefore, we will have to wait for the results of the large ongoing randomized 
trials, such as the PIONEER AF (A Study Exploring Two Strategies of Rivaroxaban and 
One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo 
Percutaneous Coro-nary Intervention) and RE-DUAL PCI (Evaluation of Dual Therapy 
With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo 
a PCI With Stenting) trials.
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SU MM A RY
Patients exhibiting high on-clopidogrel platelet reactivity (HPR) are at an increased 
risk of atherothrombotic events following percutaneous coronary interventions (PCI). 
The use of concomitant medication which is metabolized by the hepatic cytochrome 
P450 system, such as phenprocoumon, is associated with HPR. We assessed the level 
of platelet reactivity on clopidogrel in patients who received concomitant treatment 
with acenocoumarol (another coumarin derivative). Patients scheduled for PCI were 
included in a prospective, single centre, observational registry. Patients who were 
adequately pre-treated with clopidogrel were eligible for this analysis, which included 
1,582 patients, of whom 104 patients (6.6%) received concomitant acenocoumarol 
treatment.
Platelet reactivity, as measured with the VerifyNow P2Y12 assay and expressed in 
P2Y12 Reaction Units (PRU), was significantly higher in patients on concomitant 
acenocoumarol treatment (mean PRU 229 ± 88 vs. 187 ± 95; p<0.001). In patients 
with concomitant acenocoumarol use, the proportion of patients with HPR was 
higher, defined as PRU >208 (57.7% vs. 41.1%; p=0.001) and PRU ≥236 (49.0% vs. 
31.4%; p<0.001). In multivariable analysis, concomitant acenocoumarol use was 
independently associated with a higher PRU and the occurrence of HPR defined as PRU 
≥236 (OR 2.00, [1.07 - 3.79]), but not with HPR defined as PRU >208 (OR 1.37, [0.74 
- 2.54]). PRU also was significantly increased after 1:1 propensity matching (+28.2; 
p<0.001). As this was an observational study, confounding by indication can not be 
excluded, although multivariable analyses and propensity matching were performed. 
The impact of the findings from this hypothesis-generating study on clinical outcome 
requires further investigation.
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I N T RODUC T ION
Aspirin and P2Y12 inhibitors, such as clopidogrel, reduce the incidence of 
atherothrombotic events in patients undergoing percutaneous coronary interventions 
(PCI) with stent implantation (1,2). However, the anticipated antiplatelet effect of 
clopidogrel, as assessed with platelet function assays, is not achieved in all patients and 
a substantial inter-individual variability in response is observed (3-5). Approximately 
a quarter of patients exhibit high on-clopidogrel platelet reactivity (HPR), which is 
associated with a higher risk for atherothrombotic events following PCI (6-14). The 2011 
European guidelines on non ST-segment elevation acute coronary syndrome (NSTE-
ACS) issued a class IIb indication for platelet function testing in selected cases when 
clopidogrel is used and the 2011 ACCF/AHA/SCAI guidelines for PCI recommended 
platelet function testing in patients at high risk for poor clinical outcome after PCI, 
such as PCI of the left main coronary artery or the last remaining vessel (1,2). There is 
a wide variety of methods for monitoring of platelet function activity. The VerifyNow® 
P2Y12 assay is one of the standardised and user-friendly assays that has shown to 
predict clinical outcomes in large number of patients after PCI (3,4,11,14).
Part of the variability in platelet reactivity on clopidogrel is caused by the fact that 
it requires conversion into its active metabolite by hepatic cytochrome P450 (CYP) 
isoenzymes (15,16). Most of the prodrug (85%) is hydrolyzed by carboxylase to an 
inactive carboxylic acid metabolite, whereas the remaining 15% is transformed rapidly 
into its active thiol metabolite, which exerts its antiplatelet effect by irreversibly 
inhibiting the binding of adenosine diphosphate (ADP) to the P2Y12 receptor (15,16). 
The CYP2C19 gene encodes the CYP2C19 enzyme, which is involved in both steps of 
the hepatic conversion of clopidogrel (5). Different defective polymorphisms of the 
CYP2C19 gene have been discovered, of which the best known loss-of-function allele 
is CYP2C19*2 (5). Multiple factors, including these genetic polymorphisms of the CYP 
system, have been related to the occurrence of HPR (5,17-22). Furthermore, it has 
been described that co-medication can interact with the metabolism of clopidogrel 
and thereby influence platelet reactivity. This is the case with statins, calcium channel 
blockers and proton pump inhibitors (PPI), which increase platelet reactivity in 
patients treated with clopidogrel (17-25). 
Moreover, concomitant treatment with phenprocoumon has been shown to attenuate 
the response to clopidogrel (26). Similar to clopidogrel, coumarin derivatives like 
phenprocoumon and acenocoumarol need several enzymes of the cytochrome 
P450 family, such as CYP3A4, CYP2C9, and CYP2C19, to catalyse their oxidative 
metabolism. CYP3A4 plays a major role as a catalyst of phenprocoumon hydroxylation 
reaction (27,28), whereas CYP2C9 activity is known as the principal determinant for 
acenocoumarol clearance.
Since an increasing number of patients receiving clopidogrel after PCI with stent 
implantation is in need of concomitant treatment with oral anticoagulants for 
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indications such as prior mechanical valve replacement or atrial fibrillation (29,30,31), 
the aim of the present study was to evaluate if concomitant use of the coumarin 
derivative acencoumarol also leads to higher levels of platelet reactivity on clopidogrel 
in patients planned for PCI.
MET HODS
Study Population
From July 2010 to June 2013, consecutive patients with established coronary artery 
disease who were treated with clopidogrel and who were scheduled to undergo PCI 
with stent implantation were included in a prospective, single centre, observational 
registry. Baseline characteristics, including the use of co-medication such as a coumarin 
derivative, were recorded. Decisions regarding the discontinuation or continuation 
of oral anticoagulation and bridging of anticoagulation with unfractionated heparin 
were left at the discretion of the physician. Local protocol suggested to continue oral 
anticoagulation and not to bridge with heparin.
For this analysis, we selected patients who were adequately treated with clopidogrel 
before platelet function testing and of whom complete data on platelet reactivity as 
assessed with the VerifyNow P2Y12 assay was present. Data on the use or non-use of 
acenocoumarol and other oral anticoagulants was also required. Adequate treatment 
with clopidogrel was defined as either a maintenance dose of 75mg of clopidogrel for 
≥5 days, a 300mg clopidogrel loading dose ≥12 hours or a 600mg loading dose ≥6 hours 
before platelet function testing (4). Patients presenting with ST-segment elevation 
myocardial infarction and those who were treated with any oral anticoagulant other 
than acenocoumarol were excluded. The registry did not contain data on patients 
treated with non-vitamin K antagonist oral anticoagulants. There were no other 
inclusion or exclusion criteria for this analysis. The study was conducted according 
to the principles of the Declaration of Helsinki and received approval from the 
human research ethics committee Verenigde Commissies Mensgebonden Onderzoek. 
Approval for this registry included a waiver of informed consent.
Blood sampling
Blood samples were drawn before or after PCI through venipuncture in the antecubital 
vein. After discarding the first 10 ml of free flowing blood, blood samples were collected 
into 3.2% citrate tubes for performance of the platelet function test. Blood samples for 
whole blood count were drawn into tubes containing K3-EDTA.
Platelet function testing 
Platelet function testing was performed with the VerifyNow® system (Accumetrics, San 
Diego, CA, USA), which is a turbidimetric-based, point-of-care device that measures 
platelet aggregation in citrated whole blood. The P2Y12 assay results are reported as 
3.4
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P2Y12 Reaction Units (PRU) and higher PRU results indicate that platelet reactivity is 
less inhibited. The assay was performed according to the manufacturer’s test protocol, 
between 10 minutes and 2 hours after blood sampling.
Endpoints 
The primary endpoint of the present study was the magnitude of ADP-induced 
platelet reactivity, expressed in PRU measured by the VerifyNow® P2Y12 assay, in 
patients on clopidogrel with concomitant acenocoumarol treatment as compared to 
clopidogrel-treated patients without concomitant acenocoumarol treatment. The 
secondary endpoint was the ratio of patients with HPR in the group with vs. the group 
without concomitant use of acenocoumarol. The cut-off value used to identify patients 
exhibiting high on-treatment platelet reactivity (HPR) was PRU ≥236 based on the 
results of the Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-
Pretreated Patients Undergoing Elective PCI (POPular) study, in which this PRU value 
was identified as the optimal cut-off value to predict atherothrombotic events in the 
year following PCI in a comparable cohort of patients treated in our center (14). Similar 
cut-off points were found in other studies and were included in a consensus document 
(32). Additionally, a cut-off value of >208 was used as suggested in the latest consensus 
document of the Working Group on On-Treatment Platelet Reactivity (33).
Statistical analysis
As data from a registry was used, there was no power-calculation for a difference in 
PRU between both groups. Continuous variables are presented as mean ± standard 
deviation (SD). Categorical data are reported as frequencies (percentages). Categorical 
variables were compared using the chi-square test. Normally distributed continuous 
variables were compared with a two-sided unpaired t test and non-normally distributed 
variables were compared using a two-sided Wilcoxon test. 
Multivariate logistic regression analysis was performed to identify independent 
correlates of HPR according to the VerifyNow P2Y12 assay and to adjust for potential 
confounders: concomitant acenocoumarol use and clinically relevant variables known 
to influence the magnitude of platelet reactivity. All univariate variables with a p-value 
<0.10 were included in multivariable analysis. Propensity matching was performed 
through propensity score calculation using generalized boosted regression in a fixed 
1:1 matching ratio  by using the R add-on TWANG package (34). All statistical analyses 
were performed with R (version 3.1, http://www.r-project.org) and a two-tailed p-value 
of <0.05 was considered significant. The authors had full access to the data and take 
full responsibility for the integrity of the data. All authors have read and agreed to the 
manuscript as written.
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Without
acenocoumarol
With 
acenocoumarol
N = 1478 N = 104 p-value
Clinical parameters
Age (y) 64.2 ± 11.0 72.5 ± 9.2 <0.001
BMI (kg/m^2) 27.5 ± 4.3 27.0 ± 4.0 0.226
Male gender 1106 (74.8%) 75 (72.1%) 0.618
Hypertension 1157 (79.0%) 87 (87.0%) 0.073
Hypercholesterolemia 1256 (87.2%) 78 (77.2%) 0.007
Familial history of CAD 747 (54.2%) 42 (46.7%) 0.203
Diabetes Mellitus 313 (21.2%) 27 (26.0%) 0.306
Current smoking 342 (23.3%) 15 (14.6%) 0.055
NSTEMI <14d 283 (19.1%) 13 (12.5%) 0.121
Prior CABG 162 (11.0%) 24 (23.1%) <0.001
LVEF <0.001
<30% 25 (1.69%) 8 (7.69%)
30% - 49% 125 (8.46%) 17 (16.3%)
≥50% 1156 (78.2%) 71 (68.3%)
R E SULT S
Population
Between July 2010 and June 2013, a total of 1,836 patients were enrolled in this 
registry. In total, 1,582 of these patients matched the criteria for this analysis. 
Concomitant treatment with acenocoumarol was prescribed to 104 of these patients 
(6.6%). Acenocoumarol was mainly prescribed for atrial fibrillation or atrial flutter 
(approximately 70%), but also for other indications such as a decreased left ventricular 
ejection fraction and valve prosthesis. Baseline characteristics of patients with and 
without concomitant acenocoumarol treatment are shown in Table 1. Patients on 
acenocoumarol were generally older, were treated more often with a PPI, had more 
renal insufficiency and prior CABG, and had lower left ventricular ejection fraction 
values. In contrast, patients on acenocoumarol less often had hypercholesterolemia. 
Patients on acenocoumarol were less likely to receive concomitant treatment with 
aspirin. Platelet counts did not differ significantly between the two groups. Mean 
International Normalized Ratio (INR) in patients on acenocoumarol was 2.0 ± 0.8 at 
the time of PCI.
Table 1: Baseline characteristics
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Medication
Aspirin 1447 (98.0%) 32 (30.8%) <0.001
Clopidogrel loading dose# 360 (24.4%) 30 (28.8%) 0.363
Proton Pump inhibitor 0.002
None 826 (56.3%) 40 (38.8%)
Omeprazole 150 (10.2%) 10 (9.71%)
Pantoprazole 372 (25.4%) 42 (40.8%)
Other 118 (8.05%) 11 (10.7%)
Calcium Antagonist 434 (29.6%) 37 (35.6%) 0.239
Beta-blocker 1174 (80.2%) 83 (79.8%) 1.000
ACE-inhibitor 576 (39.4%) 44 (42.3%) 0.629
Indication for acenocoumarol
Atrial fibrillation/flutter - 72 (69.2%)
Decreased LVEF - 8 (7.7%)
Valve prosthesis - 7 (6.7%)
Other* - 17 (16.3%)
Laboratory Parameters
Platelet count (x10^9) 225 ± 65 220 ± 88 0.592
Mean INR - 2.0 ± 0.8
eGFR MDRD (ml/kg/1.73m^2) <0.001
eGFR >60 1300 (88.0%) 75 (72.1%)
eGFR 30-60 156 (10.6%) 28 (26.9%)
eGFR <30 21 (1.42%) 1 (0.96%)
Without 
acenocoumarol
With
acenocoumarol
Table 1: Baseline characteristics. This table displays the baseline characteristics of patients 
with and without concomitant treatment with acenocoumarol. Continuous variables are presented as 
mean ± SD. Categorical data are reported as frequencies (percentages). Numbers do not add up for all 
variables as missing data are not reported. Abbreviations: BMI = body mass index, CABG = coronary 
artery bypass grafting, CAD = coronary artery disease, d = days, eGFR MDRD = estimated Glomerular 
Filtration Rate according to the MDRD formula, LVEF = left ventricular ejection fraction, N = number 
of patients, INR = international normalized ratio, NSTEMI = non ST-elevation myocardial infarction, 
and y = years. # Patients who received a loading dose (LD) of 300mg ≥12 hours or a LD of 600 mg ≥6 
hours before testing, as opposed to a maintenance dose of 75mg of clopidogrel ≥5 days before testing, * 
The other group includes indications such as pulmonary embolisms, deep vein thrombosis, thrombus in 
left ventricle, and vascular prosthesis.
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Platelet reactivity
Platelet reactivity was significantly higher in patients with concomitant acenocoumarol 
treatment as compared to patients without acenocoumarol use (PRU 229 ± 88 vs. PRU 
187 ± 95; p<0.001) a shown in Table 2. The proportion of patients with HPR was higher 
in patients with concomitant acenocoumarol use as compared to patients without 
acenocoumarol treatment for PRU >208 (57.7% vs. 41.1%; p=0.001) and PRU ≥236 
(49.0% vs. 31.4%; p<0.001), respectively. Platelet reactivity levels were not significantly 
different between patients with and without aspirin both in patients with and without 
concomitant acenocoumarol treatment (Table 3).
Multivariable analysis 
A multivariable logistic regression analysis with ADP-induced platelet aggregation as 
measured by the VerifyNow® P2Y12 assay demonstrated that concomitant treatment 
with acenocoumarol was independently associated with an attenuated platelet 
response to clopidogrel treatment (Table 2 and Table 4). Other variables that 
showed an independent association with PRU in a linear regression analysis are age, 
gender, body mass index (BMI), diabetes mellitus (DM), platelet count, recent non ST-
elevation myocardial infarction (NSTEMI) within 14 days of PCI, renal function, PPI 
use, and the moment of blood sampling (sampling after PCI as opposed to before PCI). 
After correction for the aforementioned variables and current smoking and aspirin 
use, concomitant acenocoumarol treatment was independently associated with 
a higher PRU (+35.7 PRUs, 95% CI: 11.9-59.6; p=0.003) and the occurrence of HPR 
defined as PRU ≥236 (OR 2.00, 95% CI: 1.07-3.79; p=0.031). In logistic regression on 
HPR, all variables that were significantly associated with PRU were also significantly 
associated with HPR (Table 3). After correction for the aforementioned variables 
and current smoking and aspirin use, concomitant acenocoumarol treatment was no 
longer significantly associated with HPR defined as PRU >208 (OR 1.37, 95% CI: 0.74-
2.54; p=0.317).
Propensity matching
Propensity matching yielded results that were similar to the univariate and 
multivariable analysis, showing a significantly higher PRU in patients who are 
concomitantly treated with acenocoumarol (+28.2 PRUs; p<0.001) (Table 4).
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Table 2: Platelet reactivity levels on clopidogrel in patients with and without concomitant treatment 
with acenocoumarol. Results are described for the association between acenocoumarol use and HPR, 
defined as PRU >208 and PRU ≥236. Univariate and multivariable analysis correcting for age, gender, 
body mass index, diabetes mellitus, platelet count, recent non ST-elevation myocardial infarction 
within 14 days of PCI, renal function, proton-pump inhibitor use, the moment of blood sampling (after 
as opposed to before PCI), current smoking and aspirin use. Continuous variables are presented as 
mean ± SD. Categorical data are reported as frequencies (percentages). Numbers do not add up for all 
variables as missing data are not reported. Abbreviations: HPR = high platelet reactivity, N = number 
of patients, OR = odds ratio, PCI = percutaneous coronary intervention, PRU = P2Y12 Reaction Units, 
and 95% CI = 95% confidence interval.
With acenocoumarol
N = 1478 N = 104 p-value
Moment of blood sampling
Before PCI 885 (60.0%) 61 (58.7%) 0.861
After PCI 589 (40.0%) 43 (41.3%)
Platelet reactivity
VerifyNow P2Y12 assay PRU 187 ± 95 PRU 229 ± 88 <0.001
HPR (PRU >208) 607 (41.1%) 60 (57.7%) 0.001
HPR (PRU ≥236) 464 (31.4%) 51 (49.0%) <0.001
Univariate
HPR (PRU >208) OR 1.96 (95% CI: 1.31 - 2.94) 0.001
HPR (PRU ≥236) OR 2.10 (95% CI: 1.41 – 3.14) <0.001
Multivariate
HPR (PRU >208) OR 1.37 (95% CI: 0.74 – 2.54) 0.317
HPR (PRU ≥236) OR 2.00 (95% CI: 1.07 - 3.79) 0.031
Table 2: Platelet reactivity levels on clopidogrel in patients with and without concomitant 
treatment with acenocoumarol. 
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Table 3: Platelet reactivity in patients with and without aspirin
Aspirin use N PRU p-value
Acenocoumarol No aspirin 72 229.9 ± 83.6 0.924
Aspirin 32 227.9 ± 99.2
No acenocoumarol No aspirin 30 176.8 ± 100.7 0.570
Aspirin 1447 187.5 ± 94.4
Table 3: Platelet reactivity in patients with and without aspirin. Platelet reactivity as measured with 
VerifyNow P2Y12 assay in patients who receive concomitant treatment with aspirin vs. those who do 
not, divided in a group with acenocoumarol use and a group without acenocoumarol use. Continuous 
variables are presented as mean ± SD. Categorical data are reported as frequencies (percentages). 
Numbers do not add up for all variables as missing data are not reported. Abbreviations: N = number of 
patients and PRU = P2Y12 Reaction Units.
Multiple linear regression
Estimate p-value 95% CI
Acenocoumarol 35.73 0.003 11.88 - 59.57
Age 2.03 <0.001 1.59 - 2.47
Male gender -23.67 <0.001 -33.87 - -13.47
BMI (kg/m^2) 3.90 <0.001 2.87 - 4.93
Diabetes Mellitus 26.56 <0.001 15.96 - 37.16
Platelet count (x10^9) -0.20 <0.001 -0.26 - -0.13
eGFR MDRD 30-60 (ml/kg/1.73m^2) -37.11 0.055 -74.93 - 0.70
eGFR MDRD >60 (ml/kg/1.73m^2) -40.84 0.027 -76.95 - -4.74
NSTEMI <14d 18.94 0.009 7.83 - 30.06
Current smoking -6.59 0.228 -17.29 - 4.11
Aspirin 19.80 0.109 -4.37 - 43.96
Proton pump inhibitor
         Pantoprazole 12.62 0.015 2.49 - 22.75
         Omeprazole 30.18 <0.001 15.66 - 44.71
         Other 36.89 <0.001 20.65 - 53.12
Moment of blood sampling* 14.41 0.001 5.70 - 23.13
Acenocoumarol after PS 1:1 matching 28.21 <0.001
Table 4: Multivariable analyses including propensity matching
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Logistic regression HPR (PRU >208)
OR p-value 95% CI
Acenocoumarol 1.37 0.317 0.74 - 2.54
Age 1.04 <0.001 1.03 - 1.06
Male gender 0.66 0.002 0.51 - 0.86
BMI (kg/m^2) 1.07 <0.001 1.05 - 1.10
Diabetes Mellitus 1.80 <0.001 1.37 - 2.36
Platelet count (x10^9) 1.00 <0.001 0.99 - 1.00
eGFR MDRD 30-60 (ml/kg/1.73m^2) 0.49 0.164 0.17 - 1.30
eGFR MDRD >60 (ml/kg/1.73m^2) 0.52 0.177 0.19 - 1.31
NSTEMI <14d 1.54 0.004 1.15 - 2.06
Current smoking 0.85 0.279 0.64 - 1.13
Aspirin 0.96 0.887 0.51 1.79
Proton pump inhibitor
         Pantoprazole 1.30 0.047 1.00 - 1.69
         Omeprazole 1.86 0.001 1.29 - 2.69
         Other 2.55 <0.001 1.67 - 3.93
Moment of blood sampling* 1.73 <0.001 1.38 - 2.17
Logistic regression HPR (PRU ≥236)
OR p-value 95% CI
Acenocoumarol 2.00 0.031 1.07 - 3.79
Age 1.05 <0.001 1.04 - 1.07
Male gender 0.64 0.001 0.50 - 0.84
BMI (kg/m^2) 1.08 <0.001 1.05 - 1.11
Diabetes Mellitus 2.04 <0.001 1.55 - 2.68
Platelet count (x10^9) 1.00 <0.001 0.99 - 1.00
eGFR MDRD 30-60 (ml/kg/1.73m^2) 0.31 0.022 0.11 - 0.82
eGFR MDRD >60 (ml/kg/1.73m^2) 0.33 0.024 0.12 - 0.84
NSTEMI <14d 1.55 0.005 1.15 - 2.10
Current smoking 0.93 0.621 0.68 - 1.26
Aspirin 1.46 0.255 0.77 - 2.83
Proton pump inhibitor
         Pantoprazole 1.19 0.219 0.90 - 1.58
         Omeprazole 1.86 0.001 1.28 - 2.71
         Other 2.06 <0.001 1.34 - 3.17
Moment of blood sampling* 1.64 <0.001 1.30 - 2.09
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Table 4: Multivariable analyses including propensity matching. Multivariable analysis: 
controlling for age, gender, body mass index, diabetes mellitus, platelet count, recent non ST-elevation 
myocardial infarction within 14 days of PCI, renal function, proton-pump inhibitor use, the moment 
of blood sampling, current smoking, and aspirin use. Results for propensity matching in a 1:1 ratio are 
also described. * = blood sampling after PCI with blood sampling before PCI as reference. Abbreviations: 
BMI = body mass index, CI = confidence interval, d = days, eGFR MDRD = estimated Glomerular 
filtration rate according to the MDRD formula, HPR = high platelet reactivity, NSTEMI = non-ST-
elevation myocardial infarction, OR = odds ratio, PRU = P2Y12 Reaction Units, PS = propensity score, 
and 95% CI = 95% confidence interval.
 
DISCUS SION 
The main finding of this study was that concomitant acenocoumarol treatment in 
patients treated with clopidogrel was associated with a significantly higher level of 
platelet reactivity. In addition, the proportion of patients with HPR, defined as PRU 
≥236, was higher in patients with concomitant acenocoumarol use as compared to 
patients without acenocoumarol treatment. Multivariate logistic regression analysis 
was performed to exclude the influence of potential confounders. The results of 
this analysis support an independent association of acenocoumarol treatment with 
attenuated antiplatelet effects of clopidogrel (Table 3). A number of other well-known 
predictors of clopidogrel responsiveness, such as gender (35), age (17,36), DM (17,36), 
platelet count (37) BMI (18), renal function (17), recent ACS (17,38), and PPI use 
(21-23) were also found to be independent predictors of clopidogrel responsiveness 
in the present study, while the known independent predictor current smoking (39) 
was not significantly associated with PRU. The moment of blood sampling was also an 
independent predictor of PRU, with higher PRU values in patients from whom blood 
was sampled after PCI as compared to patients from whom blood was sampled before 
PCI. This increase in platelet reactivity after PCI is in accordance with results from a 
recently published study by Mangiacapra et al. (40).
Acenocoumarol is not the only coumarin derivative that is associated with higher levels 
of platelet reactivity in patients treated with clopidogrel. A similar effect was observed 
by Sibbing et al. in patients with concomitant phenprocoumon use (26). Sibbing et 
al. demonstrated that patients who used clopidogrel and who were concomitantly 
treated with phenprocoumon exhibited significantly higher values of ADP-induced 
platelet aggregation and showed a higher incidence of HPR (OR 2.0, 95% CI: 1.3–3.1; 
p=0.002) as assessed with the Multiplate analyzer (Dynabyte, Munich, Germany). The 
explanation of the interaction between coumarin derivatives and clopidogrel might be 
in the metabolism of both drugs. Phenprocoumon and clopidogrel share metabolism 
steps using CYP3A4. Acenocoumarol is primarily metabolized by CYP2C9, which is also 
a determinant in clopidogrel metabolism (27,28,41). Another possible explanation for 
the increase in platelet reactivity in patients using coumarin derivatives could be that 
aspirin is used less often by these patients, probably because the treating physician 
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expects that triple therapy would disproportionally increase the risk of bleeding, as 
was confirmed in a recently published study (30,42). However, Table 3 shows that 
there is no significant difference in PRU between patients receiving acenocoumarol 
and clopidogrel with or without concomitant aspirin treatment in this registry. The 
same holds true for patients without concomitant acenocoumarol treatment. Previous 
studies show that aspirin has only little influence on platelet reactivity measured 
with tests that specifically determine P2Y12 mediated platelet aggregation on P2Y12 
inhibitor treatment like VerifyNow and Multiplate (43), and this is supported by the 
results from our multivariable analysis.
The occurrence of HPR has been associated with a poor outcome in numerous studies 
(4,6-14). In this study, 49.0% of patients in the acenocoumarol group had HPR, 
compared to 31.4% in patients using clopidogrel without concomitant acenocoumarol. 
This could indicate that our findings are of major importance for daily clinical 
practice. This could create challenges for the interpretation of data regarding the 
combination of clopidogrel with coumarin derivatives, as platelet reactivity may vary 
considerably between patients. Patients with HPR on clopidogrel who develop a low 
INR, for example, may be at higher risk of stent thrombosis and other thrombotic 
events, whereas patients without HPR on clopidogrel who develop a high INR may 
actually be at higher risk of bleeding. However, we do not know if HPR is also a strong 
risk predictor for thrombotic events in patients receiving concomitant coumarin 
treatment. As only approximately 10% of the 1,069 patients in the POPular study 
were on a coumarin derivative, and other studies evaluating the relationship between 
platelet reactivity often excluded patients on oral anticoagulants, further studies are 
needed to confirm if the association between HPR and the occurrence of thrombotic 
events in patients who are concomitantly treated with coumarin derivatives. However, 
if patients who are treated with acencoumarol or phenprocoumon and who exhibit 
HPR on clopidogrel treatment do turn out to have an increased risk for the occurrence 
of thrombotic events, it is unclear what the optimal treatment strategy would be for 
these patients (3). 
Ticagrelor or prasugrel could be used to overcome HPR, as they provide more effective 
platelet inhibition compared to clopidogrel, with less inter-individual variability than 
clopidogrel (44,45). This is in part attributable to the differences in metabolism of 
these drugs compared to clopidogrel. Prasugrel undergoes metabolism to its active 
metabolite primarily by CYP3A and CYP2B6 and, to a lesser extent, by CYP2C9 and 
CYP2C19. This means that the level of platelet inhibition provided by prasugrel might 
be less affected by concomitant acencoumarol treatment, as acenocoumarol is primarly 
metabolized by CYP2C9. Ticagrelor is direct acting, and its antiplatelet effect is not 
influenced much by its metabolism, even though it is also metabolized to an active 
metabolite by CYP3A4, like clopidogrel (46). It is unknown if concomitant treatment 
with coumarin derivatives also attenuates platelet inhibition on prasugrel or ticagrelor, 
although this would not be expected based on their metabolism. The downside of the 
use of these newer drugs is that they increase the risk of bleeding and that there is 
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no substantial data on concomitant treatment with coumarin derivatives (44,45). 
The WOEST study has shown that this patient population is at high risk of bleeding 
and we should therefore be cautious with regard to the intensification of antiplatelet 
treatment (3). This means we are still in search of the optimal combination of 
antiplatelet drugs and anticoagulant drugs to minimize both bleeding and thrombotic 
events in patients with indications for both drugs (3,47). As of yet, the combination of 
any oral anticoagulant with prasugrel or ticagrelor is not recommended out of fear of 
bleeding complications and a lack of evidence (48,49). Platelet function testing might 
someday be able to assist clinicians in decision making, although very little data about 
a tailored treatment strategy is available for this subgroup of patients (50).
This is the first study that has assessed the impact of concomitant treatment with 
acenocoumarol on the antiplatelet effect of clopidogrel. There are, however, some 
limitations that need to be mentioned. First, this was an observational study in which 
treatment with acenocoumarol was not subjected to randomization, and concomitant 
use of acenocoumarol was only observed in a small number of patients (n=104). While 
the results of this study are consistent with a cross-sectional observational study in 
patients using phenprocoumon, both these studies can not account for all possible 
variables that might influence platelet reactivity results, although both studies 
attempted to correct for all known factors that influence platelet reactivity (26). Given 
the prothrombotic milieu in patients with a need for oral anticoagulants, such as 
patients with atrial fibrillation, one could speculate that there is an increased level 
of platelet reactivity on treatment with clopidogrel in all these patients, regardless 
of the use of oral anticoagulants. Since this registry did not contain patients with 
an indication for acenocoumarol who did not receive this treatment, we can not test 
this hypothesis in the current study. To eliminate bias by indication, clopidogrel-
treated subjects should be randomized to treatment with concomitant treatment with 
acenocoumarol/phenoprocoumon or no concomitant treatment with acenocoumarol/
phenoprocoumon. Such a trial might be useful now we have the results of both these 
observational studies. Second, we did not assess if the availability of clopidogrel’s 
active metabolite was decreased by concomitant acenocoumarol use, as these tests 
can only be performed in certain expert laboratories and there was no evidence for 
increased platelet reactivity with acenocoumarol use until now. Further studies might 
also focus on this aspect.
Third, we focused on measuring the platelet response rather than clinical outcome 
in this study. The relationship between this in vitro reaction and clinical outcome 
therefore remains unknown. Fourth, platelet reactivity was assessed before PCI in 
some patients, while it was assessed after PCI in others, as some patients were not 
adequately loaded until after the PCI was performed. As a stenting procedure might 
increase platelet reactivity as measured with the VerifyNow P2Y12 assay, this is a 
limitation of this registry containing data gathered in clinical practice. However, the 
distribution of samples taken before vs. after PCI was not significantly different in 
the group with acenocoumarol vs. the group without acenocoumarol (p=0.861) and 
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the effect of acenocoumarol on platelet reactivity is unlikely to be influenced by the 
performance of a PCI procedure, as was shown after correction in the multivariable 
analysis.
Fifth, platelet reactivity was only assessed with the VerifyNow P2Y12 assay in this 
study. We do not know for certain if the observed effect is test-specific, but we do not 
think that this is the case. An increase in platelet reactivity with concomitant use of a 
coumarin derivative was also measured with another test, the Multiplate, albeit with 
a different coumarin derivative (26).
In conclusion, this hypothesis-generating study showed that concomitant treatment 
with acenocoumarol significantly increases platelet reactivity and the rate of HPR in 
patients treated with clopidogrel. Since the number of patients on oral anticoagulation 
therapy undergoing PCI is increasing, and previous studies showed a correlation 
between HPR and clinical outcome, this might be an important observation. The 
impact of this possible interaction between coumarin derivatives and clopidogrel on 
the risk of bleeding and thrombotic events in patients undergoing PCI requires further 
investigation.
What is known 
about this topic?
· Clopidogrel is associated with great inter-individual 
variability in antiplatelet effect
· High platelet reactivity on clopidogrel is associated 
with an increased risk of atherothrombotic events 
following PCI in patients using dual antiplatelet 
therapy with aspirin and clopidogrel (without 
concomitant oral anticoagulants)
· Platelet reactivity on clopidogrel is influenced by 
multiple factors, including concomitant treatment 
with the oral anticoagulant phenprocoumon
What does this 
paper add?
· This was the first study that investigated the 
association between concomitant use of the oral 
anticoagulant acenocoumarol and platelet reactivity in 
patients treated with clopidogrel 
· Concomitant treatment with acenocoumarol is 
associated with an increased level of platelet reactivity 
and an increased rate of high platelet reactivity as 
assessed with the VerifyNow P2Y12 assay
Table 5. Summary
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A BST R AC T
Background: The optimal anti-thrombotic strategy in patients on long-term oral 
anticoagulation (OAC) who require percutaneous coronary intervention with stenting 
(PCI) is unclear. 
Methods and results: The WOEST study was a randomised controlled trial that 
recruited 573 patients on long-term OAC who underwent PCI.  The peri-procedural 
treatment strategy was left to the operators discretion. To assess the safety and 
feasibility of uninterrupted oral anticoagulation (UAC) and bridging therapy (BT), 
bleeding complications and MACCE were assessed in patients treated according to UAC 
(n= 241) and BT (n=322) regimen. After 30 days as well as after one year, there were no 
significant differences in bleeding complications (HR 1.14, 95% CI 0.77-1.69, p= 0.51 
and HR 1.26, 95% CI 0.94-1.69, p= 0.12 respectively) and MACCE.  MACCE tended to 
be less frequent in the UAC group (respectively HR 0.48, 95% CI 0.15-1.51, p= 0.21 
and HR 0.72, 95% CI 0.46-1.14, p= 0.16). Additionally, adjustment with a propensity 
score revealed no significant differences.  Peri-procedural INR was not associated with 
bleeding or MACCE.
Conclusion:  In the WOEST study, UAC was not associated with an increase of bleeding 
or MACCE compared to bridging therapy. This is the largest study up to now to support 
the current guidelines. 
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I N T RODUC T ION
Approximately 20-30% of patients with atrial fibrillation (AF) or mechanical 
heart valves who need OAC have concomitant ischaemic heart disease that may 
require percutaneous coronary intervention (PCI) with stenting (1,2). The optimal 
peri-procedural anticoagulation treatment during PCI is unclear. There are two options, 
the first is to continue therapeutic OAC throughout the peri-procedural period and 
the second is to discontinue OAC prior to PCI.  If the second option is chosen and 
the patient is considered to be at increased risk for thromboembolism, unfractionated 
heparin (UFH) or low molecular weight heparins (LMWH) are administered as a 
bridging therapy (BT).  In 2010, an expert consensus paper from the Working Group 
on Thrombosis of the ESC recommended the uninterrupted oral anticoagulation (UAC) 
strategy as the preferred strategy for AF patients at moderate to high risk (1). These 
recommendations are based on circumstantial evidence since there are no randomised 
trials addressing this challenging issue. The potential advantages of UAC include a 
minimised risk of atherothrombotic events, as periods with subtherapeutic INR 
values are avoided, but also a simpler peri-procedural treatment regimen. The latter 
can potentially be cost saving as patients do not require hospitalisation for warfarin 
re-initiation. Therefore, we decided to perform a sub-analysis to test the hypothesis that 
peri-procedural UAC would not increase bleeding nor thrombotic or thromboembolic 
complications in patients receiving OAC undergoing PCI in the WOEST trial (3,4). 
MET HODS
The What is the Optimal antiplatElet and anticoagulant therapy in patients with 
oral anticoagulation and coronary StenTing (WOEST) was an open label randomised 
controlled trial that recruited 573 patients on long-term OAC who underwent PCI. 
Patients were randomised to receive clopidogrel alone or clopidogrel and aspirin after 
PCI (4). The entry and exclusion criteria were described in the original publication (3,4). 
The peri-procedural treatment was left to the discretion of attending physician with 
combinations ranging from stopping OAC with no BT to UAC plus LMWH. For the 
purpose of this sub-analysis, the UAC group (n=241) was defined as the patients in whom 
OAC was continued throughout the hospitalisation.  In the BT group (n=322), OAC was 
interrupted before PCI and the operator decided if heparin or LMWH was administered 
or not. The 10 patients who were excluded from the intention to treat analysis in the 
original WOEST trial publication were also excluded from this sub-analysis (4). All 
data were collected prospectively and were entered into a central database. Follow-up 
stopped 1 year after inclusion or at the time of death. All events requiring medical 
attention were verified by a blinded event committee. Each bleeding event during 
1-year follow-up was classified separately according to the Thrombolysis in myocardial 
infarction (TIMI) criteria and the Bleeding Academic Research Consortium (BARC) 
criteria (5,6). Major adverse cardiac and cerebrovascular events (MACCE) consisted of 
death, myocardial infarction (MI), stroke, target-vessel revascularisation, and stent 
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thrombosis (according to the Academic Research Consortium (ARC) criteria) (7) and 
each individual component of the primary and secondary endpoints independently. 
Myocardial infarction (MI) and peri-procedural MI were defined according to the 
2007 definitions and were described in the original publication (6,10). The diagnosis 
of stroke was made by the treating neurologist and CT or MRI was used to distinguish 
ischaemic from haemorrhagic strokes. The study was conducted according to the 
principles of the Declaration of Helsinki. All patients gave written informed consent. 
The WOEST trial is registered with ClinicalTrials.gov, number NCT00769938. 
STAT IST IC A L A NA LYSIS
Standard statistical hypothesis tests were used for the baseline comparison: 
Chi-square or Fisher’s exact and Student’s t or Mann-Whitney where appropriate. 
Primary and secondary endpoints based on time to first event were assessed by 
comparison of Kaplan-Meier-based cumulative incidence rates with the log rank 
test. As a measure of strength, we calculated hazard ratios (HRs) and 95% confidence 
intervals (CIs). When applicable, we used multivariate Cox’s proportional hazard 
regression to correct for baseline imbalances.
Propensity scores were used to adjust for potential bias in the comparison between 
non-randomised UAC and BT groups. The propensity score was calculated as the 
predicted probability that the patient was treated by UAC as opposed to BT using 
logistic regression. We subsequently adjusted the aforementioned analyses by means 
of propensity weighing. The variables included in the propensity score analysis 
are listed in a pendix A.  All calculations were done with R software (version 3.0; 
www.r-project.org).
 
R E SULT S
The baseline characteristics of both groups are detailed in Table 1. In the UAC group, 
the use of clopidogrel at baseline was higher.  The number of smokers and mean ejection 
fraction at baseline were significantly lower in the UAC group. There was no significant 
difference in the number of patients randomised to double (clopidogrel plus OAC) or 
triple therapy (aspirin, clopidogrel and OAC) after PCI (p =0.169). 
Procedural variables are depicted in Table 2: radial access was more common and DES 
were used slightly more frequently in the UAC group. Moreover, the peri-procedural 
use of LMWH and GPIIb/IIIa blockers was significantly lower in the UAC group, 
whereas the UFH bolus was significantly larger. As expected, the peri-procedural INR 
was higher in the UAC group (2.53 vs. 1.48, p< 0.001).  Bridging in the BT group was 
performed according to local standards in each participating hospital. The length of 
hospitalisation after PCI was the same for both groups after elective PCI (median 1 
day), but was significantly longer in ACS patients in the UAC group. 
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Bridging therapy Periprocedural OAC p-value
n = 322 n = 241
Randomisation 0.169
Double therapy (OAC + clopidogrel) 151 47% 128 53%
Triple therapy (OAC + clopidogrel + ASA) 171 53% 113 47%
Clinical baseline characteristics
Age, yrs 69.9 ± 8 69.8 ± 8 0.820
Male 253 (79%) 195 (81%) 0.564
Risk factors
     BMI 27.9 ± 4·3 27·4 ± 4·2
     Diabetes 81 (25%) 59 (24%) 0.933
     Hypertension 216 (67%) 170 (71%) 0.434
     Hypercholesterolaemia 231 (72%) 164 (68%) 0.454
     Current smoker 68 (21%) 34 (14%) 0.043
     Family history for CAD 141 (44%) 97 (40%) 0.312
     History of myocardial infarction 103 (32%) 93 (39%) 0.124
     History of heart failure 81 (25%) 60 (25%) 1.0
     History of stroke 60 (18%) 39 (16%) 0.520
     History of PCI 106 (33%) 81 (34%) 0.935
     History of CABG 68 (21%) 62 (26%) 0.237
     History of gastro-intestinal bleeding 17 (5%) 11 (5%) 0.849
     History of renal failure 59 (18%) 40 (17%) 0.674
Medication on admission
     Betablocker 253 (79%) 188 (78%) 0.954
     ACE-inhibitor or ARB 214 (66%) 167 (69%) 0.535
     Calcium channel blokker 98 (30%) 66 (27%) 0.488
     Diuretic 154 (48%) 118 (49%) 0.856
     Statin 241 (75%) 181 (75%) 1.0
     Digoxin 37 (11%) 31 (13%) 0.716
     Nitrate 87 (27%) 87 (36%) 0.027
     Aspirin 120 (37%) 72 (30%) 0.082
     Clopidogrel 124 (39%) 141 (59%)  <0.001
     Insulin 28 (9%) 20 (8%) 0.989
     Oral antidiabetic 61 (19%) 47 (20%) 0.954
     Fibrate 6 (2%) 6 (2%) 0.830
     PPI use 118 (37%) 87 (36%) 0.210
          Omeprazol  60 (19%) 55 (23%)
          PPI other than omeprazol  58 (18%) 32 (13%)
 
Indication for OAC 0.328
     Atrial fibrillation/atrial flutter 198 (73%) 128 (64%)
     Mechanical valve 25 (9%) 24 (12%)
Table 1. Clinical characteristics at baseline and concomitant treatment on admission.
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     Other (Apical aneurysm, Pulmonary  
     Embolus, PAD, EF< 30%…)
47 (17%) 48 (24%)
     Mean CHADS 2 score at baseline 
     (for AF patients only)
2.78 ± 1.21 2.91 ± 1.13 0.344
Acute coronary syndrome at baseline
Acute coronary syndrome at baseline 83 (26%) 72 (30%) 0,340
Ejection Fraction
     Mean EF at baseline 47.6% ± 14.7 44.1% ± 13.8 0.018
     EF< 30% 44 (18%) 33 (21%) 0.566
Table 1: Values are mean ± SD or n (%).  
BMI=Body mass index; CAD = coronary artery disease; PCI = percutaneous coronary intervention; 
AF=atrial fibrillation;ACE-inhibitor = angiotensin-converting enzyme inhibitor; ARB= angiotensin2 
receptor blokker; 
PPI proton pump inhibitor; OAC oral anticoagulant therapy;PAD = peripheral artery disease; 
EF= Ejection Fraction; ASA= aspirin
Categories do not add up to 100% for all valuables due to missing values.
Bridging therapy Periprocedural OAC p-value
n = 322 n = 241
Procedural Characteristics
Arterial access 0.014
     - Radial 70 (22%) 75 (31%)
     - Femoral 249 (77%) 163 (68%)
INR on day of PCI 1.48 ± 0.65 2.53 ± 1.12  <0.001
Angiographic baseline characteristics
PCI vessel 0.709
     - LAD 134 (42%) 95 (39%)
     - RCA 89 (28%) 75 (31%)
     - LCX 81 (25%) 54 (22%)
Venous or arterial graft 17 (5%) 15 (6%)
Number of vessels treated 0.034
     - 1 218 (69%) 183 (76%)
     - 2 75 (24%) 50 (21%)
     - 3 20 (6%) 6 (3%)
Predilatation 240 (75%) 166 (69%) 0.166
Stent type DES (vs. BMS) 212 (62%) 166 (69%) 0.469
Patients with BMS in elective setting (no 
ACS)
71 (22%) 42 (17%) 0.181
Patients with DES in elective setting (no ACS) 163 (51%) 117 (49%)
Patients with BMS in acute coronary syndro-
me (ACS)
38 (12%) 24 (10%)
Patients with DES in acute coronary syndro-
me (ACS)
45 (14%) 48 (20%)
Table 2. Procedural characteristics
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Stent diameter (mm) 3.13 ± 0.49 3.14 ± 0.55 0.886
Total stent length (mm) 24.4 ± 14 22.7 ± 11.5 0.129
Closure device 0.882
     - No 86 (27%) 69 (29%)
     - Angio-Seal® 192 (60%) 141 (59%)
     - Other 42 (13%) 30 (12%)
ACC lesion type 0.100
     - A 50 (16%) 28 (13%)
     - B1 88 (29%) 86 (39%)
     - B2 99 (32%) 68 (30%)
     - C 69 (23%) 41 (18%)
Concomitant treatment
Peri-procedural heparin bolus  <0.001
     - No heparin bolus 29 (9%) 14 (6%)
     - Heparin bolus  <=5000 149 (47%) 100 (42%)
     - Heparin bolus    >5000 136 (43%) 123 (52%)
Mean number units peri-procedural  
heparin bolus
5,827 ± 2,713 6,796 ± 3,113
Periprocedural LMWH 95 (30%) 39 (16%)  <0.001
Periprocedural GPIIb/IIIa 44 (14%) 7 (3%)  <0.001
Periprocedural fondaparinux 3 (1%) 2 (1%) 1.0
Length of hospitalisation  <0.001
Median length of hospitalisation after PCI in 
elective setting (no ACS) in days
1 1
Median length of hospitalisation after PCI in 
acute coronary syndrome (ACS) in days
2 3
Mean length of hospitalisation after PCI in 
elective setting (no ACS) in days
2.1 2.4
Mean length of hospitalisation after PCI in 
acute coronary syndrome (ACS) in days
4 5
Table 2: Values are mean ± SD or n (%).  
ACC lesion: American College of Cardiology lesion classification; ACS= acute coronary syndrome; 
INR=international normalized ratio; 
GPIIb/IIIa: glycoprotein IIb/IIIa receptor blokker; LAD = left anterior descending coronary artery; LCX = left 
circumflex coronary artery;
LMWH = low-molecular-weight-heparin; OAC= oral anticoagulant therapy; PCI=percutaneous coronary 
intervention; RCA = right coronary artery.
Categories do not add up to 100% for all variables due to missing values.
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The rate of adverse events during the 30-day and one-year follow up is shown in 
Figure 1, Figure 2, Table 3 and Table 4. After 30 days and one year, there were no 
significant differences in the occurrence of bleeding events (19.1% vs. 17.4%, p=0.51, 
and 35.6% vs. 29.8%, p=0.12, respectively) or MACCE (1.7% vs. 3.4%, p=0.21 and 12% 
vs.16.1%, p=0.15 respectively) between the two groups. However, the incidence of 
BARC 1 bleeding was significantly higher in the UAC group after one year. The MACCE 
endpoint occurred less frequently in the UAC group than the BT group after 30 days as 
well as after one year, but this difference did not reach statistical significance. In fact, 
the number of all individual MACCE components including death, stroke, myocardial 
infarction, target vessel revascularisation and stent thrombosis was lower in the UAC 
group after one year, but these endpoints were not significantly different either. After 
adjustment with the propensity score, the proportions of bleeding events (HR 1.17, 
95% CI: 0.77-1.79, p=0.46, and HR 1.27, 95% CI: 0.93-1.73, p=0.13, respectively) and 
MACCE (HR 0.78, 95% CI 0.48-1.28, p=0.32 and HR 0.78, 95% CI 0.47-1.27, p=0.31 
respectively) after 30 days as well as after one year did not reveal any differences 
between the propensity-matched groups (Table 3, Table 4, Online Table 1, 
Online Table 2). After multivariate analysis, peri-procedural INR was not associated 
with bleeding (p= 0.09) or MACCE (p=0.21).
Figure 1: Periprocedural OAC vs. bridging: 
Figure 1: Bleeding Endpoint: Any bleeding during one year follow-up. Red line = Bridging Therapy. 
Black line: Uninterrupted Oral Anticoagulation
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The results for the subset of patients with AF were similar as compared with the total 
study population (Online Table 1 & Online Table 2, Online Figure 1 & Online 
Figure 2). In OAC patients with underlying AF requiring PCI, there were no signif-
icant differences in overall occurrence of bleeding events or MACCE after 30 days 
(bleeding: HR=1.05, 95% CI: 0.60-1.85, p=0.86, MACCE: HR = 0.17, 95% CI 0.02-1.34, 
p = 0.09) and one year (bleeding: HR=0.98, 95% CI: 0.64-1.50, p=0.93, MACCE: HR = 
0.87, 95% CI 0.49-1.56, p = 0.64) (Online Table 1, Online Table 2, Online Figure 1 and 
Online Figure 2).
Figure 2: Periprocedural OAC vs. bridging: MACCE (death, myocardial infarction, stroke, target 
vessel revascularization and stent thrombosis) during one year follow-up. 
Red line = Bridging Therapy. Black line: Uninterrupted Oral Anticoagulation
Bridging therapy Periprocedural OAC HR (95% CI)  p-value
n = 322 n = 241
Events within 30 days
Any bleeding event 56 17.4% 46 19.1% 1.14 (0.77-1.69) 0.51
Any bleeding event (after 
propensity score matched)
1.17 (0.77-1.79) 0.46
TIMI bleeding TIMI Major 7 2.2% 1 0.4% 0.19 (0.02-1.55) 0.12
TIMI Minor 32 9.9% 23 9.5% 0.97 (0.57-1.65) 0.90
TIMI Minimal 20 6.2% 24 10.0% 1.65 (0.91-2.98) 0.10
Table 3: Adverse events after 30 days.   
249
Uninterrupted oral anticoagulation versus bridging
GUSTO bleeding GUSTO severe 6 1.9% 0 0.0% 0.0 0.09
GUSTO moderate 7 2.2% 6 2.5% 1.16 (0.39-3.44) 0.80
GUSTO mild 43 13.4% 41 17.0% 1.32 (0.86-2.03) 0.20
BARC bleeding BARC 3 16 5.0% 6 2.5% 0.50 (0.20-1.28) 0.15
BARC 3c 1 0.3% 0 0.0% 0.0 0.99
BARC 3b 8 2.5% 1 0.4% 0.17 (0.02-1.33) 0.09
BARC 3a 7 2.2% 5 2.1% 0.96 (0.30-3.02) 0.94
BARC 2 23 7.1% 18 7.5% 1.06 (0.57-1.96) 0.86
BARC 1 19 5.9% 24 10.0% 1.74 (0.95-3.17) 0.07
Events within 30 days
MACCE 11 3.4% 4 1.7% 0.48 (0.15-1.51) 0.21
MACCE endpoint (after 
propensity score 
matching)
0.78 (0.48-1.28) 0.32
     All-cause death 1 0.3% 2 0.8% 2.67 (0.24-29.5) 0.42
    Cardiac death 1 0.3% 2 0.8% 2.67 (0.24-29.5) 0.42
    Non-cardiac death 0 0.0% 0 0.0%
Any myocardial infarction 4 1.2% 2 0.8 0.67 (0.12-3.64) 0.64
    STEMI 2 0.6% 1 0.4% 0.67 (0.06-7.38) 0.74
    NON-STEMI 2 0.6% 1 0.4% 0.67  (0.06-7.35) 0.74
    TVR CABG or PCI 4 1.2% 0 0.0% 0.00 0.14
     PCI TVR 3 0.9% 0 0.0%
    CABG TVR 1 0.3% 0 0.0%
Any stroke 3 0.9% 0 0.0% 0.00 0.26
    Ischaemic stroke 3 0.9% 0 0.0%
     Haemorrhagic stroke 0 0.0% 0 0.0%
     Stroke non-disabling 3 0.9% 0 0.0%
Any stent thormbosis 2 0.6% 1 0.4% 0.67 (0.06-7.35) 0.74
   Definite stent thrombosis 1 0.3% 0 0.0%
    Probable stent thrombosis 1 0.3% 1 0.4%
    Possible stent thrombosis 0 0.0% 0 0.0%
Table 3: MACCE = combination of all cause mortality, MI, TVR, stroke and stent thrombosis.
Values are n (%); % is calculated from the Kaplan-Meier curve
HR = Hazard Ratio; CI = confidence interval; STEMI= ST-elevation myocardial infarction
PCI = percutaneous coronary intervention, TVR = target vessel revascularization.
significant p values: * for P < 0.05
MI= Myocardial infarction
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Bridging therapy Periprocedural OAC HR (95% CI)  p-value
n = 322 n = 241
Bleeding events within 1 
year
Any bleeding event 95 29.8% 85 35.6% 1.26 (0.94-1.69) 0.12
Any bleeding event (after 
propensity score matching)
1.27 (0.93-1.73) 0.13
TIMI bleeding 
     TIMI Major 14 4.3% 11 4.6% 1.04 (0.47-2.30) 0.92
     TIMI Minor 62 19.3% 45 18.7% 0.97 (0.66-1.43) 0.90
     TIMI Minimal 30 9.3% 35 14.5% 1.61 (0.99-2.62) 0.06
GUSTO bleeding 
     GUSTO severe 9 2.8% 5 2.1% 0.73 (0.25-2.19) 0.59
     GUSTO moderate 18 5.6% 19 7.9% 1.43 (0·25-2.72) 0.28
    GUSTO mild 78 24.2% 66 27.4% 1.18 (0.85-1.64) 0.32
BARC bleeding
    BARC 3 30 9.3% 24 10.0% 1.07 (0.62-1.82) 0.82
    BARC 3c 3 0.9% 3 1.2% 1.33 (0,27-6,60) 0.73
    BARC 3b 12 3.7% 8 3.3% 0.88 (0.36-2.16) 0.79
     BARC 3a 15 4.7% 13 5.4% 1.16 (0.55-2.44) 0.69 
     BARC 2 49 15.2% 33 13.7% 0.90 (0.58-1.40)) 0.64
     BARC 1 28 8.7% 35 14.5% 1.73 (1.05-2.85) 0.03*
Any Blood transfusion 21 6.5% 17 7.1% 1,09° (0.55-2.12) 0.94
MACCE events within 1 
year
MACCE endpoint 52 16.1% 29 12.0% 0.72 (0.46-1.14) 0.16
MACCE endpoint (after pro-
pensity score matching)
0.78 (0.47-1.27) 0.31
All-cause death 17 5.3% 8 3.3% 0.63 (0.27-1.45) 0.27
    Cardiac death 7 2.2% 3 1.2% 0.57 (0.15-2.21) 0.41
     Non-cardiac death 10 3.1% 5 2.1% 0.67  (0.23-1.95) 0.46
Any myocardial infarction 16 5.0% 6 2.5% 0.49  (0.19-1.26) 0.14
     STEMI 3 0.9% 1 0.4%
     NON-STEMI 13 4.0% 5 2.1%
TVR CABG or PCI 26 8.1% 13 5.4% 0.65 (0.34-1.27) 0.21
PCI TVR 23 7.1% 10 4.1%
CABG TVR 3 0.9% 3 1.2%
Table 4: Adverse events after one year.
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Any Stroke 8 2.5% 3 1.2% 0.50 (0.13-1.87) 0.30
     Ischaemic stroke 7 2.2% 3 1.2%
     Hemorrhagic stroke 1 0.3% 0 0.0%
     Stroke disabling 3 0.9% 1 0.4%
     Stroke non-disabling 6 1.9% 2 0.8%
Any stent thormbosis 9 2.8% 4 1.7% 0.59 (0.18-1.92) 0.38
     Definite stent thrombosis 3 0.9% 1 0.4%
     Probable stent thrombosis 1 0.3% 1 0.4%
     Possible stent thrombosis 5 1.6% 2 0.8%
Table 4: Periprocedural OAC is the uninterrupted oral anticoagulation group. Values are n (%); % is calculated from the 
Kaplan-Meier curve. BARC: Bleeding Academic Research Consortium; CI: confidence interval; GUSTO: Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HR: Hazard Ratio; °: Odds ratio; PCI = 
percutaneous coronary intervention;  STEMI= ST-elevation myocardial infarction;  TVR = target vessel revascularization.
One patient suffered 2 strokes.
DISCUSSION
This report is the sixth large observational study on UAC or BT in patients undergoing 
PCI  in atrial fibrillation (9-13) (Online Table 3). Our main finding is that in patents 
treated with OAC  who require PCI, a peri-procedural strategy of UAC is not associated 
with more bleeding or ischemic complications as compared to a BT strategy at 30 
days or one year. These findings were consistent in the subset of patients with AF. 
Furthermore, peri-procedural INR was not associated with the occurrence of bleeding 
events or MACCE. The incidence of bleeding events was similar for both groups and 
the incidence of MACCE was slightly, but not significantly, lower in the UAC group. 
However, despite the fact that the difference in rates of MACCE did not reach statistical 
significance, the number needed to harm with BT strategy at one year follow-up was 
24, which we believe to be clinically relevant, especially since the alternative strategy 
of UAC is simpler. Patients were randomised to either double or triple therapy, but this 
had no impact on the present sub-analysis, since there was no significant difference in 
the number of patients on double and triple therapy within the investigated subgroups 
(47% vs. 53%, p=0.169)(Table 1). The adjustment with a propensity score revealed no 
significant differences in bleeding endpoint or MACCE after both 30 days and one year 
follow-up.
Recently, the safety and efficacy of BT has been evaluated in patients undergoing PCI 
and also in patients undergoing coronary angiography, pacemaker or defibrillator 
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implantation and pulmonary vein ablation (9-16). BT offered no advantages in 
any of these studies and possibly even increased bleeding events. Moreover, in the 
Atrial fibrillation undergoing coronary stenting (AFCAS) trial, the number of access 
site bleeding after PCI was higher in the BT group (9).  BT was also associated with 
prolonged hospitalisation and caused delay for an eventual invasive strategy in OAC 
patients with ACS (17,18). Therefore, a BT strategy seems to offer no advantages over 
UAC, while it does carry disadvantages.  
In contrast to coronary angiography or device implantation, PCI procedures also require 
procedural anticoagulation to avoid thrombotic complication during the intervention 
such as acute stent thrombosis (1). Theoretically, warfarin could replace LMWH and 
UFH, which are traditionally used as peri-procedural anticoagulation, since warfarin 
is known to increase to activated clotting time in a predicable fashion (19). Three other 
advantages of PCI with an UAC strategy are I) avoidance of potential thromboembolic 
complications such as stroke, which are associated with periods of subtherapeutic 
anticoagulation, II) elimination of a period of transient prothrombotic state due to 
protein C and S suppression after warfarin re-initiation (1) and III) avoidance of a time 
frame of excess bleeding risk when patients are given a short period of quadruple therapy 
(OAC, clopidogrel, aspirin and heparin) after the intervention until a therapeutic INR 
is reached. Finally, the UAC strategy offers a potential economic benefit by reducing 
hospitalisation with a few days, which are normally necessary for INR to return 
therapeutic levels (9,18). In the present study, mean hospitalisation time after PCI 
did not differ significantly in patients after elective stenting. However, hospitalisation 
was slightly longer in patients treated with UAC strategy who underwent PCI for ACS. 
This is contrary to what one would expect, but it could be a consequence of the severity 
of the disease rather than the time needed to re-initiate warfarin therapy. 
In this study, UFH was administered peri-procedurally in most patients undergoing 
PCI, whereas theoretically it could be considered to perform PCI without additional 
heparin in patients with therapeutic warfarin anticoagulation. Treating physicians did 
not avoid additional heparin bolus during PCI in most patients included in the present 
study, probably because of fear for peri-procedural thromboembolic complications 
such as stent thrombosis. On the one hand this additional heparin bolus could be 
a possible explanation for the high bleeding rate observed in both the UAC and BT 
groups and is also a possible explanation for the higher than expected bleeding rates in 
the original WOEST trial (4). On the other hand, it was recently shown that in patients 
receiving OAC who underwent transradial coronary angiography, the rate of radial 
artery occlusion is higher when these patients do not receive additional standard 
intravenous UFH bolus (20).  For the time being, the question whether a heparin bolus 
has to be given in patients with therapeutic INR requiring PCI remains unanswered. 
And if a heparin bolus is necessary, it is unclear what the optimal dosage would be. 
In the absence of randomised controlled trials comparing these two treatment 
strategies, the only available evidence comes from a few non-randomised studies 
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addressing this subject (Online Table 3 appendix table 7) In earlier reports, such 
as the AFCAS registry and the randomised Prospective Balloon Angioplasty and 
Anticoagulation (BAAS) study, the simple UAC strategy proved at least as safe as the 
more complex BT strategy (9,10). In the AFCAS registry that is designed to study AF 
patients undergoing PCI, 290 patients were treated with the UAC strategy and 161 
with the BT strategy. The conclusion was that UAC did not increase peri-operative 
bleeding nor thrombotic complications during PCI and that UAC was a simple and 
cost-effective alternative to BT (9). In the BAAS study, therapeutic INR levels (2,1-4,8) 
did not lead to higher MACCE or bleeding rate in 530 patients (12).  Also, three other 
studies including PCI patients confirm these findings and support the view that the 
UAC is a safe and cost efficient strategy in this patient subset and therefore should be 
the preferred strategy (11-13).
Published guidelines on this subject are confusing since they sometimes contain 
recommendations with opposing regimens and others even completely ignore this 
clinical challenge. Before 2010, there was a consensus that BT was to be used with 
preferably a peri-procedural INR <2.0 or even below 1.5 (21-23). In the 2005 European and 
American PCI guidelines no recommendations were made concerning this issue (24,25). 
Only recently, the 2010 European Society of Cardiology Working Group on Thrombosis 
guideline was the first to clearly recommended uninterrupted OAC as the preferred 
strategy in patients with AF undergoing PCI. Furthermore, this guideline recommended 
the radial approach as the first choice during therapeutic anticoagulation, because of 
lower rates of bleeding and possibly even mortality, especially in STEMI patients (1,26). 
This study has several limitations.  This is a non-randomised study with its inherent 
bias.  Since patients were not randomized to a UAC or BT strategy, the decisions 
made are always a result of risk-weighing in an individual patient by the patient’s 
treating physician.  In addition to the differences in peri-procedural use of OAC, other 
differences in the patient management during the one-year follow-up may account for 
modification of the final results. Even though propensity score analysis did not reveal 
any differences in the results, we can never be sure to have corrected for all baseline, 
procedural and other differences that influence outcome. Second, there is no universal 
definition of bridging therapy in this study, since every participating hospital had its 
own bridging protocol. Third, the number of patients included is relatively low and there 
was no power calculation for this sub-analysis. Nevertheless, this patient sub-analysis 
is the largest patient cohort up to now in which the question of peri-procedural UAC vs. 
BT was addressed.  Fourth, we do not have information on how many patients were in 
the therapeutic range before PCI, because control of the international normalised ratio 
(INR) was left to the specialised thrombosis service, which operates independently 
from hospitals in the Netherlands. We do know from the RELY trial,  however, that 
the quality of OAC control by this service is good, with a mean of 70% of patients in 
the therapeutic range at any given time (27). Fifth, since the study was designed in 
2008, the definition of peri-procedural MI is based on the (2nd) universal definition 
and not the most recent one out of 2012 (8). Also, this study was designed before the 
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HAS-BLED score and the CHADS 2VASC score were established and therefore, they 
could not used to estimate bleeding risk and make decisions about the use of oral 
anticoagulants (1). And finally, some data are lacking, such as the use of vitamin K to 
reverse anticoagulation, simply because these data were not collected. 
CONCLUSION
Performing PCI with a UAC strategy was not associated with an increase of the 
number of bleeding events or MACCE in this study. Furthermore, bleeding or 
MACCE were not related to INR levels. This is the largest study up to now to support 
the recommendations of the 2010 consensus of the European Society of Cardiology 
Working Group on Thrombosis to adopt a peri-procedural strategy of continuing OAC 
in a therapeutic window during PCI in patients with long term OAC indication. 
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APPENDIX
Appendix consists of Appendix A: “Variables used in the propensity score analysis” 
and Appendix B: Online Figure 1, Online Figure 2, Online Table 1, Online Table 2 and 
Online Table 3.
Appendix A: Variables used in the propensity score analysis. 
Section statistical analysis
The following variables were included in the propensity score analysis: age, gender, 
BMI, current smoker, history of MI, aspirin use at baseline, OAC use at baseline, 
clopidogrel use at baseline, ECG rhythm at baseline, ECG ST-T-segment changes, radial 
or femoral access, omeprazol use at baseline, number of vessels treated, pre-dilatation, 
stent type, stent length, maximum balloon pressure stent placement, post-dilatation, 
visible thrombus pre-PCI, calcified lesion, ACC/AHA lesion type, TIMI flow post 
procedure, peri-procedural UFH bolus, peri-procedural LMWH use, peri-procedural 
glycoprotein2b3a (GP2b3a) blocker use, and acute coronary syndrome at baseline.
Appendix B:
Online Figure 1 Appendix Figure 3: Periprocedural OAC vs. bridging in AF patient 
subgroup: Bleeding Endpoint: Any bleeding during one year follow-up. 
Red line = Bridging Therapy. Black line: Uninterrupted Oral Anticoagulation
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Online Figure 1: Periprocedural OAC vs. bridging in AF patient subgroup: Bleeding Endpoint: Any 
bleeding during one year follow-up. 
Red line = Bridging Therapy. Black line: Uninterrupted Oral Anticoagulation
Online Figure 2 Periprocedural OAC vs. bridging in AF patient subgroup: MACCE (death,  
myocardial infarction, stroke, target vessel revascularization and stent thrombosis) during  
one year follow-up. 
Red line = Bridging Therapy. Black line: Uninterrupted Oral Anticoagulation
Online Figure 1: Periprocedural OAC vs. bridging in AF patient subgroup:
Online Figure 2 Periprocedural OAC vs. bridging in AF patient subgroup: 
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C H A P T E R  4
Individualizing antiplatelet treatment

Tailored P2Y12 inhibitor treatment in patients  
undergoing non-urgent PCI - The POPular Risk  
Score Study
4 . 1
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A B S T R A C T
Background
Patients undergoing non-urgent percutaneous intervention (PCI) with stent 
implantation are treated with aspirin and the P2Y12 inhibitor clopidogrel. Due to the 
wide variability in response to clopidogrel, many patients have high platelet reactivity 
on-treatment and are therefore at increased thrombotic risk. The use of prasugrel 
instead of clopidogrel can overcome high platelet reactivity, but is associated with a 
higher bleeding risk. We developed the POPular Risk Score to tailor P2Y12 inhibitor 
treatment. The score is based on platelet reactivity (VerifyNow P2Y12 assay), CYP2C19 
genotyping and clinical risk factors.
Objective
To evaluate the use of the POPular Risk Score for selective intensification of P2Y12 
inhibitor treatment after non-urgent PCI with respect to efficacy and safety.
Methods
In this prospective cohort study, patients with a high risk score were treated with 
prasugrel and patients with a low risk score with clopidogrel. The risk score guided 
cohort was compared to a historic cohort of clopidogrel-treated patients. A combined 
thrombotic endpoint consisting of all-cause death, myocardial infarction, stroke or 
stent thrombosis and TIMI major and minor bleeding events during 1 year of follow-
up were compared.
Results
A total of 1127 patients were included in the guided cohort, 26.9% of whom were 
switched to prasugrel according to the POPular Risk score. The historic cohort 
contained 893 patients. The incidence of the combined thrombotic endpoint was 
significantly lower in the guided cohort (Odds ratio (OR) 0.42, 95% confidence interval 
(CI): 0.28 – 0.62).  This strategy was safe in this study (OR 0.32 [95% CI: 0.17 – 0.58] 
for TIMI major or minor bleeding). Results were comparable after multivariate and 
propensity score matched and weighted analysis.
Conclusion
Selective intensification of P2Y12 inhibitor treatment after non-urgent PCI based on 
the POPular Risk Score is associated with a reduction in thrombotic risk without an 
increase in bleeding risk.
4.1
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A B B R E V I A T I O N S  A N D  A C R O N Y M S :
ACS = acute coronary syndrome  
CI = confidence interval 
HPR = high platelet reactivity 
OR = odds ratio 
PCI = percutaneous coronary intervention 
POPular = Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pre-
treated Patients Undergoing Elective PCI  
TIMI = Thrombolysis In Myocardial Infarction 
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I N T RODUC T ION
Current guidelines recommend the use of dual antiplatelet therapy consisting of aspirin 
and the P2Y12-inhibitor clopidogrel for patients undergoing non-urgent percutaneous 
coronary intervention (PCI) with stent implantation.1 However, pharmacodynamic 
studies show wide variability in the patients’ response to clopidogrel, and high platelet 
reactivity (HPR) while on clopidogrel treatment is associated with stent thrombosis, 
myocardial infarction and death after stenting.2-6 
Part of the variability in platelet reactivity on clopidogrel is due to its metabolism. 
Clopidogrel is a pro-drug that depends on cytochrome P450 isoenzyms for its 
activation. The CYP2C19 enzym in particular plays an important role in clopidogrel’s 
effect on platelet reactivity. There are different defective polymorphisms of the gene 
encoding this enzym, of which the loss-of-function CYP2C19*2 and *3 alleles are the 
most common. Both alleles are associated with higher levels of platelet reactivity and a 
higher incidence of thrombotic events in patients treated with clopidogrel (in particular 
in those who have a high baseline risk for experiencing coronary thrombosis).7-10
The more potent P2Y12 inhibitors prasugrel and ticagrelor might be used to improve 
clinical outcome in PCI patients. Both prasugrel and ticagrelor show less inter-
individual variability in platelet inhibition, are not influenced by CYP2C19 loss-of-
function polymorphisms and reduce thrombotic events as compared to clopidogrel 
in acute coronary syndrome (ACS) patients. However, this reduction in thrombotic 
events comes at the cost of an increase in bleeding events.11,12
After the Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-
Pretreated Patients Undergoing Elective PCI (POPular) study was finished in our center 
and its results showed that HPR was associated with adverse outcomes following PCI, 
the POPular Risk Score was designed.3 The aim of this score is to identify non-urgent 
PCI patients treated with clopidogrel who are at high thrombotic risk, to select them 
for treatment with a stronger P2Y12 inhibitor. Our hypothesis was that this strategy 
of selective intensification of P2Y12 inhibitor treatment reduces thrombotic events 
without substantially increasing the rate of serious bleeding events. To study the 
efficacy of the risk score based strategy we aimed to compare thrombotic and bleeding 
rates of a risk score guided cohort as compared to a historic cohort in which treatment 
was not tailored based on this risk score.
M E T H O D S
The components of the POPular Risk Score are shown in Figure 1. Platelet reactivity 
was measured using the VerifyNow® P2Y12 assay (Accumetrics, San Diego, California, 
USA). Based on the results of the POPular study, in which arterial blood was sampled 
before PCI, the cut-off value for HPR was defined as ≥236 P2Y12 reaction units (PRU).
3 
The CYP2C19 genotype was determined using a validated TaqMan StepOnePlus assay. 
4.1
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Patients were classified as extensive metabolizer (CYP2C19 *1/*1), intermediate 
metabolizer (CYP2C19 *1/*2 or *1/*3) or poor metabolizer (CYP2C19 *2/*2, *2/*3 or 
*3/*3).7 The clinical risk factors diabetes mellitus3,13-16, adjoined length of stents of 
>30mm17,18 and a reduced left ventricular ejection fraction16 were also included in the 
risk score.
Patients were given 2 points for HPR or CYP2C19 poor metabolizer phenotype, 1 point 
for CYP2C19 intermediate metabolizer phenotype and 0.5 point each for the presence 
of diabetes mellitus, (adjoined) length of stent(s) >30mm or a left ventricular ejection 
fraction <30%. In patients with a risk score of ≥2, the patient’s treating physician was 
advised to switch to prasugrel; patients with a risk score <2 continued clopidogrel 
treatment for 1 year. The risk score was introduced in routine clinical practice in our 
center in July 2010.
Study populations
We compared two prospectively collected cohorts containing data from patients 
with established coronary artery disease undergoing non-urgent PCI with stent 
implantation in the St. Antonius Hospital in Nieuwegein, the Netherlands. All 
patients were adequately treated with clopidogrel (75 mg daily for ≥5 days, or a loading 
dose of 300 mg ≥6h or 600 mg ≥2h) and aspirin (80-100 mg daily) prior to platelet 
function testing. The following exclusion criteria were used: patients undergoing 
urgent revascularization, defined as patients with ACS with positive troponin value 
in the last 14 days before PCI, patients with a history of stroke or transient ischemic 
attack, patients who were treated with an oral vitamin K antagonist or non-vitamin K 
Figure 1: the POPular Risk Score.
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antagonist oral anticoagulants, patients with a platelet count <100 x 109/L and patients 
who had been treated with a glycoprotein IIb/IIIa-inhibitor before a blood-sample could 
be collected. The study was conducted according to the principles of the Declaration of 
Helsinki and received approval from the human research ethics committee Verenigde 
Commissies Mensgebonden Onderzoek. Approval for this registry included a waiver 
of informed consent.
Guided cohort: study group with treatment adjustment
The guided cohort included consecutive patients who underwent non-urgent PCI with 
stent placement in whom the POPular Risk Score was determined between 5 July 2010 
and 30 May 2013 in the St. Antonius Hospital (Nieuwegein, the Netherlands). Baseline 
characteristics such as cardiovascular risk factors and co-morbidities were recorded 
for each patient. A blood sample was taken either by venapunction, from the arterial 
sheath or through an intravenous line before or shortly after PCI. The first 5mL of blood 
was discarded, after which a 2mL 3.2% citrate tube, two K3-EDTA anticoagulated tubes 
(one 3mL and one 4.5mL tube) and a 4mL lithium heparin anticoagulated tube were 
filled. Hemoglobin, hematocrit, platelet count (EDTA whole blood) and renal function 
(lithium heparin plasma) values were determined and the VerifyNow® assay (citrate 
whole blood) was performed. Genomic DNA was isolated from EDTA whole blood from 
a separate tube to identify the presence of a CYP2C19*2 and/or *3 allele. The POPular 
Risk Score was calculated and for each patient with a score ≥2 and a body weight ≥60 
kg and age <75 years, the treating physician was advised to switch from clopidogrel to 
prasugrel 10mg once daily. For patients with a score ≥2 and a body weight <60 kg or 
age ≥75 years, the use of prasugrel 5mg once daily was advised.19 The recommended 
duration of dual antiplatelet therapy was 1 year for all patients. Decisions regarding 
management of dual antiplatelet therapy during follow-up were at the discretion of 
the treating physician. Follow-up was obtained from the patient’s medical records 
regarding hospital admissions and outpatient department visits. The patient’s general 
practitioner or the patient was contacted when deemed necessary to complete follow-
up.
Historic cohort: control group without treatment adjustment
The historic cohort included patients from the POPular study, which was performed 
between December 2005 and December 2007.3 Comparable to the guided cohort, 
all patients underwent non-urgent PCI with stent implantation in the St. Antonius 
Hospital. Following PCI, multiple platelet function tests and CYP2C19 genotyping 
were performed and all patients were treated with clopidogrel for 1 year. Follow-up 
was obtained by telephone contact with all patients at 30 days and 12 months and 
verified using source documents from medical records during this study. The POPular 
Risk Score was retrospectively calculated in this historic cohort.
4.1
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Follow-up and endpoints
Follow-up for the occurrence of adverse events was acquired for 1 year after PCI in both 
cohorts. The primary endpoint of this study was a combined thrombotic endpoint, 
which consisted of all-cause death, nonfatal nonprocedural myocardial infarction, 
nonfatal ischemic stroke and nonfatal nonprocedural definite stent thrombosis. An 
event was deemed procedural if it occurred within 24 hours of the PCI procedure. 
Non-procedural events were included in the endpoint because the strategy employed in 
the guided cohort would not be able to prevent events occurring due to the procedure, 
as treatment was altered after PCI. Myocardial infarction was defined as the occurrence 
of ischemic symptoms and a spontaneous troponin T value (i.e., not periprocedural) or 
creatine kinase myocardial band level above the upper reference limit.
Stent thrombosis was defined according to the Academic Research Consortium 
statement.20 Bleeding events were recorded and classified according to Thrombolysis 
In Myocardial Infarction (TIMI) bleeding criteria (major or minor) in both cohorts.21 
For the historic cohort, all end points were adjudicated through review of medical 
records and source documents by an independent committee blinded for platelet 
function data.
Statistical analysis
Data are presented as mean ± standard deviation (SD) for continuous variables 
and as counts (percentages) for categorical variables. Creatinine clearance was 
calculated in all patients using the Modification of Diet in Renal Disease formula. 
A decreased kidney function was defined as an estimated creatinine clearance <60 
mL/min. The chi-square test was used to detect differences in categorical variables. 
Normally distributed continuous variables were compared with a two-sided unpaired 
t-test and non-normally distributed variables were compared using a two-sided 
Wilcoxon test. Multivariate logistic regression analysis was performed to adjust for 
potential confounders. All univariate variables with a p-value <0.10 were included in 
multivariable analysis.
The guided and historic cohorts were compared in total, but comparisons were also 
made based on stratification by high and low risk score, both within cohorts and 
between the guided and historic cohort.
Propensity matching was performed through propensity score calculation using 
generalized boosted regression in a fixed 1:1 matching ratio by using the R add-on 
TWANG package.22 All statistical analyses were performed with R (version 3.1, 
http://www.r-project.org). Two sided p-values <0.05 were considered significant. The 
authors had full access to the data and take full responsibility for the integrity of the 
data. All authors have read and agreed to the manuscript as written. 
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In the guided cohort, smoking was significantly more common (22.0% versus 
11.2%, p<0.001) and the incidence of hypertension (83.3% versus 77.5%, p=0.001) 
and hypercholesterolemia (91.8% versus 80.7%, p<0.001) was higher. There was 
significantly more use of proton-pump inhibitors in the guided cohort and patients 
in the guided cohort less often had a decreased kidney function (10.5% versus 17.0%, 
p<0.001) or a history of myocardial infarction (31.2% versus 56.4%, p<0.001). Blood 
was sampled for platelet function testing either before PCI (59.1%) or shortly after PCI 
(40.9 %) in the guided cohort, and before PCI in all patients in the historic cohort. In 
the guided cohort, 791 patients (70.2%) had a low and 336 patients (29.8%) had a high 
risk score; the historic cohort included 528 patients (59.1%) with a low and 365 patients 
(40.9%) with a high risk score (Table 2). The differences in baseline characteristics 
between patients with a high and low risk score within both cohorts are shown in 
Appendix I and II.
Table 1: Baseline characteristics of the guided and the historic cohort
Baseline characteristics Guided Historic
N = 1127 N = 893 p-value
Clinical parameters
Age (years) 63.9 ± 10.8 63.7 ± 10.5   0.687
BMI (kg/m^2) 27.5 ± 4.2 27.2 ± 3.9   0.099 
Male gender 849 (75.3%) 666 (74.6%)   0.737
Hypertension 939 (83.3%) 692 (77.5%)   0.001
Hypercholesterolemia 1035 (91.8%) 721 (80.7%) <0.001
Family history of CAD 563 (50.0%) 543 (60.8%) <0.001
Diabetes Mellitus 237 (21.0%) 167 (18.7%)   0.214
Current smoking 248 (22.0%) 100 (11.2%) <0.001
Previous myocardial infarction 352 (31.2%) 504 (56.4%) <0.001
Previous CABG 132 (11.7%) 81 (9.1%)    0.065
LVEF   0.642
 <30% 17 (1.5%)  15 (1.7%)
 30% - 49% 161 (14.3%) 140 (15.7%)
 ≥50% 949 (84.2%) 738 (82.6%)
Medication
ASA 1104 (98.0%) 866 (97.0%)   0.205
Clopidogrel loading dose* 395 (35.0%) 446 (49.9%) <0.001
Proton Pump inhibitor use 456 (40.5%) 245 (27.4%) <0.001
Calcium Antagonist 314 (28.0%) 343 (38.4%) <0.001
Beta-blocker 902 (80.5%) 682 (76.4%)   0.027
ACE-inhibitor 422 (37.7%) 317 (35.5%)   0.336
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AT-II antagonist 204 (18.2%) 0 (0%) <0.001
Lipid lowering treatment 1019 (90.4%) 707 (79.2%) <0.001
PCI procedure
Sheath size <0.001
- 6F 1083 (97.0%) 761 (85.4%)
- 7F 34 (3.0%) 130 (14.6%)
Arterial access-site <0.001
- Femoral 1014 (91.2%) 864 (99.3%)
- Radial 98 (8.8%) 6 (0.7%)
Number of segments treated
- 1
- 2
- 3
- ≥4
918 (82.1%)
174 (15.6%)
23 (2.1%)
3 (0.3%)
611 (68.4%)
226 (25.3%)
51 (5.7%)
5 (0.6%)
<0.001
Number of stents used
- 1
- 2
- 3
- 4
- ≥5
Total stent length (mm)
739 (66.1%)
285 (25.5%)
66 (5.9%)
21 (1.9%)
7 (0.6%)
26.4 ± 17.9
533 (59.8%)
234 (26.3%)
89 (10.0%)
28 (3.1%)
7 (0.8%)
28.2 ± 16.9
  0.002
  0.019
Treated vessel(s):
- LAD 500 (44.4%) 434 (48.6%)   0.064
- RCA
- RCx
421 (37.4%)
320 (28.4%)
329 (36.8%)
292 (32.7%)
  0.849
  0.041
Stent type BMS only 128 (11.4%) 326 (36.7%) <0.001
Bifurcation lesion 198 (17.6%) 30 (3.4%) <0.001
Laboratory Parameters
Hemoglobin 8.6 ± 0.9 8.5 ± 0.9   0.014
Renal function (MDRD)
- eGFR >60
- eGFR 30-60
- eGFR <30
1000 (89.5%)
108 (9.7%)
9 (0.8%)
680 (83.0%)
126 (15.4%)
13 (1.6%)
<0.001
eGFR MDRD (ml/kg/1.73m^2) 85.8 ± 21.8 75.0 ± 18.5 <0.001
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Table 1: Baseline characteristics. Baseline characteristics of patients in the guided and historic 
cohorts. Continuous variables are presented as mean ± SD. Categorical data are reported as frequencies 
(percentages). Numbers do not add up for all variables as missing data are not reported. Abbreviations: 
ACE = angiotensin-converting enzyme, AT-II = angiotensine II, BMI = body mass index, BMS = 
bare-metal stent, CABG = coronary artery bypass grafting, CAD = coronary artery disease, eGFR MDRD 
= estimated Glomerular Filtration Rate according to the MDRD formula, LAD=left anterior descending 
artery, LVEF = left ventricular ejection fraction, N = number of patients, RCA = right coronary artery, 
RCx = circumflex artery. 
* Patients who received a clopidogrel loading dose of 300mg ≥12 hours or 600 mg ≥6 hours before 
platelet function testing, as opposed to a maintenance dose of 75mg started ≥5 days before platelet 
function testing
Figure  2:  This figure shows the incidence of the combined thrombotic endpoint stratified by POPular 
Risk score for both the historic cohort (left) and the guided cohort (right). The groups of patients with 
risk scores 4.5 and 5.0 were combined with patients with a risk score of 4.0 due to the small number 
of patients in these groups. Orange signifies that these patients were advised to be treated with 
clopidogrel and purple signifies that the patients were advised to use prasugrel.
Figure 2: Combined thrombotic endpoint stratified by POPular Risk Score
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Guided Historic
N = 1127 N = 893 p-value
PRiS score
Mean (IQR) 0.5 (0.0; 2.0) 1.0 (0.0; 2.5) <0.001
- Low risk score (<2 points) 791 (70.2%) 528 (59.1%) <0.001
- High risk score (≥2 points) 336 (29.8%) 365 (40.9%)
Platelet reactivity
VerifyNow P2Y12 assay PRU 182 ± 96 PRU 211 ± 76 <0.001
HPR (PRU ≥236) 326 (28.9%) 356 (39.9%) <0.001
CYP2C19 metabolizer status   0.756
- Extensive Metabolizer (*1/*1) 822 (73.1%) 627 (71.8%)
- Intermediate Metabolizer (*1/*2, *1/*3) 274 (24.4%) 225 (25.8%)
- Poor Metabolizer (*2/*2, *2/*3, *3/*3) 29 (2.6%) 21 (2.4%)
Clinical characteristics
LVEF <30% 17 (1.5%)  15 (1.7%)   0. 899
Adjoined stent length >30mm 218 (19.3%) 221 (24.7%)   0.004
Diabetes Mellitus 237 (21.0%) 167 (18.7%)   0.214
Table 2: Continuous variables are presented as mean ± SD unless stated otherwise. Categorical data 
are reported as frequencies (percentages). Numbers do not add up for all variables as missing data 
are not reported. Abbreviations: HPR = high platelet reactivity, IQR=interquartile range,  LVEF = left 
ventricular ejection fraction, N = number of patients, OR = odds ratio, PCI = percutaneous coronary 
intervention, PRU = P2Y12 Reaction Units, and 95% CI = 95% confidence interval.
Table 2: POPular Risk Score in the guided and the historic cohort
R E S U L T S
A total of 1127 patients were included in the risk-score guided cohort. One-year follow-
up was complete in 1119 patients (99.3%). For patients with a high risk score who 
were advised to switch from clopidogrel to prasugrel, the switch was made in 304 out 
of the 336 patients (90.5%). In the remaining patients, the reason for not switching 
was not registered in the patient records. The historic cohort contained 893 patients 
who fulfilled the in- and exclusion criteria that were used for the guided cohort. 
One-year follow-up was available for all of these patients. Baseline characteristics of 
both cohorts are shown in Table 1. Age, gender, body mass index, diabetes mellitus, 
left ventricular ejection fraction, the use of acetylsalicylic acid and ACE-inhibitors and 
a history of coronary artery bypass grafting surgery were not significantly different 
between both cohorts.
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Endpoints Guided cohort Historic cohort
N = 1127 N = 893
Combined thrombotic endpoint
- Rates
 - Low risk score (<2) 25 (3.2%) 24 (4.5%)
 - High risk Score (≥2) 17 (5.1%) 51 (14.0%)
 - Overall 42 (3.7%) 75 (8.4%)
- Univariate analysis
- Multivariable analysis*
OR 0.42 (95% CI: 0.28 – 0.62)
OR 0.45 (95% CI: 0.30 – 0.67)
- Propensity weigthedy
- Propensity score matchedz
OR 0.52 (95% CI: 0.29 – 0.92)
OR 0.51 (95% CI: 0.29 – 0.87)
All-cause death 16 (1.4%) 17 (1.9%)
Myocardial infarction 23 (2.0%) 52 (5.8%)
Stroke 7 (0.6%) 9 (1.0%)
Definite stent thrombosis 2 (0.2%) 10 (1.1%)
Nonprocedural TIMI major  
bleeding
-Rates
 - Low risk score (<2) 3 (0.4%) 15 (2.8%)
 - High risk Score (≥2) 5 (1.5%) 7 (1.9%)
 - Overall 8 (0.7%) 22 (2.5%)
- Univariate analysis
- Multivariable analysisx
- Propensity weightedy
OR 0.28 (95% CI: 0.12 – 0.61)
OR 0.40 (95% CI: 0.16 – 0.93)
OR 0.41 (95% CI: 0.15 – 1.12)
- Propensity score matchedz OR 0.34 (95% CI: 0.15 – 0.72)
Nonprocedural TIMI major or 
minor bleeding
-Rates
 - Low risk score (<2) 9 (1.1%) 20 (3.8%)
 - High risk Score (≥2) 6 (1.8%) 16 (4.4%)
 - Overall 15 (1.3%) 36 (4.0%)
Table 3: Clinical endpoints
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Combined thrombotic endpoint
The combined thrombotic endpoint occurred in 42 patients (3.7%) in the guided 
cohort versus 75 patients (8.4%) in the historic cohort (p<0.001)(Table 3). Figure 2 
shows the higher incidence of thrombotic events in patients with a risk score >2 in the 
historic cohort as compared to the guided cohort.
Focusing on the patients with a low risk score, treated with clopidogrel in both cohorts, 
the combined thrombotic endpoint occurred in 25 patients in the guided cohort (3.2%) 
versus 24 patients (4.5%) in the historic cohort (p=0.195). In contrast, in the patients 
with a high risk score the combined thrombotic endpoint occurred in 17 patients in 
the guided cohort (5.1%) - who were advised to use prasugrel - versus 51 patients in the 
historic cohort (14.0%) treated with clopidogrel (p<0.001)(Figure 3).
Univariate analysis showed an odds ratio (OR) of 0.42 (95% confidence interval (CI): 
0.28 – 0.62) for the occurrence of the combined thrombotic endpoint in the guided 
cohort as compared to the historic cohort. The results of multivariate logistic regression 
showed similar results with an OR of 0.45 (95% CI: 0.30 – 0.67). Propensity weighted 
analysis and propensity score matched analysis, which included 440 patients in both 
cohorts, both showed results that were consistent with the multivariable analysis (OR 
0.52 and 0.51, respectively).
- Univariate analysis
- Multivariable analysisx
- Propensity weigthedy
OR 0.32 (95% CI: 0.17 – 0.58)
OR 0.42 (95% CI: 0.22 – 0.80)
OR 0.43 (95% CI: 0.19 – 0.93)
- Propensity score matchedz OR 0.69 (95% CI: 0.25 – 1.83)
Table 3. The rates of the clinical endpoints and results from the univariate, multivariate and 
propensity analyses.
* Corrected for age, history of CABG, Risk score ≥2 and Hb.
x Corrected for age and the use of BMS stents only.
y Analysis weigthed based on a propensity score including the following factors: age, gender, body 
mass index, diabetes mellitus, current smoking, hypercholesterolemia, hypertension, family history of 
coronary artery disease, previous myocardial infarction, previous coronary artery bypass grafting 
surgery, MDRD estimated glomerular filtration rate, use of bare metal stents only, treatment of a 
bifurcation lesion, PCI of the LAD, PCI of the RCx, number of segments treated, total stent length, 
total amount of stents used, calcium antagonist use, proton pump inhibitor use, lipid lowering drug 
use, hemoglobin level.
z A total of 440 patients matched based on a propensity score including the factors mentioned under y.
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Figure 3: The combined thrombotic endpoint stratified by cohort and risk score
Figure 3 shows the incidence of the combined thrombotic endpoint for the high (filled) and low (hatched) 
risk score patients in both the guided cohort (purple) and the historic cohort (orange).
Figure 4 shows the incidence of TIMI major bleeding for the high (filled) and low (hatched) risk score 
patients in both the guided cohort (purple) and the historic cohort (orange).
Figure 4: TIMI major bleeding stratified by cohort and risk score
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Bleeding complications
With regard to bleeding complications, the event rate of nonprocedural TIMI major 
bleeding was significantly lower in the guided cohort (8 patients [0.7%]) as compared to 
the historic cohort (22 patients [2.5%], OR 0.28, 95% CI: 0.12 – 0.61)(Figure 4). None 
of these patients experienced intracranial bleeding. The difference between the guided 
and historic cohort remained significant after multivariable analysis and propensity 
matched analysis and was no longer significant in the propensity weighted analysis 
(Table 3). In patients from the guided cohort with a high risk score, who were advised 
to use prasugrel, nonprocedural TIMI major bleeding occurred in 5 (1.5%) patients, 
while TIMI major bleeding occurred in 3 (0.4%) patients with a low risk score treated 
with clopidogrel (OR 3.97, 95% CI: 0.97 – 19.43). In the historic cohort, in which 
all patients were treated with clopidogrel, no significant difference was observed in 
nonprocedural TIMI major bleeding between the high and the low risk group (7 [1.9%] 
versus 15 [2.8%] patients, OR 0.67, 95% CI: 0.25 – 1.60).
The combined nonprocedural TIMI major or minor bleeding endpoint occurred in 15 
patients (1.3%) in the guided cohort versus 36 patients (4.0%) in the historic cohort 
(OR 0.32, 95% CI: 0.17 – 0.58)(see figure in Appendix III). This difference also 
remained significant after multivariable analysis and propensity weighted analysis, 
while it was no longer significant in the propensity matched analysis. There was no 
significant difference between patients with a high and low risk score in the guided 
cohort (1.8% versus 1.1%, OR 1.58, 95% CI: 0.53 – 4.42) and the historic cohort 
(4.4% versus 3.8%, OR 1.16, 95% CI: 0.59 – 2.27). 
 
D I S C U S S I O N
The POPular Risk Score, based on the VerifyNow P2Y12 point-of-care platelet function 
test, CYP2C19 genotyping and clinical risk factors, was developed to discriminate 
between patients treated with clopidogrel with a high risk versus a low risk of thrombotic 
events after non-urgent PCI with stenting. Selective intensification of P2Y12 inhibitor 
treatment based on this risk score was associated with a reduction in the occurrence 
of thrombotic events; mainly driven by a reduction in nonprocedural myocardial 
infarction and stent thrombosis. Moreover, this strategy did not result in an increased 
incidence of bleeding events. The reduction in thrombotic events with prasugrel is in 
line with the findings of the Trial to Assess Improvement in Therapeutic Outcomes by 
Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 
(TRITON–TIMI) 38 study that investigated the use of clopidogrel versus prasugrel in 
ACS patients undergoing PCI.11 
There was a non-significant difference in TIMI major bleeding between the 
prasugrel-treated high risk score group and the clopidogrel-treated low risk score 
group of the guided cohort. Furthermore, the rate of TIMI major bleeding was not 
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significantly different between the high risk groups of the guided cohort and the 
historic cohort (1.5% versus 1.9%, p=0.662). The incidence of major bleeding events was 
low in both cohorts. In the TRITON-TIMI 38 study, performed to study the differences 
in thrombotic and bleeding events between patients treated with clopidogrel or 
prasugrel, a significant but small increase in major bleeding was associated with the 
use of prasugrel. Tailoring of antiplatelet therapy using the POPular Risk score – which 
leads to prasugrel use in approximately 1/3 of patients – is therefore unlikely to cause 
a clinically relevant increase in bleeding events. 
Given the much higher costs of treatment with prasugrel and ticagrelor compared to 
generic clopidogrel, a selective intensification of antiplatelet treatment might also be 
cost effective.11,12
To our knowledge, this is the first study in which antiplatelet treatment was tailored 
based on a combination of platelet reactivity, CYP2C19 phenotype and clinical 
risk factors. Tailoring based on platelet function testing alone has been tested in 
the Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And 
Safety (GRAVITAS) trial, in which patients with HPR were treated with double dose 
clopidogrel. Although this strategy was associated with a moderate reduction in 
HPR, no improvement in clinical outcome was found.23 The Assessment by a Double 
Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-
guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption 
versus Continuation One Year after Stenting (ARCTIC) trial also did not show any 
improvement in clinical outcome using a strategy based on platelet function testing, 
although this study also used doubled doses of clopidogrel in most patients with HPR.24 
Another limitation of  randomized clinical trials performed so far, is the low event rate 
in the selected populations. Therefore, changing treatment in only approximately 30% 
of patients (patients with HPR) may not result in a significant difference. A recent 
meta-analysis also revealed that the magnitude of the association between HPR and 
the risk of major adverse cardiovascular events is strongly dependent on the level 
of cardiovascular risk faced by the patients on clopidogrel.25 Our prospective cohort 
study showed higher event rates compared to many large randomized clinical trials, 
possibly due to the fact that a more all-comer population was included.
Some smaller registries have shown that selective use of prasugrel instead of 
clopidogrel based on platelet reactivity is associated with lower rates of thrombotic 
events. Mayer et al., for example, compared a guided and a historic cohort of HPR 
patients (571 versus 428 patients) and showed that a primary endpoint consisting of 
death from any cause or stent thrombosis after 30 days was significantly lower in the 
guided cohort with a hazard ratio of 0.32 (p=0.009).26 However, treatment decisions in 
the guided cohort were based on individual risk assessment without a strict treatment 
protocol based on HPR and options included re-testing, re-loading of clopidogrel and 
switching to prasugrel. Only 115 of the patients in the guided cohort were ultimately 
treated with prasugrel.
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Another single-center prospective registry conducted by Aradi et al. included ACS 
patients who underwent successful PCI and in whom platelet reactivity was measured.27 
Outcomes were compared between three groups: 128 HPR patients treated with a 
high-dose clopidogrel, 91 HPR patients treated with prasugrel and 522 patients 
with normal platelet reactivity treated with clopidogrel. The risk of all-cause death, 
myocardial infarction, stent thrombosis or stroke at 1 year after PCI was significantly 
higher in the high-dose clopidogrel group as compared to the normal platelet reactivity 
group (hazard ratio 2.27; p<0.0001), while patients who were switched to prasugrel had 
outcomes similar to the normal platelet reactivity group (hazard ratio: 0.90; p=0.76). 
In a multivariate model, HPR with high-dose clopidogrel, but not with prasugrel, was 
an independent predictor of the composite ischemic endpoint (hazard ratio: 1.90; 
p=0.01).
There are some limitations to our study that merit mention. Both study cohorts 
were prospectively collected using comparable inclusion criteria in the same study 
center, but in different time periods. Although we corrected for a number of potential 
confounders by performing multivariate analyses and propensity matching, this may 
not account for all differences in these cohorts, including unmeasured variables. For 
example, newer generations of drug-eluting stents generally result in lower rates 
of stent thrombosis, which may partly explain the difference in stent thrombosis 
between our two study cohorts. Another limitation is the lack of a blinded clinical 
event committee for the guided cohort. Moreover, this study was limited by a low 
bleeding rate, possibly due to the use of exclusion criteria. The POPular Risk Score was 
used in this study to assess a patient’s thrombotic risk, but further refinement of this 
score may also need to focus on the occurrence of bleeding complications.
Furthermore, approximately 10% of patients with a high risk score were not switched 
to prasugrel in the guided cohort. As the P2Y12 inhibitor was not changed by the study 
team, but a treating physician was advised to change the prescription, factors related 
to the individual patient might have influenced the choice not to switch; i.e. bleeding 
risk, co-medication, patients preferences or costs (for prasugrel 5mg the patient has to 
pay extra in the Netherlands). Unfortunately, the reason for not switching could not be 
uncovered from the patient records in almost all patients. This might have been mainly 
influenced by logistical issues rather than perceived relative contra-indications for the 
use of prasugrel. 
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C O N C L U S I O N
Selective intensification of P2Y12 inhibitor treatment with prasugrel instead of 
clopidogrel, based on the POPular Risk Score, is associated with a lower rate of 
thrombotic events during 1 year follow-up in patients undergoing non-urgent PCI with 
stent implantation, without a significant increase in bleeding events. A randomized 
controlled trial is needed to confirm the benefit of tailoring treatment based on this 
risk score.
I M P A C T  O N  D A I L Y  P R A C T I C E 
Multiple trials have shown that treatment with doubled doses of clopidogrel based on 
platelet reactivity levels is ineffective in reducing the incidence of thrombotic events 
after non-urgent PCI. This prospective cohort study shows that selective intensification 
of P2Y12 inhibitor treatment with prasugrel based on a risk score is associated with a 
reduced thrombotic risk after non-urgent PCI. These results have to be validated in a 
randomized controlled trial.
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Baseline characteristics Low risk score High risk score
N = 791 N = 336 p-value
Clinical parameters
Age (y) 62.4 ± 10.4 67.4 ± 10.9 <0.001  
BMI (kg/m^2) 27.2 ± 3.9 28.3 ± 4.7 <0.001
Male gender 619 (78.3%) 230 (68.5%) 0.001
Hypertension 651 (82.3%) 288 (85.7%)   0.187
Hypercholesterolemia 729 (92.2%) 306 (91.1%)   0.622
Family history of CAD 416 (52.6%) 147 (43.8%)   0.008
Diabetes Mellitus* 130 (16.4%) 107 (31.8%) <0.001
Current smoking 199 (25.2%) 49 (14.6%) <0.001
Previous myocardial infarction 258 (32.6%) 94 (28.0%)   0.142
Previous CABG 84 (10.6%) 48 (14.3%)   0.099
LVEF   0.999
 <30% * 12 (1.5%) 5 (1.5%)
 30% - 49% 113 (14.3%) 48 (14.3%)
 ≥50% 666 (84.2%) 283 (84.2%)
Medication
Aspirin 774 (97.9%) 330 (98.2%)     0.869
Clopidogrel loading dose# 260 (32.9%) 135 (40.2%)   0.022
Proton Pump inhibitor use 294 (37.2%) 162 (48.2%)   0.001
Proton Pump inhibitor type <0.001
- Pantoprazole 186 (23.8%) 75 (22.5%)
- Omeprazole 69 (8.8%) 62 (18.6%)
- Esomeprazole 24 (3.1%) 16 (4.8%)  
- Rabeprazole 21 (1.9%) 11 (1.2%)
- Lansoprazole   4 (0.5%)   0 (0.0%)  
Calcium Antagonist 203 (25.8%) 111 (33.0%)   0.016
Beta-blocker 627 (79.8%) 275 (82.3%) 0.363
ACE-inhibitor 308 (39.2%) 114 (34.1%)   0.126
AT-II antagonist 123 (15.7%) 81 (24.3%)   0.001
Lipid lowering treatment 722 (91.3%) 297 (88.4%) 0.163
PCI procedure
Sheath size   0.809
- 6F 759 (96.8%) 324 (97.3%)
- 7F 25 (3.2%) 9 (2.7%)  
Appendix I: Baseline characteristics of the guided cohort stratified by low risk score and high 
risk score
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Access-site 0.203
- Femoral 708 (90.4%) 306 (93.0%)
- Radial 75 (9.6%) 23 (7.0%)
Number of segments treated
- 1
- 2
- 3
- ≥4
662 (84.4%)
107 (13.6%)
13 (1.7%) 
2 (0.3%)
256 (76.6%)
67 (20.1%)  
10 (3.0%)
1 (0.3%)
  0.013
Number of stents used
- 1
- 2
- 3
- 4
- ≥5
Total stent length per patient (mm) *
539 (68.8%)
186 (23.7%)
41 (5.2%) 
12 (1.5%) 
6 (0.8%)  
25.9 ± 17.5
200 (59.9%)
99 (29.6%)
25 (7.5%)
9 (2.7%)  
1 (0.3%)
 27.4 ± 18.9
  0.030
  0.218  
Treated vessel(s):
- LAD 353 (44.6%) 147 (43.8%) 0.837
- RCA
- RCx
292 (36.9%)
226 (28.6%)
129 (38.4%)
94 (28.0%)
0.688
  0.896
Stent type BMS only 71 (9.0%) 57 (17.0%) <0.001
Bifurcation lesion 131 (16.6%) 67 (19.9%) 0.201
Laboratory Parameters
Hemoglobin 8.8 ± 0.8 8.2 ± 0.9  <0.001
Platelet count (x10^9) 224.9 ± 59.9 211.6 ±  55.9 <0.001
Renal function (MDRD)
- eGFR >60
- eGFR 30-60
- eGFR <30
725 (92.4%)
56 (7.1%)
4 (0.5%)
275 (82.8%) 
52 (15.7%) 
5 (1.5%)
<0.001
eGFR MDRD (ml/kg/1.73m^2) 75.9 (17.2) 73.7 (20.2) 0.105
Baseline characteristics. This table displays the baseline characteristics of patients in the guided 
and historic cohorts. Continuous variables are presented as mean ± SD. Categorical data are reported 
as frequencies (percentages). Numbers do not add up for all variables as missing data are not reported. 
Abbreviations: ACE = angiotensin-converting enzyme, AT-II = angiotensine II, BMI = body mass index, 
BMS = bare-metal stent, CABG = coronary artery bypass grafting, CAD = coronary artery disease, d = 
days, eGFR MDRD = estimated Glomerular Filtration Rate according to the MDRD formula, LAD=left 
anterior descending artery, LVEF = left ventricular ejection fraction, N = number of patients, RCA = 
right coronary artery, RCx = circumflex artery, and y = years. # Patients who received a loading dose 
(LD) of 300mg ≥12 hours or a LD of 600 mg ≥6 hours before testing, as opposed to a maintenance dose 
of 75mg of clopidogrel ≥5 days before testing. * part of the risk score.
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Appendix II: Baseline characteristics of the control cohort stratified by low and high risk
Baseline characteristics Low risk High risk
N = 528 N = 365 p-value
Clinical parameters
Age (y) 62.2 ± 10.1 65.8 ± 10.7 <0.001
BMI (kg/m^2) 26.8 ± 3.6 27.8 ± 4.3 <0.001
Male gender 428 (81.1%) 238 (65.2%) <0.001
Hypertension 400 (75.8%) 292 (80.0%) 0.158
Hypercholesterolemia 431 (81.6%) 290 (79.5%) 0.469
Family history of CAD 312 (59.1%) 231 (63.3%) 0.233
Diabetes Mellitus 72 (13.6%) 95 (26.0%) <0.001
Current smoking 65 (12.3%) 35 (9.6%) 0.246
Previous myocardial infarction 296 (56.1%) 208 (57.0%) 0.837
Previous CABG 42 (8.0%) 39 (10.7%) 0.201
LVEF 0.034
 <30% 6 (1.1%)   9 (2.5%)
 30% - 49% 72 (13.6%) 68 (18.6%)
 ≥50% 450 (85.2%) 288 (78.9%)
Medication
Aspirin 518 (98.1%) 348 (95.3%) 0.030
Clopidogrel loading dose# 253 (47.9%) 193 (52.9%) 0.165
Proton Pump inhibitor use 142 (26.9%) 103 (28.2%) 0.719
Proton Pump inhibitor type 0.991
-  Pantoprazole 70 (13.3%) 50 (13.7%)
-  Omeprazole 44 (8.3%) 34 (9.3%)
-  Esomeprazole 20 (3.8%) 14 (3.8%)
-  Rabeprazole   7 (1.3%)   4 (1.1%)
-  Lansoprazole   1 (0.2%) 1 (0.3%)
Calcium Antagonist 199 (37.7%) 144 (39.5%) 0.644
Beta-blocker 405 (76.7%) 277 (75.9%) 0.840
ACE-inhibitor 184 (34.8%) 133 (36.4%) 0.677
Lipid lowering treatment 423 (80.1%) 284 (77.8%) 0.453
PCI procedure
Sheath size 0.735
- 6F 447 (85.0%) 314 (86.0%)
- 7F 79 (15.0%) 51 (14.0%)
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Baseline characteristics. This table displays the baseline characteristics of patients in the guided 
and historic cohorts. Continuous variables are presented as mean ± SD. Categorical data are reported 
as frequencies (percentages). Numbers do not add up for all variables as missing data are not reported. 
Abbreviations: ACE = angiotensin-converting enzyme, AT-II = angiotensine II, BMI = body mass index, 
BMS = bare-metal stent, CABG = coronary artery bypass grafting, CAD = coronary artery disease, d = 
days, eGFR MDRD = estimated Glomerular Filtration Rate according to the MDRD formula, LAD=left 
anterior descending artery, LVEF = left ventricular ejection fraction, N = number of patients, RCA = 
right coronary artery, RCx = circumflex artery, and y = years. # Patients who received a loading dose 
(LD) of 300mg ≥12 hours or a LD of 600 mg ≥6 hours before testing, as opposed to a maintenance dose 
of 75mg of clopidogrel ≥5 days before testing.
Access-site 1.000
- Femoral 508 (99.2%) 356 (99.4%)
- Radial 4 (0.8%) 23 (7.0%)
Number of segments treated
- 1
- 2
- 3
- ≥4
372 (70.5%)
127 (24.1%)
26 (4.9%) 
3 (0.6%)
239 (65.5%)
99 (27.1%)     25 (6.8%)
2 (0.5%)
0.391
Number of stents used
- 1
- 2
- 3
- 4
- >4
Total stent length per patient (mm)
318 (60.2%)
139 (26.3%)
54 (10.2%) 
11 (2.1%) 
6 (1.1%) 
28.1 ± 17.1
215 (59.2%)
95 (26.2%) 
 
35 (9.6%)
17 (4.7%)
1 (0.3%)  
 
28.3 ± 16.7
  0.165
0.905
Treated vessel(s):
- LAD 248 (47.0%) 186 (51.0%)   0.269
- RCA
- RCx
196 (37.1%)
177 (33.5%)
133 (36.4%)
115 (31.5%)
  0.891    0.576
Stent type BMS only 188 (35.9%) 138 (37.9%)   0.584
Bifurcation lesion 15 (2.8%) 15 (4.1%)   0.398
Laboratory Parameters
Hemoglobin 8.7 ± 0.9 8.2 ± 0.9 <0.001
Platelet count (x10^9) 280.8 ± 86.1 266.0 ± 71.7 0.007
Renal function (MDRD)
- eGFR >60
- eGFR 30-60
- eGFR <30
416 (86.1%)
63 (13.0%) 
  4 (0.8%)
264 (78.6%)     63 (18.8%) 
9 (2.7%)
0.007
eGFR MDRD (ml/kg/1.73m^2) 87.6 (20.5) 81.6 (24.0) <0.001
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Appendix III: TIMI major or minor bleeding stratified by cohort and risk score
This figure shows the incidence of TIMI major or minor bleeding for the high (filled) and low (hatched) 
risk score patients in both the guided cohort (purple) and the historic cohort (orange).
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CYP2C19 genotype-guided antiplatelet therapy in 
ST-segment elevation myocardial infarction  
patients-Rationale and design of the Patient  
Outcome after primary PCI (POPular) Genetics study.
4 . 2
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A B S T R A C T
Rationale: In patients with ST-segment elevation myocardial infarction (STEMI) 
who undergo primary percutaneous coronary intervention (pPCI), the use of dual 
antiplatelet therapy is essential to prevent atherothrombotic complications. Therefore, 
patients are treated with acetylsalicylic acid and clopidogrel, prasugrel or ticagrelor. 
Clopidogrel, however, shows a major inter-individual variation in antiplatelet effect, 
which is correlated to an increase in atherothrombotic events in patients with high 
platelet reactivity. This inter-individual variation is partly a result of CYP2C19 genetic 
variants. Ticagrelor and prasugrel reduce atherothrombotic events, but increase 
bleeding rate and drug costs, as compared to clopidogrel. CYP2C19 based tailoring of 
antiplatelet therapy might be beneficial to STEMI patients.
Study design: POPular Genetics (NCT01761786) is a randomized, open label, multicenter 
trial involving 2700 STEMI patients who undergo pPCI. Patients are randomized to 
CYP2C19 genotyping or routine ticagrelor or prasugrel treatment. In the genotyping 
group *1/*1 (wild-type) patients receive clopidogrel and patients carrying one or two 
*2 or *3 loss-of-function alleles receive ticagrelor or prasugrel. The primary net clinical 
benefit endpoint is the composite of death, (recurrent) myocardial infarction, definite 
stent thrombosis, stroke and PLATO major bleeding at 1 year. Primary safety endpoint 
is the composite of PLATO major and minor bleeding. Cost-effectiveness and quality of 
life will be assessed by calculating Quality Adjusted Life Years (QALYs), net costs per 
life-year and per QALY gained.
Conclusion: The POPular Genetics study is the first large-scale trial comparing CYP2C19 
genotype  guided antiplatelet therapy to a non-tailored strategy in terms of net clinical 
benefit, safety and cost-effectiveness.
4.2
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B A C K G R O U N D  A N D  R A T I O N A L E
Each year 3 million people worldwide suffer from an ST-segment elevation myocardial 
infarction (STEMI).(1) Primary percutaneous coronary intervention (pPCI) with stent 
implantation is the preferred method of reperfusion for STEMI, granted this treatment 
is available shortly after first medical contact. In these patients, treatment with dual 
antiplatelet therapy (DAPT) is essential to prevent recurrent atherothrombotic events 
like stent thrombosis.(2) For many years, clopidogrel and acetylsalicylic acid (ASA) was 
standard DAPT treatment in STEMI patients. 
Clopidogrel is a prodrug, that is transformed into its active metabolite by hepatic 
cytochrome P450 enzymes. The active metabolite irreversibly inhibits the P2Y12 
receptor on platelets, resulting in inhibition of platelet aggregation.(3) However, 
approximately 30% of Caucasian patients show an inadequate response to clopidogrel, 
when measured with different platelet function tests.(4) Genetic variations such as 
the CYP2C19 *2 and *3 loss-of-function (LoF) alleles account for part of the variation 
in clopidogrel response. Patients who carry a LoF allele turn out to have a higher 
atherothrombotic risk after PCI compared to non-carriers.(5-8)
Recently, two new antiplatelet drugs – ticagrelor and prasugrel – have been introduced. 
Prasugrel, like clopidogrel, is a thienopyridine drug, which irreversibly inhibits the 
P2Y12 receptor. CYP2C19 plays only a minimal role in prasugrel metabolism.(1) In 
contrast, ticagrelor is not a prodrug, but a direct acting P2Y12-inhibitor that reversibly 
inhibits the platelet.(9) Ticagrelor and prasugrel have advantages over clopidogrel: 
both show a stronger antiplatelet effect with much less inter-patient variation, a faster 
onset of action – especially important in the acute STEMI setting – and a reduction 
in atherothrombotic events, as shown in the Study of Platelet Inhibition and Patient 
Outcomes (PLATO) and the Trial to Assess Improvement in Therapeutic Outcomes by 
Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 
(TRITON-TIMI) 38.(1, 9-11) This includes a significant reduction in mortality in 
ticagrelor treated patients compared to clopidogrel.(1) Another advantage is that 
the occurrence of atherothrombotic events in patients using ticagrelor or prasugrel 
is not influenced by CYP2C19 genotype.(9, 12) Nowadays, the European Society of 
Cardiology (ESC) STEMI guideline recommends ticagrelor and prasugrel as first choice 
P2Y12 inhibitor in STEMI patients.(2)  
Despite the advantages outlined in the last paragraph, both ticagrelor and prasugrel 
also have important drawbacks compared to clopidogrel. First, non-CABG related 
major bleeding rates – known from previous studies to be correlated to an increase 
in mortality – was increased in both the PLATO and the TRITON-TIMI 38 study.(13, 
14) Second, uncertainty about dose adjustments for low body weight and higher age in 
patients using prasugrel, the mandated bidaily dosing of ticagrelor, and the frequently 
observed side effect of dyspnoea in patients using ticagrelor, are all factors that limit 
general use of these newer drugs.(15) Third, both ticagrelor and prasugrel result in 
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a major increase in drug costs compared to generic clopidogrel. The price difference 
varies between countries, but in The Netherlands, for instance, the newer drugs result 
in an almost 20-fold increase in drug cost. 
With those pros and cons in mind, a tailored antiplatelet strategy would be promising, 
if it turns out to be capable of selecting the best P2Y12 inhibitor for the individual 
patient. Nevertheless, it is still being discussed which tailoring method is most 
promising. There were high hopes for platelet function testing as a tailoring method; 
however, multiple large trials did not show a benefit for a platelet function based 
tailoring strategy.(16-18) A CYP2C19 genotype based tailoring strategy has not 
been evaluated in a randomized manner in a STEMI population so far. However, the 
randomized Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased 
Clopidogrel Response After PCI (TAILOR-PCI) study currently evaluates CYP2C19 
genotype based tailoring in 5945 ACS and stable coronary artery disease patients 
undergoing PCI, using clopidogrel as the routine care comparator (NCT01742117). The 
pharmacogenetic post hoc analysis performed in the PLATO and TRITON TIMI-38 
study suggests that the atherothrombotic risk of non-carriers of a CYP2C19 LoF allele 
(*1/*1 genotype) treated with clopidogrel is comparable with the atherothrombotic 
risk of those treated with either ticagrelor or prasugrel.(9, 19) This suggests that non-
carriers of a LoF allele can be treated effectively with clopidogrel, while patients who 
carry a LoF allele benefit most from the use of ticagrelor or prasugrel. This is in line 
with the 2009 Food and Drug administration (FDA) recommendation to “consider 
alternative treatment or treatment strategies in patients identified as CYP2C19 poor 
metabolizers”.(20) With decreasing costs per genetic test and the introduction of fast 
and easy to use point-of-care genotyping devices, genotyping is now achievable and 
more affordable for use in daily clinical practice.(21) 
The POPular Genetics study is the first large scale randomized clinical trial to assess 
CYP2C19 genotyping as a method for tailoring antiplatelet therapy in STEMI patients 
undergoing pPCI. The study tests the hypothesis that a CYP2C19 genotype guided 
antiplatelet strategy is non-inferior to a strategy with ticagrelor or prasugrel in terms 
of net clinical benefit and superior in terms of safety. Also, a tailored approach is 
expected to be cost-effective.
S T U D Y  O B J E C T I V E S
The primary objective of the POPular Genetics study is divided into three different 
components: net clinical benefit, safety and cost-effectiveness, all for 1 year follow-
up. The definitions of all components of the study objectives are shown in appendix 
table 1.
With regard to net clinical benefit, it will be determined whether CYP2C19 genotype 
guided antiplatelet therapy is non-inferior to antiplatelet therapy with either ticagrelor 
or prasugrel in STEMI patients who have undergone pPCI for a combined endpoint 
4.2
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consisting of all-cause mortality, (recurrent) myocardial infarction (MI), definite stent 
thrombosis, stroke and PLATO major bleeding. If non-inferiority is proven, an analysis 
will be performed for superiority. 
With regard to safety, it will be determined whether CYP2C19 genotype guided 
antiplatelet therapy is superior to a strategy with ticagrelor or prasugrel in terms of a 
combined endpoint of PLATO major and minor bleeding. 
Cost-effectiveness and quality of life will be assessed in both treatment groups by 
calculation of Quality Adjusted Life Years (QALYs), net costs per life-year gained and 
net costs per QALY. This includes direct/indirect and medical/non-medical costs. 
A secondary objective is to examine the primary endpoints for 30 days instead of 1 
year follow-up. Also, both efficacy and safety will be studied in more detail, using the 
items of the primary endpoint as separate parameters and in different combinations, 
adding cardiovascular and cerebrovascular death, probable and possible stent 
thrombosis, urgent target vessel revascularization (uTVR) and hospital admission 
for acute coronary syndrome (ACS) to the efficacy analysis, and (non-)CABG-related 
bleeding, major-, minor-, life threatening-, fatal-, intracranial and bleeding requiring 
transfusion to the bleeding analysis, both for 30 days and 1 year follow-up. Bleeding 
will be defined according to the PLATO, TIMI and BARC bleeding classifications to 
make the study comparable to previous and future publications. Another secondary 
objective is to compare the number of patients in whom the antiplatelet drugs are 
prematurely discontinued or switched to another drug and the number of heart failure 
events that occur during follow-up.
In the tertiary objectives we evaluate whether clopidogrel in non-carriers of a CYP2C19 
LoF allele is non-inferior to ticagrelor and prasugrel in carriers of a LoF allele in terms 
of efficacy and superior in terms of safety. 
S T U D Y  D E S I G N  A N D  P O P U L A T I O N
The POPular Genetics study is a prospective, randomized, open label, multicenter trial, 
including 2700 patients. The study population consists of STEMI patients in whom 
pPCI with stent implantation is performed within 12 hours after onset of symptoms. 
STEMI is defined according to the 2012 ESC STEMI guideline. The inclusion and 
exclusion criteria are listed in Table 1.(22) After pPCI, patients who consent to study 
participation are randomized in a 1:1 ratio to the CYP2C19 genotype guided strategy 
(intervention group) versus a non-tailored strategy using ticagrelor or prasugrel 
treatment (control group) in a randomization schedule blocked by study site (Figure 
1). Randomization and genotyping, if applicable, is performed within 48 hours after 
pPCI. The study is approved by the local ethics committee and will be conducted 
according to the ethical principles of the declaration of Helsinki and Good Clinical 
Practice guidelines.
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C Y P 2 C 1 9  G E N O T Y P I N G
A blood sample will be collected in all patients, during or shortly after the PCI procedure. 
This sample is used for genotyping, complete blood count and measurement of cardiac 
biomarkers. Genotyping will be performed by using a validated TaqMan StepOnePlus 
assay, the point-of-care SPARTAN RX device using buccal swabs, the Verigene device 
or another assay, whichever is available in each study center. For validation purposes, 
Figure 1 : This figure is a flowchart describing the POPular Genetics study.
Prasugrel/ticagrelor
for at least 1 year
Clopidogrel
for at least 1 year
Prasugrel/ticagrelor
for at least 1 year

STEMI
Primary PCI
R 
Genetic testing for CYP2C19*2 and *3 No genetic testing 
CYP2C19*2 or *3 carrier?
Yes No 
Prasugrel /ticagrelor
for at least 1 year 
Clopidogrel 
for at least 1 year 
Prasugrel / ticagrelor
f or at least 1 year 
Combined endpoint of death, MI, stent thrombosis, stroke and
PLATO major bleeding at 1 year 
Clopidogrel 
for at least 1 year 
First 100 patients
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genotyping results obtained by the SPARTAN RX, Verigene device or other assay are 
retested with the TaqMan StepOnePlus assay in the central laboratory, within five 
days. The CYP2C19 genotype of patients in the control group will be determined 
after the last patient has completed the follow-up period. Genotyping results of the 
intervention group patients will be made available to the patients’ general practitioner, 
treating cardiologist and community pharmacist.
T R E A T M E N T  R E G I M E N S  A N D  C O N C O M I T A N T 
M E D I C A T I O N
All treatment before randomization will be administered according to the local 
protocols. Accordingly, patients will receive a loading dose of DAPT (Aspegic 500mg 
iv plus clopidogrel 600mg, ticagrelor 180mg or prasugrel 60mg) and 5000 units 
heparin in the ambulance or as soon as possible after arriving in the hospital. Patients 
who are already treated with aspirin or DAPT may receive a new loading dose which 
Table 1 – inclusion and exclusion criteria
Inclusion criteria
1) more than 21 years of age with symptoms of acute myocardial infarction of more than 30 
minutes but less than 12 hours
2) performed primary PCI with stent implantation for STEMI
Exclusion criteria
1) unable to give informed consent or a life expectancy of less than one year
          2) malignancy with increase in bleeding risk*
          3) women who are known to be pregnant or who have given birth within the past 90 days or who are  
          breastfeeding
          4) having received thrombolytic therapy within the previous 24 hours or oral anticoagulants during 
         the previous 7 days
          5) severe renal function impairment needing dialysis 
          6) confirmed or persistent severe hypertension (SBP > 180 mmHg and/or DBP > 110 mmHg) at 
          randomization
          7) contraindication to anticoagulation or at increased bleeding risk*
          8) cardiogenic shock (SBP ≤ 80mmHg for >30 mins) or intra-aortic balloon pump placed
          9) history of major surgery, severe trauma, fracture or organ biopsy within 90 days prior to 
          randomisation
10) clinically significant out of range values for platelet count or haemoglobin at screening*
 * according to the investigator. SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure
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is to the discretion of the treating physician. Before or during PCI, antithrombotic 
agents like glycoprotein (GP)IIb/IIIa-inhibitors, bivalirudin and heparin may be 
used. Furthermore, the choice of PCI techniques, like the access site, use of thrombus 
aspiration, pre-dilatation and type of stents implanted, will also be at the discretion 
of the treating physician. 
After randomization, all patients in the intervention group who carry one or more 
CYP2C19 *2 or *3 LoF alleles will receive ticagrelor or prasugrel, while non-carriers will 
receive clopidogrel. ASA 80mg or Ascal 100mg is prescribed to all patients, irrespective 
of treatment group. DAPT is continued for at least one year after PCI, according to the 
2012 ESC guideline.(22) Patients who are switched from clopidogrel to ticagrelor or 
prasugrel will receive a loading dose before they start with the maintenance dose. When 
patients are switched from ticagrelor or prasugrel to clopidogrel the administration 
of a loading dose is optional. The maintenance dose is 75 mg daily for clopidogrel, 
10 mg daily for prasugrel (patients older than 75 years or weighing less than 60 kg 
will receive 5 mg) and 90 mg bidaily for ticagrelor. Prasugrel is contra-indicated in 
patients with a history of stroke or TIA; in those patients ticagrelor is prescribed. 
Ticagrelor is contra-indicated in patients who are using a strong CYP3A4 inhibitor, 
like clarithromycin, erythromycin, itraconazole, ketoconazole or voriconazole. In 
patients using clopidogrel the concomitant use of omeprazole or esomeprazole is 
discouraged. Additional drug therapy, for instance with beta-blockers, ACE-inhibitors 
and cholesterol-lowering agents is left to the discretion of the treating physician. 
When the use of oral anticoagulants becomes indicated after the start of the study, 
changes in antiplatelet treatment can be initiated at the discretion of the cardiologist. 
In contrast to the study procedures described above, the first 100 patients randomized 
to the control group - until February 2012 - received clopidogrel in the ambulance and 
during follow-up. This treatment was the standard of care during that period. Because 
the new ESC guidelines, published in 2012, recommend ticagrelor or prasugrel as first 
choice P2Y12-inhibitor in STEMI patients, we amended the protocol. Since the protocol 
amendment, all patients included in the control group are now prescribed ticagrelor or 
prasugrel. No changes were made regarding the intervention group.
As both ticagrelor and prasugrel have shown superiority to clopidogrel in an unselected 
ACS population and both drugs are not influenced by CYP2C19 gene variance, the 
choice between ticagrelor and prasugrel is made according to local protocol and the 
choice of the treating cardiologist.
F O L L O W - U P
All efficacy and safety endpoints occurring during one year follow-up will be recorded 
by the investigators using hospital patient files, pharmacy records and patient 
questionnaires. Patients are asked to fill out a questionnaire 9 times during 1 year 
follow-up – every month up to 6 months and every two months up to 12 months after 
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pPCI – to obtain information about changes in antiplatelet drug use, co-medication, 
drug compliance and adverse or endpoint events. After 30 days, 6 months and 1 year 
patients are requested to fill out Short Form (SF-) 36 and EuroQol-5D questionnaires 
to asses quality of life. After 6 months and 1 year patients are also requested to fill out 
the Short Form - Health and Labour Questionnaire (SF-HLQ).(23, 24)
S T U D Y  E N D P O I N T S  A N D  D A T A  A N A L Y S I S
A blinded clinical endpoint committee (CEC) will adjudicate the following study 
endpoints: death (cardiovascular, cerebrovascular or unknown cause), stroke, 
(recurrent) MI, stent thrombosis (classified according to the Academic Research 
Consortium (ARC) criteria), uTVR, hospital admission for ACS and bleeding 
complications (defined according to the PLATO, TIMI and BARC bleeding scores).(25, 
26)
The primary analysis will be on an intention to treat principle. For all events used in 
the analyses t=0 is defined as the time of randomization.. As mentioned previously, 
we chose to amend our study protocol when we were confronted with the change in 
guideline. The primary net clinical benefit endpoint will be analyzed using all patients 
included after the protocol amendment. In a secondary analysis we will use all patients 
included before and after the protocol amendment where we will stratify the cohort 
accordingly. Also, a secondary analysis will be performed on actual treatment received 
using all patients before and after the protocol amendment and by using the end time 
of the PCI procedure as t=0. Multiple subgroup analysis are planned, e.g. according 
to age, gender and diabetes. The event rate curves will be estimated using the 
Kaplan-Meier method. The two study groups will be compared with the use of hazard 
ratios and two-sided 95% confidence intervals and by using the log-rank test. 
S A M P L E  S I Z E  A N D  P L A N N E D  A N A L Y S I S
The sample size calculation is based on the estimated event rates for the primary net 
clinical benefit endpoint, because the required number of patients for the primary 
safety endpoint is smaller. The estimated event rate of the intervention group is 16.9%, 
based on two studies closely resembling the POPular Genetics study population. The 
estimation of the thrombotic event rate was based on a selection of 893 STEMI patients 
in the Central Holland Acute Myocardial Infarction (CHAIR) registry (to be published), 
and the bleeding rate was based on the reported bleeding rates in the control group of 
the On-Time 2 study.(27) The event rate for the control group is estimated to be 18.8%, 
which is based on the PLATO STEMI subgroup analysis.(22) Using a power of 0.8, an 
alpha of 0.05 and setting the non-inferiority threshold at 0.02, the required number 
of patients is 2474, i.e. 1237 per group. Combined with the 200 patients who were 
included before the protocol amendment in February 2012, a total study population of 
2700 patients is needed.
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Evaluation by an independent data safety monitoring board (DSMB) will be performed 
after 1 month follow-up data of the first 1000 patients is available. Study data will be 
monitored by an independent monitoring office.
Cost-effectiveness analysis will be conducted based on within-trial observed outcomes 
and costs. Differences in costs of genotyping and screening versus treatment and 
difference in event costs will be divided by the difference in life years and QALYs to 
render the cost-effectiveness and cost-utility ratios, respectively. Cost-effectiveness 
will be estimated from both a health care and societal perspective by using 
“state-of-the-art” methods following the Dutch guidelines for pharmacoeconomic 
research.(28) A scenario analysis will be conducted for several subgroups of patients, 
e.g. based on age. Further sensitivity analysis will be carried out for several relevant 
parameters. First, univariate sensitivity analysis will be conducted for various cost 
estimates (e.g. genotyping, event costs), effect estimates for CYP2C19 genotyping 
including variation of CYP2C19 prevalence and discount rates. Bootstrapping of the 
randomized clinical trial data (10,000 replicates) will be used to derive 95% CIs for the 
cost-effectiveness ratios (CERs) and cost-utility ratios (CURs) and threshold probabilities. 
Cost-effectiveness acceptability curves will be constructed to describe uncertainty 
around estimated CER and CUR. The friction cost method will be used for estimating 
the per patient indirect non-medical cost due to sickness leave. Costs for sickness leave 
will be calculated separately for men and women based on recorded hospitalization 
days, reported absenteeism due to illness and reported (policlinic) specialist and 
general practitioner visits.
The POPular Genetics study is registered on ClinicalTrials.gov (NCT01761786) 
and is approved by the local ethics committee. The trial is supported by a grant for 
research focused on cost-effectiveness by ZonMW, a Dutch organization funded by the 
government promoting health care research and the implementation of study results 
in daily practice. The authors are solely responsible for the design and conduct of this 
study, all study analyses, the drafting and editing of the paper and its final contents.
P R E S E N T  S T A T U S
The first patient was enrolled in June 2011. Over 650 patients were enrolled at 
1 October 2013. Baseline characteristics of those patients are shown in Table 2. 
Currently six study centers are actively enrolling patients and recruitment of the last 
patient is expected in 2016.
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S U M M A R Y
The randomized, open label, multicenter POPular Genetics study is the first 
large scale randomized clinical trial to assess the net clinical benefit, safety and 
cost-effectiveness of CYP2C19 genotype guided antiplatelet therapy compared to a 
non-tailored strategy with ticagrelor or prasugrel use in STEMI patients undergoing 
pPCI with stent implantation. 
Age (years) 60.8 years
Male 76.3
Hypertension 43.3
Diabetes Mellitus 12.5
Current smoker 48.1
Hypercholesterolemia 42.5
Family history of CAD 39.3
Prior MI 8.5
Prior PCI 5.9
Prior CABG 2.0
Anterior wall infarction on ECG 43.0
Heterozygous for CYP2C19 LoF allele* 29.0
Homozygous for CYP2C19 LoF allele* 2.2
All results are in percentages, unless stated otherwise. *only available for patients in the 
intervention group. CAD = coronary artery disease
Table 2 – baseline characteristics of the first 650 patients
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Appendix table 1 - endpoint definitions
All cause mortality. Subsequently, death will be further classified as 
death from cardiovascular cause, death from cerebrovascular cause, 
death as a result of heart failure or death from another/unknown
cause
Stroke Acute new neurological deficit ending in death or lasting >24 hours not due to another readily identifiable cause such as trauma
(Recurrent) MI MI is defined according to the criteria described in the ESC Third Universal definition of myocardial infarction(29)
Stent thrombosis
Stent thrombosis will be classified according to the ARC-criteria, taking 
into account the level of documentation (definite, probable or possible) 
and timing (acute, subacute, late and very late)(26)
Urgent target vessel
revascularization 
(uTVR)
uTVR during the hospitalization period will be defined as a new 
episode of ischemic signs or symptoms at rest that necessitates an 
unplanned PCI or CABG in any segment of the target vessel.
uTVR after the hospitalization period will be defined as signs or 
symptoms of recurrent ischemia leading to hospital admission
and revascularization of any segment of the target vessel prior to 
discharge.
For every uTVR, it will also be adjudicated whether it was a target 
lesion revascularization (including 5mm proximal and distal to the
target lesion) or not
Hospital admission 
for ACS
Any hospital admission lasting for at least 24 hours and in which
the patient is diagnosed with new onset acute coronary syndrome
(unstable angina or MI), according to the ESC guideline criteria
Bleeding All bleeds will be scored using the PLATO, TIMI and BARC bleeding classifications(25)
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Heart failure 
The heart failure endpoint is defined as first hospitalization for heart 
failure or heart failure related mortality.
Death due to heart failure is defined as:
- Pump failure death during the course of or in the immediate 
period after a heart failure hospitalization (as defined
hereunder).
- Sudden cardiac death during a heart failure hospitalization 
or in the immediate period after a heart failure 
hospitalization (as defined hereunder); or in a patient who 
developed a heart failure diagnosis (as defined hereunder 
without the requirement of hospitalization) during 
follow-up in the absence of evidence of ACS or pulmonary 
embolism. A diagnosis of heart failure must be present to
attribute sudden cardiac death to heart failure.
Hospitalization for heart failure is defined as:
- Hospital admission, emergency department visit, or 24 hour 
observation stay with at least 2 signs and/or symptoms of 
HF among the following:
(1) At least 2 signs and/or symptoms of HF among the following: 
Shortness of breath, dyspnea on exertion, paroxysmal 
nocturnal dyspnea, orthopnea, fatigue/reduce exercise 
tolerance, pulmonary edema, jugular venous distension, 
rales, third heart sound, hepatojugular reflux, altered 
hemodynamics, peripheral edema, cardiomegaly. 
(2) Treatment with or increase in dosage if previously prescribed
for another cause (i.e. hypertension) of loop diuretics or 
treatment with intravenous vasoactive agents, specifically for 
the symptoms described above.
                and at least 1 of the following:
- Brain Natriuretic Peptide (BNP) > 400 pg/mL OR the 
following N-Terminal-proBNP levels according to age: < 50 
years, > 450 ng/L; 50-75 years, > 900 ng/L; > 75 years, >
1800 ng/L
or
- Structural heart disease with documentation of systolic 
dysfunction (LVEF <40%) or diastolic dysfunction.
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A BST R AC T
Background: International guidelines do not provide uniform recommendations 
regarding the use of antiplatelet treatment in the perioperative period in patients 
undergoing coronary artery bypass grafting (CABG).
Methods: A questionnaire was sent to all 16 cardiothoracic centres in the 
Netherlands to determine which antiplatelet treatment is used in the perioperative 
setting. Furthermore, a single-centre prospective observational cohort study was 
performed which included all patients undergoing isolated CABG in July 2014.
Results: Eleven centres responded to the survey. Acetylsalicylic acid monotherapy 
was discontinued before surgery in 6 centres. In patients with an acute coronary 
syndrome receiving dual antiplatelet therapy (DAPT), most centres discontinued 
the P2Y12 inhibitor preoperatively. DAPT was restarted after surgery in 4 centres. 
However, 6 centres continued DAPT in patients who had undergone coronary 
stenting within one month of surgery. In patients with coronary stents, variation 
in the management of antiplatelet therapy increased in proportion to the interval 
between stenting and surgery. A total of 70 patients were included in the registry. 
Acetylsalicylic acid monotherapy was discontinued in 51% of patients and restarted 
in all patients. P2Y12 inhibitor treatment was discontinued before surgery in 70% of 
patients and re-initiated after CABG in 29%.
Conclusions: Major differences were observed in the preoperative and postoperative 
management of antiplatelet treatment between different Dutch cardiothoracic 
centres and within a single centre. Part of this variation is probably due to lack of 
evidence and differences between the current guidelines; however, many of the 
strategies were not in accordance with any of these guidelines.
5
318
Chapter 5
I N T RODUC T ION
Most patients scheduled to undergo coronary arterial bypass grafting (CABG) are 
treated with acetylsalicylic acid (ASA) with or without a P2Y12 inhibitor (clopidogrel, 
prasugrel, ticagrelor) before surgery. The current guidelines from the American 
College of Cardiology (ACC)/American Heart Association (AHA), European Society 
of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) 
provide different recommendations regarding the continuation or (temporary) 
cessation of antiplatelet drugs during the perioperative period[1–4]. In general, it is 
recommended to continue ASA during and after CABG[1–4]. However, some guidelines 
state that it can be reasonable to discontinue ASA several days before CABG in patients 
with stable coronary heart disease[2,3]. The guidelines are consistent in their advice 
to discontinue P2Y12 inhibitors before surgery in stable patients without recent 
coronary stent implantation, although there is no consistency regarding the timing 
of discontinuation. In high-risk groups, i.e. patients who have recently undergone 
coronary stent implantation[2] or patients with a high risk for thrombotic events[4], it is 
recommended not to interrupt dual antiplatelet therapy (DAPT) treatment. Physicians 
have to decide whether the increased risk of bleeding with continued antiplatelet 
therapy outweighs the risk of thrombotic events associated with the discontinuation 
of these drugs before CABG. The use of DAPT after CABG in patients who recently 
experienced an acute coronary syndrome (ACS) is also a subject of debate[5]. Recent 
reports have shown that treatment is not re-initiated after surgery in a large portion 
of patients[6], despite the fact that re-initiation is recommended in the guidelines[3,4]. 
We aimed to describe the use of antiplatelet treatment in the perioperative period in 
patients undergoing CABG in contemporary practice in the Netherlands.
 
M AT ER I A L S A ND MET HODS
First, a survey was sent to all 16 centres in the Netherlands in which CABG surgery 
is performed. The head of the department of each centre was contacted. The survey 
consisted of both open and closed questions so that respondents could indicate how 
predefined groups of patients would be treated in general (i.e. mono antiplatelet 
therapy versus DAPT, patients after ACS and/or recent stent implantation) and which 
patients were exempted from standard treatment protocols. The survey is shown 
online as Electronic Supplementary Material.
Second, we conducted a prospective, observational pilot study in the St. Antonius 
Hospital in Nieuwegein. All patients undergoing isolated CABG in July 2014 were 
included in this registry. There were no exclusion criteria. Baseline data, antiplatelet 
treatment and postoperative complications (with 30 days of follow-up) were registered 
in all patients. The study was conducted according to the principles of the Declaration 
of Helsinki and received approval from the local Human Research Ethics Committee. 
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The local ethics committee provided a waiver for written informed consent, as the 
study was not associated with any risk.
R E SULT S
Survey
Between November 2014 and April 2015, 11 out of the 16 Dutch centres in which 
cardiothoracic surgery is performed, including our own centre, responded to the 
questionnaire. The other centres are listed in the acknowledgements.
Six out of 11 centres answered that ASA monotherapy was routinely discontinued 
before CABG, while 5 centres always continued ASA monotherapy (Table 1). Fig. 1A 
to 1C show the perioperative management of antiplatelet treatment in patients with 
ACS undergoing CABG during the index admission, between the index admission and 
1 month after the ACS or between 1 month and 12 months after the ACS. Preoperative 
management differed slightly between centres, but postoperative management was 
the same for the different groups. Fig. 2A to 2C show the perioperative management 
of antiplatelet treatment in patients undergoing CABG within 1 month, between 1 and 
6 months and between 6 and 12 months after coronary stent implantation.
Number of centres following each strategy
ASA monotherapy 
(N)
DAPT Clopidogrel
(N)
DAPT Prasugrel 
(N)
DAPT Ticagrelor
(N)
Continue: 5 - - -
Discontinue:
- 1 day - - - -
- 2 days - - - 1
- 3 days 1
- 4 days 1 1 1 1
- 3-5 days 1 - - -
- 5 days 2 1 3 5
- 5-7 days - - - 1
- 7 days - 1 2 1
- 7-10 days 1 6 1
Table 1. The preoperative management of patients on ASA monotherapy and patients on DAPT with 
clopidogrel, prasugrel or ticagrelor. ASA: Acetylsalicylic acid, DAPT: dual antiplatelet therapy,  
N: number of centres.
Table 1. Preoperative management of antiplatelet therapy
ASA acetylsalicylic acid; BMS bare metal stent; CABG coronary artery bypass grafting; DAPT dual 
antiplatelet therapy; DES drug-eluting stent; ICW in consultation with; No number; P2Y12 P2Y12 
inhibitor
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7
1
3
1
8
2
7
1
33
1
3
8
3
1
3
77
1
2 
7 
2 
 
 
Perioperative management of DAPT in 
patients with an ACS and CABG during 
admission 
Perioperative management of DAPT in 
patients undergoing CABG <1 month after 
ACS 
Perioperative management of DAPT in 
patients undergoing CABG 1 - 12 months 
after ACS 
Preoperative                 Postoperative Preoperative                 Postoperative Preoperative                 Postoperative 
 
No. of centers                           No. of centers 
 
No. of centers                           No. of centers 
 
No. of centers                           No. of centers 
Continue 
ASA & 
P2Y12 
Does not 
restart DAPT 
Continue 
ASA & 
stop 
P2Y12 
Stop ASA 
& P2Y12 
First dose of 
DAPT < 24 
hours 
First dose of 
DAPT > 24 
hours 
Continue 
ASA & 
P2Y12 
Does not 
restart DAPT 
Continue 
ASA & 
stop 
P2Y12 
Stop ASA 
& P2Y12 
First dose of 
DAPT after 
<24 hours 
First dose of 
DAPT after 
>24 hours 
Does not 
restart DAPT Continue 
ASA & 
stop 
P2Y12 
Stop ASA 
& P2Y12 
First dose of 
DAPT after 
<24 hours 
First dose of 
DAPT after 
>24 hours 
A           B         C 
2
7
7
1
33
1
1
2
2
6
1
3
2
7
4
3
1
3
2
1
2
2
6
2
3
1
1
3
1
3
2
2
6
2
1
4
3
34
1
1
1
3
 
 
Perioperative management of DAPT in 
patients with a stent implant <1 month 
prior to CABG 
Perioperative management of DAPT in 
patients with a stent 1 - 6 months prior to 
CABG 
Perioperative management of DAPT in 
patients with a stent 6 - 12 months prior to 
CABG 
Preoperative                 Postoperative Preoperative                 Postoperative Preoperative                 Postoperative 
 
No. of centers                           No. of centers 
 
No. of centers                           No. of centers 
 
No. of centers                           No. of centers 
A             B            C 
Continue 
ASA & 
P2Y12 
Does not 
restart DAPT 
Continue 
ASA & 
stop P2Y12 
Stop ASA 
& P2Y12 
First dose of 
DAPT after 
<24 hours 
First dose of 
DAPT after 
>24 hours Stop ASA 
& continue 
P2Y12 
First dose of 
DAPT after 
>24 hours 
DES only 
Continue 
ASA & 
P2Y12 
Does not 
restart DAPT 
Continue 
ASA & 
stop P2Y12 
Stop ASA 
& P2Y12 
First dose of 
DAPT after 
<24 hours 
First dose of 
DAPT after 
>24 hours 
Stop ASA 
& continue 
P2Y12 
First dose of 
DAPT after 
<24 hours 
DES only 
Continue 
ASA & 
stop P2Y12 
BMS only 
First dose of 
DAPT after 
>24 hours 
DES only 
Continue 
ASA & 
P2Y12 Does not 
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Fig. 2A, 2B and 2C Perioperative management of DAPT in patients undergoing CABG less than 1 
month, between 1-6 months and between 6-12 months after stent implantation
Fig. 1A, 1B and 1C Perioperative management of DAPT in patients with ACS and CABG during the 
same admission, CABG <1 month and CABG 1-12 months after ACS. ACS acute coronary syndrome; 
ASA acetylsalicylic acid; CABG coronary artery bypass grafting; DAPT dual antiplatelet therapy; No 
number; P2Y12 P2Y12 inhibitor
Figure 1
Figure 2
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In the 4 centres in which ASA treatment was discontinued before surgery, one centre 
discontinued ASA 5 days before surgery, a second centre 4 days, a third centre 3 
days and the fourth centre 2 days prior to surgery. This discrepancy in the time of 
discontinuation of treatment also applied to the management of P2Y12 inhibitor use 
(Table 1).
Registry
A total of 70 patients underwent isolated CABG in the St. Antonius Hospital in 
Nieuwegein in July 2014 and were included in this pilot study. Baseline data are 
presented in Table 2. Of these 70 patients, 41 were on ASA monotherapy, 28 used 
a P2Y12 inhibitor and 1 patient was on ASA plus acenocoumarol treatment before 
surgery. From the 28 patients using a P2Y12 inhibitor, 9 were on clopidogrel and 19 
were on ticagrelor. 
Table 2. Baseline characteristics
Characteristics N = 70 N (%)
Patient characteristics
Male 57 (81.4)
Age, mean, (SD), y 65.5 ± 10.1
Body mass index, mean, (SD) 28.0 ± 3.2
Current smoker 14 (20.3)
Ex-smoker (>6 weeks) 19 (27.5)
Family history for CAD 8 (12.1)
Medical history
Hypertension 58 (82.9)
Diabetes Mellitus 21 (30.0)
Dyslipidaemia 37 (52.9)
Angina pectoris month prior to surgery* 50 (71.4)
TIA/Stroke 6 (8.6)
COPD 6 (8.6)
Chronic kidney disease (eGFR MDRD4 <60ml/min) 3 (4.3)
Peripheral arterial disease 3 (4.3)
Heart failure (NYHA class III or IV) 9 (12.9)
ACS 39 (55.7)
- MI 34 (48.6)
Prior PCI 18 (26.1)
- PCI + Stent 11 (15.7)
Prior CABG 0 (0.0)
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Pre-operative medication use
Oral Nitrates 15 (21.4)
Beta-blockers 57 (81.4)
ACE inhibitor 38 (54.3)
AT-II-antagonists 17 (24.3)
Diuretics 18 (25.7)
Statins and other lipid lowering drugs 67 (95.7)
Oral anti-diabetics 16 (22.9)
Insulin 8 (11.4)
Surgery
Coronary artery disease
- One vessel 10 (14.3)
- Two vessel 9 (12.9)
- Three vessel 51 (72.9)
Timing:
- Elective/planned 66 (94.3)
- Urgent 2 (2.9)
- Emergency 2 (2.9)
EuroScore (SD) 3.2 ± 2.6
Table 2. Data are presented as number and percentage unless otherwise indicated. 
Denominators to derive percentages are based on available data for each characteristic. *Any 
Canadian Cardiovascular Society class angina.  
SD: Standard Deviation. y: year. CAD: Coronary Artery Disease. NYHA: New York Heart 
Association Functional Classification. CVA: Cerebral Vascular Accident. TIA: Transient 
Ischaemic Attack.  COPD: Chronic Obstructive Pulmonary Disease. eGFR MDRD: 
Estimated Glomerular Filtration Rate according to the Modification of Diet in Renal Disease 
formula. ACS: Acute Coronary Syndrome. MI: Myocardial Infarction.N: number of patients. 
PCI: Percutaneous Coronary Intervention. CABG: Coronary Artery Bypass Grafting. (N)
OAC: (New) Oral Anticoagulants. LMWH: Low Molecular Weight Heparine. 
Table 3 shows the preoperative management for patients treated with ASA monotherapy, 
for patients using clopidogrel as part of DAPT treatment and for patients using 
ticagrelor as part of DAPT treatment. Of the total of 70 patients, 2 were on clopidogrel 
due to intolerance for ASA. One of them continued to use clopidogrel. One patient was 
treated with triple therapy (ASA/clopidogrel/acenocoumarol) and the last patient was 
treated with clopidogrel and acenocoumarol. The patient on triple therapy continued 
the acenocoumarol and stopped ASA and clopidogrel. The patient on acenocoumarol 
plus clopidogrel treatment continued the acenocoumarol and stopped the clopidogrel. 
Fig. 3 shows the number of days that medication was discontinued preoperatively. In 
the group of patients who discontinued ticagrelor, 8 patients had experienced an ACS 
less than 1 month before surgery. In the group that continued ticagrelor, 5 patients had 
experienced an ACS within 1 month before surgery.
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ASA monotherapy DAPT clopidogrel DAPT ticagrelor
Preoperative
Continued 21 1 6
Discontinued 20 4 13
Days discontinued,
median (IQR) 6 (2) 6 (3.5) 5 (5.5)
Postoperative
No restart 0 2 10
Restart 20 2 3
Days after CABG until restart,
median (IQR) 
1 (0) 2.5 (3) 1 (2)
Table 3: Management of antiplatelet therapy in the pilot study
Table 3: Preoperative management of patients on ASA monotherapy and of clopidogrel and 
ticagrelor in patients on DAPT. 
ASA: Acetylsalicylic Acid. DAPT: Dual Antiplatelet Therapy.
Fig. 3 Number of days ASA was discontinued preoperatively in patients on ASA 
monotherapy and the number of days clopidogrel and ticagrelor were discontinued in 
patients on DAPT. ASA acetylsalicylic acid; DAPT dual antiplatelet therapy
5
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After surgery, 68 out of 70 patients received ASA. Treatment was started the day 
after surgery in all patients. All these patients received a loading dose of 500 mg 
intravenously. The two patients who did not receive ASA postoperatively were both 
preoperatively treated with clopidogrel monotherapy due to ASA intolerance. Both 
these patients received their first doses of clopidogrel the day after surgery. 
Fig. 4 shows the postoperative management of P2Y12 inhibitors. Patients who received 
a P2Y12 inhibitor after CABG did not receive a loading dose, but a regular maintenance 
dose. There was no apparent relationship between restarting DAPT postoperatively 
and a preoperative history of ACS or percutaneous coronary intervention (PCI) with 
stent implantation. The incidence of postoperative complications within 30 days was 
low. Myocardial infarction (MI), stroke and death were not observed, while Bleeding 
Academic Research Consortium (BARC) type 4 major bleeding occurred in 3 patients 
and 2 patients needed surgery for mediastinitis. Due to the small study population 
with subgroups and low incidence of postoperative complications, we decided not to 
analyse these postoperative complications in more detail. 
DISCUS SION
The results from this national survey regarding the perioperative management of 
antiplatelet treatment in CABG patients show major variability across the different 
Dutch centres. This variability partly reflects the disparity in recommendations in the 
different international guidelines[1–4]. A survey regarding antithrombotic treatment 
in CABG patients conducted in 1989 also showed major differences in antithrombotic 
treatment between Dutch cardiothoracic centres [7]. Although some treatment 
strategies that were used at the time (coumarins and dipyridamole) have since been 
abandoned for routine use in CABG patients, the variability in treatment strategies 
persists.
CABG in patients using ASA monotherapy
The management of patients with ASA monotherapy differs greatly between 
centres, both in continuing or discontinuing ASA before surgery and in the timing 
of discontinuation. Although it might be reasonable to stop ASA in patients with 
the highest bleeding risk[3,4], the guidelines do not support discontinuation of ASA 
in the majority of patients, contrary to what appears to be the standard in many 
cardiothoracic centres who responded to this survey. The differences regarding the 
preoperative discontinuation of ASA in the guidelines and routine treatment in these 
centres might be caused by a lack of convincing evidence from randomised clinical 
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trials. A recent meta-analysis including a total of 2399 patients showed that ASA 
exposure within 7 days before CABG, with or without concomitant surgery, resulted 
in a 44% reduction in the odds of MI[8]. However, it also resulted in a dose-dependent 
increase in blood loss, an increased volume of red cell transfusion and rate of surgical 
re-exploration without an effect on mortality.
In the largest randomised clinical trial to date regarding the preoperative use of 
ASA in CABG patients (n=2100), [9] no differences were observed between patients 
using ASA or placebo with regard to any of the primary outcomes, death, MI, stroke, 
renal failure, pulmonary embolism and bowel infarction at 30 days after surgery (RR 
0.94 95% CI 0.80 – 1.12). There were also no significant differences in the number of 
reoperations for bleeding or cardiac tamponade. Therefore, there is no clear benefit of 
ASA treatment before CABG.
The postoperative use of ASA in CABG patients is recommended in all guidelines as 
it has been proven to increase venous graft patency and reduces the occurrence of 
ischaemic events during follow-up in all patients regardless of revascularisation 
strategy[10–13].
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Fig. 4A and 4B Postoperative management of 
clopidogrel and ticagrelor in patients preoperatively on 
DAPT. DAPT dual antiplatelet therapy
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CABG in patients using DAPT
Our survey revealed that the discrepancies in treatment strategies between the 
different centres were even greater in patients who received DAPT. Centres also differed 
in postoperative antiplatelet management, but the majority of centres stop the P2Y12 
inhibitor without restarting it after surgery. The timing of discontinuation of the 
P2Y12 inhibitor varied roughly from 4 to 10 days between  centres. A recent study from 
Hansson et al. shows that it is safe to discontinue ticagrelor 3 days and clopidogrel 5 
days prior to CABG [14]. Many guidelines mention the option of preoperative bridging 
therapy with small molecule GPIIb/IIIa inhibitors (i.e. eptifibatide or tirofiban) or 
cangrelor after discontinuation of P2Y12 inhibitors in patients with increased risk for 
ischaemic events (e.g. with recently implanted drug-eluting stent (DES)), but there is 
still little clinical evidence for this strategy. None of the respondents mentioned the 
use of this strategy in their centre.
Not restarting the P2Y12 inhibitor after surgery is not supported by the guidelines, 
which recommend restarting DAPT after CABG as soon as it is considered safe and 
to continue DAPT for at least 12 months following ACS (class I, level A)[3,15]. The 
ESC guidelines on revascularisation and non-ST-segment elevation ACS (NSTE-ACS) 
were updated after we received answers for our survey, but the 2011 ESC guideline on 
NSTE-ACS also stated that ticagrelor or clopidogrel should be considered to be (re-)
started after CABG surgery as soon as considered safe (class IIa, level  B)[16]. The 
recommendations from these guidelines are based on sub-analyses from three large 
randomised trials in ACS patients: the Clopidogrel in Unstable Angina to Prevent 
Recurrent Events (CURE) study[17], the TRial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In 
Myocardial Infarction (TRITON-TIMI 38) and the PLATelet inhibition and patient 
Outcomes (PLATO) study[18,19]. These three trials all showed some benefit 
of continuation of DAPT after CABG in sub-analyses. However, the trials are 
underpowered and these post-hoc analyses have many limitations. The reason for the 
discontinuation of study treatment after surgery in a substantial number of patients 
is not reported in these trials, so there might be a selection bias. Furthermore, the 
percentage of patients who underwent CABG was relatively low (16.5% in CURE, 2.5% 
in TRITON-TIMI 38, and 6.8% in PLATO).
There is still much uncertainty as to how P2Y12 inhibitor treatment improves clinical 
outcome in this group and which patients should receive it at which particular moment. 
Outcomes might be improved due to an increase in vein graft patency with the use of 
a P2Y12 inhibitor, as vein graft occlusion occurs in up to 26% of grafts after 1 year in 
patients using ASA monotherapy[20]. Multiple studies investigating the routine use of 
P2Y12 inhibitors in CABG patients are currently recruiting patients, including the The 
Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary 
Artery Bypass Grafting Surgery (POPular CABG) study (clinicaltrials.gov identifier 
NCT02352402) and the Study Comparing Ticagrelor With Aspirin for Prevention 
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of Vascular Events in Patients Undergoing CABG (TiCAB) study (clinicaltrials.gov 
identifier NCT01755520). Data from these studies might help us better assess the 
benefits and risks of antiplatelet therapy in all patients undergoing CABG.
CABG after PCI without prior ACS
For patients undergoing CABG after PCI without prior ACS it is recommended to 
continue DAPT for at least 1 month after implantation of a bare metal stent (BMS) 
(class I, level A) and at least 6 months after a new-generation DES (class I, level B)[4]. 
However, the guidelines do not specify which postoperative therapy is advised if the 
target vessel has been bypassed.
The guidelines offer different options for the timing of both preoperative 
discontinuation and postoperative re-initiation of P2Y12 inhibitor treatment. It 
should be considered to withhold clopidogrel and ticagrelor for 5 days and prasugrel 
for 7 days prior to surgery (class IIA, level C)[1–4]. Postoperatively, DAPT should 
be restarted within 24 hours if it is deemed safe, with a loading dose of the P2Y12 
inhibitor to optimise vein graft patency (Class IIA, level C)[3,4]. The guideline from the 
American College of Chest Physicians specifies that when CABG is performed less than 
6 weeks after BMS or less than 6 months after DES, DAPT should be continued during 
surgery to prevent stent thrombosis (Grade 2C)[2].
Registry results
The results of our registry in the St. Antonius Hospital demonstrate that there are 
major differences even in a single centre. Generally, the P2Y12 inhibitor is discontinued 
for a shorter time period before surgery than is advised by the guidelines. The reasons 
for this could be that patients were considered to be at higher risk for ischaemic events.
Limitations
Multiple limitations regarding the survey and registry merit mention. A questionnaire 
will only result in a general depiction of clinical practice, although we tried to include 
open questions to gather information regarding treatment of patients who did not fall 
into standard treatment protocols. However, treatment might actually differ from the 
answers provided by the responders as individual physicians might deviate from local 
protocols. Furthermore, only 69% of centres responded to our questionnaire. 
The pilot study is limited due to its single-centre nature and the small population 
size. Another limitation for both studies is that the new ESC guideline regarding 
non-ST-segment-elevation myocardial infarction was published after the survey and 
the registry were conducted. Adherence to the guidelines might have increased since.
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CONCLUSION
Dutch cardiothoracic centres are not unified in their perioperative management of 
antiplatelet therapy in patients undergoing isolated CABG. The lack of evidence from 
randomised controlled trials could contribute to these differences between centres. 
More evidence from ongoing trials is essential to better evaluate the benefits and risks 
of antiplatelet therapy in CABG patients and strengthen the recommendations of the 
guidelines.
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Summary
S U M M A R Y
This thesis concerns antiplatelet therapy and platelet function testing in patients 
undergoing percutaneous coronary interventions (PCI’s) and coronary artery bypass 
grafting surgery (CABG). The goal of this thesis was to further our understanding 
of factors that influence platelet reactivity as measured with platelet function tests, 
to search for the optimal treatment for specific subgroups of patients and to tailor 
antiplatelet therapy for individual patients. I focused my attention mainly on the use 
of the antiplatelet drug clopidogrel, which is a P2Y12 inibitor. Furthermore, I aimed to 
investigate the current use of antiplatelet treatment in CABG patients and to identify 
knowledge gaps for future research.
The introduction to this thesis, Chapter 1, contains two reviews regarding the use 
of different platelet function tests in both the PCI and CABG population in which 
the association between platelet reactivity and both bleeding and thrombotic events 
is shown. Furthermore, the concept of a therapeutic window of platelet reactivity is 
described and tested in Chapter 1.3. Seventeen studies including 20,839 PCI patients 
were used for the analysis. The majority of patients were treated with clopidogrel 
(97% versus 3% with prasugrel). Patients with high platelet reactivity (HPR) had a 
significantly higher risk for stent thrombosis (ST) with a risk ratio (RR) of 2.73 (95% 
confidence interval [CI]: 2.03-3.69, p<0.001) and a slight reduction in bleeding (RR: 
0.84, 95% CI: 0.71-0.99, p=0.04) compared to patients with optimal platelet reactivity 
(OPR). In contrast, patients with low platelet reactivity (LPR) had a higher risk for 
bleeding (RR: 1.74, 95% CI: 1.47-2.06, p<0.00001), without benefit regarding ST (RR: 
1.06, 95% CI: 0.68-1.65, p=0.78) as compared to patients with OPR. Mortality was 
significantly higher in patients with HPR compared with other categories (p<0.05). 
This again underlines the prognostic value of platelet reactivity in PCI patients.
In Chapter 2, the influence of different factors on platelet reactivity test results in 
PCI patients is investigated. The chapter starts with a systematic review regarding 
the influence of performing a PCI procedure with stent implantation on platelet 
reactivity (Chapter 2.1). Most studies that were found in this systematic search 
showed an increase in platelet reactivity immediately after PCI as compared to 
before PCI. Therefore, the platelet reactivity on treatment during follow-up in these 
patients might be lower than suggested by a platelet function test performed on a 
blood sample taken shortly after a PCI procedure. We further investigated the effects 
of a PCI procedure on platelet reactivity as measured with the VerifyNow P2Y12 assay 
in a prospective cohort study including 111 patients undergoing a planned PCI. 
Moreover, we compared the effect of different sources of blood (venous or arterial) 
and the use of heparin and bivalirudin on platelet reactivity (Chapter 2.2). The results 
from this study led to the following conclusions: 1) platelet reactivity on clopidogrel 
is increased directly after PCI as compared to before and 24 hours after PCI, 2) No 
individual component of the PCI procedure was identified to be solely responsible 
for this increase in platelet reactivity, 3) platelet reactivity is higher in arterial 
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samples than in venous samples, 4) the administration of heparin increases platelet 
reactivity while the administration of bivalirudin does not, and finally 5) accounting 
for the aforementioned effects on platelet reactivity on treatment with clopidogrel, 
by using standardized testing methods and corresponding cut-off values, could lead 
to improved identification of patients at higher thrombotic risk after PCI. In the last 
part of this chapter, the influence of hematocrit on platelet reactivity as measured 
with the VerifyNow P2Y12 assay was studied. Results from this post-hoc analysis of 
a prospective cohort study containing 978 patients undergoing elective PCI showed 
that hematocrit is significantly associated with platelet reactivity expressed in P2Y12 
Reaction Units (PRU) as measured with the VerifyNow P2Y12 assay. It is unclear if this 
relation between hematocrit and platelet reactivity exists only in vitro or also in vivo. 
However, correcting PRU for hematocrit, as was previously suggested in the literature, 
does not improve prediction of thrombotic events following PCI.
The issues related to the concomitant use of oral anticoagulants and antiplatelet 
agents in patients undergoing PCI are described in Chapter 3. The chapter starts with 
a review of current literature and related correspondence. The efficacy of triple therapy 
(an oral anticoagulant, aspirin and clopidogrel) in atrial fibrillation patients who need 
to undergo PCI with stent placement has never been proven, but this strategy does 
increase bleeding risk significantly. New evidence, including a randomised controlled 
trial and a real-life nationwide registry of more than 12,000 patients, showed the great 
potential of the combination of a vitamin K antagonist and clopidogrel without aspirin 
to improve clinical outcomes in comparison to triple therapy. Therefore, it might 
be a reasonable option to treat patients on long-term oral anticoagulant for atrial 
fibrillation who undergo PCI with the only combination that has shown favourable 
results as compared to the recommended triple therapy (Chapter 3.1). Furthermore, 
this chapter includes a hypothesis-generating study regarding the effect of the use of 
the vitamin K antagonist acenocoumarol on platelet reactivity on clopidogrel (Chapter 
3.4). This prospective cohort study included 1,582 patients undergoing elective PCI 
showed that the concomitant treatment with acenocoumarol is associated with a 
significant increase in platelet reactivity and the rate of HPR in patients treated with 
clopidogrel. Since the number of patients on oral anticoagulation therapy undergoing 
PCI is increasing, and previous studies showed a correlation between HPR and 
clinical outcome, this might be an important observation. The impact of this possible 
interaction between coumarin derivatives and clopidogrel on the risk of bleeding and 
thrombotic events in patients undergoing PCI still requires further investigation. This 
chapter ends with a sub-analysis of an open label randomised controlled trial which 
included 573 patients on long-term oral anticoagulation who underwent PCI (Chapter 
3.5). In this sub-analysis, the strategy of discontinuation of the oral anticoagulant 
before PCI, with or without bridging with heparins, was compared to uninterrupted 
oral anticoagulation. Performing PCI with the uninterrupted oral anticoagulation 
strategy was not associated with an increase of the number of bleeding events or major 
adverse cardiac and cerebrovascular events in this study. Furthermore, bleeding or 
major adverse cardiac and cerebrovascular events were not related to international 
normalized ratio (INR) levels.
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Chapter 4 of this thesis focuses on the individualization of antiplatelet treatment 
in PCI patients. The first part of this chapter is a prospective cohort study in which 
antiplatelet treatment in patients undergoing non-urgent PCI was guided by a risk 
score (the POPular Risk score) based on platelet reactivity (VerifyNow P2Y12 assay), 
CYP2C19 genotyping and clinical risk factors. Patients with a high risk score were 
treated with prasugrel and patients with a low risk score with clopidogrel. The risk 
score guided cohort was compared to a historic cohort of clopidogrel-treated patients. 
A combined thrombotic endpoint consisting of all-cause death, myocardial infarction, 
stroke or stent thrombosis and TIMI major and minor bleeding events during 1 year of 
follow-up was compared between both groups. A total of 1,127 patients were included 
in the guided cohort, 26.9% of whom were switched to prasugrel according to the 
POPular Risk score. The historic cohort contained 893 patients. The incidence of the 
combined thrombotic endpoint was significantly lower in the guided cohort (Odds 
ratio [OR] 0.42, 95% CI: 0.28 – 0.62). This strategy was safe in this study (OR 0.32 
[95% CI: 0.17 – 0.58] for TIMI major or minor bleeding). Results were comparable 
after multivariate and propensity score matched and weighted analysis. We concluded 
that the selective intensification of P2Y12 inhibitor treatment after non-urgent PCI 
based on the POPular Risk Score is associated with a reduction in thrombotic risk 
without an increase in bleeding risk. This is an important step towards tailored 
antiplatelet treatment in PCI patients. However, these results have to be reproduced 
in a randomized trial before this strategy can be recommended for routine use in daily 
clinical practice.
The second part of this chapter describes the rationale and design of the randomized, 
open label, multicenter POPular Genetics study, which is the first large-scale 
randomized clinical trial to assess the net clinical benefit, safety and cost-effectiveness 
of CYP2C19 genotype guided antiplatelet therapy compared to a non-tailored strategy 
with ticagrelor or prasugrel use in ST-segment elevation myocardial infarction (STEMI) 
patients undergoing primary PCI with stent implantation. In the intervention arm 
of this trial, patients with loss-of-function allele for the CYP2C19 gene encoding the 
CYP2C19 enzyme are treated with ticagrelor or prasugrel instead of clopidogrel, while 
all patients without loss-of-function alleles are treated with clopidogrel. Recruitment 
for this trial is still ongoing.
In Chapter 5 the perioperative management of antiplatelet drugs in patients 
undergoing isolated CABG in Dutch cardiothoracic centres is shown. A questionnaire 
was sent to all 16 cardiothoracic centres in the Netherlands to study which antiplatelet 
treatment is used in the perioperative setting. Furthermore, a single centre prospective 
observational cohort study, which included all patients undergoing isolated CABG 
during one month in one centre, was performed as a pilot study. Our survey showed 
major differences in treatment protocols, both pre- and postoperatively, across the 
different centres.  Furthermore, major differences in antiplatelet treatment strategies 
were even found in the pilot study. Part of this variation is probably due to differences 
between current guidelines; however, many of the treatment strategies used are not in 
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accordance with any of these guidelines! A lack of evidence from randomized clinical 
trials in CABG patients contributes to these discrepancies. Much more research in 
this patient population is necessary. With the conduct of the “The Effect Of Ticagrelor 
On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass 
Grafting Surgery” (POPular CABG) study (clinicaltrials.gov identifier NCT02352402) 
we hope to answer some of the questions that have been left unanswered.
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D U T C H  S U M M A R Y
Dit proefschrift gaat over plaatjesremmende medicatie en plaatjesfunctietesten in 
patiënten die percutane coronaire interventies (PCI’s) en coronaire bypass chirurgie 
(CABG) ondergaan. Het doel van dit proefschrift was om factoren in kaart te brengen 
die de reactiviteit van bloedplaatjes gemeten met plaatjesfunctietesten beïnvloeden, 
om te zoeken naar de optimale behandeling voor specifieke subgroepen van patiënten 
en om een behandeling op maat te creëren. Hierbij heb ik mij met name gericht op 
het gebruik van de plaatjesremmer clopidogrel, een zogenoemde P2Y12 inhibitor. 
Bovendien heb ik ernaar gestreefd om het gebruik van plaatjesremmende medicatie 
in CABG-patiënten te beschrijven en kennislacunes te identificeren voor toekomstig 
onderzoek.
De introductie van dit proefschrift, Hoofdstuk 1, bevat twee reviews over het gebruik 
van verschillende plaatjesfunctietesten in zowel de PCI- als de CABG-populatie. De 
associatie tussen de gemeten plaatjesreactiteit en zowel bloedingen als thrombotische 
events wordt weergegeven. Vervolgens wordt het concept van een therapeutisch 
“window” beschreven en getest in Hoofdstuk 1.3. Zeventien studies met totaal 20.839 
PCI-patiënten werden geïncludeerd in deze analyse. Het merendeel van deze patiënten 
werd behandeld met clopidogrel (97% versus 3% met prasugrel). Patiënten met hoge 
plaatjesreactiviteit (HPR) hadden significant meer risico op het ontwikkelen van 
stenttrombose (ST) met een risk ratio (RR) van 2.73 (95% betrouwbaarheidsinterval 
[BI]: 2,03-3,69, p<0,001) en een lichte afname in bloedingen (RR: 0,84, 95% BI: 0,71-
0,99, p=0,04) in vergelijking met patiënten met optimale plaatjesreactiviteit (OPR). 
Daarentegen hadden patiënten met lage plaatjesreactviteit (LPR) een hoger risico op 
bloeding (RR: 1,74, 95% BI: 1,47-2,06, p<0,00001), zonder een vermindering in ST 
(RR: 1,06, 95% CI: 0,68-1,65, p=0,78) vergeleken met patiënten met OPR. De sterfte 
was significant hoger in de groep patiënten met HPR dan in de andere categoriën 
(p<0.05). Dit benadrukt opnieuw de prognotische waarde van plaatjesreactiviteit in 
PCI-patiënten. 
In Hoofdstuk 2 wordt de invloed van verschillende factoren op de gemeten 
plaatjesreactiviteit in PCI-patiënten onderzocht. Het hoofdstuk begint met een 
systematische review over de invloed van het uitvoeren van een PCI-procedure met 
stentplaatsing op plaatjesreactiviteit (Hoofdstuk 2.1). De meeste studies die werden 
gevonden in deze systematische zoekactie, toonden een toename van plaatjes-
reactiviteit direct na een PCI in vergelijking met voor een PCI. De plaatjesreactiviteit 
van patiënten die behandeld worden met plaatjesremmers, zou dan lager kunnen zijn 
gedurende de follow-up dan gesuggereerd wordt door een test die uitgevoerd wordt 
op een bloedmonster dat kort na een PCI-procedure afgenomen wordt. Vervolgens 
hebben we zelf de effecten van een PCI-procedure op plaatjesreactiviteit onder 
clopidogrel onderzocht in een prospectieve cohort studie van 111 patiënten die een 
electieve PCI-procedure ondergingen. Ook hebben wij het effect van het gebruik van 
verschillende bloedmonsters (arterieel en veneus) en het effect van het gebruik van 
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heparine en bivalirudine op plaatjesreactiviteit onderzocht in deze studie (Hoofdstuk 
2.2). De conclusies van deze studie waren: 1) plaatjesreactiviteit onder gebruik van 
clopidogrel is direct na PCI verhoogd vergeleken met voor en 24 uur na PCI, 2) er 
werd geen individuele component van de PCI-procedure gevonden die in zijn eentje 
verantwoordelijk was voor deze stijging in plaatjesreactiviteit, 3) plaatjesreactiviteit 
is hoger in arteriële dan veneuze bloedmonsters, 4) de toediening van heparine 
verhoogt plaatesreactiviteit, terwijl de toediening van bivalirudine dit niet doet en 
tenslotte 5) wanneer rekening gehouden wordt met de eerder genoemde factoren 
die plaatjesreactiviteit onder clopidogrel beïnvloeden, door gestandaardiseerde 
testmethoden en bijpassende afkapwaarden te gebruiken, zou kunnen leiden tot 
een verbetering van de identficering van patiënten die een hoger risico hebben op 
thrombotische events na PCI. In het laatste deel uit dit hoofdstuk wordt de invloed 
van hematocriet op plaatjesreactiviteit, gemeten met de VerifyNow P2Y12 assay, 
onderzocht. De resultaten van deze post-hoc analyse van een prospectieve cohort 
studie bevat 978 patiënten die een electieve PCI ondergingen laat zien dat hematocriet 
significant geassocieerd is met plaatjesreactiviteit uitgedruk in P2Y12 Reaction Units 
(PRU) gemeten met de VerifyNow P2Y12 assay. Het is onduidelijk of deze relatie 
tussen plaatjesreactiviteit en hematocriet alleen in vitro bestaat of ook in vivo. Het 
corrigeren van de PRU voor de hematocriet waarde, zoals eerder gesuggereerd werd in 
de literatuur, verbetert de voorspelling van het optreden van trombotische events na 
PCI echter niet.
De problemen gerelateerd aan het gelijktijdig gebruik van orale anticoagulantia 
en plaatjesremmers in patiënten die een PCI ondergaan, worden beschreven in 
Hoofdstuk 3. Het hoofdstuk start met een review van de huidige literatuur over dit 
onderwerp en gerelateerde correspondentie. De effectiviteit van “triple” therapie (een 
oraal anticoagulantium, aspirine en clopidogrel) in patiënten met atriumfibrillatie die 
een PCI met stentplaatsing moeten ondergaan, is nooit bewezen, maar deze strategie 
verhoogt wel het bloedingsrisico significant. Een recente gerandomiseerde trial en 
een recente real-life nationale registry met meer dan 12.000 patiënten lieten zien 
dat de combinatie van een vitamine K antagonist met clopidogrel en zónder aspirine 
de uitkomsten zou kunnen verbeteren in vergelijking met triple therapie. Het zou 
daarom een redelijke optie kunnen zijn om patënten met langdurige behandeling met 
anticoagulantia vanwege atriumfibrilleren die een PCI ondergaan te behandelen met 
de enige combinatie van middelen die een goed resultaat heeft laten zien in vergeljking 
met triple therapie (Hoofdstuk 3.1). Daarnaast staat in dit hoofdstuk een hypothese-
genererende studie betreffende het mogelijke effect van het gebruik van de vitamine 
K antagonist acenocoumarol op plaatjesreactiviteit onder clopidogrel (Hoofdstuk 
3.4). Deze prospectieve cohortstudie waarin 1.582 patiënten werden geïncludeerd 
die een electieve PCI ondergingen, toonde aan dat de gelijktijdige behandeling met 
acenocoumarol geassocieerd was met een significant verhoogde plaatjesreactiviteit en 
incidentie van HPR in patiënten behandeld met clopidogrel. Dit kan een belangrijk 
gegeven zijn, omdat de groep patiënten met orale anticoagulantia die een PCI moeten 
ondergaan steeds groter wordt en eerdere studies een correlatie hebben laten zien 
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tussen HPR en een slechtere klinische uitkomst na PCI. Meer onderzoek is nodig om 
de impact van deze mogelijke interactie tussen coumarine derivaten en clopidogrel op 
het risico van bloedingen en trombotische events in patiënten die een PCI ondergaan 
te onderzoeken. Het hoofdstuk eindigt met een sub-analyse van een open-label 
gerandomiseerde gecontroleerde trial die 573 patiënten includeerde die langdurig 
orale anticoagulantia moesten gebruiken en een PCI moesten ondergaan (Hoofdstuk 
3.5). In deze sub-analyse werd de strategie van het stoppen van orale anticoagulantia 
vóór PCI, met of zonder overbrugging met heparines, vergeleken met het continueren 
van orale anticoagulantia. Het uitvoeren van een PCI bij patiënten met continuering 
van de orale anticoagulantia was niet geassocieerd met een toename in het aantal 
bloedingen of majeure cardiale en cerebrovasculaire events in deze studie. Deze events 
waren ook niet gerelateerd aan international normalized ratio (INR) waarden.
Hoofdstuk 4 van dit proefschrift richt zich op de individualisering van 
plaatjesremmende behandeling in PCI-patiënten. Het eerste deel uit dit hoofdstuk is 
een prospectieve cohort studie waarin plaatjesremmede behandeling in patiëntien die 
een niet urgente PCI-behandeling ondergingen, werd gestuurd door een risico score 
(de POPular Risk score) gebaseerd op plaatjesreactiviteit (VerifyNow P2Y12 assay), 
CYP2C19 genotype en klinische factoren. Patiënten met een hoge risicoscore werden 
behandeld met prasugrel en patiënten met een lage risicoscore met clopidogrel. De 
risicoscore-gestuurde groep werd vergeleken met een historisch cohort van patiënten 
die allen behandeld werden met clopidogrel. Een gecombineerd eindpunt van dood, 
myocardinfarct, beroerte of stenttrombose en TIMI “major” en “minor” bloedingen 
gedurende 1 jaar follow-up werden vergeleken tussen beide groepen. Totaal 1.127 
patiënten werden geïncludeerd in het risicoscore-gestuurde cohort, van wie 26,9% werd 
omgezet naar prasugrel op basis van de POPular Risk score. Het historische cohort 
bevatte 893 patiënten. De incidentie van het gecombineerd trombotische eindpunt was 
significant lager in het risicoscore-gestuurde cohort (Odds ratio [OR] 0,42, 95% [CI]: 
0,28 – 0,62). Deze strategie was veilig in deze studie (OR 0.32 [95% CI: 0.17 – 0.58] voor 
TIMI major of minor bloedingen). De resultaten waren vergelijkbaar na multivariate en 
propensity score “matched” en “weighted” analyse. Wij concludeerden dat de selectieve 
versterking van P2Y12 inhibitor behandeling na een niet urgente PCI op basis van de 
POPular Risk Score geassocieerd is met een reductie in het trombotisch risico zonder 
een toename in bloedingsrisico. Dit is een belangrijke stap naar behandeling op maat 
met plaatjesremmers in PCI-patiënten. Deze resultaten moeten echter gereproduceerd 
worden in een gerandomiseerde trial voordat deze strategie voor routine gebruik kan 
worden aangeraden.
Het tweede deel van dit hoofdstuk beschrijft de rationale en het ontwerp van 
de gerandomiseerde, open label, multicenter POPular Genetics studie, wat de 
eerste gerandomiseerde klinische trial die op grote schaal het netto klinische 
voordeel, de veiligheid en de kosten-effectiviteit van CYP2C19 genotype-gestuurde 
plaatjesremmende therapie vergelijkt met een routinematige behandeling met 
ticagrelor of prasugrel in ST-segment elevatie myocardinfarct (STEMI) patiënten 
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die een primaire PCI met stentplaatsing ondergaan. In de interventiegroep in deze 
trial worden patiënten met een “loss-of-function” allele van het CYP2C19 gen (wat 
het CYP2C19 enzyme codeert) behandeld met ticagrelor of prasugrel in plaats van 
clopidogrel, terwijl alle patiënten zonder zo’n loss-of-function allel behandeld worden 
met clopidogrel. Er worden op dit moment nog patiënten voor deze trial geïncludeerd.
In Hoofdstuk 5 wordt het perioperatieve beleid getoond ten aanzien van 
plaatjesremmende medicatie in patiënten die een geïsoleerde CABG ondergaan in 
Nederlands thoraxchirurgische centra. Er is een vragenlijst gestuurd naar alle 16 
thoraxchirurgische centra in Nederland om te onderzoeken welke plaatjesremmende 
therapie gebruikt wordt in de perioperatieve setting. Daarnaast is er als pilot een 
prospectieve observationele cohort-studie uitgevoerd waarin alle patiënten die 
een geïsoleerde CABG ondergingen gedurende één maand in ons centrum werden 
geïncludeerd. Onze vragenlijst liet grote verschillen zien in behandelprotocollen, 
zowel pre- als postoperatief, tussen de verschillende centra. Er waren bovendien grote 
verschillen in plaatjesremmende behandeling in de pilot-studie. Een deel van de variatie 
komt waarschijnlijk door de verschillen tussen de huidige richtlijnen, echter, vele van 
de strategieën die gebruikt worden, worden door geen enkele richtlijn ondersteund! 
Een gebrek aan bewijs uit gerandomiseerde studies in CABG-patiënten draagt bij aan 
deze verschillen. Er is veel meer onderzoek nodig in deze patiëntenpopulatie. Met 
het uitvoeren van de “The Effect Of Ticagrelor On Saphenous Vein Graft Patency In 
Patients Undergoing Coronary Artery Bypass Grafting Surgery” (POPular CABG) 
studie (clinicaltrials.gov identifier NCT02352402) hopen we sommige van de vragen 
die tot nog toe onbeantwoord zijn, te kunnen beantwoorden.
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